» 20th International Congress

Date: Thursday, January 1, 1970

Time: 12:00am-12:00am

Meeting:

12:30pm-2:00pm: “Two odd targets” strategy in deep brain stimulation for Parkinson’s disease with unilateral dystonia

S. Sekimoto, G. Oyama, T. Jo, A. Nakajima, Y. Shimo, M. Nakajima, A. Umemura, M. Ito, H. Arai, N. Hattori (Bunkyo-ku, Japan)

12:30pm-2:00pm: "Atypical" atypical parkinsonism

S.T. Hirschbichler, R. Erro, M. Stamelou, C. Ganos, B. Balint, K.P. Bhatia (London, United Kingdom)

12:30pm-2:00pm: 1-year clinical outcomes in patients with parkinsonism syndrome with/without type 2 diabetes

E. Shalaeva, B. Janabaev, Q. Matmurotov, U. Kasimov, U. Pulatov, A. Bobabekov, M. Bozorboev (Tashkent, Uzbekistan)

12:30pm-2:00pm: A case of PD with non -motor symptoms onset

L. Khachatryan, N. Gasparyan, E. Mamyan, N. Mamyan, A. Hakobyan (Yerevan, Armenia)

12:30pm-2:00pm: A case of thalamic malignant glioma formation in a patient with STN-DBS for Parkinson’s disease

A. Tomskiy, A. Gamaleya, N. Gubareva, Y. Latyshev, G. Kobyakov, L. Shishkina, I. Pronin (Moscow, Russia)

12:30pm-2:00pm: A case series of sigmoid volvulus in Parkinson’s disease

K. Khalid, A. McColl, M. Gosney, A.K. Chatterjee (Reading, United Kingdom)

12:30pm-2:00pm: A cognitive monitoring program for individuals with Parkinson’s disease submitted to deep brain stimulation

L. Fontão, R. Barreto, L. Ruano, A. Sousa, A.I. Martins, A. Costa, A. Aires, C. Sousa, J. Lima, J. Pais, M.J. Rosas, R. Vaz, V.T. Cruz (Santa Maria da Feira, Portugal)

12:30pm-2:00pm: A comparison study of health-related quality of life between female and male patients with Parkinson’s disease

B. Donmez Colakoglu, T. Kahraman, E. Goz, F. Soke, A. Genc, P. Keskinoglu (Izmir, Turkey)

12:30pm-2:00pm: A computerized cognitive behavioral therapy randomized, controlled, pilot trial for insomnia in Parkinson’s disease (The ACCORD-PD study)

S. Patel, O. Ojo, G. Genc, L. Wang, J. Benab, M. Drerup, N. Foldvary, A. Ahmed, H.H. Fernandez (Cleveland, OH, USA)

12:30pm-2:00pm: A cross-sectional study of sensor-based gait analysis in atypical Parkinsonian disorders

C. Raccagni, H. Gassner, S. Eschlböck, S. Bösch, F. Krismer, M. Nocker, K. Seppi, W. Poewe, J. Klucken, G. Wenning (Innsbruck, Austria)

12:30pm-2:00pm: A dopamine-dependent activity of the STN in the control of balance in Parkinson’s disease

G. Arnulfo, N.G. Pozzi, C. Palmisano, A. Canessa, J. Brumberg, C.A. Frigo, G. Pezzoli, F. Steigerwald, J. Volkmann, I.U. Isaias (Würzburg, Germany)

12:30pm-2:00pm: A longitudinal observational study of a cohort of patients with PSP/CBD: The JALPAC project

T. Tokuda, T. Ikeuchi, H. Takigawa, I. Aiba, T. Shimohata, M. Morita, O. Onodera, S. Murayama, K. Nakashima (Kyoto, Japan)

12:30pm-2:00pm: A multi-site survey of Parkinson’s disease deep brain stimulation center best practice: moving toward a standard of care for DBS

A.A. Butala, K.A. Mills, P. Schmidt, M.S. Okun, Z. Mari (Baltimore, MD, USA)

12:30pm-2:00pm: A new tool to measure the impact of deep brain stimulation on Parkinson’s disease patients: Development and validation of the deep brain stimulation impairment scale (DBS-IS)

F. Maier, C.J. Lewis, A.A. Kühn, H. Krug, J. Volkmann, A.D. Kirsch, L. Wojtecki, A. Schnitzler, G. Deuschl, J.K. Krauss, C. Woopen, L. Timmermann (Cologne, Germany)

12:30pm-2:00pm: A novel interdisciplinary palliative care clinic for advanced Parkinson’s disease and Parkinsonian syndromes

K.K. Tuck, L. Mann, S. Anderson, T. Borcich, J. Wilhelm, L. Bryans, J. Carter (Portland, OR, USA)

12:30pm-2:00pm: A novel phenotype of amyloid precursor protein (APP) mutation presenting with dementia, and symptoms of both progressive supranulcear palsy (PSP) and multisystem atrophy (MSA)

J.E. Staisch, M. Padmanaban, J. Mastrianni, T. Xie (Chicago, IL, USA)

12:30pm-2:00pm: A pilot study of horizontal current steering with chronically implanted segmented electrodes for STN-DBS in Parkinson’s disease

F. Steigerwald, L. Mueller, S. Johannes, C. Matthies, J. Volkmann (Würzburg, Germany)

12:30pm-2:00pm: A polysomnography study of REM sleep without atonia and REM sleep behavior disorder in MSA and PD

C. Kaindlstorfer, G. Wenning, S. Bösch, B. Frauscher, F. Krismer, M. Nocker, G. Ransmayr, C. Scherfler, K. Seppi, A. Stefani, W. Poewe, B. Högl (Innsbruck, Austria)

12:30pm-2:00pm: A prospective study of patients’ expectations in subthalamic nucleus deep brain stimulation for Parkinson’s disease

N.R. Mundil, H.Y. Ling, H. Hasegawa, M. Samuel, K. Ashkan (London, United Kingdom)

12:30pm-2:00pm: A study to assess the quality of life and strain in caregivers of people with Parkinson’s disease in India

F. Pullishery, F. Fawaz (Malappuram, India)

12:30pm-2:00pm: Accuracy of intraoperative CT during DBS procedures: Comparison with postoperative MRI

L. Verhagen Metman, P. van den Munckhof, R. Bakay, G. Stebbins, M. Bot (Chicago, IL, USA)

12:30pm-2:00pm: Airway protective mechanisms and deep brain stimulation in Parkinson’s disease

M.S. Troche, A.E. Brandimore, K.W. Hegland, P.W. Davenport, K.F. Foote, M.S. Okun (New York, NY, USA)

12:30pm-2:00pm: Allele specificity in neurodegenerative olfactory dysfunction

B.A. Chase, K. Markopoulou, P. Robowski, A. Strongosky, E. Narozanska, E.J. Sitek, M. Berdynski, M. Barcikowska, M.C. Baker, R. Radamakers, J. Slawek, Z.K. Wszolek (Omaha, NE, USA)

12:30pm-2:00pm: Alpha-synuclein aggregates of cardiac sympathetic nerves in synucleinopathies and in neurologically unimpaired subjects. Correlation with sympathetic denervation

M. Carmona-Abellán, I. Marcilla, I. Martínez-Valbuena, T. Tuñón, R. Luquin-Piudo (Pamplona, Spain)

12:30pm-2:00pm: An elderly patient presenting as pure akinesia with gait freezing (PAGF): Idiopathic aqueductal stenosis-associated hydrocephalus

K.Y. Kwon, J.J. Joo, B.J. Ahn, D.K. Yeo (Gumi, Kyeongsangbuk-do, Korea)

12:30pm-2:00pm: An innovative international educational network to improve physicians’ current management practices of patients with cervical dystonia and spasticity

C. Colosimo, K. Bhatia, R. Bhidayasiri, T.M. Chung, L.J. Jacinto, T. Landreau, K. Fheodoroff (Terni, Italy)

12:30pm-2:00pm: An international, randomized, sham controlled trial of focused ultrasound thalamotomy for essential tremor

W. Ondo, J. Elias, N. Alicacem, P. Ghanouni (Houston, TX, USA)

12:30pm-2:00pm: An investigation of Parkinson’s disease patients’ desired control over the DBS stimulator

C.S. Kubu, J. Vitek, S.E. Cooper, A. Machado, P.J. Ford (Cleveland, OH, USA)

12:30pm-2:00pm: Analysis of the olfactory impairments in PINK1 deficient mice

A. Hummel, A. Zimprich, L. Garret, B. Sperling, F. Giesert, J. Nagler, H. Fuchs, V. Gailus-Durner, M. Hrabé de Angelis, S.M. Koch, D. Vogt Weisenhorn, W. Wurst (Neuherberg, Germany)

12:30pm-2:00pm: Anosmia predicts development of more severe motor symptoms including freezing of gait and impaired balance at 2 year follow-up in PD

N.I. Bohnen, J. Haugen, V. Kotagal, K.A. Frey, R.L. Albin, M.L.T.M. Muller (Ann Arbor, MI, USA)

12:30pm-2:00pm: Anti-LGI1 encephalitis presenting as a progressive supranuclear palsy-like syndrome

G.A. Da Prat, E.M. Gatto, G.G. Persi, V. Parisi, D. Lisei, L. Rattagan, M. Bres Bullrich, S. Camerlingo, C. Rugilo, M. Titulaer, G. Rojas (Caba, Argentina)

12:30pm-2:00pm: AntiParkinsonian medication adjustments following deep brain stimulation of subthalamic nucleus in patients with advanced Parkinson’s disease

A. Gamaleya, E. Bril, A. Tomskiy, A. Poddubskaya, N. Gubareva, N. Fedorova, V. Shabalov (Moscow, Russia)

12:30pm-2:00pm: Anxiety and freezing of gait: A new perspective for early intervention

K.A. Ehgoetz Martens, J.M. Hall, M. Gilat, M.J. Georgiades, C.C. Walton, S.J.G. Lewis (Camperdown, Australia)

12:30pm-2:00pm: Anxiety in patients with Parkinson’s disease

K. Zhu, J.J. van Hilten, J. Marinus (Leiden, Netherlands)

12:30pm-2:00pm: Anxiolytic-like activity of the adenosine A_2A receptor antagonist, istradefylline (KW-6002) in rodent models of anxiety

K. Yamada, M. Kobayashi, J. Kase, A. Mori, P. Jenner, T. Kanda (Shizuoka, Japan)

12:30pm-2:00pm: Apathy and striatal dopamine defects in non-demented patients with Parkinson’s disease

S.J. Chung, J.J. Lee, J.H. Ham, P.H. Lee, Y.H. Sohn (Seoul, Korea)

12:30pm-2:00pm: Appendicitis and risk of Parkinson’s disease: A Danish nationwide population-based cohort study

E. Svensson, E. Horváth-Puhó, M. Stockholm, H. Toft-Sørensen, P. Borghammer (Aarhus N, Denmark)

12:30pm-2:00pm: Application and correlates of the PSP quality of life scale

L.A. Higginbotham, V. Johnson, A. Pantelyat (Baltimore, MD, USA)

12:30pm-2:00pm: Application of Parkinson’s well-being map to assess impairment of digestive system in patients of Tomsk region, Russia

Y. Mironova, I. Zhukova, N. Zhukova, V. Alifirova, O. Izhboldina, A. Latypova, M. Nikitina (Tomsk, Russia)

12:30pm-2:00pm: Application of the MDS research criteria for prodromal Parkinson’s disease to the longitudinal population-based Bruneck study cohort

P. Mahlknecht, A. Gasperi, P. Willeit, S. Kiechl, H. Stockner, J. Willeit, G. Rungger, W. Poewe, K. Seppi (Innsbruck, Austria)

12:30pm-2:00pm: Apraxia of speech as the initial manifestation of progressive supranuclear palsy

J.J. Bravo, M.J. Gallardo, J.P. Cabello, R.E. Ibañez, J. Vaamonde (Ciudad Real, Spain)

12:30pm-2:00pm: Are inflammatory bowel disease and/or treatment with aminosalicylates protective factors against Parkinson’s disease?

F. Escamilla-Sevilla, J. Pinel-Ríos, C.J. Madrid-Navarro, R. Piñar-Morales, J.D. Herrera-García, M.J. Pérez-Navarro, C. Del Canto-Pérez, M.J. Cabello-Tapia, M.d.m. Martín-Rodríguez, D. Sánchez-Capilla, M.J. Piña-Vera, A. Aguilar-Muñoz, V. Campos-Arillo, J. Gutiérrez-García, C.E. Chamorro-Santos, M.R. Gómez-García, A. Mínguez-Castellanos (Granada, Spain)

12:30pm-2:00pm: Are people with Parkinson’s disease living in care homes in the UK underserved? Identifying models of care and barriers to care access

L.L. Oates, A. Hand, R.W. Walker, W.K. Gray, P. Reynolds, L. Cockram (North Shields, United Kingdom)

12:30pm-2:00pm: Articulography reveals disturbed speech motor control in ET patients treated with VIM-DBS

M.T. Barbe, D. Mücke, A. Hermes, T.B. Roettger, J. Becker, M. Opitz, T.A. Dembek, M. Hartinger, I.G. Meister, V. Visser-Vandewalle, M. Grice, L. Timmermann (Cologne, Germany)

12:30pm-2:00pm: Assessing the impact of PD motor symptom states on quality of life in patients with advanced Parkinson’s disease

Y. Jalundhwala, P. Kandukuri, T. Marshall, A. Yucel, K. Chatamra, K. Sail (Mettawa, IL, USA)

12:30pm-2:00pm: Assessment and connection to care: The vital role of the social worker in an interdisciplinary home visit program for advanced Parkinson’s disease patients

M.M. Sweeney, A.C. Lemen, S.E. Oyler, R.M. Gilbert, A. Fazl, J. Chodosh, A. Di Rocco, J.E. Fleisher (New York, NY, USA)

12:30pm-2:00pm: Assessment of freezing of gait in Parkinson’s disease patients treated with STN-DBS

K. Peterova, E. Ruzicka, R. Jech, J. Rusz, E. Plananská, L. Brabcová, H. Brozová (Prague, Czech Republic)

12:30pm-2:00pm: Assessment of gait dysfunction in patients with Parkinson’s disease and REM behavioral disorder

L.R. Niemand, A. Dang, C. Singer, C.C. Luca (Miami, FL, USA)

12:30pm-2:00pm: Assessment of malnutrition in patients with Parkinson’s disease

O. Yilmaz Kusbeci, I. Inci, B. Donmez Colakoglu, N. Erdogmus Ince, R. Cakmur (Izmir, Turkey)

12:30pm-2:00pm: Assessment of olfactory dysfunction in Parkinson’s disease with an objective test

Y. Sucullu Karadag, N. Turkmen, O. Gulten, A. Eryilmaz, A. Altundag, N. Subutay Oztekin, F. Ak (Ankara, Turkey)

12:30pm-2:00pm: Assessment of the quality of life of patients with Parkinson’s disease

S. Lukmonov, D. Tolibov, A. Sobirov, F. Yunusov, K. Abdukhalimova, D. Jamilov, R. Agzamov, S. Tursunov (Tashkent, Uzbekistan)

12:30pm-2:00pm: Associated and predictive factors of depressive symptoms in patients with Parkinson’s disease

K. Zhu, J.J. Van Hilten, J. Marinus (Leiden, Netherlands)

12:30pm-2:00pm: Association between clinical features and pre- and post-synaptic dopaminergic dysfunction in multiple system atrophy: [18F]-FP-CIT PET and [18F]-FDG PET analyses

H.S. Ryu, M. Oh, M.J. Kim, S. You, Y.J. Kim, J. Kim, K. Kim, H. Moon, J. Oh, J.S. Kim, S.J. Chung (Seoul, Korea)

12:30pm-2:00pm: Association of mood and affective disorders with pain in Parkinson’s disease

J.S. Kim, W. Jang, J. Park, E. Oh, J. Youn, J.W. Cho (Seoul, Korea)

12:30pm-2:00pm: Association of UV radiation with Parkinson’s disease incidence: A nationwide French ecologic study

A. Elbaz, K. Sofiane, L. Wald, A. Dugravot, A. Singh-Manoux, F. Moisan, A. Kravietz (Villejuif, France)

12:30pm-2:00pm: Ataxic gait in subjects with essential tremor and thalamic neurostimulation is caused by posteromedial current spread in the (sub)thalamic area

M.M. Reich, J. Brumberg, N. Pozzi, M. Åström, R. Nijlunsing, T. Musacchio, F. Steigerwald, G. Marotta, A. Buck, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)

12:30pm-2:00pm: Atypical Parkinsonian disorders: Insights for a differential diagnosis through the analysis of oculomotor profile in MSA, PSP and CBD patients

F. Rosini, G. Lucii, P. Federighi, E. Pretegiani, F. Giannini, R. Rocchi, A. Federico, A. Rufa (Siena, Italy)

12:30pm-2:00pm: Atypical parkinsonism in C9orf72 expansions: A case report and systematic review of 45 cases from the literature

C. Wilke, J.K. Pomper, S. Biskup, C. Puskás, D. Berg, M. Synofzik (Tübingen, Germany)

12:30pm-2:00pm: Auditory function and speech discrimination abilities are impaired in progressive supranuclear palsy

C. Vitale, G. Santangelo, R. Allocca, T. Abbate, S. Peluso, G. De Michele, M. Moccia, M. Picillo, D. Tafuri, P. Barone, M. Cavaliere (Naples, Italy)

12:30pm-2:00pm: Autonomic failure and circadian rhythm of arterial blood pressure in IDIOPATHIC REM behaviour disorders and Parkinson’s disease

R. Zangaglia, E. Guaschino, N. Ghiotto, B. Minafra, M. Terzaghi, G. Capone, A. Spiritelli, D. Bosone, C. Pacchetti (Pavia, Italy)

12:30pm-2:00pm: Awareness and perception of gastrointestinal symptoms in Parkinson´s disease: A survey of patients and caregiving relatives

P. Themann (Halsbrücke, Germany)

12:30pm-2:00pm: Bacterial biofilm formation on neurostimulation systems

A. Wloch, B. Hong, M. Abdallat, A. Winkel, A. Saryyeva, G. Lütjens, M. Stiesch, J.K. Krauss (Hannover, Germany)

12:30pm-2:00pm: Barriers to providing quality care for people with Parkinson’s living in care homes in the UK: The role of staff training

L.L. Oates, A. Hand, R.W. Walker, W.K. Gray (North Shields, United Kingdom)

12:30pm-2:00pm: Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease. PPMI cohort

T. Simuni, D. Weintraub, C. Caspell-Garcia, M. Walker, C.S. Coffey, S. Lasch, C. Tanner, D. Jennings, K. Kieburtz, K. Marek, On behalf of the PPMI Investigators (Chicago, IL, USA)

12:30pm-2:00pm: Bilateral subthalamic nucleus deep-brain stimulation (STN-DBS) in the management of idiopathic Parkinson’s disease: Results of our first 20 cases

E.M. Rezk, A.A.E. Shakal, S.M. Tourky (Tanta-Gharbeya, Egypt)

12:30pm-2:00pm: Bing-Neel syndrome presenting with Parkinsonian features: A case report

P.M. Barbosa, S. D'Sa, K.M. Ardeshna, J. Rees, A.J. Lees, T.T. Warner (London, United Kingdom)

12:30pm-2:00pm: Blunted perception of respiratory resistive loads in Parkinson’s disease

K.W. Hegland, M.S. Troche, M.S. Okun, A.E. Brandimore (Gainesville, FL, USA)

12:30pm-2:00pm: Body weight determinants in Parkinson’s disease: A multifactorial study

A. Bril, M. Rossi, S. Fariña, P. Morisset, L. Sorrentino, M. Iglesias, A. Medina Escobar, P. Millar Vernetti, D. Cerquetti, S. Perez Lloret, M. Merello (Buenos Aires, Argentina)

12:30pm-2:00pm: Bradykinesia of external urethral sphincter in a Patient with Parkinson’s disease: Case report

I.E. Estrada-Bellmann, A. Gutierrez, H.J. Villarreal, J.J. Peña, D. Ortiz (Monterrey, Mexico)

12:30pm-2:00pm: Brain structural abnormalities in multiple system atrophy patients with cognitive impairment

E. Fiorenzato, R. Biundo, L. Weis, K. Seppi, M. Onofrj, P. Cortelli, H. Kaufmann, W. Poewe, F. Krismer, G. Wenning, A. Antonini (Venice-Lido, Italy)

12:30pm-2:00pm: Broadening the evaluative scope of quality of life in Parkinson’s: Testing the construct validity of the ICECAP-O instrument

Y. Xin, J. Lewsey, R. Gray, C.E. Clarke, E. McIntosh (Glasgow, United Kingdom)

12:30pm-2:00pm: Burden of movement disorders in Cameroon: In/out patient population study

J.N. Doumbe, Y. Mapoure, E. Cubo, T. Nyinyikua, K. Kompoliti (Douala, Cameroon)

12:30pm-2:00pm: Can a leopard changes its spots? How impulse control disorder affects subthalamic stimulation paradigm

N.G. Pozzi, B. Minafra, M. Picascia, R. Zangaglia, D. Servello, C. Pacchetti (Pavia, Italy)

12:30pm-2:00pm: Can deep brain stimulation implantation cause multiple system atrophy? A retrospective review of MSA patients

E.A. Coon, B.T. Klassen, J.E. Ahlskog, P.A. Low, W. Singer (Rochester, MN, USA)

12:30pm-2:00pm: Can intraoperative clinical testing really predict the effects of deep brain stimulation in the subthalamic nucleus?

J. Blume, J. Schlaier, F. Zeman, E. Rothenfußer, A. Brawanski, U. Bogdahn, M. Lange (Regensburg, Germany)

12:30pm-2:00pm: Can stimulation of deep brain tissue improve the expression of the mouth in Parkinson’s disease patients?

M.V. Alvarez, P.M. Grogan (San Antonio, TX, USA)

12:30pm-2:00pm: Cancer comorbidity among PD patients; a population based large-scale cohort study

R. Gurel, N. Giladi, V. Rozani, T. Gurevich, B. El-Ad, B. Hemo, J. Tsamir, C. Peretz (Tel Aviv, Israel)

12:30pm-2:00pm: Cardiometabolic syndrome and risk of Parkinson’s disease: A case-control study in Mexican population

G. Parra-López, L. Bazán-Rodríguez, M. Rodríguez-Violante, A. Cervantes-Arriaga, A. Jorge de Saráchaga, M. Escobar-Barrios, E. Carreón-Bautista (Mexico City, Mexico)

12:30pm-2:00pm: Cardiovascular and cerebrovascular disorders are associated with a higher prevalence of parkinsonism: Data from a neuroepidemiologic community-based survey

S.M. Fereshtehnejad, M. Shafieisabet, A. Rahmani, A. Delbari, J. Lökk (Stockholm, Sweden)

12:30pm-2:00pm: Cerebral vasoreactivity in Parkinson’s disease and multiple system atrophy: A pilot study

E. Indelicato, F.E. Pontieri, D. Benincasa, A. Fanciulli, F. Orzi, M. Giovannelli, G. Sette (Rome, Italy)

12:30pm-2:00pm: Changes in mood and behavior following DBS – Measurement by self-reported questionaires

I. Galazky, S. Hubich, T. Zähle, J. Voges (Magdeburg, Germany)

12:30pm-2:00pm: Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension (nOH)

C. Francois, K. McLeod, A. Duhig, A. Ogbonnaya, A. Quillen, J. Cannon, B. Padilla, C.A. Shibao, I. Biaggioni (Deerfield, IL, USA)

12:30pm-2:00pm: Characterization of burning mouth syndrome in patients with Parkinson’s disease

P.J. Blanchet, D. Bonenfant, P.H. Rompré, N. Rei, N. Jodoin, V.L. Soland, V. Rey, C. Brefel-Courbon, F. Ory-Magne, O. Rascol (Montreal, QC, Canada)

12:30pm-2:00pm: Characterization of sleep disturbances in a prospective population-based cohort to investigate Parkinson’s disease

S. Tunc, J. Hampf, E.J. Vollstedt, K. Hückelheim, E. Warrlich, C. Kritzinger, C. Bibergeil, J. Graf, C. Klein, M. Kasten (Lübeck, Germany)

12:30pm-2:00pm: Chin EMG variance and dream-enactment behavior during polysomnography in Parkinson’s disease

Y. Shen, K.P. Xiong, C.J. Mao, C.F. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: Chronic acquired hepatocerebral degeneration: Efficacy of liver transplatation in 10 patients

J. Martins, J. Alves, S. Cavaco, J. Gandara, S. Ferreira, H. Pessegueiro, M. Magalhães (Porto, Portugal)

12:30pm-2:00pm: Chronic directional subthalamic nucleus deep brain stimulation in Parkinson’s disease – A pilot study

P. Reker, T.A. Dembek, A. Gierich, J. Wirths, H.S. Dafsari, J. Roediger, M.T. Barbe, L. Timmermann, V. Visser-Vandewalle (Cologne, Germany)

12:30pm-2:00pm: Chronic levodopa treatment accelerates the disorders of circadian rhythm in 6-OHDA induced Parkinson’s disease model

S. Li, Y. Wang, W. Liu, D. Lv, C. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: Clinical and biological predictors of excessive daytime sleepiness in early Parkinson’s disease

T. Simuni, J. Long, C. Caspell-Garcia, C.S. Coffey, W. Oertel, S. Lasch, K. Marek, On behalf of the PPMI Sleep Working Group (Chicago, IL, USA)

12:30pm-2:00pm: Clinical and instrumental features of multiple system atrophy with laryngeal stridor

M. Todisco, R. Zangaglia, B. Minafra, M. Terzaghi, E. Alfonsi, P. Vitali, C. Pacchetti (Pavia, Italy)

12:30pm-2:00pm: Clinical and polysomnographic features correlates to sleep-disordered breathing in multiple system atrophy

B. Cao, Q. Wei, R. Ou, B. Zhao, T. Hu, H. Shang (Chengdu, People's Republic of China)

12:30pm-2:00pm: Clinical characteristics of Parkinson’s disease and essential tremor patients undergoing deep brain stimulation surgery: Five-year data from Columbia University Medical Center (2009 – 2014)

M. Kestenbaum, D. Robakis, B. Ford, R.N. Alcalay, E.D. Louis (Tel Aviv, Israel)

12:30pm-2:00pm: Clinical correlates of depression and anxiety in patients with Parkinson’s disease

H.D. Hambardzumyan, H.M. Manvelyan (Yerevan, Armenia)

12:30pm-2:00pm: Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson’s disease: A prospective study

T. Kitta, I. Yabe, Y. Kanno, H. Chiba, K. Moriya, I. Takahashi, M. Matsushima, H. Sasaki, N. Shinohara (Sapporo, Japan)

12:30pm-2:00pm: Clinical features of Parkinson’s disease patients developing stridor with acute respiratory failure

J. Tashiro, S. Hamada, H. Soma, M. Nonaka, S. Honma, K. Hamada, A. Takei, F. Moriwaka, K. Tashiro (Sapporo, Japan)

12:30pm-2:00pm: Clinical outcome of constant current deep brain stimulation in patients with medication-refractory essential tremor

A. Rezaei Haddad, K. Ashkan (Coventry, United Kingdom)

12:30pm-2:00pm: Clinical outcome of subthalamic deep brain stimulation in Parkinson’s disease – The Helsinki experience

M. Koivu, A. Huotarinen, F. Scheperjans, R. Kivisaari, E. Pekkonen (Helsinki, Finland)

12:30pm-2:00pm: Clinical phenotype (motor and neuropsychological presentation) and neuroimaging in Sardinian patients affected by atypical parkinsonisms, carriers of 20-22 repeats of C9ORF72 hexanucleotide expansion

G. Orofino, A. Cannas, P. Solla, M.M. Mascia, M.R. Murru, G. Borghero (Monserrato, Italy)

12:30pm-2:00pm: Clinical predictors of progressive supranuclear palsy (PSP) pathology in PSP syndrome

I. Aiba, Y. Saito, Y. Yokokawa, M. Kenjo, T. Katayama, R. Hashimoto, S. Sakakibara, A. Inukai, M. Mimuro, Y. Iwasaki, M. Yoshida (Nagoya, Japan)

12:30pm-2:00pm: Clinical profile and outcome of hospitalized patients with Parkinson’s disease

P. Chatterjee, K. Chatterjee, R. Banerjee, S. Choudhury, B. Mondal, M. Ummekulsum, S.S. Jha, S. Chatterjee, S.S. Anand, H. Kumar (Kolkata, India)

12:30pm-2:00pm: Clinical profile of Parkinson’s disease at the neurology department of Point G Teaching Hospital

T. Coulibaly, A.S. Sissoko, T. Coulibaly, L. Guida, K. Mamadou, G.C. Oumar (Bamako, Mali)

12:30pm-2:00pm: Clinicopathological characteristics of co-existant Parkinson’s disease and corticobasal degeneration: A case study

K. Andruska, C. Kilbane, E. Plowey, K. Poston (Stanford, CA, USA)

12:30pm-2:00pm: Clusterin CSF levels in differential diagnosis of neurodegenerative disorders

M. Frolova, H. Prikrylova Vranova, E. Henykova, J. Mares, M. Kaiserova, K. Mensikova, M. Vastik, P. Hlustik, J. Zapletalova, M. Strnad, D. Stejskal, P. Kanovsky (Olomouc, Czech Republic)

12:30pm-2:00pm: Cognition, vision and visuo-cognition in gait in Parkinson’s disease

S. Stuart, B. Galna, S. Lord, L. Rochester (Newcastle upon Tyne, United Kingdom)

12:30pm-2:00pm: Cognitive change following deep brain stimulation in patients with movement disorders

J. Khan, Z. Quamhawi, Y.F. Tai, P.G. Bain, D. Nandi, S. Gunning, N. Pavese (London, United Kingdom)

12:30pm-2:00pm: Cognitive decline in Parkinson’s disease: Impact on quality of life of caregivers

R.A. Lawson, A.J. Yarnall, G.W. Duncan, F. Johnston, T.K. Khoo, D. Collerton, J.P. Taylor, D.J. Burn (Newcastle upon Tyne, United Kingdom)

12:30pm-2:00pm: Cognitive functioning in Parkinson’s disease and Parkinson plus syndrome

S. Mina, V.K. Verma, K.S. Anand (New Delhi, India)

12:30pm-2:00pm: Cognitive impairment in Parkinson’s disease

B. Kurbanov (Tashkent, Uzbekistan)

12:30pm-2:00pm: Cognitive impairment in patients with progressive supranuclear palsy and multiple system atrophy

M. Vecerkova, M. Kaiserova, L. Hvizdosova, S. Kurcova, P. Kanovsky (Olomouc, Czech Republic)

12:30pm-2:00pm: Cognitive outcome in the patients with Parkinson’s disease one year after subthalamic implants in Taiwan

Y.F. Chen, C.C. Chang, W.F. Chen, F.Y. Shih, M.Y. Lan, T.K. Lin, Y.F. Chen, Y.Y. Chang (Kaohsiung, Taiwan)

12:30pm-2:00pm: Cognitive profile in the Parkinsonian variant of multiple system atrophy: Findings from a Tunisian cohort

A. Nasri, M. Ben Djebara, I. Kacem, Y. Sidhom, A. Gargouri, R. Gouider (Tunis, Tunisia)

12:30pm-2:00pm: Comorbid conditions associated with Parkinson´s disease: A longitudinal study

D. Santos García, E. Suarez Castro, I. Expósito, T. de Deus, C. Tuñas, D. Núñez Arias, Á. Aneiros, M. López Fernández, J. Naveiro, J. Abella, M.A. Llaneza, V. Vilas, M. Macías (Ferrol, Spain)

12:30pm-2:00pm: Comorbidity and Parkinson’s disease phenotype, dopaminergic function and CSF biomarkers

T. Yousaf, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

12:30pm-2:00pm: Comparative analysis of freezing of gait in distinct parkinsonism types by diffusion tensor imagining and cognitive profiles

H. Onder, E.S. Topcuoglu, A.C. Has, K.K. Oguz, B. Elibol (Ankara, Turkey)

12:30pm-2:00pm: Comparative gait analysis of patients with vascular parkinsonism and idiopathic Parkinson’s disease

B. Mondal, S. Choudhury, M.U. Kulsum, P. Chatterjee, S. Chatterjee, K. Chatterjee, R. Banerjee, S.S. Jha, S.S. Anand, H. Kumar (Kolkata, India)

12:30pm-2:00pm: Comparing psychosocial risk factors in patients with functional movement disorders and patients with psychogenic non-epileptic seizures

C.W. Maurer, G.M. Capitan, G. Limachia, K. LaFaver, E. Considine, A. Curran, W.C. LaFrance, M. Hallett (Bethesda, MD, USA)

12:30pm-2:00pm: Comparing the characteristics of patients with Parkinson’s disease speech with and without deep brain stimulation

M.R. Olchik, A.L. Bressanelli, M. Presotto, A.F.S. Schuh, C.R.M. Rieder (Porto Alegre, Brazil)

12:30pm-2:00pm: Comparison of clinically derived and model based programming parameters of subthalamic nucleus stimulation in Parkinson’s disease

R. Reese, M.M. Reich, R. Nilunsing, W. Pollet, J. Volkmann (Würzburg, Germany)

12:30pm-2:00pm: Comparison of cognitive and neuropsychological manifestations in patients with progressive supranuclear palsy (Psp) and Parkinson’s disease

M.U. Kulsum, S.S. Anand, S. Chatterjee, P. Chatterjee, B. Mondal, S. Choudhury, K. Chatterjee, R. Banerjee, S.S. Jha, H. Kumar (Kolkata, India)

12:30pm-2:00pm: Comparison of effect of variable deep brain stimulation (DBS) frequencies on gait and balance in Parkinson’s disease (PD) patients with either bilateral GPi or STN stimulators employing wearable wireless sensors

A. Deep, A. Lieberman, R. Dhall, T. Lockhart, C. Frames, S. Shafer, N. Tateuchi, E. Simpson, M. McCauley, N. Krishnamurthi (Phoenix, AZ, USA)

12:30pm-2:00pm: Comparison of four DBS lead designs under voltage and current operating modes based on patient specific simulations

F. Alonso, N. Göransson, P. Zsgimond, K. Wårdell (Linköping, Sweden)

12:30pm-2:00pm: Composite autonomic symptom scale-31 (COMPASS-31) is useful for evaluation of autonomic dysfunction in patients with parkinsonism

Y. Kim, J.M. Seok, H.J. Kim, J. Youn, B.J. Kim, J.W. Cho (Seoul, Korea)

12:30pm-2:00pm: Comprehensive motor and non-motor staging system in Parkinson’s disease: Results from a global cross-sectional study

C. Rodriguez-Blazquez, A. Rizos, K.R. Chaudhuri, P. Martinez-Martin, NILS, EUROPAR and MDS Non-Motor PD Study Groups (Madrid, Spain)

12:30pm-2:00pm: Constant-current stimulation in Parkinson’s disease patients

P. Amami, M. Mascia, L. Romito, A. Albanese (Rozzano, Italy)

12:30pm-2:00pm: Consumption of Yerba Mate (Ilex Paraguariensis) in Parkinson’s disease patients from Uruguay

I. Amorín, A. Lescano, N. Ramírez, V. Raggio, R. Buzó (Montevideo, Uruguay)

12:30pm-2:00pm: Correlations among motor, cognitive, and neuropsychiatric symptoms in Parkinson’s disease without dementia

M. Gang, Y. Nishio, T. Baba, A. Takeda, E. Mori (Sendai, Japan)

12:30pm-2:00pm: Cortical and subcortical contribution in the production of reaching movements in Parkinson’s disease

A. Canessa, N.G. Pozzi, G. Arnulfo, J. Brumberg, F. Steigerwald, M.F. Ghilardi, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)

12:30pm-2:00pm: Could smell test differ from scans without evidence of dopaminergic deficit and Parkinson’s disease?

S.J. Kang, J.Y. Ahn, H.T. Kim (Seoul, Korea)

12:30pm-2:00pm: Could tonic chin electromyogram density be a potential marker for differentiating atypical Parkinsonian syndromes from Parkinson’s disease among alpha-synucleinopathies?

Y. Wang, K.P. Xiong, Y. Shen, P.C. He, C.J. Mao, J. Li, J.Y. Huang, C.F. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: Creative thinking and parkinsonism: Preliminary clinical data on the role of frontal area

M. Canesi, M. Rusconi, E. Cereda, F. Moroni, A. Ranghetti, V. Cereda, G. Pezzoli (Milano, Italy)

12:30pm-2:00pm: Dat-SPECT in multiple system atrophy (MSA)

I. Toyoshima, T. Hatakeyama, Y. Takeda, K. Obara, M. Kobsysdhi, C. Wada (Yurihonjo, Japan)

12:30pm-2:00pm: DBS of the STN in 44 patients with Parkinson’s disease – Radiological and clinical outcome

R.C. Nickl, P. Fricke, S. Johannes, R.I. Ernestus, F. Steigerwald, M.M. Reich, V. Sturm, J. Volkmann, C. Matthies (Würzburg, Germany)

12:30pm-2:00pm: DBS programming requirements and longevity

M. Tagliati, E. Karst (Los Angeles, CA, USA)

12:30pm-2:00pm: DBS related on-state freezing of gait – A case series

Y.C. Tai, E. Everingham, D. Tsui, V. Fung, N. Mahant (Kaohsiung, Taiwan)

12:30pm-2:00pm: DBS targeting: Validation of 3T MR image guided targeting using post-mortem 17T MR microscopy

J.D. Hilliard, T. Morishita, C.H. Lee, S.J. Blackband, M.S. Okun, K.D. Foote (Gainesville, FL, USA)

12:30pm-2:00pm: Deceleration capacity of heart rate indicates autonomic dysfunction in patients with PSP

V. Ries, N. Mix, D. Vadasz, A. Bauer, W.H. Oertel (Marburg, Germany)

12:30pm-2:00pm: Deep brain stimulation effect on the quality of life of individuals with Parkinson’s disease

A. Ayres, M. Ghisi, A.M. Freiry, B.S.F. Oliveira, A.F.S. Schuch, C.R.M. Rieder, M.R. Olchik (Porto Alegre, Brazil)

12:30pm-2:00pm: Deep brain stimulation in a Parkinsonian patient with sever psychiatric complication

T. Ichikawa, Y. Hashimoto, T. Obuchi, K. Kobayashi, H. Oshima (Ageo, Japan)

12:30pm-2:00pm: Deep brain stimulation in early stage Parkinson’s disease: Is it disease modifying?

M.L. Hacker, M. Turchan, J. Tonascia, P.E. Konrad, T.L. Davis, J.S. Neimat, F.T. Phibbs, A.L. Sternberg, D.M. Shade, L.T. Drye, D. Charles (Nashville, TN, USA)

12:30pm-2:00pm: Deep brain stimulation in the STN of a Parkinsonian rat model overexpressing human A53T α-synuclein in the substantia nigra – A proof of principle

T. Musacchio, M. Rebenstorff, F. Fluri, C. Kleinschnitz, J.M. Brotchie, J. Volkmann, J.B. Koprich, C.W. Ip (Würzburg, Germany)

12:30pm-2:00pm: Deep brain stimulation in the treatment of cerebellar tremor in young patients

A. Landi, A. Trezza, D. Pirillo, M. Pilleri, A. Antonini, E.P. Sganzerla (Monza, Italy)

12:30pm-2:00pm: Deep brain stimulation may lead to dramatic worsening of slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature

C. Laurencin, W. Meissner, C. Tranchant, T. Witjas, F. Viallet, P. Damier, T. Danaila, J.L. Houeto, A. Eusebio, S. Thobois (Lyon, France)

12:30pm-2:00pm: Deep brain stimulation of the globus pallidus interna improves performance in complex oculomotor tasks

C.A. Antoniades, P. Rebelo, C. Kennard, T. Aziz, A.L. Green, J.J. FitzGerald (Oxford, United Kingdom)

12:30pm-2:00pm: Deep brain stimulation outcomes for dystonia in adult and pediatric patients at Gillette Children’s Specialty Healthcare

T. Feyma, S. Roiko, M. Gormley, A. Laine, J. Gettings, P. Graupman (Saint Paul, MN, USA)

12:30pm-2:00pm: Defining the pathology underlying cortico-basal syndrome: A European study

R.C. Lamb, M.C. Darvell, J.D.S. Woodside, J.D. Rohrer, A.J. Lees, H.R. Morris (London, United Kingdom)

12:30pm-2:00pm: Dementia in adult type 2 diabetes patients – An analysis from the multicenter German/Austrian diabetes patient follow-up registry DPV

N. Prinz, L. Wang, J. Stingl, M.D. Denkinger, P. Fasching, P.M. Jehle, S. Merger, S. Mühldorfer, A. Schuler, A. Zeyfang, M. Sharma, R.W. Holl (Ulm, Germany)

12:30pm-2:00pm: Dementia in Parkinson’s disease is associated with increased diffusivity in amygdala and external capsule

A. Umemura, T. Oeda, K. Yamamoto, M. Kohsaka, S. Tomita, K. Park, H. Sugiyama, H. Sawada (Kyoto, Japan)

12:30pm-2:00pm: Demographic feature and clinical characteristic of patients with Parkinson’s disease in Isfahan, Iran

M. Salari (Isfahan, Islamic Republic of Iran)

12:30pm-2:00pm: Depression and anxiety in Parkinson’s disease with rapid eye movement sleep behavior disorder

Y. Saitoh, Y. Mukai, T. Sakamoto, M. Murata (Tokyo, Japan)

12:30pm-2:00pm: Depression, anxiety, and apathy in Parkinson’s disease: Insights from neuroimaging studies

M.C. Wen, L.L. Chan, L.C.S. Tan, E.K. Tan (Singapore, Singapore)

12:30pm-2:00pm: Detrusor overactivity is associated with frontal dysfunction in patients with Parkinson’s disease?

T. Uchiyama, T. Yamamoto, K. Suzuki, T. Kadowaki, Y. Watanabe, K. Hashimoto, T. Shingo, K. Kaga, C. Shibata-Yamaguchi, T. Yamanishi, R. Sakakibara, S. Kuwabara, K. Hirata (Tochigi, Japan)

12:30pm-2:00pm: Developing palliative care clinics for patients with advanced Parkinson’s disease: Practical approaches, challenges, and experiences

C.L. Dietiker, N.B. Galifianakis, M. Katz, S.L. Heath (San Francisco, CA, USA)

12:30pm-2:00pm: Development and external validation of a prognostic model of mortality in Parkinson’s disease

A.D. Macleod, I. Dalen, O.B. Tysnes, J.P. Larsen, C.E. Counsell (Aberdeen, United Kingdom)

12:30pm-2:00pm: Diagnostic value of cardiac 123I-MIBG SPECT and CT co-registration in PD and MSA-P

C. Kaindlstorfer, F. Krismer, A. Fanciulli, S. Eschlböck, M. Nocker, S. Bösch, K. Mair, C. Scherfler, A. Djamshidian-Tehrani, C. Uprimny, E. Donnemiller, I. Virgolini, K. Seppi, W. Poewe, G. Wenning (Innsbruck, Austria)

12:30pm-2:00pm: Diagnostic value of combined acute levodopa challenge and olfactory testing to predict Parkinson’s disease diagnosis

M. Rossi, C. Terroba Chambi, A. Bril, P. Millar Vernetti, D. Cerquetti, A. Cammarota, M. Merello (Buenos Aires, Argentina)

12:30pm-2:00pm: Difference between physiologically defined subthalamic nucleus target and final lead placement: Influence in clinical outcome

A. Medina, D. Cerquetti, M. Merello (Buenos Aires, Argentina)

12:30pm-2:00pm: Direct assessment of psychosocial measures using eye tracking technology in advanced ALS – Can preserved autonomy and psychological wellbeing modify disease course?

K. Linse, W. Rüger, M. Joos, H. Schmitz-Peiffer, A. Storch, A. Hermann (Dresden, Germany)

12:30pm-2:00pm: Disease progression and clinical characteristics of Parkinson’s disease patients with type 1 diabetes – An analysis on 18,162 patients from the DPV registry

L. Wang, N. Prinz, A. Marcus, K. Laubner, A. Zimmerman, S. Zlamal-Fortunat, M. Sharma, R. Holl (Tübingen, Germany)

12:30pm-2:00pm: Disease stage classification of the cerebellar variant of multiple system atrophy based on voxel-based morphometry

T. Taguchi, K. Nanri, Y. Ueta, H. Terashi, H. Aizawa (Tokyo, Japan)

12:30pm-2:00pm: Distribution of oscillatory activities in MRI confirmed subthalamic nucleus subregions

M. Beudel, A. Oswal, A. Jha, T. Foltynie, L. Zrinzo, M. Hariz, P. Limousin, S. Derrey, H. Akram, L. Vladimir, P. Brown (Groningen, Netherlands)

12:30pm-2:00pm: Do subjective ratings of the Parkinson’s disease sleep scale-2 converge with results from polysomnography in early Parkinson’s disease? – A report from the DeNoPa cohort

F. Sixel-Döring, J. Zimmermann, M.L. Muntean, B. Mollenhauer, C. Trenkwalder (Kassel, Germany)

12:30pm-2:00pm: Do-not-resuscitate utilization in inpatient Parkinson’s disease in the United States

A. Mahajan, A. Patel, G. Nadkarni, C. Sidiropoulos (Detroit, MI, USA)

12:30pm-2:00pm: Does body mass index influence outcome of deep brain stimulation in Parkinson’s patients?

H. Abboud, G. Genc, D. Reyes, N.R. Thompson, R. Cerejo, K. Wilson, A. Ahmed, M. Gostkowski, A. Machado, H.H. Fernandez (Cleveland, OH, USA)

12:30pm-2:00pm: Does GPi-DBS help non motor symptoms in cervical dystonia patients? A retrospective study of 17 patients

L. Lowry, B. Hammersley, M. Bonello, P. Byrne, N.A. Fletcher, J.O. Farah, P.R. Eldridge, S.H. Alusi (Liverpool, United Kingdom)

12:30pm-2:00pm: Does link between fatigue syndrome and camptocormia in patients with Parkinson’s disease exist?

V. Datieva, O. Levin (Moscow, Russia)

12:30pm-2:00pm: Dopamine transporter, depression and anxiety differences between tremor-predominant and non-tremulous PD are already evident within 2 years of PD diagnosis

Q. Hu, F. Zhou, C.P. Jedynak, L.S. Rosenthal, Z. Mari, B.M. Jedynak (Baltimore, MD, USA)

12:30pm-2:00pm: Dophaminergic therapy and its influence on the olfactory function of patients with Parkinson’s disease

O. Izhboldina, I. Zhukova, N. Zhukova, V. Alifirova, A. Latypova, M. Nikitina, Y. Mironova (Tomsk, Russia)

12:30pm-2:00pm: Dorsal simultanagnosia as a cortical sign in the tauopathy spectrum

B. Bergmans, O. Deryck, R. Bruffaerts (Brugge, Belgium)

12:30pm-2:00pm: Double-blind, placebo-controlled trial of a fermented milk containing multiple probiotic strains and prebiotic fiber for constipation associated with Parkinson’s disease

E. Cereda, C. Pacchetti, C. Bolliri, E. Cassani, L. Iorio, C. Pusani, G. Pinelli, G. Privitera, I. Cesari, S.A. Faierman, R. Caccialanza, G. Pezzoli, M. Barichella (Pavia, Italy)

12:30pm-2:00pm: Drug induced parkinsonism: Role of functional imaging and follow up

A.S. Shetty, H.J. Shah, V.R. Lele, P.M. Wadia (Mumbai, India)

12:30pm-2:00pm: DTI tractographic correlates of weight gain in Parkinson’s disease patients after STN DBS

O.F. Ahmad, L. Huang, N. Vanegas-Arroyave, K. Zaghloul, S.G. Horovitz, C. Lungu (Bethesda, MD, USA)

12:30pm-2:00pm: Dyadic decision making & decisional satisfaction in advanced Parkinson’s disease

B. Habermann, J.Y. Shin (Newark, DE, USA)

12:30pm-2:00pm: Dynamics in statin use, low density lipoprotein cholesterol levels and Parkinson’s disease. A population-based cohort study using big-data

V. Rozani, N. Giladi, B. Elad, T. Gurevich, J. Tsamir, B. Hemo, C. Peretz (Petach Tikva, Israel)

12:30pm-2:00pm: Dystonia in a medieval scribe: Analysis of Bernard Blancard’s handwriting over four decades

D.E. Thorpe, N. Melson, J.E. Alty (York, United Kingdom)

12:30pm-2:00pm: E-counselling to movement disorder callers in Africa

M. Busgopaul (Nouvelle France, Mauritius)

12:30pm-2:00pm: Early stridor onset predicts survival in multiple system atrophy

G. Giannini, G. Calandra-Buonaura, F. Mastrolilli, M. Righini, M.L. Bacchi-Reggiani, P. Guaraldi, F. Provini, P. Cortelli (Bologna, Italy)

12:30pm-2:00pm: EBM review on the diagnostic work-up of multiple system atrophy

I. Stankovic, A. Antonini, A. Berardelli, C. Colosimo, A. Fanciulli, S. Fox, B. Frauscher, H. Kaufmann, V.S. Kostic, F. Krismer, P. Low, W. Meissner, M.T. Pellecchia, W. Poewe, K. Seppi, S. Tsui, H. Watanabe, G.K. Wenning, On behalf of the MODIMSA EBM Working Group (Belgrade, Serbia)

12:30pm-2:00pm: Effect of bilateral subthalamic nuclei deep brain stimulation on impulse control disorders in PD

R. Borgohain, P.K. Pesala, R.K. Mridula, A.K. Puligopu, V.V.P. Kagita, S.A. Jabeen, M.A. Kanikannan (Hyderabad, India)

12:30pm-2:00pm: Effect of frequency modulation on freezing of gait in PD patients after bilateral STN DBS

R.M. Kandadai, V.V.P. Kagita, S.A. Jabeen, A.K. Puligopu, M.A. Kanikannan, R. Borgohain (Hyderabad, India)

12:30pm-2:00pm: Effect of STN-DBS on impulse control disorder and affective behavioral complications of Parkinson’s disease: A 1-year longitudinal study

S.M. Omarova, N.V. Fedorova, E.V. Bril, A.A. Tomskiy, A.A. Gamaleya (Moscow, Russia)

12:30pm-2:00pm: Effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson’s disease: 7- year follow-up

G. Ehm, H.J. Kim, B.S. Jeon, D.G. Kim, S.H. Paek (Goyang, Korea)

12:30pm-2:00pm: Effectiveness and micro-electrodes findings of deep brain stimulation of the STN via a parietal approach in post-infectious previously implanted Parkinson´s patients

W.O. Contreras Lopez, L. Batista, A. Azevedo, M.J. Teixeira, E.T. Fonoff (São Paulo, Brazil)

12:30pm-2:00pm: Effectiveness of bilateral pallidal deep brain stimulation in a patient with dystonia associated to neurodegenerative ataxia: Follow-up to 18 months

P.A. Millan, J.M. Cardenas (Cali, Colombia)

12:30pm-2:00pm: Effectiveness of occupational therapy multi-domain group therapy program for Parkinson’s disease

R.K.M. Wong, D.S.W. Tsang, C.K.Y. Lau, A.Y.Y. Chan, D.T.M. Chan, X. Zhu, W. Poon, V.C.T. Mok (Hong Kong, Hong Kong)

12:30pm-2:00pm: Effects of antidepressants on gait parameters in Parkinson’s disease

D. Martinez-Ramirez, J.C. Giugni, W. Deeb, M.S. Okun, C.J. Hass (Gainesville, FL, USA)

12:30pm-2:00pm: Effects of deep brain stimulation in the nucleus entopeduncularis on neuronal network activity after apomorphine-induced deficient sensorimotor gating in a rat model

K. Schwabe, L. Götz, J.K. Krauss, M. Alam (Hannover, Germany)

12:30pm-2:00pm: Effects of subthalamic deep brain stimulation in motor and nonmotor function in Parkinson’s disease patients with parkin mutation

L.M. Oliveira, R.G. Cury, H.F. Chien, J.G. Santos, M.G. Ghilardi, R.B. Machado, E.T. Fonoff, B.R. Egberto (São Paulo, Brazil)

12:30pm-2:00pm: Efficacy of deep brain stimulation (DBS) patient education and post operative support: A summary of 3 months monitoring of unscheduled patient phone requests. An Australian private neurology clinic experience

K.A. O'Maley, P. Poortvliet, L.J. Cooke, P.A. Silburn (Brisbane, Australia)

12:30pm-2:00pm: Efficacy of the bilateral subthalamic stimulation in Parkinson’s disease, results from the Neuromodulation Centre in Budapest

A. Kelemen, L. Eröss, D. Albert, I. Rózsa, E. Csibri, L. Entz, D. Fabó, L. Halász, G. Rudas, P. Barsi, P. Golopencza, G. Tamás (Budapest, Hungary)

12:30pm-2:00pm: Efficiency of intraoperative microelectrode recording in patients with deep brain stimulation of the subthalamic nucleus. Three-year comparative research

N. Gubareva, E. Bril, A. Tomskiy, N. Fedorova, S. Asriyants (Moscow, Russia)

12:30pm-2:00pm: Electric stimulation of the nucleus subthalamicus is able to modulate prepulse inhibition. A pilot study in Parkinson´s disease

J. Schuster, I. Galazky, M. Kühne, S. Specht, S. Nullmeier, H.J. Heinze, A. Kupsch, T. Zaehle, J. Voges, P. Panther (Magdeburg, Germany)

12:30pm-2:00pm: Electrophysiological activity of anatomically identified STN subterritories in Parkinson’s disease

N.G. Pozzi, G. Arnulfo, F. Steigerwald, A. Canessa, R. Nickl, C. Matthies, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)

12:30pm-2:00pm: Emotion processing in Parkinson’s disease – Possible link between inability to decode complex emotional stimuli and impairment of executive functions

E. Klimiec, K. Kowalska, P. Pasinska, A. Szyper, T. Dziedzic, A. Slowik, A. Klimkowicz-Mrowiec (Krakow, Poland)

12:30pm-2:00pm: Emotional valence and arousal ratings from rewarding and fearful stimuli are not influenced by levodopa in Parkinson’s disease

T. Serranova, T. Sieger, P. Dušek, E. Ruzicka, R. Jech (Prague, Czech Republic)

12:30pm-2:00pm: Employing intraoperative microelectrode recordings during "asleep" deep brain stimulation surgery of the globus pallidus internus in Parkinson’s disease

J.E. Quintero, N.S. Timoney, J.H. Smith, F. McCarron, G.A. Gerhardt, C.G. van Horne (Lexington, KY, USA)

12:30pm-2:00pm: Ethnic differences in rates of Parkinson’s in New Zealand: A nation-wide prevalence and incidence study

T.L. Pitcher, D.J. Myall, M.R. MacAskill, J.F. Pearson, C.J. Lacey, J.C. Dalrymple-Alford, T.J. Anderson (Christchurch, New Zealand)

12:30pm-2:00pm: Evaluation of stigmatization and quality of life before and after botulinum toxin treatment in hemifacial spasm

B. Yuksel, F. Genc, A. Yaman, P. Dogan Ak, E. Ozaydin Goksu, A. Aybar, Y. Bicer Gomceli (Antalya, Turkey)

12:30pm-2:00pm: Evaluation of the [ 99mTc] – TRODAT- 1 SPECT in the diagnosis of Parkinson’s disease and other movement disorders

G. Fabiani, R. Martins Filho, H.A.G. Teive (Campina Grande do Sul, Brazil)

12:30pm-2:00pm: Evaluation of the accuracy of stereotactic DBS electrode implantation by post-operative image fusion

P. Fricke, S. Johannes, R. Nickl, R.I. Ernestus, F. Steigerwald, J. Volkmann, C. Matthies (Würzburg, Germany)

12:30pm-2:00pm: Evolution of mild Parkinsonian signs in a longitudinal population-based cohort

J. Hampf, S. Tunc, J. Graf, K. Hückelheim, E.J. Vollstedt, B. Staemmler, C. Klein, M. Kasten (Luebeck, Germany)

12:30pm-2:00pm: Exercise induced analgesia is present in people with Parkinson’s disease

N.E. Allen, N. Moloney, L.M. Hassett, C.G. Canning, S.J.G. Lewis, K. Cruz-Mavignier, B.K. Barry (Lidcombe, Australia)

12:30pm-2:00pm: Exploring association of GBA variants with pre-diagnostic features of PD in the PREDICT-PD cohort: A nested case-control study

L. R'Bibo, N.E. Mencacci, A. Schrag, J.P. Bestwick, L. Peress, J. Masters, G. Giovannoni, A.J. Lees, J. Hardy, N.W. Wood, A.J. Noyce (London, United Kingdom)

12:30pm-2:00pm: Face and color recognition after subthalamic nucleus stimulation in Parkinson’s disease

A. Gündüz, S. Yagci, S. Aydin, B.Ç. Poyraz, G. Genç, S. Oguz, H. Apaydin, G. Kiziltan, H. Hanagasi, M. Hanci, S. Ertan (Istanbul, Turkey)

12:30pm-2:00pm: Falls in Parkinson’s disease : Effects on health related quality of life

T.H. Farombi, J. Yaria, M.O. Owolabi, A. Ogunniyi (Ibadan, Nigeria)

12:30pm-2:00pm: Feasibility and preliminary outcomes of an interdisciplinary home visit program for patients with advanced Parkinson’s disease

J.E. Fleisher, M.M. Sweeney, S. Oyler, A.C. Lemen, A. Fazl, G. Dacpano, R.M. Gilbert, A. Di Rocco, J. Chodosh (New York, NY, USA)

12:30pm-2:00pm: Finger tapping distance in idiopathic normal pressure hydrocephalus changes in parallel with frontal lobe function

N. Nishida, Y. Sano, A. Kandori, H. Toda, S. Matsumoto, K. Iwasaki, M. Ishikawa (Osaka, Japan)

12:30pm-2:00pm: First documented case of burning mouth syndrome (BMS) responsive to levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson’s disease (PD)

X.X. Yu, H. Fernandez (Cleveland, OH, USA)

12:30pm-2:00pm: Focusing precision and lesion size in cerebello-thalamo-tractotomy by MR imaging-guided high intensity focused ultrasound (MRgFUS)

R.G. Bauer, E. Martin, S. Hägele-Link, K. Georg, W.A. Nikolas, L. Anita, J. Alfred, B. Amanda, S.R. Sebastian, W. Beat (St. Gallen, Switzerland)

12:30pm-2:00pm: Frequency and characteristics of diplopia in non-demented patients with Parkinson’s disease

K.A. Schindlbeck, W. Naumann, D.J. Friedrich, S. Schönfeld, A. Maier, F. Klostermann, F. Marzinzik (Berlin, Germany)

12:30pm-2:00pm: Frequency and factors associated with neuropathic pain in patients with Parkinson’s disease

J.F. Pascacio-Astudillo, A.L. Bazàn-Rodrìguez, M. Rodrìguez-Violante, A. Cervantes-Arriaga (Mèxico City, Mexico)

12:30pm-2:00pm: Frequency of non-motor symptoms in Iranian patients with Parkinson’s disease

M. Salari, O. Mirmosayyeb (Isfahan, Islamic Republic of Iran)

12:30pm-2:00pm: Functional motor outcomes after globus pallidus internus deep brain stimulation in Huntington´s disease – A case report

T.T.C. Capato, R.G. Cury, R. Gimaães, E.T. Fonoff, M.S. Haddad (São Paulo, Brazil)

12:30pm-2:00pm: Fundamental differences in Parkinsonian rat limbic regions contribute to anxious behavior and diminished responsiveness to diazepam

K.A. O'Connor, P.J. Feustel, A. Ramirez-Zamora, E. Molho, J.G. Pilitsis, D.S. Shin (Albany, NY, USA)

12:30pm-2:00pm: Gastrointestinal non-motor symptoms in PD: Correlation between objective markers and subjective symptoms

K. Knudsen, T. Fedorova, K. Østergaard, K. Krogh, P. Borghammer (Aarhus C., Denmark)

12:30pm-2:00pm: Gender differences in heart rate variability among patients affected by Parkinson’s disease

P. Solla, E. Erriu, C. Cadeddu, L. Cugusi, G. Costantini, S. Nieddu, M.R. Aresu, R. Farris, M. Meloni, D. Fonti, G. Mercuro, F. Marrosu (Monserrato (Cagliari), Italy)

12:30pm-2:00pm: Gender effect on non-motor symptoms in Parkinson’s disease: Are men more at risk for most of them?

R. Vasta, A. Nicoletti, G. Mostile, G. Nicoletti, G. Arabia, G. Iliceto, P. Lamberti, R. Marconi, L. Morgante, P. Barone, A. Quattrone, M. Zappia (Catania, Italy)

12:30pm-2:00pm: Generation and characterization of iPSC-derived nigral dopaminergic and pyramidal glutamatergic neurons from patients affected by multiple system atrophy

G. Monzio Compagnoni, E. Frattini, S. Salani, F. Fortunato, N. Bresolin, S. Corti, G.P. Comi, A. Di Fonzo (Milan, Italy)

12:30pm-2:00pm: Genetic risk of Parkinson’s disease in the general population

S. Darweesh, V. Verlinden, H. Adams, A. Uitterlinden, A. Hofman, B. Stricker, C. van Duijn, P. Koudstaal, M.A. Ikram (Rotterdam, Netherlands)

12:30pm-2:00pm: Glucagon-like peptide 1 analogues for treating multiple system atrophy: A translational study

F. Bassil, M.H. Canron, A. Vital, E. Bezard, Y. Li, N.H. Greig, P.O. Fernagut, W.G. Meissner (Bordeaux, France)

12:30pm-2:00pm: Greater incidence of depressive symptoms in atypical parkinsonism: Importance of early screening

L. Almeida, B. Ahmed, R. Walz, S. De Jesus, A. Patterson, D. Martinez-Ramirez, D. Vaillancourt, D. Bowers, H. Ward, M.S. Okun, M. Armstrong, N. McFarland (Gainesville, FL, USA)

12:30pm-2:00pm: Group meetings for newly diagnosed Parkinson’s disease patients and their spouses: A preliminary experience

N. Geva, A. Hilel, Y. Manor, S. Arad, A. Ezra, N. Giladi, T. Gurevich (Tel Aviv, Israel)

12:30pm-2:00pm: Hand skin temperature and its response to cooling in clinical differentiation of multiple system atrophy and Parkinson’s disease

S. Augustis, T. Fiesel, W.H. Jost (Kaunas, Lithuania)

12:30pm-2:00pm: Head and trunk control during stair ascent and descent in people with Parkinson’s disease

Z.J. Conway, P.A. Silburn, T.D. Blackmore, M.H. Cole (Brisbane, Australia)

12:30pm-2:00pm: Headache in patients with Parkinsons disease: Pilot study results

V. Aldinio, N.S. Araoz Olivos, R. Maiola, F.E. Micheli (Buenos Aires, Argentina)

12:30pm-2:00pm: Health related quality of life in patient with Parkinson’s disease using deep brain stimulators (DBS)- A cross sectional study

F. Pullishery, A. Abraham (Malappuram, India)

12:30pm-2:00pm: Health-related quality of life of multisystem atrophy and progressive supranuclear palsy patients

M. Figura, L. Milanowski, B. Kierdaszuk, A. Bartoszek, P. Janik, Z. Jamrozik (Warsaw, Poland)

12:30pm-2:00pm: Heart rate variability and sympathetic skin response are useful in the evaluation of Parkinson’s disease, AMS, and Parkinson plus syndrome, but underutilized in daily clinical practice

R.C. Callejas Rojas, B. Estañol Vidal (Mexico, Mexico)

12:30pm-2:00pm: High frequency of mutations in the glucocerebrosidase (GBA) gene among Ashkenazi Jews with dementia with Lewy bodies

T. Shiner, A. Mirelman, M. Gana Weisz, A. Bar-Shira, E. Ash, R. Cialic, T. Gurevich, N. Bregman, A. Orr-Urtreger, N. Giladi (Tel Aviv, Israel)

12:30pm-2:00pm: High voltage stimulation of the VIM thalamus mimicking PSP in a patient with ET + PD

A.K. Patterson, L. Shahgholi, C.W. Hess (Gainesville, FL, USA)

12:30pm-2:00pm: Higher doses of dopamine agonists, impulse control disorders and history of deep brain stimulation (DBS): Risk factors for dopamine agonists withdrawal syndrome (DAWS)?

X. Garcia, S. Patel, M.E. Mohammad, X.X. Yu, K. Sutton, K. O'Donnell, H. Fernandez (Cleveland, OH, USA)

12:30pm-2:00pm: How do patients experience deep brain stimulation surgery: A prospective patient satisfaction survey

A. Fazl, M. Gillego, A. Mogliner, M.H. Pourfar (New York, NY, USA)

12:30pm-2:00pm: How long is the wait to see a Parkinson’s disease specialist in the United States?

S.G. Reich, K. Holmes, J. Martello, K. Maki (Baltimore, MD, USA)

12:30pm-2:00pm: How many and which kind of Parkinson’s disease patients need deep brain stimulation surgery? An evaluation based on clinical observation of patients with disease history of 15th year or more

H. Shibayama, T. Fukumoto, M. Tomura, K. Tokumoto, H. Yano, K. Tajima, F. Mitobe, F. Katada, S. Sato, T. Fukutake (Kamogawa City, Chiba, Japan)

12:30pm-2:00pm: Hyposmia as a predictor of non-motor symptom in patients with de novo Parkinson’s disease

M. Sanoeva, N. Mansurova, A. Prokhorova (Bukhara, Uzbekistan)

12:30pm-2:00pm: Hypothalamic alpha-synuclein pathology and its relation to non-motor symptoms and disease progression in Parkinson’s disease

E. De Pablo-Fernandez, R. Courtney, J.L. Holton, T.W. Warner (London, United Kingdom)

12:30pm-2:00pm: Hypothalamic volume loss is associated with reduced melatonin output in Parkinson’s disease

D.P. Breen, C. Nombela, R. Vuono, P.S. Jones, K. Fisher, D.J. Burn, D.J. Brooks, A.B. Reddy, J.B. Rowe, R.A. Barker (Cambridge, United Kingdom)

12:30pm-2:00pm: Identification of barriers preventing disclosure of non-motor symptoms in Parkinson’s patients to healthcare providers

C.S. Hurt, L. Rixon, K.R. Chaudhuri, R. Moss-Morris, M. Samuel, R.G. Brown (London, United Kingdom)

12:30pm-2:00pm: Identification of premotor Parkinson’s disease

K.C. Hughes, X. Gao, M.A. Schwarzschild, A. Ascherio (Boston, MA, USA)

12:30pm-2:00pm: Identification of unique metabolite signatures in post-mortem DBS human tissue using LC-HRMS

V. Vedam-Mai, S. Sternberg, M. Williams, T. Garrett, M.S. Okun (Gainesville, FL, USA)

12:30pm-2:00pm: Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review

C.M.K.E. de Cuba, A. Albanese, A. Antonini, G. Cossu, G. Deuschl, R. Eleopra, A. Galati, C.F.E. Hoffman, K. Knudsen, A. Landi, M.M.R. Lanotte, A. Marcante, A. Mosch, M. Pilleri, M.M. Reich, V. Ricchi, S. Rinaldo, L.M. Romito, F. Saba, H.E. Sacristan, P.R. Schuurman, A. Trezza, P. van den Munckhof, J. Volkmann, M. Zibetti, M.F. Contarino (Amsterdam, Netherlands)

12:30pm-2:00pm: Idiopathic Parkinson’s disease presenting with dysphagia 15 years before PD diagnosis

T. Munteanu, C. Goggins, D. Costigan, J. Molloy, T. O'Dwyer, T. Lynch (Dublin, Ireland)

12:30pm-2:00pm: Imaging correlates of hypodipsia in progressive supranuclear palsy

G. Respondek, T. Conrad, I. Riederer, T. Reeß, G. Rus, K. Koch, G. Höglinger, C. Zimmer (Munich, Germany)

12:30pm-2:00pm: Imaging-based differential diagnosis between multiple system atrophy and Parkinson’s disease

W. Sako, T. Abe, N. Murakami, Y. Miyazaki, Y. Izumi, M. Harada, R. Kaji (Tokushima, Japan)

12:30pm-2:00pm: Impact of a holistic and interdisciplinary care for patients with Parkinson’s disease – Cologne Parkinson’s network. Results of a randomized study with subanalysis

R.A. Dano, J. Schill, L. Rochhausen, K. Williamson, L. Timmermann, C. Eggers (Cologne, Germany)

12:30pm-2:00pm: Impact of autonomic dysfunction on disease progression and survival in Parkinson’s disease

E. De Pablo-Fernandez, C. Tur, T. Revesz, J.L. Holton, T.T. Warner (London, United Kingdom)

12:30pm-2:00pm: Impact of cardiovascular risk factors in the evolution and treatment of Parkinson’s disease in Mexican population

G. Parra-López, L. Bazán-Rodríguez, M. Rodríguez-Violante, A. Cervantes-Arriaga, A. Jorge-de Sarachaga, D. Cruz-Fino, J. Pascacio-Astudillo, R. Llorens-Arenas (Mexico City, Mexico)

12:30pm-2:00pm: Impact of comorbidities and compliance initiatives in management of patients with early Parkinson’s disease

A.V. Shalaeva, N.A. Dadabaeva, R.M. Allanov, M.B. Bozorboev, E. Shalaeva (Tashkent, Uzbekistan)

12:30pm-2:00pm: Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson’s patients

T.E. Tong, M.L. Ng, N. Yan (Hong Kong, Hong Kong)

12:30pm-2:00pm: Impact of neurogenic orthostatic hypotension on healthcare utilization and costs associated with falls in Parkinson’s disease

C. Francois, I. Biaggioni, C.A. Shibao, A. Ogbonnaya, H.C. Shih, E. Farrelly, A. Ziemann, A. Duhig (Deerfield, IL, USA)

12:30pm-2:00pm: Impact of pre- and postdiagnosis physical activity on the progression of Parkinson’s disease

I.F. Shih, K.C. Paul, Y. Bordelon, J.M. Bronstein, B. Ritz (Los Angeles, CA, USA)

12:30pm-2:00pm: Impact of self-efficacy education on physical and psychosocial functioning in newly-diagnosed Parkinson patients

D. Cook, C. McRae, R. Kumar (Englewood, CO, USA)

12:30pm-2:00pm: Impact of subclinical apathy prior to deep brain stimulation on the quality of life of patients with Parkinson’s disease

M.A. Higuchi, T. Mishima, H. Abe, T. Morishita, S. Fujioka, J. Fukae, Y. Tsuboi (Fukuoka, Japan)

12:30pm-2:00pm: Impact of the combined depletion of monoamines on the effectiveness of deep brain stimulation of the subthalamic nucleus

A. Benazzouz, C. Delaville, E. Faggiani (Bordeaux, France)

12:30pm-2:00pm: Impaired color discrimination selectively associates with postural instability and gait difficulties in Parkinson’s disease

J.D. Haugen, M.L.T.M. Muller, N.I. Bohnen (Ann Arbor, MI, USA)

12:30pm-2:00pm: Impaired hippocampal neurogenesis associates with serotonergic axonal degeneration in transgenic rat and mouse models of Parkinson’s disease

Z. Kohl, J. Deußer, D. Amato, C.P. Müller, O. Riess, E. Masliah, S. Nuber, J. Winkler (Erlangen, Germany)

12:30pm-2:00pm: Implantable pulse generator (IPG) longevity decreases following each replacement surgery in Parkinson’s disease (PD) patients treated with bilateral sub-thalamic nucleus deep brain stimulation (STN-DBS)

S.D. Israeli-Korn, S. Tessler, G. Yahalom, S. Benizri, O.S. Cohen, C. Shabat, H. Strauss, N. Warmann-Alaluf, E. Stein, Z. Zibly, R. Spiegelman, S. Hassin (Ramat Gan, Israel)

12:30pm-2:00pm: Implications of direct and indirect costs in health-related quality of life in Parkinson’s disease: A cross-sectional study in Mexico

M. Rodríguez-Violante, A. Jorge de Saráchaga, A. Cervantes-Arriaga, H. Soto-Molina, M. Márquez-Cruz (Mexico City, Mexico)

12:30pm-2:00pm: Improvement of impulse control disorder in Parkinson’s disease patients treated with subthalamic nucleus stimulation

E.J. Choi, J.K. Gu, D.G. Lee, S.M. Kim, J.K. Lee, C.S. Lee (Seoul, Korea)

12:30pm-2:00pm: Improving parkinsonism in DBS poor-responders by surgical lead revision of subthalamic electrodes

R.C. Nickl, M.M. Reich, S. Johannes, F. Steigerwald, P. Fricke, V. Sturm, R.I. Ernestus, J. Volkmann, C. Matthies (Würzburg, Germany)

12:30pm-2:00pm: Impulse control disorders after STN DBS for Parkinson’s disease

P.G. Frederic, P. Camille, J. Nicolas, S. Abbas, F. Maria, P. Michel (Montreal, QC, Canada)

12:30pm-2:00pm: Impulse control disorders in Parkinson’s disease – Determinants and effect of DBS

A.K. Puligopu, P.K. Pesala, V.V.P. Kagita, R.M. Kandadai, S.A. Jabeen, M.A. Kanikannan, R. Borgohain, A. Kumar (Hyderabad, India)

12:30pm-2:00pm: In vivo validation of a new wireless portable stimulator for chronic deep brain stimulation in freely moving rats

F. Naudet, F. Kölbl, G. N'kaoua, E. Faggiani, B. Ribot, S. Renaud, N. Lewis, A. Benazzouz (Bordeaux, France)

12:30pm-2:00pm: Incidence and characteristics of gait dysfunction after subthalamic nucleus deep brain stimulation

V. Velez-Aldahondo, A.B. Millard, J.R. Jagid, C.C. Luca (Miami, FL, USA)

12:30pm-2:00pm: Incidence of dynamic aphasia in progressive supranuclear palsy

E.I. Giyazitdinova, B.T. Muinjonov, G.S. Rakhimbaeva, Y.A. Musaeva (Taskent, Uzbekistan)

12:30pm-2:00pm: Incidence of dystonia in patients with progressive supranuclear palsy

E.I. Giyazitdinova, B.T. Muinjonov, G.S. Rakhimbaeva, Y.A. Musaeva (Taskent, Uzbekistan)

12:30pm-2:00pm: Increased access to training in a Parkinson-specific rehabilitation approach through online learning

C. Fox, L. Guse, L. Ramig (Tucson, AZ, USA)

12:30pm-2:00pm: Increased monosaccharide intake in patients with Parkinson’s disease

E. Schaeffer, A. Schermann, F. Zirbs, D. Berg (Tübingen, Germany)

12:30pm-2:00pm: Influence of motor manifestation and onset’s side on the spectrum of non-motor symptoms in patients with Parkinson’s disease

M.A. Nikitina, I.A. Zhukova, V.M. Alifirova, N.G. Zhukova, O.P. Izhboldina, J.S. Mironova, M.A. Titova, N.G. Brazovskaya (Tomsk, Russia)

12:30pm-2:00pm: Influence of onset age on the progression of non-motor symptoms in Parkinson’s disease: A prospective study from Southwest China

R. Ou, B. Cao, Q. Wei, K. Chen, W. Song, J. Yang, B. Zhao, Y. Wu, H. Shang (Chengdu, People's Republic of China)

12:30pm-2:00pm: Influence of vibration to quality of life of patients with Parkinson’s disease

V. Rashidov (Tashkent, Uzbekistan)

12:30pm-2:00pm: Inhibition of nociceptive responses by modulating serotonergic signals at the rostral ventromedial medulla in 6-OHDA-induced Parkinson’s disease rat model

C. Wang, C. Mao, F. Wang, J. Yang, X. Zhang, Y. Yang, C. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: Initial clinical description of progressive supranuclear palsy in the Luxembourg Parkinson’s study

P. Kolber, G. Hipp, M. Kerschenmeyer, K. Roomp, S.K. Mosch, L. Longhino, A. Schweicher, M. Faltz, V.P. Satagopam, N. Goncharenko, M. Gantenbein, M. Vaillant, F. Betsou, A. Chioti, R. Schneider, R. Krüger (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm: Innsbruck multiple system atrophy cohort study – An interim analysis

S. Eschlböck, T. Benke, S. Bösch, A. Djamshidian-Tehrani1, A. Fanciulli, R. Granata, C. Kaindlstorfer, G. Kiss, F. Krismer, K. Mair, M. Nocker, C. Raccagni, C. Scherfler, K. Seppi, W. Poewe, G. Wenning (Innsbruck, Austria)

12:30pm-2:00pm: Introducing the 2nd edition of the occupational therapy for people with Parkinson’s: Best practice guidance

A. Aragon (Bath, United Kingdom)

12:30pm-2:00pm: Irritable bowel syndrome is more prevalent than functional constipation in Parkinson’s disease: Clinical spectrum and changes in gut microbiota

T. Mertsalmi, V. Aho, P.A.B. Pereira, L. Paulin, E. Pekkonen, P. Auvinen, F. Scheperjans (Helsinki, Finland)

12:30pm-2:00pm: Is awake intraoperative mapping still necessary for bilateral subthalamic stimulation for Parkinson’s disease in a modern surgical environment?

Y. Zouitina, M. Lefranc, P. Merle, O. Godefroy, M. Tir, P. Krystkowiak (Amiens, France)

12:30pm-2:00pm: Is continuous twenty four hour blood pressure monitoring a suitable tool in evaluating sleep disturbances in Parkinson’s disease?

M. Hahne, D. Hartmann, C. Thomopoulos, A. Ramih, M. Esther, Y. Guangji, G. Bernd, W. Dirk, R. Heinz, J. Wolfgang (Bad Neustadt, Germany)

12:30pm-2:00pm: Is inter-limb coupling modified by subthalamic deep brain stimulation and dopaminergic medication in Parkinson’s disease?

C. Duval, J.F. Daneault, A.F. Sadikot (Montréal, QC, Canada)

12:30pm-2:00pm: Is the PPN a valuable target for deep brain stimulation in treatment of Parkinsonian disorders? Experience of a patient’s series

I. Galazky, A. Kupsch, E. Wirkus, F. Casjens, S. Specht, H.J. Heinze, J. Voges (Magdeburg, Germany)

12:30pm-2:00pm: Is there any relationship between olfactory dysfunction and memory disorder?

H. Onuma, Y. Kobayashi, A. Kumon, K. Hasegawa (Sagamihara-city, Japan)

12:30pm-2:00pm: Italian olfactory identification test (IOIT) scores correlates with clinical features in Parkinson’s disease

E. Brahimi, N. Tambasco, P. Eusebi, P. Nigro, E. Sacchini, S. Simoni, E. Marsili, F. Ripandelli, M. Romoli, P. Calabresi (Perugia, Italy)

12:30pm-2:00pm: J-FIRST: First-in-Japan observational study of Parkinson’s disease treatments and nonmotor symptoms

T. Maeda, Y. Shimo, S.W. Chiu, T. Yamaguchi, K. Kashihara, Y. Tsuboi, M. Nomoto, N. Hattori, H. Watanabe, H. Saiki (Akita, Japan)

12:30pm-2:00pm: Jan Evangelista Purkinje: Contributions to study of anatomy and physiology of movement disorders

R. Fekete (Valhalla, NY, USA)

12:30pm-2:00pm: Jaw opening dystonia and blepharospasm following bilateral VIM DBS for postural and action dystonic tremor

V. Paramanandam, D.A. Olszewska, C. Fearon, B. Magennis, B. Cheeran, T. Lynch (Dublin, Ireland)

12:30pm-2:00pm: Lead angle matters: Side effects of deep brain stimulation improved with adjustment of lead angle

M.H. Pourfar, A.Y. Mogilner (New York, NY, USA)

12:30pm-2:00pm: Leukocyte perturbations suggest immune dysregulation in progressive supranuclear palsy

M.C. Schiess, J.O. Suescun, A. Actor, A. Gonzales, K.C. Smith (Houston, TX, USA)

12:30pm-2:00pm: Life expectancy and dementia – Two sides of the coin in Parkinson’s disease

S. Tursunov, G. Rakhimbaeva, F. Yunusov, K. Abdukhalimova, R. Agzamov, R. Mirzaev, D. Lutfullaeva, J. Olimov (Tashkent, Uzbekistan)

12:30pm-2:00pm: Life satisfaction in Parkinson’s disease – associated factors

K. Rosqvist, P. Hagell, P. Odin, S. Iwarsson, H. Ekström, M.H. Nilsson (Lund, Sweden)

12:30pm-2:00pm: Long-term efficacy of safinamide on mood in Parkinsonian patients with fluctuations

C. Cattaneo, E. Mueller, M. Sardina (Bresso, Italy)

12:30pm-2:00pm: Long-term incidence of Parkinson’s disease in rural areas of Finland

J. Isotalo, T. Vahlberg, V. Kaasinen (Turku, Finland)

12:30pm-2:00pm: Longitudinal assessment of caregiver strain in Parkinson’s disease

C.K. Okoro, P. Schmidt, S.S. Wu, J.G. Goldman (Chicago, IL, USA)

12:30pm-2:00pm: Longitudinal assessment of sleep in an incident Parkinson’s disease cohort

S.T. O'Dowd, G.W. Duncan, T.K. Khoo, A.J. Yarnall, R.A. Lawson, D.J. Burn, K.N. Anderson (Newcastle upon Tyne, United Kingdom)

12:30pm-2:00pm: Longitudinal changes of speech and voice disorders following subthalamic stimulation in Parkinson’s disease patients

T. Tsuboi, H. Watanabe, Y. Tanaka, R. Ohdake, K. Kawabata, K. Hara, M. Ito, M. Hirayama, Y. Fujimoto, Y. Kajita, M. Katsuno, G. Sobue (Nagoya, Japan)

12:30pm-2:00pm: Longitudinal evolution of excessive daytime sleepiness in early Parkinson’s disease

T. Simuni, C. Caspell-Garcia, J. Long, C.S. Coffey, W. Oertel, S. Lasch, K. Marek, On behalf of the PPMI Sleep Working Group (Chicago, IL, USA)

12:30pm-2:00pm: Longitudinal evolution of possible REM sleep behavior disorder in early Parkinson’s disease

W. Oertel, T. Simuni, C. Caspell-Garcia, J. Long, C.S. Coffey, A. Iranzo, G. Mayer, L. Chahine, S. Lasch, K. Marek, On behalf of the PPMI Sleep Working Group (Marburg, Germany)

12:30pm-2:00pm: Loss of FBXO7 (PARK15) leads to disturbances in proteasomal function and models parkinsonism-like and pyramidal symptoms in mice

S. Vingill, D. Brockelt, N. Schwedhelm-Domeyer, L. Tatenhorst, S. Goebbels, P. Lingor, K.A. Nave, J. Stegmueller (Goettingen, Germany)

12:30pm-2:00pm: Low cerebrospinal fluid 3,4-dihydroxyphenylacetic acid and 3,4-dihydroxyphenylglycol levels are biomarkers of Parkinsonian disorders, including PSP

A. Stefani, C. Holmes, E. Olivola, Y. Sharabi, D. Goldstein (Rome, Italy)

12:30pm-2:00pm: LRRK2, MAPT and HTRA2 mutations in the pedigree of familial neurodegenerative parkinsonism with cognitive deterioration spanning five generations in a genetically isolated population of south-eastern Moravia, Czech Republic

T. Bartonikova, R. Vodicka, K. Mensikova, R. Vrtel, P. Kanovsky, P. Otruba, M. Vastik, L. Mikulicova, S. Kurcova, P. Jugas, J. Ovecka, L. Sachova, F. Dvorsky (Olomouc, Czech Republic)

12:30pm-2:00pm: Magnetic resonance characteristic of Parkinson’s disease based on the presence of cognitive impairment

F.B. Doniyorova (Tashkent, Uzbekistan)

12:30pm-2:00pm: Magnetic resonance diffusion tensor imaging for the pedunculopontine nucleus: Correlation between neuroimaging and cytoarchitectonic features

A.T.D.L. Alho, C. Hamani, E.J.L. Alho, R.E. da Silva, G.A.B. dos Santos, R.C. Neves, C.M.M. Araujo, G. Magalhães, L.T. Grinberg, H. Heinsen, E.T. Fonoff, E. Amaro-Junior (São Paulo, Brazil)

12:30pm-2:00pm: Meaningful life attitudes support positive coping in patients with idiopathic Parkinson’s disease

S. Gräber, J. Meinhardt, E. Schäffer, A. Apel, D. Berg (Tübingen, Germany)

12:30pm-2:00pm: Measurement of effect of variable deep brain stimulation (DBS) frequencies on static postural control in Parkinson’s disease (PD) patients with bilateral STN or GPi stimulators by employing force plate

A. Deep, A. Lieberman, R. Dhall, T. Lockhart, S. Shafer, C. Frames, N. Tateuchi, E. Simpson, M. McCauley, N. Krishnamurthi, S. Syed (Phoenix, AZ, USA)

12:30pm-2:00pm: Measurement of night time sleep using an accelerometry based system

M. Horne, S. McGregor, G. Hamilton, D. O'Driscoll, R. Blaze, P. Churchward (Parkville, Australia)

12:30pm-2:00pm: Measuring interdependence of the health status of people with Parkinson’s disease and their spouses

F. Noubary, S.D. Gunnery, E.M. Naumova, M. Saint-Hilaire, C.A. Thomas, L. Tickle-Degnen (Boston, MA, USA)

12:30pm-2:00pm: Medication errors: The role of the nurse in an interdisciplinary home visit program for advanced Parkinson’s disease patients

S.E. Oyler, J.E. Fleisher, M.M. Sweeney, A.C. Lemen, A. Fazl, G. Dacpano, R.M. Gilbert, A. Di Rocco, J. Chodosh (New York, NY, USA)

12:30pm-2:00pm: MicroRNA as diagnostic biomarkers in Parkinson’s disease and multiple system atrophy

C.C. Starhof, K. Winge, N. Heegaard, A.M. Hejl (København, Denmark)

12:30pm-2:00pm: Midbrain atrophy differentially progresses between Richardson’s Syndrome, progressive supranuclear palsy-parkinsonism and Parkinson’s disease: Longitudinal MRI study

Y.E. Huh, M. Hwang, J.K. Park, J.W. Cho (Seoul, Korea)

12:30pm-2:00pm: Mild Parkinsonian signs and TIA/stroke

J.L. Adams, N. Dahodwala (Rochester, NY, USA)

12:30pm-2:00pm: Minimal impact of “interleaving” on neuromodulation device battery drain when interleave frequency is halved

Y.M. Fernandez, D.L. Caputo, D.P. Schneider, S.F. Danish, R.J. Dipaola, E.L. Hargreaves (New Brunswick, NJ, USA)

12:30pm-2:00pm: Modeling trajectories of brain damage in progressive supranuclear palsy: A longitudinal multimodal MRI study

F. Caso, F. Agosta, M. Lukic-Jecmenica, I. Petrovic, P. Valsasina, P.M. Ferraro, A. Meani, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)

12:30pm-2:00pm: Modulation and mechanism for the neuroprotective effects of 17-beta-estradiol: Relevance to depressive symptoms in Parkinson’s disease

P. Kumar, N. Baquer (New Delhi, India)

12:30pm-2:00pm: Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease: Meta-analysis of individual participant data from seven prospective observational studies

F. Yang, N.L. Pedersen, W. Ye, Z. Liu, M. Norberg, L. Forsgren, Y. Trolle Lagerros, R. Bellocco, L. Alfredsson, A. Knutsson, J.H. Jansson, R. Galanti, A.C.J. Lager, M. Araghi, M. Lundberg, C. Magnusson, K. Wirdefeldt (Stockholm, Sweden)

12:30pm-2:00pm: Morbidity and comorbidity of deep brain stimulation for Parkinson’s disease – A thirteen-years retrospective cohort study

S.Y. Chen, Y.H. Pan, S.H. Lin (Hualien, Taiwan)

12:30pm-2:00pm: Mortality after deep brain stimulation surgery for patients with advanced Parkinson’s disease

H.S. Ryu, S. You, M.J. Kim, Y.J. Kim, J. Kim, K. Kim, S.J. Chung (Seoul, Korea)

12:30pm-2:00pm: Motivators and barriers to participation in exercise in Parkinson’s disease

M. Afshari, Y. Kianirad, D. Bega (Chicago, IL, USA)

12:30pm-2:00pm: Motor and non-motor symptoms in Parkinson’s disease: Correlation and impact on quality of life and activities of daily living

P. Bugalho, T. Lampreia, R. Miguel, M. Mendonça, A. Caetano, R. Barbosa (Lisbon, Portugal)

12:30pm-2:00pm: Motor features and response to levodopa in Parkinson’s disease with normal olfactory function

M. Rossi, A. Medina Escobar, A. Bril, P. Millar Vernetti, J.I. De Palo, D. Cerquetti, M. Merello (Buenos Aires, Argentina)

12:30pm-2:00pm: Motor rigidity selectively associates with impaired odor identification in Parkinson’s disease

J.D. Haugen, M.L.T.M. Muller, V. Kotagal, K.A. Frey, R.L. Albin, N.I. Bohnen (Ann Arbor, MI, USA)

12:30pm-2:00pm: Motor symptoms in patients with early stages of Parkinson’s disease

E.N. Gubanova, N.V. Fedorova (Moscow, Russia)

12:30pm-2:00pm: Movement disorders (Parkinson’s disease) in Uzbekistan: Epidemiologic, clinical and therapeutic aspects

N. Eshakulova, A. Umarov, N. Tuychibaeva, G. Rakhimbaeva, M. Ataniyazov (Tashkent, Uzbekistan)

12:30pm-2:00pm: Movement disorders after stroke in the third Moroccan level hospital, Marrakech

A. Chahidi, M. Chraa, N. Kissani (Beni Mellal, Morocco)

12:30pm-2:00pm: Movement disorders in patients with Japanese encephalitis: Experience in a tertiary care hospital in north eastern region of India

A.R. Barua, N.C. Borah, P.S. Deb, A. Hatibaruah (Guwahati, India)

12:30pm-2:00pm: MR-guided high intensity focused ultrasound in Parkinson’s disease: A series of 5 cases

N. Wegener, G. Kaegi, R. Bauer, B. Werner, E. Martin, S.R. Schreglmann, A. Lebeda, S. Haegele-Link (St. Gallen, Switzerland)

12:30pm-2:00pm: MRI-supported diagnosis of multiple system atrophy: Implications for clinical trials

F. Krismer, G.K. Wenning, S. Bajaj, M. Schocke, C. Scherfler, W. Poewe, K. Seppi (Innsbruck, Austria)

12:30pm-2:00pm: Multimodal voxel-based analysis of the infratentorial brain region in Richardson’s syndrome, progressive supranuclear palsy-parkinsonism, Parkinson variant of multiple system atrophy and Parkinson’s disease

M. Seki, C. Müller, E. Reiter, M. Nocker, M. Schocke, E. Gizewski, C. Kremser, G. Wenning, W. Poewe, K. Seppi, C. Scherfler (Innsbruck, Austria)

12:30pm-2:00pm: Multiple system atrophy with motor fluctuations: A presynaptic disease variant?

Y. Compta, S.C. Cerquera, N. Falgàs, E. Gelpí, V. Puente, A. Cámara, L. Planellas, M.J. Martí, F. Valldeoriola (Barcelona, Spain)

12:30pm-2:00pm: Multiple system atrophy: A comparison between clinical subtypes

L.B. Barcelos, R.A. Saba, S.M.A. Silva, V. Borges, H.B. Ferraz (Sao Paulo, Brazil)

12:30pm-2:00pm: Multiple-source current steering in bilateral subthalamic nucleus deep brain stimulation for Parkinson’s disease: Our experience

J.M. Cardenas Prieto, P.A. Millan Giraldo (Cali, Colombia)

12:30pm-2:00pm: Muscle ceroid-lipofuscine-like deposits in a patient with FTD due to a progranulin mutation

R. Terlizzi, M.L. Valentino, A. Bartoletti-Stella, M. Columbaro, S. Piras, P. Martinelli, P. Parchi, S. Capellari (Bologna, Italy)

12:30pm-2:00pm: Musical ear syndrome as a presenting symptom of Lewy body disorder

S.J. Song, D. Lee, Y.N. Kwon, T.B. Ahn (Seoul, Korea)

12:30pm-2:00pm: My PD Journey: Experiences reported by people with Parkinson’s disease in several European countries – A quantitative and qualitative study

A. Schrag, O. Rascol, R. Merritt, S. Hotham, G. Bartl, L. Graham, On behalf of the European Parkinson's Disease Association (EPDA) and the Movement Disorder Society- European Section European Section (London, United Kingdom)

12:30pm-2:00pm: Neurocognitive domains of impulsivity in Parkinson’s disease (PD) and the effects of dopaminergic replacement therapy (DRT)

M. Sousa, N. Canário, F. Moreira, C. Duarte, M. Castelo-Branco, C. Januário (Coimbra, Portugal)

12:30pm-2:00pm: Neurophysiological assessment of corticospinal tract activation due to subthalamic deep brain stimulation in patients with Parkinson’s disease

P. Mahlknecht, H. Akram, D. Georgiev, J. Candelario, A. Zacharia, Z. Kefalopoulou, L. Zrinzo, J. Hyam, M. Hariz, C. Milabo, T. Foltynie, J.C. Rothwell, P. Limousin (Innsbruck, Austria)

12:30pm-2:00pm: Neuropsychiatric disturbances in Parkinson’s disease patients’ with chronic pain

G. Pavlic, I. Moldovanu, N. Diaconu, L. Rotaru (Chisinau, Republic of Moldova)

12:30pm-2:00pm: Neuropsychological assessment in the Luxembourg Parkinson’s cohort (HELP-PD)

G. Hipp, P. Kolber, K. Roomp, M. Kerschenmeyer, S.K. Mosch, L. Longhino, A. Schweicher, M. Faltz, V.P. Satagopam, N. Goncharenko, M. Gantenbein, M. Vaillant, F. Betsou, A. Chioti, R. Schneider, R. Schneider, R. Balling, N.J. Diederich, R. Krüger (Belvaux, Luxembourg)

12:30pm-2:00pm: Neuropsychological safety of bilateral pallidal (GPi) deep brain stimulation (DBS) for Parkinson’s disease (PD) under general anesthesia

A.I. Tröster, F.A. Ponce, L. Autry, M. Lambert, V.G. Evidente, S. Oravivattanakul, A. Lieberman, G. Moguel-Cobos, N. Salins, K. Hanson (Phoenix, AZ, USA)

12:30pm-2:00pm: Nighttime sleep problems in patients with Parkinson’s disease: Risk factors and longitudinal associations

K. Zhu, J.J. van Hilten, J. Marinus (Leiden, Netherlands)

12:30pm-2:00pm: Non motor symptoms burden and motor staging of Parkinson’s disease: Evidence for dichotomy and non-motor dominant subtypes from analysis of 249 cases

K. Ray Chaudhuri, A. Sauerbier, T. Thavayogarajah, A. Rizos, L. Perkins, C. Rodriguez Blazquez, P. Martinez-Martin, On behalf of EUROPAR, the MDS Non-Motor PD Study Group, The NILS Group (London, United Kingdom)

12:30pm-2:00pm: Non motor symptoms of Parkinson’s disease: Prevalence and impact on quality of life

M. Chraa, K. Choulli, N. Kissani (Marrakech, Morocco)

12:30pm-2:00pm: Non-contact boxing in Parkinson’s disease

Z.R. Yee, S.H.X. Liew (Singapore, Singapore)

12:30pm-2:00pm: Non-motor outcomes of subthalamic stimulation in Parkinson’s disease depend on the location of active contacts

H.S. Dafsari, J.N. Petry-Schmelzer, K. Ashkan, L. Weis, T. Dembek, M. Samuel, A. Rizos, M. Silverdale, J. Evans, P. Martinez-Martin, A. Antonini, K.R. Chaudhuri, V. Visser-Vandewalle, L. Timmermann (Cologne, Germany)

12:30pm-2:00pm: Non-motor symptoms (NMS) as a determinant of caregiver burden in a cohort of older patients with Parkinson’s disease (PD)

S. Gangadharan, N. Bareham, A. Johnson, M. Rees, A. Withenage, C.P. Padmakumar (Newcastle, Australia)

12:30pm-2:00pm: Non-motor symptoms in a PPMI cohort of p.A53T α-synuclein mutation-related and sporadic Parkinson’s disease patients

C. Koros, M. Stamelou, I. Beratis, N. Papagiannakis, A.M. Simitsi, D. Papadimitriou, S. Fragiadaki, D. Kontaxopoulou, S.G. Papageorgiou, L. Stefanis (Athens, Greece)

12:30pm-2:00pm: Non-motor symptoms in advanced Parkinson’s disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis

K.R. Chaudhuri, E. Terasawa, Y. Jalundhwala, D. Macaulay, R. Ayyagari, Z.Y. Zhou, T. Marshall, K. Chatamra, A. Yucel, K. Sail (London, United Kingdom)

12:30pm-2:00pm: Non-motor symptoms in PD candidates for DBS treatment

M.G. dos Santos Ghilardi, R.C.R. Martinez, R.G. Cury, J.R. Aranha, M.J. Teixeira, E.R. Barbosa, E.T. Fonoff (Sao Paulo, Brazil)

12:30pm-2:00pm: Non-motor symptoms in progressive supranuclear palsy

R. Ou, W. Song, Q. Wei, K. Chen, B. Cao, Y. Hou, B. Zhao, H. Shang (Chengdu, People's Republic of China)

12:30pm-2:00pm: Non-motor symptoms trajectory in Parkinson’s disease: Magnitude and importance of the change

C. Rodriguez-Blazquez, A. Rizos, K.R. Chaudhuri, P. Martinez-Martin, NILS, EUROPAR and the MDS Non Motor PD Study Groups (Madrid, Spain)

12:30pm-2:00pm: Nutritional status and quality of life in patients with Parkinson’s disease in a tertiary hospital in Northeast Mexico

I.E. Estrada, P. Ancer, H.J. Villarreal, C. Lopez, J. Rocha, A. Treviño, J.J. Peña, D. Ortiz (Monterrey, Mexico)

12:30pm-2:00pm: Objectives of the MDS rare movement disorders study group

E.M. Gatto, A. Albanese, K. Bathia, F. Cardoso, M. Cesarini, A. Chade, P. Chana, A. De la Cerda:Chile, A. Espay, J. Etcheverry, J. Ferreira, P. Garcia Ruiz, J. Jankovic, H. Jinnah, R. Kaji, K. Kotschet, C. Marras, J. Miyasaki, F. Morgante, A. Münchau, P. Pal, M.C. Rodriguez Oroz, M. Rodríguez Violante, A. Sanguinetti, L. Schoel (Buenos Aires, Argentina)

12:30pm-2:00pm: Objectivisation of postural disorders in patients with Parkinson’s disease during the screening stage for DBS

A.G. Buniak, I.P. Maryenko, S.A. Likhachev (Minsk, Belarus)

12:30pm-2:00pm: Olfactory deficit characterization in Parkinson’s disease

A.M. Crespo-Cuevas, L. Ispierto, A. Planas, D. Vilas, A. Planas, J. Sanchez, I. Isern, J. De Haro, R. Alvarez (Badalona, Spain)

12:30pm-2:00pm: Olfactory loss – early non-motor symptom in Parkinson’s disease

A. Kadirova, K. Mirzaeva, G. Rakhimbaeva (Tashkent, Uzbekistan)

12:30pm-2:00pm: Olfactory testing in differential diagnosis of atypical essential tremor and tremor-dominant Parkinson’s disease

O. Izhboldina, I. Zhukova, N. Zhukova, V. Alifirova, A. Latypova, M. Nikitina, Y. Mironova (Tomsk, Russia)

12:30pm-2:00pm: Orthostatic intolerance and falls in Parkinson’s disease

A. Fanciulli, C. Dallinger, G. Goebel, R. Granata, S. Duerr, F. Sprenger, F. Krismer, C. Mueller, S. Boesch, M. Nocker, C. Scherfler, K. Seppi, W. Poewe, G.K. Wenning (Innsbruck, Austria)

12:30pm-2:00pm: Oxysterol and chitotriosidase as biomarkers for atypical Parkinsonian symptoms?

M. Schuberth, G. Nübling, J. Hauer, T. Marquardt, S. Lorenzl (München, Germany)

12:30pm-2:00pm: P100 latency of pattern reversal visual evoked potential and visual hallucination in Parkinson’s disease

M. Kohsaka, T. Oeda, A. Umemura, S. Tomita, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Kyoto, Japan)

12:30pm-2:00pm: Pain correlates with sleep disturbances in Parkinson’s disease

Y. Fu, C. Mao, L. Ma, M. Ding, Y. Wang, C. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: Pan American multiple system atrophy (PANMSA) consortium database

M. Cesarini, A. Sanguinetti, J. Etcheverry, E. Mosto, I. Litvan, E.M. Gatto (Buenos Aires, Argentina)

12:30pm-2:00pm: Parasacral effects of electrical stimulation on lower urinary tract symptoms and constipation in patients with Parkinson’s disease: Preliminary data

I.V. Brandi, L.F. Silva, A.M. Lanzarini, A.F.A. Musengante (Salvador, Brazil)

12:30pm-2:00pm: Parkinson’s disease and the frequent reasons for emergency admission in Metropolitan Medical Center; a 2 year retrospective study

C.L. Go, K.A. Wong (Manila, Philippines)

12:30pm-2:00pm: Parkinson’s disease is characterised by differences in lower limb joint kinetics during stair ascent and descent

Z.J. Conway, T.D. Blackmore, P.A. Silburn, M.H. Cole (Brisbane, Australia)

12:30pm-2:00pm: Parkinson’s disease prodromal dysautonomia versus pure autonomic failure and MSA

M. Rosso, A. Merola, A.J. Espay, S. Maule, M. Zibetti, A. Romagnolo, L. Lopiano (Torino, Italy)

12:30pm-2:00pm: Parkinson’s in an aging population: Implications from a nation-wide prevalence and incidence study in New Zealand

D.J. Myall, T.L. Pitcher, M.R. MacAskill, J.F. Pearson, C.J. Lacey, J.C. Dalrymple-Alford, T.J. Anderson (Christchurch, New Zealand)

12:30pm-2:00pm: Parkinson’s syndrome as possible manifestation of lamina quadrigemina tumor or inflammation

N.M. Pavlyshyna, I.V. Khubetova (Odessa, Ukraine)

12:30pm-2:00pm: Parkinsonian syndrome prevalence in the world

F. Gulyamova (Tashkent, Uzbekistan)

12:30pm-2:00pm: Parkinsonism and movement disorders in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)

I. Amorín, A. Lescano, A. Panuncio, V. Raggio, R. Buzó (Montevideo, Uruguay)

12:30pm-2:00pm: Parkinsonism in patients with CADASIL

S.K. Song, J.H. Kang (Jeju-si, Korea)

12:30pm-2:00pm: Parkinsonism risk factors in Salt Lake City, Utah

D. Shprecher, K. Gannon, M. Halverson, R. Savica (Sun City, AZ, USA)

12:30pm-2:00pm: Patient-centered educational intervention using hand-held electronic devices

N. Hellmers, A. Hanineva, J.C. Stribling, J. Carter, C. Henchliffe (New York, NY, USA)

12:30pm-2:00pm: Patient-centered outcomes of DBS in Parkinson’s disease

J. Karl, B. Ouyang, K. Colletta, L. Verhagen (Chicago, IL, USA)

12:30pm-2:00pm: Patients’ employment status and quality of life affect caregivers burden in Parkinson’s disease in Singapore

K.M. Prakash, N.V. Nadkarni, W.K. Lye, E.C. Lim, E.K. Tan (Singapore, Singapore)

12:30pm-2:00pm: Phenomenology of dyskinesias induced by subthalamic stimulation in Tourette syndrome

L.M. Romito, D. Calandrella, C. Bagella, G. Messina, F. Ferré, A. Franzini (Milan, Italy)

12:30pm-2:00pm: Phenotypic differences between African American and Caucasian Parkinson’s disease patients

M.O. Bailey, B. Ouyang, G.T. Stebbins, L.M. Shulman, L.L. Barnes, D.A. Hall (Chicago, IL, USA)

12:30pm-2:00pm: Physical therapy practice variability and outcomes for people with Parkinson’s disease: Data from the National Parkinson Foundation quality improvement initiative (NPF-QII)

M.R. Rafferty, P.N. Schmidt, S.T. Luo, K. Li, F. Cubillos, C. Marras, T. Davis, E.C. Nelson, T. Simuni (Chicago, IL, USA)

12:30pm-2:00pm: Pisa syndrome in Parkinson’s disease effectively treated with subthalmic deep brain stimulation: Case report

C.A. Artusi, A. Romagnolo, M. Zibetti, M.G. Rizzone, A. Merola, F. Dematteis, M. Lanotte, L. Lopiano (Torino, Italy)

12:30pm-2:00pm: Predicting poor functional outcome in Parkinson’s disease

A.D. Macleod, C.E. Counsell (Aberdeen, United Kingdom)

12:30pm-2:00pm: Predictors of clinically meaningful change in PDQ-39 in Parkinson’s disease

T. Simuni, S. Wu, Y. He, C. Marras, T. Davis, E. Nelson, F. Cubillos, P. Schmidt, On behalf of the NPF QII Investigators (Chicago, IL, USA)

12:30pm-2:00pm: Predictors of transfer to community hospital or nursing home after discharge of inpatients with Parkinson’s disease: A Japanese single center retrospective study

K. Ikeda, K. Takahashi, T. Furuya, A. Miyake, T. Mitsufuji, A. Tanaka, Y. Ito, T. Sasaki, Y. Nakazato, N. Araki, T. Yamamoto (Saitama-ken, Japan)

12:30pm-2:00pm: Preliminary results for a study on quality of life in Huntington’s disease patients and their caregivers in Peru

A. Vishnevetsky, M.A. Inca-Martinez, M. Illanes-Manrique, M. Cornejo-Olivas (Lima, Peru)

12:30pm-2:00pm: Preliminary results of a cross-linguistic comparison on dysarthria in Parkinson’s disease

J. Sadat, R. Cardoso, H. Santos, J. Carvalho, I. Guimarães, F. Viallet, J.J. Ferreira, S. Pinto (Aix-en-Provence, France)

12:30pm-2:00pm: Premotor symptoms as prognostic indicators of Parkinson’s disease: A nationwide population-based and case-control study

M.H. Chang (Taichung, Taiwan)

12:30pm-2:00pm: Prevalence and characterisation of vocal fold motion impairment (VFMI) in patients with multiple system atrophy

M. Renaud, D. Robert, A. Lagier, H. Somma, S. Soulayrol, D. Korchia, F. Fluchère, S. Grimaldi, T. Witjas, J.P. Azulay, A. Eusebio (Marseille, France)

12:30pm-2:00pm: Prevalence and incidence of PSP and CBS: A new prospective study in the UK

J.B. Rowe, I.T. Coyle-Gilchrist (Cambridge, United Kingdom)

12:30pm-2:00pm: Prevalence and risk factors for orthostatic hypotension in early PD

C. McDonald, R.A. Lawson, G.W. Duncan, T.K. Khoo, D.J. Brooks, R.A. Barker, A.J. Yarnall, D.J. Burn (Newcastle upon Tyne, United Kingdom)

12:30pm-2:00pm: Prevalence and risk factors of orthostatic hypotension in Thai Parkinson’s disease patients

S. Klanbut, S. Wongwiwatthananukit, C. Suthisisang, R. Bhidayasiri, S. Phattanarudee (Bangkok, Thailand)

12:30pm-2:00pm: Prevalence of hemifacial spasm in Northern Cyprus

S. Usar Incirli, F. Selcuk, C.M. Akbostanci (Nicosia, Cyprus)

12:30pm-2:00pm: Prevalence of Parkinson’s disease and myotonic dystrophy in the nomadic population: Mongolian study

T. Sosorburam, B. Samdan, J. Amar (Ulan-Bator, Mongolia)

12:30pm-2:00pm: Prevalence of Parkinson’s disease in the region of Coquimbo, Chile

M. Contreras, P. Pizarro, U. Hernandez, C. Gomez, J. Gajardo (La Serena, Chile)

12:30pm-2:00pm: Prevalence of Parkinson’s disease in Ukraine

Y.O. Trufanov, N.K. Svyrydova, A.I. Galusha, G.M. Chupryna, O.V. Popov, M.V. Nechkalyuk (Kyiv, Ukraine)

12:30pm-2:00pm: Prodromal Parkinson’s disease in Argentinean patients with Gaucher disease type 1: Preliminary report

E.M. Gatto, J.L. Etcheverry, N. Basack, L. Aversa, N. Fernández Escobar, B. Soberón, A. Sanguinetti, M. Cesarini, G. Drelichman, E.M. Gatto (Buenos Aires, Argentina)

12:30pm-2:00pm: Progression of microglial activation and neuroinflammatory responses in a transgenic mouse model of multiple system atrophy

V. Refolo, S. Venezia, G.K. Wenning, M. Romero-Ramos, N. Stefanova (Innsbruck, Austria)

12:30pm-2:00pm: Progressive supranuclear palsy as a manifestation of the second stage of CADASIL syndrome

B. Muinjonov, E. Giyazitdinova, G. Rakhimbaeva (Tashkent, Uzbekistan)

12:30pm-2:00pm: Promoting optimal physiotherapy practice worldwide: Role of the Association of Physiotherapists in Parkinson’s disease Europe (APPDE)

M. Graziano, D. Jones, B. Ramaswamy, F. Lindop (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm: PROSPECT: A UK-based longitudinal observational study of PSP, CBD, MSA and atypical parkinsonism syndromes

J. Woodside, R. Lamb, V. Chelban, D. Burn, A. Church, A. Gerhard, M. Hu, N. Leigh, J. Rowe, H. Houlden (London, United Kingdom)

12:30pm-2:00pm: Prospective evaluation of pallidal deep brain stimulation in Huntington’s disease

S. Zittel, V. Tadic, C. Moll, A. Fellbrich, N. Brüggemann, D. Rasche, T. Bäumer, V. Tronnier, A. Münchau (Luebeck, Germany)

12:30pm-2:00pm: Pshychoeducational interventions for demented patients with parkinsonism and their families

P.N.S. Almeida, A.C.P. Koutsandréou, A.C.M. Neri (Salvador, Brazil)

12:30pm-2:00pm: PSP and HIV: Causality or coincidence?

L.A. Crespo Araico, P. Agüero Rabes, E. Viedma Guiard, P. Martinez Ulloa, C. Estévez Fraga, A. Alonso Cánovas, I. Corral Corral, L. Cabañes Martinez, E. Navas Elorza, J.C. Martinez Castrillo, I. Avilés Olmos (Madrid, Spain)

12:30pm-2:00pm: Pulmonary dysfunction in Parkinson’s disease: A feature of early disease?

G. Baille, T. Perez, D. Devos, L. Defebvre, C. Moreau (Lille, France)

12:30pm-2:00pm: Quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson’s disease

H.S. Dafsari, L. Weiss, M. Silverdale, P. Reddy, A. Rizos, M. Samuel, E. Perrier, J. Evans, K. Ashkan, J.N. Petry-Schmelzer, V. Visser-Vandewalle, A. Antonini, P. Martinez-Martin, K.R. Chaudhuri, L. Timmermann (Cologne, Germany)

12:30pm-2:00pm: Quality of life and epidemiological profile of patients undergoing botulinum toxin treatment

G. Amorelli, L.F. Vasconcellos, M. Spitz, L.F. Fraga (Rio de Janeiro, Brazil)

12:30pm-2:00pm: Quality of life and living with Parkinson’s in Ireland

I. Cassidy, P. Meskell, M.P. Butler, M. Richardson, C. Kennedy, S. Coote, P. Boers (Limerick, Ireland)

12:30pm-2:00pm: Quality of life of Parkinson’s disease patients in a tertiary hospital in Hong Kong

H.F. Chan, Y.F. Cheung, D.K.W. Chau, T. Fung, I. Chan, W.C. Fong (Hong Kong, Hong Kong)

12:30pm-2:00pm: Quantification of striatal dopamine transporters with [18F]PR04.MZ in patients with progressive supranuclear palsy and Parkinson’s disease

P. Chana-Cuevas, C. Juri, V. Kramer, R. Pruzzo, P. Riss, A. Amaral, F. Rösch, H. Amaral (Santiago, Chile)

12:30pm-2:00pm: Quantification of tremor and rigidity during deep brain stimulation surgery for Parkison’s disease

P. Poortvliet, A. Fytagoridis, T. Coyne, P. Silburn (Brisbane, Australia)

12:30pm-2:00pm: Quantitative MRI measurement of regional cerebellar involvement in patients with progressive supranuclear palsy

Y. Lee, D.K. Lee, J.M. Lee, S.J. Chung, J.J. Lee, Y.H. Sohn, P.H. Lee (Seoul, Korea)

12:30pm-2:00pm: RBD increase non-motor symptom in Parkinson’s disease

Y. Wu, Y. Liu, X. Zhu, X. Zhang, S. Kuo, W.G. Ondo (Shanghai, People's Republic of China)

12:30pm-2:00pm: Real-world safety of deep brain stimulation in patients with ≤7.5 years between disease onset and device implant

M.C. Schiess, L. Tonder, M. Wells, T. Weaver, V. Stoker (Houston, TX, USA)

12:30pm-2:00pm: Recharge frequency is not driven by therapy power usage in patients implanted with rechargeable deep brain stimulation systems

T. Weaver, P. Konrad, L. Timmerman, G. Molnar, K. Stromberg (Minneapolis, MN, USA)

12:30pm-2:00pm: Rechargeable pacemaker technology in deep brain stimulation: A step forward, but nor for everyone

J. Runge, A. Wloch, M. Abdallad, M. Manu, J.K. Krauss (Hannover, Germany)

12:30pm-2:00pm: Recognition of parkinsonism in African Americans in a community-based sample

D.A. Hall, B. Ouyang, J.M. Shulman, L.M. Shulman, D.A. Bennett, L.L. Barnes (Chicago, IL, USA)

12:30pm-2:00pm: Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy

F. Bassil, P.O. Fernagut, E. Bezard, Q. Hoang, D. Ringe, G.A. Petsko, W.G. Meissner (Bordeaux, France)

12:30pm-2:00pm: Reduction in battery longevity for each subsequent implantable pulse generator (IPG) in patients with Parkinson’s disease (PD) treated with bilateral subthalamic nucleus deep brain stimulation (STN-DBS) may be due to both programming changes and IPG model – a case series

S.D. Israeli-Korn, S. Tessler, G. Yahalom, S. Benizri, O.S. Cohen, C. Shabat, H. Strauss, N. Warmann-Alaluf, E. Stein, Z. Zibly, R. Spiegelman, S. Hassin, S. Hassin (Ramat Gan, Israel)

12:30pm-2:00pm: Regular exercise is associated with better two-year outcomes in Parkinson’s disease: National Parkinson foundation quality improvement initiative (NPF-QII) data

M.R. Rafferty, P.N. Schmidt, S.T. Luo, K. Li, F. Cubillos, C. Marras, T. Davis, E.C. Nelson, T. Simuni (Chicago, IL, USA)

12:30pm-2:00pm: Rehabilitation of dysphagia in Parkinson’s disease: Effect of chin-down postural maneuver

A. Ayres, G.P. Jotz, C.R.M. Rieder, M.R. Olchik (Porto Alegre, Brazil)

12:30pm-2:00pm: Relationship between cognitive functions and striatal 123I-FP-CIT uptake in Parkinson’s disease

H. Sawada, T. Sekiguchi, M. Takahashi, A. Inaba, S. Orimo (Tokyo, Japan)

12:30pm-2:00pm: Relationship between fatigue and sleep disturbances in patients with Parkinson’s disease: A study using Parkinson’s disease sleep scale-2

K. Suzuki, A. Numao, T. Kadowaki, S. Suzuki, Y. Watanabe, M. Miyamoto, T. Miyamoto, T. Uchiyama, K. Hashimoto, H. Fujita, Y. Watanabe, T. Matsubara, K. Hirata (Mibu, Japan)

12:30pm-2:00pm: Relationship between the MDS-UPDRS and quality of life in Parkinson’s disease: A large international multicenter study of 3206 patients (the QUALPD study)

M. Škorvánek, P. Martinez-Martin, N. Kovacs, I. Zezula, M. Rodriguez-Violante, J.C. Corvol, P. Taba, K. Seppi, O. Levin, A.E. Schrag, T. Foltynie, M. Alvarez-Sanchez, T. Arakaki, Z. Aschermann, I. Aviles-Olmos, E. Benchetrit, C. Benoit, A. Bergareche-Yarza, A. Cervantes-Arriaga, A. Chade, F. Cormier, V. Datieva, D.A. Gallagher, N. Garretto, Z. Gdovinova, O. Gerschanik, M. Grofik, V. Han, J. Huang, L. Kadastik-Eerme, M.M. Kurtis, G. Mangone, J.C. Martinez-Castrillo, A. Mendoza-Rodriguez, M. Minar, H.P. Moore, M. Muldmaa, C. Mueller, B. Pinter, W. Poewe, K. Rallmann, E. Reiter, C. Rodriguez-Blazquez, C. Singer, B.C. Tilley, P. Valkovic, C.G. Goetz, G.T. Stebbins (Kosice, Slovakia (Slovak Republic))

12:30pm-2:00pm: Results from a double-blind trial of pallidal DBS for Tourette’s syndrome: Are there any predictors of surgery outcome?

Z. Kefalopoulou, L. Zrinzo, M. Jahanshahi, J. Candelario, C. Milabo, M. Beigi, H. Akram, J. Hyam, J. Clayton, L. Kass-Iliyya, M. Silverdale, J. Evans, P. Limousin, M. Hariz, E. Joyce, T. Foltynie (London, United Kingdom)

12:30pm-2:00pm: Retinal nerve fiber layer thinning: A window into rapid eye movement sleep behavior disorders in Parkinson’s disease

C.J. Mao, Z.J. Yang, J. Wei, J.R. Zhang, Y.P. Yang, C.F. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: Risks and predictive factors for pneumonia amongst Parkinson’s disease patients with dysphagia

K.H. Goh, H.L. Ng, K.Y. Tay, S. Acharyya, S.Y.E. Ng, J.P.L. Boo, A.H.J. Kooi, W. Li, W.L. Au, L.C.S. Tan (Singapore, Singapore)

12:30pm-2:00pm: Role of contact polarity on therapeutic impedances at two deep brain stimulation (DBS) targets

N. Bukhari, B.H. Kopell, R.A. Ramdhani (New York, NY, USA)

12:30pm-2:00pm: Rotenone and Parkinson’s disease (PD): Effect modification by membrane transporter variants

S.M. Goldman, F. Kamel, C. Meng, M. Korell, D.M. Umbach, J. Hoppin, G.W. Ross, C. Marras, M. Kasten, A. Chade, K. Comyns, D. Sandler, A. Blair, C.M. Tanner (San Francisco, CA, USA)

12:30pm-2:00pm: Safety of deep brain stimulation for movement disorders: A single-centre long-term standardized recording and analysis

C. Bagella, D. Calandrella, G. Zorzi, G. Messina, F. Carella, A. Franzini, C.E. Marras, N. Nardocci, L.M. Romito (Milan, Italy)

12:30pm-2:00pm: Serum brain-derived neurotrophic factor as an indication of disease state in parkinsonism and RBD

K. Csencsits-Smith, J. Suescun, A. Gonzalez, A. Actor, M. Schiess (Houston, TX, USA)

12:30pm-2:00pm: Single versus multiple microelectrode recordings (MER) in STN-DBS-surgery for PD: A randomized double-blind controlled trial

S. Bjerknes, A.E. Konglund, E. Ilstad, U. Pham, M. Skjelland, E. Dietrichs, M. Toft (Oslo, Norway)

12:30pm-2:00pm: Sleep deprivation (SD) amongst carers of patients with Parkinson’s disease (PD)

D. Kulatunga, H. Avery, A.K. Chatterjee, A. Plowman, J. Caffrey, S. Pradhan (Reading, United Kingdom)

12:30pm-2:00pm: Sleep disordered breathing in patients of Parkinson’s disease with REM sleep behavior disorder

R. Yadav, N. Kamble, J. Saini, K. Kumar, P.K. Pal (Bangalore, India)

12:30pm-2:00pm: Sleep disorders in progressive supranuclear palsy

B. Muinjonov, E. Giyaziddinova (Tashkent, Uzbekistan)

12:30pm-2:00pm: Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism

F. Krismer, B. Pinter, C. Müller, P. Mahlknecht, M. Nocker, E. Reiter, A. Djamshidian-Tehrani, S.M. Bösch, G.K. Wenning, C. Scherfler, W. Poewe, K. Seppi (Innsbruck, Austria)

12:30pm-2:00pm: Speech 10 years post bilateral STN-DBS for Parkinson’s disease

E. Tripoliti, P. Mahlknecht, L. Zrinzo, M. Hariz, T. Foltynie, J. Candelario, P. Limousin (London, United Kingdom)

12:30pm-2:00pm: Speech evaluation in Parkinson’s disease using a transcribed version of the Frenchay dysarthria assessment

M. Löhle, A. Zenker, R. Jäckel, C. Bosredon, R. Hoffmann, A. Storch (Rostock, Germany)

12:30pm-2:00pm: Spinal cord stimulation improves freezing of gait in Parkinson’s disease in chronic implanted stn-dbs patients: A case report

C.O. Souza, C.P. Souza, A.L. Pardini, D. Boari, L.A. Teixeira, E.R. Barbosa, E.T. Fonoff (Sao Paulo, Brazil)

12:30pm-2:00pm: Spinal fluid biomarkers for multiple system atrophy – A pilot study

W. Singer, A. Schmeichel, D.M. Goldstein, J.D. Schmelzer, A.D. Zeller, T.L. Gehrking, P.A. Low (Rochester, MN, USA)

12:30pm-2:00pm: Statistical aspects when exploring the association between change in body mass index (BMI), UPDRS scores and survival in the NET PD long-term study-1

A. Perez, A.M. Wills, J. Wang, X. Su, J. Morgan, S.S. Rajan, M. Leehey, G.M. Pontone, K.L. Chou, C. Umeh, Z. Mari, J. Boyd, For the NINDS NET-PD Investigators (Austin, TX, USA)

12:30pm-2:00pm: Stereotactic pallidotomy for Parkinson’s disease in El Salvador: One year follow up

S.L. Peña, R.E. Amaya (San Salvador, El Salvador)

12:30pm-2:00pm: Stereotactic surgery targeting on ventral oral posterior/ventral intermediate (Vop/Vim) in patients with upper limb dystonia: Neuronal activity and optimal effective site

N. Murase, M. Matsuhashi, K. Maeda, S. Kawarazaki, M. Nakamura, T. Thukahara, H. Hirabayashi (Kyoto City, Japan)

12:30pm-2:00pm: Stimulation of the globus pallidus internus in the treatment of Parkinson’s disease: Long-term results of a monocentric follow-up

M.L. Lachenmayer, C. Bettschen, I. Debove, J. Muellner, C. Bernasconi, J.M. Burgunder, J.K. Krauss, M. Oertel, A. Kaelin, C. Pollo, M. Schuepbach (Bern, Switzerland)

12:30pm-2:00pm: Strengths and weaknesses of patient-reported outcomes following DBS surgery: Comparing clinician, patient, and caregiver assessments

L. Shahgholi, W. Deeb, K. Foote, A. Shukla, U. Akbar, J.P. Rossi, S. De Jesus, M.S. Okun (Gainesville, FL, USA)

12:30pm-2:00pm: Subjective report does not predict objective swallow impairment in atypical Parkinsonian syndromes

L. Shahgholi, S. De Jesus, A. Paterson, W. Deeb, N.R. McFarland, K. Hegland (Gainesville, FL, USA)

12:30pm-2:00pm: Subthalamic nucleus deep brain stimulation modulate catecholamine levels with significant relations to clinical outcome after surgery in patients with Parkinson’s disease

T. Yamamoto, T. Uchiyama, Y. Higuchi, M. Asahina, S. Hirano, Y. Yamanaka, S. Kuwabara (Chiba, Japan)

12:30pm-2:00pm: Successful DBS: Doctors happy, patients not – Why?

M.H. Strothjohann, B. Holzinger, G.A. Fuchs, F. Weber (Bad Camberg, Germany)

12:30pm-2:00pm: Suggested protocol for electroconvulsive therapy for depression in a Parkinson’s disease patient with a deep brain stimulator: A case report

K. Dashtipour, M. Pereau, D. Trenkle, C. Osorio, K. Stoletniy (Loma Linda, CA, USA)

12:30pm-2:00pm: Surgical replacement of implantable pulse generators in deep brain stimulation: Adverse events and risk factors in a multicenter cohort

E. Jiltsova, A. Fytagoridis, T. Heard, J. Samuelsson, P. Zsigmond, S. Skyrman, T. Skoglund, T. Coyne, P. Silburn, P. Blomstedt (Uppsala, Sweden)

12:30pm-2:00pm: Survey of prodromal symptoms of Parkinson’s disease in Japan

M. Yogo, M. Morita, M. Suzuki (Katsushika-ku, Japan)

12:30pm-2:00pm: Survival and risk of mortality of synucleinopathies: A 15 years population-based study (1991 – 2005)

R. Savica, J. Bower, C. Hagen, A.J. Eric, M.M. Mielke (Rochester, MN, USA)

12:30pm-2:00pm: Swallowing in individuals with Parkinson’s disease: A study of FEES

A. Ayres, M.R. Olchik, C.R.M. Rieder, G.P. Jotz (Porto Alegre, Brazil)

12:30pm-2:00pm: Sweet spot of antidystonic effect in pallidal neurostimulation

M.M. Reich, F. Lange, R. Nijlunsing, J. Roothans, M. Rezhkov, M. Åström, N. Pozzi, F. Steigerwald, R. Nickl, C. Matthies, J. Volkmann (Wuerzburg, Germany)

12:30pm-2:00pm: Systematic literature review of droxidopa in clinical trials for neurogenic orthostatic hypotension (nOH) in parkinsonism

S. Tashiro, K. Dashtipour, J.J. Chen, K. Frei, E. Rashidian (Loma Linda, CA, USA)

12:30pm-2:00pm: Targeting TLR4 for disease modification in multiple system atrophy: Experimental evidence

S. Venezia, V. Refolo, N. Stefanova (Innsbruck, Austria)

12:30pm-2:00pm: Tau dysfunction in the basal ganglia of a mouse model of tauopathy related to PSP

A. Damianich, M. Sartor, S. Espindola, I.R.E. Taravini, O.S. Gershanik, J.E. Ferrario, M. Avale (Buenos Aires, Argentina)

12:30pm-2:00pm: Thalamic deep brain stimulation for cerebellar outflow tremor and midbrain tremor: a case series

P. Anprasertporn, B.L. Guthrie, H.C. Walker (Birmingham, AL, USA)

12:30pm-2:00pm: Thalamic-subthalamic deep brain stimulation for refractory orthostatic tremor: A report of 3 cases

D. Athauda, D. Georgiev, I. Iciar Aviles-Olmos, A. Peters, B. Day, P. Brown, L. Zrinzo, M. Hariz, P. Limousin, T. Foltynie (London, United Kingdom)

12:30pm-2:00pm: The association between objectively measured physical activity and health-related-quality of life in people with Parkinson’s disease

J.M.T. Van Uem, I. Liepelt-Scarfone, B. Cerff, M. Kampmeyer, J. Prinzen, M. Zuidema, M.A. Hobert, S. Hucker, S. Del Din, S. Gräber, D. Berg, W. Maetzler (Tübingen, Germany)

12:30pm-2:00pm: The basal ganglia muscarine receptors impairment in progressive supranuclear palsy

B. Muinjonov, E. Giyaziddinova, G. Rakhimbaeva (Tashkent, Uzbekistan)

12:30pm-2:00pm: The care needs project: Understanding the experience of people with Parkinson’s in institutional care and understanding the care needs of people with Parkinson’s

A. Hand, R.W. Walker, W.K. Gray, L.L. Oates (North Shields, United Kingdom)

12:30pm-2:00pm: The Catalan multiple system atrophy-registry (CMSAR)

F. Antonelli, E. Muñoz, J. Pagonabarraga, J. Hernández-Vara, A. Bayes, O. de Fabregues, F. Valldeoriola, E. Tolosa, Y. Compta, M. Ezquerra, R. Fernandez, M. Calopa, S. Jauma, M. Pujol, V. Puente, A. Cámara, L. Planellas, M.J. Martí (Barcelona, Spain)

12:30pm-2:00pm: The changing profile of informal carers for people with Parkinson’s with disease progression

A. Hand, R.W. Walker, W. Gray, K. Baker (North Shields, United Kingdom)

12:30pm-2:00pm: The combined effect of REM sleep behavior disorder and hyposmia on cognition and motor phenotype in Parkinson’s disease

S.B. Koh, S.H. Kang, H.M. Lee, W.K. Seo, J.H. Kim (Seoul, Korea)

12:30pm-2:00pm: The condition of cerebral hemodynamics in the secondary vascular parkinsonism

D. Akramova, A. Umarov, G. Rakhimbaeva, M. Ataniyazov, D. Shosaidova (Tashkent, Uzbekistan)

12:30pm-2:00pm: The core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD): Tolerability of preoperative neuropsychological testing for deep brain stimulation in Parkinson’s disease

G.D. Pal, V. Persinger, B. Bernard, B. Ouyang, C. Goetz, L. Verhagen (Chicago, IL, USA)

12:30pm-2:00pm: The effect of a structured medication review on quality of life in patients with Parkinson’s disease. An interim analysis

A. Verbeek, N. Oonk, E. Munster, K. Movig, K. ter Huurne, H. Nijmeijer, J. van der Palen, L. Dorresteijn (Eerbeek, Netherlands)

12:30pm-2:00pm: The effect of short pulse width neurostimulation in GPi-DBS

K. Kimura, H. Kishida, N. Ueda, K. Hamada, T. Kawasaki, F. Tanaka (Yokohama, Japan)

12:30pm-2:00pm: The effects of 60 Hz frequency of STN-DBS on gait in Parkinson’s disease

H. Brozová, K. Peterová, E. Ruzicka, J. Rusz, E. Plananská, L. Brabcová, R. Jech (Prague 2, Czech Republic)

12:30pm-2:00pm: The effects of dysphagia course for speech & language pathologist in Israel on clinical-related knowledge and confidence

Y. Manor, H. Shabtai, O. Sella (Tel-Aviv, Israel)

12:30pm-2:00pm: The effects of fluvoxamine maleate in a post-natal stress rat model of neurodegeneration

E. Dalle, W. Daniels, M. Mabandla (Durban, South Africa)

12:30pm-2:00pm: The evolution of REM sleep behavior disorder in Parkinson’s disease: The DeNoPa cohort at 2-year follow-up

F. Sixel-Döring, J. Zimmermann, A. Wegener, B. Mollenhauer, C. Trenkwalder (Kassel, Germany)

12:30pm-2:00pm: The finger tapping and disrupted smooth pursuit to detect the hepatic encephalopathy: Results of the subgroup analysis of movement disorders in non-Wilsonian hepatic cirrhotic patients

K. Methawasin, P. Chonmaitree, C. Wongjitrat, S. Rattanamongkolgul, T. Asawavichienjinda (Ongkharak, Thailand)

12:30pm-2:00pm: The heterogeneity of fatigue in different stages of Parkinson’s disease

M.R. Nodel, N.N. Yakhno (Moscow, Russia)

12:30pm-2:00pm: The impact of a movement disorders specialist on resident knowledge, as measured by the resident in-service training examination (RITE)

A. Killoran (Morgantown, WV, USA)

12:30pm-2:00pm: The importance of Ishihara testing in early diagnosing of Parkinson’s disease

S. Mirdedaev, K. Mirzayeva, D. Baykhonova (Tashkent, Uzbekistan)

12:30pm-2:00pm: The influences of STN-DBS and levodopa on cardiovascular autonomic function in patients with Parkinson’s disease: Evaluated by trigonometric regressive spectral analysis

K. Li, M. Wolz, R. Haase, H. Reichmann, T. Ziemssen (Dresden, Germany)

12:30pm-2:00pm: The initial motor symptom of Parkinson’s disease in relation to age at onset and gender: A Sri Lankan perspective

V. Suriyakumara, R. Gamage, H. Gunasekara, T. Fernando, A. Jayasuriya, R. Wijeyekoon, T. Muthukuda, R. De Silva (Nugegoda, Sri Lanka)

12:30pm-2:00pm: The long-term follow-up of subthalamic nucleus deep brain stimulation comparing medication alone in advanced Parkinson’s disease patients

S.H. Lin, S.Y. Chen, F.S. Jaw (Hualien, Taiwan)

12:30pm-2:00pm: The National Parkinson Foundation mentoring and networking program: Phase I the process

C.B. Hunter, P.R. Palmentera, B. Vernon, A. Silver, K. Arney, J. Fleisher, F. Cubillos (Houston, TX, USA)

12:30pm-2:00pm: The non-motor side of the honey-moon period of Parkinson’s disease

R. Erro, M. Picillo, C. Vitale, M. Amboni, M. Moccia, M.T. Pellecchia, P. Barone (London, United Kingdom)

12:30pm-2:00pm: The non-motors symptoms in Parkinson’s disease patients with freezing of gait

H.C. Huang, M.K. Lu, C.H. Tsai (Taichung, Taiwan)

12:30pm-2:00pm: The prevalence of constipation and irritable bowel syndrome in Parkinson’s disease patients according to Rome III diagnostic criteria

T. Mishima, J. Fukae, S. Fujioka, K. Inoue, Y. Tsuboi (Fukuoka, Japan)

12:30pm-2:00pm: The prevalence of gastrointestinal disorders and non-motor symptoms in a cohort of patients with Parkinson’s disease

P.J. Hobson, J.R. Meara (Rhyl, United Kingdom)

12:30pm-2:00pm: The relation between dream content and non-motor symptoms in Parkinson’s disease and idiopathic REM sleep behavior disorder

P. Bugalho, T. Lampreia, R. Miguel, M. Mendonça, A. Caetano, R. Barbosa (Lisbon, Portugal)

12:30pm-2:00pm: The relationship between blood pressure, sex and survival in multiple system atrophy

T. Gurevich, A. Fisher, L. Markin, A. Rozenberg, E. Atanasova Mishkova- Serafimova, D. Klepikov, A. Ezra, J. Knaani, N. Giladi, C. Peretz (Tel Aviv, Israel)

12:30pm-2:00pm: The relationship between body composition and postural instability in idiopathic Parkinson’s disease

K.S. Diab, L.A. Hale, D.L. Waters, M.A. Skinner, G. Hammond-Took (Baghdad, Iraq)

12:30pm-2:00pm: The relationship between the cognitive phenotype and 5-HT2A receptor in PD with visual hallucinations

S.S. Cho, A.P. Strafella, S. Duff-Canning, M. Zurowski, A.C. Vijverman, V. Bruno, C. de Aquino, M. Criaud, P.M. Rusjan, S. Houle, S.H. Fox (Toronto, ON, Canada)

12:30pm-2:00pm: The role of diabetes mellitus and hyperglycemia in early de novo Parkinson’s disease patients

S. Polychronis, G. Pagano, M. Politis (London, United Kingdom)

12:30pm-2:00pm: The score changes of clinical symptom assessment scales for multiple system atrophy in 2-3 years

M. Matsushima, I. Yabe, I. Takahashi, K. Sakushima, F. Nakano, M. Hirotani, T. Kano, K. Horiuchi, H. Houzen, H. Sasaki (Sapporo, Japan)

12:30pm-2:00pm: The social value of improvement in activities of daily living from levodopa-carbidopa intestinal gel use among the advanced Parkinson’s disease population

K. Sail, T. Shih, J. Sullivan, J. Yash, E. van Eijndhoven, C. Zadikoff, T. Marshall, D. Lakdawalla (Mettawa, IL, USA)

12:30pm-2:00pm: The study of clinical outcome of deep brain stimulation for the idiopathic Parkinson’s disease at 6 months follow-up

P. Papitak, M. Aphiwatthanakun, T. Srikijvilaikul, N. Limotai (Bangkok, Thailand)

12:30pm-2:00pm: The subthalamic nucleus activity during gait in Parkinson’s disease

A. Leporini, G. Arnulfo, N.G. Pozzi, C. Palmisano, J. Brumberg, A. Canessa, C.A. Frigo, G. Pezzoli, F. Steigerwald, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)

12:30pm-2:00pm: The value of preference-based measures of quality of life in people with Parkinson’s: A systematic review

Y. Xin, E. McIntosh (Glasgow, United Kingdom)

12:30pm-2:00pm: Theta burst repetitive transcranial magnetic stimulation in a case with cortical-basal ganglionic degeneration

A. Demirtas-Tatlidede, Z. Matur, B. Bilgic, H. Hanagasi, M. Emre, H. Gurvit, E. Oge (Istanbul, Turkey)

12:30pm-2:00pm: Three cases of neuronal intranuclear inclusion disease (NIID)

Y. Miyamoto, Y. Morita, K. Furuta, Y. Osaki, H. Arahata, A. Watanabe, N. Fujii, T. Iwaki, H. Furuya (Kochi, Japan)

12:30pm-2:00pm: Tourette syndrome treated by continuous electrical neuromodulation (DBS): Targeting the comorbidities?

F. Cyprien, L. Cif, V. Gonzalez, E. Sanrey, J. Perez, P. Coubes (Montpellier, France)

12:30pm-2:00pm: Toward clinical use of electrode localizations in deep brain stimulation therapy

S. Ewert, A. Horn, P. Plettig, M. Ruch, A. Kühn (Berlin, Germany)

12:30pm-2:00pm: Tractography patterns of subthalamic nucleus deep brain stimulation

N.S. Vanegas-Arroyave, P.M. Lauro, L. Huang, M. Hallett, S. Horovitz, K.A. Zaghloul, C. Lungu (New York, NY, USA)

12:30pm-2:00pm: Traditional trial-and-error versus neuroanatomical-3D-image software-assisted deep brain stimulation programming in patients with Parkinson’s disease

N. Pavese, S. Rodemark, Y.F. Tai, N. Yousif, D. Nandi, P.G. Bain (London, United Kingdom)

12:30pm-2:00pm: Trajectories of prediagnostic functioning in Parkinson’s disease during 14 years before clinical onset

S. Darweesh, V. Verlinden, B. Stricker, A. Hofman, P. Koudstaal, M.A. Ikram (Rotterdam, Netherlands)

12:30pm-2:00pm: Transcranial unilateral MR guided high intensity focused ultrasound in Parkinson’s disease or essential tremor seems to be save concerning dysphagia and dysarthria

S. Hägele-Link, N.A. Wegener, S.R. Schreglmann, J. Rosenfeld, M. Mueller-Baumberger, R. Bauer, A. Lebeda, B. Werner, E. Martin, G. Kägi (St. Gallen, Switzerland)

12:30pm-2:00pm: Transient mild hyperglycemia as diagnostic tool for idiopatic Parkinson’s disease triggered by psychoemotional stress

M.N. Khanova, K.A. Rasulova (Tashkent, Uzbekistan)

12:30pm-2:00pm: Transient, symptomatic, non-infectious hypodensity around deep brain stimulation electrode

F. Alonso-Frech, J.A. Barcia Albacar, M.J. Catalán Alonso, C. Fernández, E. López Valdes, M. Yus (Madrid, Spain)

12:30pm-2:00pm: Translation of the European physiotherapy guideline for Parkinson’s disease to Portuguese

T.T.C. Capato, L.R.S. Almeida, J.M.M. Domingos, B. Bolem, S. Keus (São Paulo, Brazil)

12:30pm-2:00pm: Treating Parkinson’s 2015–A nationwide survey of treatment responses and complications in 1000 Irish patients with Parkinson’s disease

C. Stubbe, P. Bogdanova-Mihaylova, N. Kavanagh, K. Mulpeter, D. Bradley, T. Lynch, T. Counihan, P. Brown, S. O'Sullivan, R.A. Walsh (Dublin, Ireland)

12:30pm-2:00pm: Treatment of lipopolysaccharide-induced parkinsonism

I. Niehaus (Rendsburg, Germany)

12:30pm-2:00pm: Triple stimulation technique findings in patients with Parkinson’s disease and multiple system atrophy

H. Wang, Q. Ding, J. Yuan, L. Cui (Beijing, People's Republic of China)

12:30pm-2:00pm: Twelve-week sensor assessment in Parkinson’s disease: Impact on quality of life

J.M.T. Van Uem, K.S. Maier, A.T. Santos, O. Fagerbakke, F. Larsen, J.J. Ferreira, W. Maetzler (Tübingen, Germany)

12:30pm-2:00pm: Two years after unilateral Forel’s H campotomy for Parkinson’s disease: Quality of life, motor and cognitive outcomes of eleven patients

F. Godinho, M.O. Oliveira, P. Terzian, C. Costa, P. Gordon, M.S. Rocha (São Paulo, Brazil)

12:30pm-2:00pm: Types of farming and prevalence and incidence of Parkinson’s disease: French nationwide study

S. Kab, J. Spinosi, L. Chaperon, A. Dugravot, A. Singh-Manoux, F. Moisan, A. Elbaz (Saint-Maurice, France)

12:30pm-2:00pm: Unawareness of causes of sudden deterioration in Parkinson’s patients in movement disorder clinic

V. Paramanandam, D.A. Olszewska, C. Fearon, B. Magennis, T. Lynch (Dublin, Ireland)

12:30pm-2:00pm: Understanding, predicting, and preventing falls in progressive supranuclear palsy

B.R. Bluett, I. Litvan, S. Cheng, J. Juncos, Y. Bordelon, D.E. Riley, D. Standaert, S.G. Reich, D.A. Hall, B. Kluger, D. Shprecher, C. Marras, J. Jankovic (Las Vegas, NV, USA)

12:30pm-2:00pm: Underutilization of physiotherapy for Parkinson’s disease in the United States

M.E. Fullard, D.P. Thibault, A. Hill, J. Fox, A.W. Willis (Philadelphia, PA, USA)

12:30pm-2:00pm: Unilateral dual lead thalamic deep brain stimulation improves refractory essential tremor

D. Isaacs, J.T. Butler, C. Tolleson, F. Phibbs, J. Fang, P. Hedera (Nashville, TN, USA)

12:30pm-2:00pm: Unilateral focused ultrasound thalamotomy in tremor-dominant Parkinson’s disease

B.B. Shah, D.S. Huss, S. Sperling, M.B. Harrison, J. Elias (Charlottesville, VA, USA)

12:30pm-2:00pm: Unilateral microelectrode mapping to guide bilateral deep brain stimulation electrode implantation: A retrospective study of anatomical lead placement and DBS programming outcomes

T.M. Herrington, K. Kanoff, J. Simon, E.N. Eskandar (Boston, MA, USA)

12:30pm-2:00pm: Unilateral MR-guided high intensity focused ultrasound ablation of the cerebellothalamic tract in essential tremor

S.R. Schreglmann, S. Hägele-Link, R. Bauer, N. Wegener, A. Lebeda, B. Werner, E. Martin, G. Kägi (London, United Kingdom)

12:30pm-2:00pm: Unusual motor and non-motor symptoms and signs in the early stage of Parkinson´s disease

H.A.G. Teive, D.C. Bertucci, R.P. Munhoz (Curitiba, Brazil)

12:30pm-2:00pm: Unusual phenotype of pathologically confirmed progressive supranuclear palsy with autonomic dysfunction and cerebellar ataxia

S. Kurcova, K. Mensikova, L. Tuckova, J. Ehrmann, P. Kanovsky (Olomouc, Czech Republic)

12:30pm-2:00pm: Upregulated vascular endothelial nitric oxide synthase in Parkinson’s disease cases that have received subthalamic stimulation: A post-mortem evaluation

C. Mantanona, L. Hodgson, J.L. Elson, I.S. Pienaar (Newcastle upon Tyne, United Kingdom)

12:30pm-2:00pm: Use of the physiotherapy in the treatment of initial stages of Parkinson’s disease

O.L. Tondiy (Kharkiv, Ukraine)

12:30pm-2:00pm: Usefulness of total neuropathy score revised as a screening tool of peripheral neuropathy in patients with Parkinson’s disease

P.W. Ko, J.S. Park, K. Kang, H.W. Lee (Daegu, Korea)

12:30pm-2:00pm: Vagotomy and Parkinson’s disease risk: A Swedish register-based matched cohort study

B. Liu, F. Fang, N.L. Pedersen, A. Tillander, J.F. Ludvigsson, A. Ekbom, P. Svenningsson, H. Chen, K. Wirdefeldt (Stockholm, Sweden)

12:30pm-2:00pm: Validation study of Parkinson anxiety scale, Czech version

N. Zemanová, M. Baláz (Brno, Czech Republic)

12:30pm-2:00pm: Valproate-induced reversible parkinsonism – A case series

R.M. Simões, N. Inácio, V.B. Silva, A. Arraiolos, P. Alegria, N. Canas, J. Vale (Loures, Portugal)

12:30pm-2:00pm: Variability in the ideal target of GPi DBS for Parkinson’s disease requires advanced direct targeting for optimal results

J.D. Hilliard, T. Morishita, M.S. Okun, K.D. Foote (Gainesville, FL, USA)

12:30pm-2:00pm: Verb naming in hypokinetic and hyperkinetic movement disorders: Preliminary results

E. Bayram, M.C. Akbostanci (Ankara, Turkey)

12:30pm-2:00pm: Vocal fold augmentation in patients with Parkinson’s disease: A case series and review of the literature

A.A. Thekdi (Houston, TX, USA)

12:30pm-2:00pm: VOP/ZI deep brain stimulation for the relief of tremor in multiple sclerosis

V. Levi, G. Messina, R. Cordella, I. Dones, A. Franzini (Milano, Italy)

12:30pm-2:00pm: Wearable sensors and decision algorithms for advanced therapy referral in Parkinson’s disease

D.A. Heldman, J.P. Giuffrida, E. Cubo (Cleveland, OH, USA)

12:30pm-2:00pm: Weight changes in PD patients post-DBS: A look at the factors involved

B. Ahmed, L.B. Almeida, A. Bona, S. De Jesus, D. Martinez-Ramirez, M.S. Okun (Gainesville, FL, USA)

12:30pm-2:00pm: When DBS can be of benefit in Huntington’s disease

J. Karl, K. Shannon, K. Slavin, L. Verhagen (Chicago, IL, USA)

12:30pm-2:00pm: Work-related stress and risk for Parkinson’s disease

J. Sieurin, R. Andel, E.G. Valdes, N.L. Pedersen, K. Wirdefeldt (Stockholm, Sweden)

12:30pm-2:00pm: Zolpidem ameliorates the freezing of gait in a patient with PAGF (pure akinesia with freezing of gait)-the possible neural mechanism

C.H. Tsai, H.C. Huang, J.R. Duann, B.L. Liu, H.C. Lin, M.K. Lu, J.C. Chen (Taichung, Taiwan)

12:30pm-2:00pm: α-synuclein CSF levels correlate with urinary dysfunction in early de novo Parkinson’s disease patients

G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

12:30pm-2:00pm: α-synuclein in peripheral organs decreases in Lewy body disease complicated by Alzheimer’s disease

H. Sumikura, J. Fujigasaki, Y. Nakano, A. Uchino, Y. Saito, H. Mochizuki, S. Murayama (Tokyo, Japan)

12:30pm-2:00pm: "Are patients with familial ET distinct from those with sporadic ET? Insight from 250 patients"

M. Manjunath, A. Lenka, K. Jhunjhunwala, K.S. Bhalsing, P.K. Pal (Bengaluru, India)

12:30pm-2:00pm: DYT2 screening in early-onset isolated dystonia in Italy

C. Reale, F. Invernizzi, M. Carecchio, S. Petrucci, G. Zorzi, F. Zibordi, M. Ginevrino, E.M. Valente, N. Nardocci, B. Garavaglia (Milan, Italy)

12:30pm-2:00pm: SLC6A17 mutations are not a common cause of intellectual disability and movement disorders in a large cohort of consanguineous Iranian families

I.A. Meijer, L.J. Azcona, H. Darvish, C. Paisán-Ruiz (New York, NY, USA)

12:30pm-2:00pm: 1 to 40 years later: Delayed effects of brain radiation presenting as parkinsonism

R. Mehanna, J. Jimenez-Shahed, I. Itin, R. Mehanna (Houston, TX, USA)

12:30pm-2:00pm: A 12-month, 2-arm, 2-period, randomized, controlled trial of a digital solution for the management of Parkinson’s disease (PD): Rationale and study design

S. Papapetropoulos, G. Mitsi (Boston, MA, USA)

12:30pm-2:00pm: A clinico-genetical study in a large cohort of patients with spastic paraplegia type 4 (SPG4)

A. Orlacchio, M. Mearini, L. Pedace, A. Casella, C. Montecchiani, F. Gaudiello, M. Maurialuisa, R. Massa, C. Caltagirone, R.P. Munhoz, J.L. Pedroso, O.G.P. Barsottini, T. Kawarai (Rome, Italy)

12:30pm-2:00pm: A comparative study of clinical profile of patients of drug induced parkinsonism with idiopathic Parkinson’s disease

S. Kushwaha, R. Mistry, A. Anthony, S. Khurana (Delhi, India)

12:30pm-2:00pm: A comprehensive characterisation of the salivary proteome of patients with Parkinson’s disease

J.M. Masters, A.J. Noyce, S. Lynham, T.T. Warner, G. Giovannoni, G.B. Proctor (Herts, United Kingdom)

12:30pm-2:00pm: A descriptive study on the safety and feasibility of mesenchymal stem cell therapy for Parkinson’s disease: A case series

M.J.O.V. Buensalido, J.J.A. Tiongson (Pasig City, Philippines)

12:30pm-2:00pm: A heterozygous splicing variant in NPC2 in a patient with PSP

C. Castro-Fernández, C. García-Sancho, V. Rodríguez-Sureda, R. Martínez-Regueiro, P. Aguiar, P. Blanco-Arias, C. Pérez-Sousa, P. Díaz, C. Domínguez, M. Fernández-Prieto, T. García-Sobrino, J. Cortés, M. Arias, M.J. Sobrido (Santiago de Compostela, Spain)

12:30pm-2:00pm: A homozygous loss-of-function mutation in DNAJA3 causes hereditary motor and sensory neuropathy with spastic paraplegia (HMSN type V)

T. Kawarai, R. Miyamoto, Y. Kuroda, M. Omoto, M. Ueyama, N. Murakami, T. Furukawa, R. Oki, A. Mori, Y. Osaki, C. Banzrai, H. Nodera, A. Orlacchio, A. Hashiguchi, Y. Higuchi, H. Takashima, T. Kanda, Y. Izumi, Y. Nagai, T. Mitsui, R. Kaji (Tokushima, Japan)

12:30pm-2:00pm: A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity

L.V. Kalia, K. Menezes, Y. Zhang, S. Ishikura, N. Tran, H. Chau, A.M. Lozano, S.K. Kalia, J.G. Culotti, S. Suo, W.S. Ryu (Toronto, ON, Canada)

12:30pm-2:00pm: A novel haplotype in LRRK2 is associated with risk for multiple system atrophy in the Korean population

L.L. Farrell, E. Scott, H.J. Kim, I. Guella, S. Bortnick, E.M. Nosova, B. Jeon, C.W. Sin, H. Park, S.S. Park, M.J. Farrer (Vancouver, Cameroon)

12:30pm-2:00pm: A novel homozygous DJ1 mutation causes parkinsonism and ALS in a Turkish family

H.A. Hanagasi, A. Giri, G. Guven, B. Bilgic, A.K. Hauser, M. Emre, P. Heutink, N. Basak, T. Gasser, J. Simón-Sánchez, E. Lohmann (Istanbul, Turkey)

12:30pm-2:00pm: A novel phenotype associated with GRN mutations: Spastic ataxia

I. Faber, J.R.M. Prota, A.R.M. Martinez, B.S. Carvalho, Í.T. Lopes-Cendes, M.C. França Jr (Campinas, Brazil)

12:30pm-2:00pm: A novel single molecule imaging approach to detect individual protein oligomers in CSF from patients with Parkinson’s disease (PD)

S. Gandhi, M.H. Horrocks, S.F. Lee, N.W. Wood, D. Klenerman (London, United Kingdom)

12:30pm-2:00pm: A peripheral pathway to restless legs syndrome? Clues from familial amyloid polyneuropathy

T. Teodoro, P. Viana, D. Abreu, I. Conceição, R. Peralta, J.J. Ferreira (Lisboa, Portugal)

12:30pm-2:00pm: A phase 3, placebo-controlled study with an open-label extension: Sustained incobotulinumtoxinA efficacy in upper-limb post-stroke spasticity over 48 weeks

P. Kanovský, A. Brashear, E.P. Elovic, M.C. Munin, A. Hanschmann, R. Hiersemenzel, C. Marciniak (Olomouc, Czech Republic)

12:30pm-2:00pm: A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome

J. Jankovic, J. Jimenez-Shahed, C. Budman, B. Coffey, T.K. Murphy, D. Shprecher, D. Stamler (Houston, TX, USA)

12:30pm-2:00pm: A pilot study of whole exome sequencing in progressive supranuclear palsy

K.Y. Mok, A. Tucci, R. de Silva, H.R. Morris, A.B. Singleton, H. Houlden, J. Hardy, IPDGC (London, United Kingdom)

12:30pm-2:00pm: A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD)

H.H. Fernandez, S.A. Factor, R.A. Hauser, J. Jimenez-Shahed, W. Ondo, M.S. LeDoux, D. Shprecher, T. Simuni, D. Stamler, K.E. Anderson (Cleveland, OH, USA)

12:30pm-2:00pm: A rare genetic transcriptomopathy syndrome involving TAF1 leading to insights into more common neurologic disorders, including X-linked dystonia-parkinsonism (XDP)

G.J. Lyon (New York, NY, USA)

12:30pm-2:00pm: A strategy to classify Parkinson’s disease patients with dyskinesia: The analysis of center of pressure with impact of cognitive loading

W. Buated, P. Lolekha, T. Fujinami, S. Hidaka (Nomi, Japan)

12:30pm-2:00pm: A survey of movement disorders in a large sample of patients treated with antipsychotic medication

B. Balint, H. Killaspy, T.R.E. Barnes, N. Freemantle, E. Joyce, D. Martino, K.P. Bhatia (London, United Kingdom)

12:30pm-2:00pm: A validation study of a smartphone-based finger tapping application for quantitative assessment of bradykinesia in Parkinson’s disease

C.Y. Lee, S.J. Kang, Y.E. Kim, U. Lee, H.I. Ma, Y.J. Kim (Anyang-si, Gyeonggi-do, Korea)

12:30pm-2:00pm: A web resource on levodopa-induced dyskinesia (LID) genetics

M. Falla, H. Blankenburg, P. Gruber, I. Pichler, C. Schwienbacher, A. Hicks, F. Domingues, P.P. Pramstaller (Bolzano/Bozen, Italy)

12:30pm-2:00pm: A whole brain anatomical network model and its application in PD research

X. Lei, T. Chen, X. Hu, B. Zhang (Kunming, People's Republic of China)

12:30pm-2:00pm: Age associated effects of levodopa administration on striatal acetylcholinesterase activity

M. Messripour, A. Mesripour (Isfahan, Islamic Republic of Iran)

12:30pm-2:00pm: Alcohol-responsive action myoclonus of the leg in prostate cancer: A novel paraneoplastic syndrome

P. Termsarasab, S.J. Frucht (New York, NY, USA)

12:30pm-2:00pm: Alpha synuclein and crystallin expression in human lens in Parkinson’s disease

S.A. Schneider, E. Richert, G. Kuhlenbäumer, B. Nölle, K.P. Bhatia, G. Deuschl, J. Roider, A. Klettner (München, Germany)

12:30pm-2:00pm: Alpha-synuclein – super-resolution microscopy reveals potential new role of alpha-synuclein at the pre-synapse

J. Lautenschlaeger, F. Stroehl, A. Stephens, C.F. Kaminski, G.S. Kaminski Schierle (Cambridge, United Kingdom)

12:30pm-2:00pm: Alpha-synuclein gene variants may predict neurostimulation outcome

D. Weiss, S. Herrmann, L. Wang, C. Schulte, K. Brockmann, C. Plewnia, T. Gasser, M. Sharma, A. Gharabaghi, R. Krüger (Tübingen, Germany)

12:30pm-2:00pm: Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker

S.J. Chung, J. Kim, H.J. Lee, H.S. Ryu, K.W. Jung, M.J. Kim, M.J. Kim, S.M. Hong, S.J. Myung (Seoul, Korea)

12:30pm-2:00pm: Alpha-synuclein levels and dimerization in erythrocytes of Parkinson’s disease patients

N. Papagiannakis, C. Koros, M. Stamelou, A.M. Simitsi, M. Maniati, R. Antonelou, D. Papadimitriou, G. Dermentzaki, M. Moraitou, H. Michelakakis, L. Stefanis (Chaidari, Greece)

12:30pm-2:00pm: Alterations in 14-3-3 protein phosphorylation as a biomarker for neurodegeneration

T. Yacoubian, X. Chi, G. Cutter, M. McFerrin (Birmingham, AL, USA)

12:30pm-2:00pm: Altered connectivity within the cerebello-thalamo-cortical network in essential tremor: A resting state fMRI study

V. Nicoletti, I. Pesaresi, S. Fabbri, S. Giannoni, U. Bonuccelli, M. Cosottini, R. Ceravolo (Pisa, Italy)

12:30pm-2:00pm: Altered glutamate response and calcium dynamics in iPSC derived striatal neurons from XDP-patients

P. Capetian, N. Stanslowsky, E.M. Bernhardi, M. Naujock, K. Grütz, A. Domingo, P. Seibler, F. Wegner, C. Klein (Lübeck, Germany)

12:30pm-2:00pm: Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease

C. Max, A. Westenberger, N. Brueggemann, A. Domingo, K. Gruetz, H. Pawlack, A. Weissbach, A.A. Kuehn, J. Spiegler, A.E. Lang, J. Sperner, V.S.C. Fung, J. Schallner, G. Gillessen-Kaesbach, A. Muenchau, C. Klein (Lübeck, Germany)

12:30pm-2:00pm: An exuberant cortical γb influences the unmasking and intensity of dyskinesia in 6-OHDA-treated freely-moving rats

S. Galati, V. D'Angelo, A. Salvadè, A. Kaelin, A. Stefani (Lugano, Switzerland)

12:30pm-2:00pm: An open label trial to test the modulation of cerebellar motor pathways in primary orthostatic tremor using rTMS and fMRI

C. Gallea, E. Roze, S. Lehéricy, M. Vidailhet, S. Meunier (Paris, France)

12:30pm-2:00pm: An optimized formulation of velocity distribution in digital spiral analysis to differentiate essential tremor and Parkinson’s disease

K.H. Chen, Y.J. Chen, P.C.L. Lin, B.S. Yang, C.H. Lin, R.M. Wu (Hsin-Chu, Taiwan)

12:30pm-2:00pm: Analysis of LINGO1 and LINGO2 genes in essential tremor and Parkinson’s disease

N.Y. Abramycheva, M.S. Stepanova, E.Y. Fedotova, E.O. Ivanova, S.N. Illarioshkin (Moscow, Russia)

12:30pm-2:00pm: Analysis of MAPT, GRN and C9orf72 genes in progressive supranuclear palsy, corticobasal syndrome and frontotemporal lobar degeneration in Russian population

E.Y. Fedotova, N.Y. Abramycheva, M.S. Stepanova, A.S. Vetchinova, S.N. Illarioshkin (Moscow, Russia)

12:30pm-2:00pm: Analysis of relationships between spinal deformity and walking ability in Parkinson’s disease patients

Y. Nakamura, Y. Machida, T. Hanawa, M. Kanai, K. Tajima, S. Asano (Satte, Japan)

12:30pm-2:00pm: Analysis of temporal gait features extracted from accelerometer-based signals during ambulatory walking in Parkinson’s disease

M. Boutaayamou, M. Demonceau, O. Brüls, J.G. Verly, G. Garraux (Liège, Belgium)

12:30pm-2:00pm: Analysis of the genetic variability in Parkinson’s disease from southern Spain

S. Bandres-Ciga, N.E. Mencacci, R. Durán, F.J. Barrero Hernández, F. Escamilla-Sevilla, S. Morgan, J. Hehir, F. Vives, J. Hardy, A.M. Pittman (Granada, Spain)

12:30pm-2:00pm: Apathy phenotype in Parkinson’s disease: Motor and non-motor features

S. Varanese, A. Di Rocco, M.F. Ghilardi, N. Modugno, R. Gilbert-Wolf, B. Perfetti (Pozzilli, Italy)

12:30pm-2:00pm: APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa

H. Shill, E.J. Pappert, A. Agro, B. Dzyngel, T. Bilbault, R. Hauser, S. Isaacson (Phoenix, AZ, USA)

12:30pm-2:00pm: Apocyanin ameliorates post-stroke movement disorder in rats: Possible role of neurochemical and inflammatory alterations

M. Kapoor, R. Sandhir, B. Nehru (Chandigarh, India)

12:30pm-2:00pm: Assessment of Parkinson’s disease risk loci as DNA methylation quantitative trait loci

D.G. Hernandez, C. Letson, J. Simon-Sanchez, T.R. Price, M.A. Nalls, A.B. Singleton (Bethesda, MD, USA)

12:30pm-2:00pm: Association analysis of SNP rs11868035 in SREBF1 with Parkinson’s disease, amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population

X. Yuan, Y. Chen, B. Cao, Q. Wei, R. Ou, H. Shang (Chengdu, People's Republic of China)

12:30pm-2:00pm: Association of four new candidate genetic variants with Parkinson’s disease in Han Chinese

L. Wang, L. Cheng, N.N. Li, W.J. Yu, X.Y. Sun, R. Peng (Chengdu, People's Republic of China)

12:30pm-2:00pm: Association of Parkinson’s disease severity and cortical and subcortical cognitive markers

H. Duran-Meza, A.D. Santana-Vargas, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, G. Millan-Rosas, U. Jimenez-Correa, M. Lopez-Ruiz (Mexico City, Mexico)

12:30pm-2:00pm: Associations between cerebrospinal fluid proteins and cytokines in Parkinson’s disease

R. Wijeyekoon, S. Moore, K. Farrell, D. Breen, R. Barker, C.H. Williams-Gray (Cambridge, United Kingdom)

12:30pm-2:00pm: Astroglia exert a neuro-protective role in Parkinson’s disease by reducing oxygen stress through dopamine-induced activation of the pentose-phosphate pathway

K. Mashima, S. Takahashi, T. Iizumi, T. Abe, N. Suzuki (Tokyo, Japan)

12:30pm-2:00pm: Augmentation and impulse control disorders in restless legs syndrome – Coexistence or association?

B. Heim, L. Zamarian, A. Heidbreder, A. Stefani, M.T. Pertl, E. Brandauer, K. Seppi, M. Delazer, W. Poewe, B. Högl, A. Djamshidian (Innsbruck, Austria)

12:30pm-2:00pm: Automated assessment of advanced motor Parkinson’s disease; a pilot study of the Parkinson’s KinetiGraph as an objective tool for measurement of motor fluctuations

P. Bogdanova-Mihaylova, N. Kavanagh, R.A. Walsh (Dublin, Ireland)

12:30pm-2:00pm: Automated Telehealth Diagnostics for Remote Parkinson Monitoring

D.A. Heldman, D.A. Harris, T. Felong, B. Goldberg, J.P. Giuffrida, E.R. Dorsey, M.A. Burack (Cleveland, OH, USA)

12:30pm-2:00pm: Bcr-Abl tyrosine-kinase inhibitors (B-ATKI) and Parkinson’s disease (PD)

E.A. Shamim, S.F. Baker, F.F. Liu, K.K. Mane, J.G. Layug, S. Vupputuri, C.C. DiStasio, S.M. Khandhar, C. Neff, S. Van Den Eeden, C. Lungu, R. Cooley, H.S. Martel, C. Chen, J. Dorman, M.A. Sinkiewicz, J. Klingman (Largo, MD, USA)

12:30pm-2:00pm: Beyond initial clinical phenotype of Madelung disease: Myoclonus, gait disorder and multisystem involvement led to genetic diagnosis

R. López-Blanco, A. Rojo-Sebastián, M.H. Torregrosa-Martínez, M. Molina-Sánchez, A. Blázquez-Encinar, M.Á. Martín-Casanueva (Madrid, Spain)

12:30pm-2:00pm: Bi-hemispheric phase synchronization in patients with Parkinson’s disease during stance, gait and upper limb motor tasks

M. Plotnik, Y. Miron, S. Hassin-Baer, O.S. Cohen, S. Kimel-Naor, I. Blatt, R. Inzelberg, J.W. Kantelhardt (Tel Hashomer, Israel)

12:30pm-2:00pm: Brain metabolic profile changes reflect subtle pathological alterations in different murine models of Parkinson’s disease

E. Glaab, F. Giesert, C. Jaeger, P. Dirscherl, A. Zimprich, A. Ulusoy, D.A. Di Monte, P. Garcia, R. Balling, W. Wurst, D. Truembach, M. Buttini, D. Vogt-Weisenhorn (Esch-Alzette, Luxembourg)

12:30pm-2:00pm: Bristle hair may point to hereditary spastic paraplegia type SPG35/ FAHN

T.W. Rattay, A.S. Söhn, K.N. Karle, S. Wiethoff, J. Reichbauer, M. Döbler-Neumann, I. Krägeloh-Mann, A. Münchau, B. Wilken, P. Bauer, L. Schöls, R. Schüle (Tübingen, Germany)

12:30pm-2:00pm: C9ORF72 intermediate repeat copies as a rare genetic cause of atypical Parkinsonian syndromes or Parkinson’s disease complicated by psychosis in a Sardinian population

M. Meloni, A. Cannas, P. Solla, M.M. Mascia, G. Orofino, R. Farris, D. Ciaccio, E. Binaghi, M.R. Murru, F. Marrosu (Cagliari, Italy)

12:30pm-2:00pm: Can body worn cameras help us understand the complex relationship between physical activity and falls in people with Parkinson’s?

K. Baker, M. Harvey, J. Monaghan, L. Rochester (Newcastle Upon Tyne, United Kingdom)

12:30pm-2:00pm: Caring for the majority: Telemedicine management of Parkinson’s disease (PD) in underserved populations in People’s Republic of China: A randomized trial

P.B. Chan, S. Liu, Z. Gu, J. An, C.M. Tanner (Beijing, People's Republic of China)

12:30pm-2:00pm: Carrier mediated delivery system bearing dopamine for effective management of parkinsonism

V. Bhargava, S. Bhargava (Kanpur, India)

12:30pm-2:00pm: Cell-surface expression of dopamine transporter facilitates the uptake of α-synuclein

J. Kobayashi, T. Hasegawa, S. Yoshida, N. Sugeno, R. Oshima, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

12:30pm-2:00pm: Cellular senescence induced by paraquat drives neuropathology associated with Parkinson’s disease

S.J. Chinta, G. Woods, M. Demaria, J. Campisi, J.K. Andersen (Novato, CA, USA)

12:30pm-2:00pm: Cerebellar atrophy in Parkinson’s disease and its implication for network connectivity

J.M. Shine, C. O'Callaghan, M. Hornberger, G.M. Halliday, S.J.G. Lewis (Palo Alto, CA, USA)

12:30pm-2:00pm: Changes in serum amino acid levels with progression of Parkinson’s disease

M. Figura, K. Kusmierska, E. Bucior, S. Szlufik, D. Koziorowski, Z. Jamrozik, A. Friedman, P. Janik (Warsaw, Poland)

12:30pm-2:00pm: Characterisation of the A30P mutation in alpha-synuclein gene in patient-derived cellular model of Parkinson’s disease

B.F.R. Santos, P.A. Barbuti, I. Boussaad, A. Hummel, R. Krüger (Belval, Luxembourg)

12:30pm-2:00pm: Characteristics of the interaction between different toxic aggregated species of alpha-synuclein and cell membrane

A.T. Marvian, D. Morshedi, F. Aliakbari, H. Ghapani, M. Nasuti (Tehran, Islamic Republic of Iran)

12:30pm-2:00pm: Characterization of striatal TH-immunoreactive cells in chronic and acute L-DOPA treatment in a mice model of Parkinson´s disease

G. Gomez, M. Bordone, S.I. Sanz-Blasco, M.A. Bernardi, J.E. Ferrario, I.R.E. Taravini, M.G. Murer, O.S. Gershanik (Buenos Aires, Argentina)

12:30pm-2:00pm: Children with idiopathic tics reveal additional features of hyperkinetic movement disorders

P.F. Sinnige, R. Brandsma, W. Eggink, M.J. Kuiper, I.J. Lunsing, M. Boon, C.C.S. Delnooz, M.E. van Egmond, O.G.F. Sinnige, J.J. de Vries, P.J. Hoekstra, D.A. Sival (Groningen, Netherlands)

12:30pm-2:00pm: Chorea – Ballism drug induced in replacement treatment with thyroid hormones – Case presentation

M. Sabau (Oradea, Romania)

12:30pm-2:00pm: Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the MPTP mouse model of Parkinson’s disease

H. Tang, R. Zhu, L. Gao, K. Nie, S. Feng, Z. Duan, Y. Zhang, X. Zhao, L. Wang, J. Zhao, Z. Huang, Y. Zhang, L. Wang (Guangzhou, People's Republic of China)

12:30pm-2:00pm: Ciprofloxacin as the cause of syndroma extrapiramidale

D. Imamovic, N. Subasic, A. Nakicevic, E. Suljic (Sarajevo, Bosnia and Herzegowina)

12:30pm-2:00pm: Circadian dysfunction in Parkinson’s disease: Effects on impaired gait initiation and locomotion

L. Alibiglou, J. Stewart, G. Bachman, C. Cooper, L. Liu, S. Ancoli-Israel (Chicago, IL, USA)

12:30pm-2:00pm: Clinical and genetic analyses in a cohort of the Taiwanese patients with apparently sporadic pure spastic paraplegia

Y.Y. Chang, Y.F. Chen, T.H. Yeh, Y.R. Wu, C.H. Tsai, Y.C. Chang, W.J. Hwang, H.C. Kuo, C.C. Huang, C.C. Lin, Y.Y. Jian, H.C. Shen, C.S. Lu, M.Y. Lan (Kaohsiung, Taiwan)

12:30pm-2:00pm: Clinical and imaging deterioration of a mild case of Wilson’s disease after chelation therapy

C. Kleoniki, K. Spiridon, T. Cristos, K. Aristidis (Ioannina, Greece)

12:30pm-2:00pm: Clinical and MRI-characteristics of drug-induced parkinsonism in Uzbekistan

A. Umarov, A. Prokhorova, G. Rakhimbaeva, K. Mirzaeva, N. Tuychibaeva (Tashkent, Uzbekistan)

12:30pm-2:00pm: Clinical and neuroimaging outcomes up to 18 years after fetal tissue transplant for Parkinson’s disease

C. Henchcliffe, J. Carter, A. Hanineva, Y. Kang, J. Babich, S.M. Gollomp, A.P. Strafella, A. Fasano, L.D. Ravdin, N. Hellmers, C. McRae (New York, NY, USA)

12:30pm-2:00pm: Clinical aspects of postural instability in Parkinson’s disease

T.S. Lovtsova, A.F. Vasilenko (Chelyabinsk, Russia)

12:30pm-2:00pm: Clinical exome sequencing – diagnostic yield in a sample of German patients with Parkinson’s disease

B. Schormair, G. Machetanz, B. Mollenhauer, C. Trenkwalder, J. Winkelmann (Neuherberg, Germany)

12:30pm-2:00pm: Clinical phenotype of Parkinsonian patients with α-synuclein mutation: Our case report and review of the literature

P. Nigro, N. Tambasco, M. Romoli, S. Simoni, E. Sacchini, E. Brahimi, E. Marsili, F. Ripandelli, P. Prontera, P. Calabresi (Perugia, Italy)

12:30pm-2:00pm: Clinical predictors of airway protective dysfunction in Parkinson’s disease

M.S. Troche, A.E. Brandimore, B. Schumann, M.S. Okun, K.W. Hegland (New York, NY, USA)

12:30pm-2:00pm: Clinical presentations of 2 Parkin / lysosomal storage disorder heterozygotes with Parkinson’s disease

M. Barkhuizen, D.G. Anderson, A.F. Grobler, S.J. Lubbe, H.R. Morris (Potchefstroom, South Africa)

12:30pm-2:00pm: Clinical profile of Wilson’s disease at Yangon General Hospital, Myanmar

S.M.M. Aye, K.M.P.P. Kyaw, Z. Myint Shwe, O. Ohnmar, Y.M. Aye, W.M. Thit (Yangon, Myanmar)

12:30pm-2:00pm: Clinically ‘slight’ bradykinesia in Parkinson’s disease is accurately detected using evolutionary computation analysis of finger tapping

J.E. Alty, J. Cosgrove, M.A. Lones, S.L. Smith, K. Possin, N. Schuff, S. Jamieson (Leeds, United Kingdom)

12:30pm-2:00pm: Coding and non-coding glucocerebrosidase variants have an impact on cognitive decline in Parkinson’s disease

C. Schulte, I. Liepelt-Scarfone, C.E. Hagen, A.K. Hauser, K. Brockmann, T. Gasser, J.B. Schulz, K. Reetz, S. Gräber, B. Mollenhauer, C. Trenkwalder, K. Witt, N. Schmidt, R. Dodel, M. Balzer-Geldsetzer, U. Wüllner, T. Klockgether, A. Spottke, A. Storch, H.U. Wittchen, O. Riedel, S. Baudrexel, E. Kalbe, D. Berg, M.M. Mielke (Tübingen, Germany)

12:30pm-2:00pm: Cognitive and depressive behavior changes in aged mice with heterozygous deletions of VMAT2 or of DAT

K. Ma, J. Huang, L. Liu, H. Jiang, X. Xu, C. Han, Y. Shen, Y. Xia, S. Guo, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: Cognitive impairments in children with tic disorders and Tourette syndrome

D. Aminova (Tashkent, Uzbekistan)

12:30pm-2:00pm: Colonic microbiome in Korean patients with Parkinson’s disease

D. Lee, Y.N. Kwon, T.B. Ahn (Seoul, Korea)

12:30pm-2:00pm: Comparing tremor- and non-tremor effects of ethanol in patients with essential tremor

J. Thompson-Westra, G. McCrossin, B. Voller, S. Auh, C. Lungu, S. Tinaz, V. Ramchandani, M. Hallett, D. Haubenberger (Bethesda, MD, USA)

12:30pm-2:00pm: Comparison of two protocols for neural induction and cultivation of iPSCs derived neural stem cells

M.G. Pauly, P. Capetian, B. Meier, V. Krajka, F. Stengel, P. Seibler, C. Klein (Lübeck, Germany)

12:30pm-2:00pm: Computational analysis of expression profiling data in a neuronal model of X-linked dystonia-parkinsonism

A. Domingo, A. David, G. Karen, L.V. Lee, R. Rosales, R.D. Jamora, R. Shamir, C. Klein, A. Westenberger (Lübeck, Germany)

12:30pm-2:00pm: Constipation in early de novo Parkinson’s disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers

G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

12:30pm-2:00pm: Construction of a levodopa-response index from wearable sensors for quantifying Parkinson’s disease motor functions: Preliminary results

M. Memedi, D. Nyholm, J. Westin, M. Senek, A. Medvedev, H. Askmark, S.M. Aquilonius, F. Bergquist, R. Constantinescu, F. Ohlsson, J. Spira, S. Lycke, A. Ericsson (Falun, Sweden)

12:30pm-2:00pm: Correlation among DNA methylation status and LINE-1 expression in rat brain

S. Mukherjee, K. Upadhyaya, D. Sharma (New Delhi, India)

12:30pm-2:00pm: Correlation between tremor severity of essential tremor and perpendicular displacement in digital spiral analysis

K.H. Chen, Y.J. Chen, P.C. Lin, B.S. Yang, C.H. Lin, R.M. Wu (Hsin-Chu, Taiwan)

12:30pm-2:00pm: Cortical impairment as marker of dementia risk in probable REM sleep behavior disorder in Parkinson’s disease

A.D. Santana-Vargas, H. Duran-Meza, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, M. Lopez-Ruiz, G. Millan-Rosas, U. Jimenez-Correa (Mexico City, Mexico)

12:30pm-2:00pm: Cortical role in the freezing of gait in Parkinson’s disease

M. Mihara, H. Otomune, H. Fujimoto, K. Konaka, Y. Watanabe, H. Mochizuki (Suita, Japan)

12:30pm-2:00pm: Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

12:30pm-2:00pm: Cyclic glycine-proline increased in the cerebrospinal fluid of Parkinson’s patients after supplementation of blackcurrant anthocyanins: Potential biomarker for treatment

J. Guan, Y. Alamri, D. Fan, M. MacAskill, T. Anderson (Auckland, New Zealand)

12:30pm-2:00pm: De novo mutations in PDE10A cause childhood-onset chorea with bilateral striatal lesions

N.E. Mencacci, E.J. Kamsteeg, L. R'Bibo, D. Lynch, B. Balint, M. Willemsen, M. Adams, S. Wiethoff, J. Ng, E. Meyer, L. Veneziano, P. Giunti, D. Hughes, M. Carecchio, G. Zorzi, C. Barzaghi, B. Garavaglia, N. Nardocci, V. Salpietro, J. Hardy, A. Pittman, H. Houlden, M. Kurian, L. Vissers, N. Wood, K. Bhatia (Londond, United Kingdom)

12:30pm-2:00pm: Defective ubiquitinated mitochondria accumulation in aged Parkinsonian LRRK2^R1441G knockin mice

H.F. Liu, P.W.L. Ho, L.F. Li, G.C.T. Leung, C.S.C. Lam, M.H.W. Kung, D.B. Ramsden, S.L. Ho (Hong Kong, Hong Kong)

12:30pm-2:00pm: Deficiency of HGprt in Lesch-Nyhan disease is associated with abnormal dopaminergic neurodevelopment in vivo

J.E. Visser, J.S. Witteveen, N.H.M. van Bakel, G.J.M. Martens, S.M. Kolk (Nijmegen, Netherlands)

12:30pm-2:00pm: Deletions at 22q11.2 in idiopathic Parkinson’s disease: A combined analysis of GWAS data

K.Y. Mok, U. Sheerin, J. Simón-Sánchez, A. Salaka, L. Chester, V. Escott-Price, K. Mantripragada, K.M. Doherty, A.J. Noyce, N.E. Mencacci, S.J. Lubbe, International Parkinson's Disease Genomics Consortium (IPDGC), C.H. Williams-Gray, R.A. Barker, K.D. van Dijk, H.W. Berendse, P. Heutink, J.C. Corvol, F. Cormier, S. Lesage, A. Brice, K. Brockmann, C. Schulte, T. Gasser, T. Foltynie, P. Limousin, K.E. Morrison, C.E. Clarke, S. Sawcer, T.T. Warner, A.J. Lees, H.R. Morris, M.A. Nalls, A.B. Singleton, J. Hardy, A.Y. Abramov, V. Plagnol, N.M. Williams, N.W. Wood (London, United Kingdom)

12:30pm-2:00pm: Depression and apathy in restless legs syndrome

Y. Kaji, K. Ouchi, K. HIrata (Mibu, Japan)

12:30pm-2:00pm: Detailed proteomic analysis of early PD brain highlights altered expression of mitochondrial proteins as an important event in sporadic PD

S. Gandhi, C.E. Murray, W.E. Heywood, J.L. Holton, K. Mills, T. Revesz (London, United Kingdom)

12:30pm-2:00pm: Detection of leucine-rich repeat kinase 2 in human biofluids

E. Mutez, W. Sibran, T. Comptdaer, P. Semaille, M. Drouyer, S. Bleuse, L. Defebvre, A. Destee, M.C. Chartier-Harlin, J.M. Taymans (Lille, France)

12:30pm-2:00pm: Developing a new home monitoring device for dyskinesia in Parkinson’s disease

J.E. Alty, J. Cosgrove, M.A. Lones, S. Jamieson, P. Duggan-Carter, C. Peacey, C. Wicks, R.F. Naylor, A.J. Turner, S.L. Smith (Leeds, United Kingdom)

12:30pm-2:00pm: Development of the UK hereditary spastic paraplegia registry: Analysis of SPAST patients reveals high rate of psychiatric comorbidities

V. Chelban, A. Tucci, H. Houlden (Chisinau, Republic of Moldova)

12:30pm-2:00pm: Diagnostic sensitivity and remote monitoring of motor and non-motor dysfunction in Parkinson’s disease

K. Muhammed, S. Arora, M. Hu, M. Husain (Oxford, United Kingdom)

12:30pm-2:00pm: Difference of REM sleep behavior disorder between the onset of before and after Parkinson’s disease

T. Nomura, Y. Inoue, K. Nakashima (Yonago, Japan)

12:30pm-2:00pm: Differences between responders and non-responders of Istradefylline for the wearing off in Parkinson’s disease

A. Yoritaka, H. Mori, N. Hattori (Saitoma, Japan)

12:30pm-2:00pm: Differences of gut bacterial community relate to pathology progress in Parkinson’s disease

T. Minato, S. Hasegawa, Y. Fujisawa, H. Tsuji, T. Asahara, K. Nomoto, A. Okamoto, T. Maeda, K. Ohno, M. Hirayama (Nagoya, Japan)

12:30pm-2:00pm: Different patterns of spontaneous brain activity between tremor-dominant and postural instability/gait difficulty subtypes of Parkinson’s disease: A resting-state fMRI study

H. Chen, Z. Wang, J. Fang, L. Gao, T. Feng (Beijing, People's Republic of China)

12:30pm-2:00pm: Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease

J. Varghese, K. Terpstra, S. Chiu, R. Mishra, Y. Bureau (London, ON, Canada)

12:30pm-2:00pm: Differential vulnerability to α-synuclein pathology among neuronal subpopulations

E. Luna, D.M. Riddle, V.M.Y. Lee, K.C. Luk (Philadelphia, PA, USA)

12:30pm-2:00pm: Differentiated versus undifferentiated mesenchymal stem cell therapy in paraquat model of Parkinson’s disease

S.I. El-Jaafary, H.S. Abdel Tawab, M.Y. Elwash, H. Gabr, H.M. Saad Eldien (Cairo, Egypt)

12:30pm-2:00pm: Differentiating Parkinson’s disease from advanced essential tremor using EMG

M. Muthuraman, J. Raethjen, G. Deuschl, S. Groppa (Mainz, Germany)

12:30pm-2:00pm: Diffusion tensor imaging (DTI) within the primate caudate nucleus marks dopaminergic (DA) and serotonergic (5-HT) lesions

S. Thobois, E. Météreau, M. Beaudoin-Gobert, S. Duperrier, L. Tremblay, V. Sgambato-Faure (Bron, France)

12:30pm-2:00pm: Diffusion tensor imaging biomarkers of nigrostriatal neurodegeneration in early Parkinson’s disease

J.A. Pineda-Pardo, G. Foffani, J.A. Obeso (Madrid, Spain)

12:30pm-2:00pm: Digitizing tablet and Fahn-Tolosa-Marín tremor ratings have comparable minimum detectable change

R.J. Elble (Springfield, IL, USA)

12:30pm-2:00pm: Discrimination of Parkinson’s disease participants from healthy controls using telephone-quality voice recordings

S. Arora, A. Tsanas (Oxford, United Kingdom)

12:30pm-2:00pm: Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease from OFF to fully ON

H. Shill, E.J. Pappert, A. Agro, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

12:30pm-2:00pm: Disruption of circadian rhythm function and anti-oxidation via SIRT1-BMAL1 pathway in 6-OHDA induced Parkinson’s disease model

Y. Wang, S. Li, C. Mao, Y. Yang, F. Wang, C.F. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: Dissecting the molecular mechanisms of Fyn-mediated levodopa induced dyskinesias

M.P. Bordone, M.A. Bernardi, A. Damianich, S. Sanz-Blasco, G. Gómez, I.R.E. Taravini, M.E. Avale, O.S. Gershanik, J.E. Ferrario (Buenos Aires, Argentina)

12:30pm-2:00pm: DJ-1 regulates intracellular signaling in a highly cell type specific manner

F. Giesert, D.M. Vogt Weisenhorn, U. Hafen, A. Romanov, A. Kurz-Drexler, W. Wurst (Neuherberg, Germany)

12:30pm-2:00pm: Do different tic phenotypes have different responses to comprehensive behavioral intervention for tics (CBIT)?

W. Deeb, L. Almeida, H. Simpson, I. Malaty, M. Okun (Gainesville, FL, USA)

12:30pm-2:00pm: Do environmental factors influence the age at onset of Parkinson’s disease in LRRK2 G2019S carriers?

S. Elincx-Benizri, L. Greenbaum, G. Yahalom, T. Tsafnat, S. Israeli-Korn, O.S. Cohen, H. Strauss, S. May, R. Djaldetti, N. Warman Alaluf, S. Hassin-Baer (Ramat Gan, Israel)

12:30pm-2:00pm: Do mutations in the TGM6 (SCA35) gene cause early-onset Parkinson’s disease?

A. Westenberger, M. Svetel, N. Dragaševic, I. Brænne, V. Dobricic, A.A. Hicks, A. Tomic, N. Kresojevic, H. Pawlack, K. Grütz, A. Domingo, J. Erdmann, V.S. Kostic, C. Klein (Luebeck, Germany)

12:30pm-2:00pm: Does VIM deep brain stimulation affect swallowing?

S. De Jesus, J. Hicks, L. Almeida, L. Shahgholi, A. Patterson, A. Bona, B. Ahmed, K. Hegland, M. Okun (Gainesville, FL, USA)

12:30pm-2:00pm: Dopamine D3 receptor Ser9Gly variant is a risk factor for impulse control disorders in Parkinson’s disease

A. Kishore, S. Krishnamoorthy, R. Rajan, S. Sarma, M. Banerjee (Trivandrum, India)

12:30pm-2:00pm: Drp1 inhibition amelioratesα-synuclein-mediated neurodegeneration in rats

S. Bido, L. Arcuri, M. Helly, R. Fan, K. Tieu, E. Bezard (Bordeaux, France)

12:30pm-2:00pm: Drug-induced parkinsonism in Taiwan

J.J. Lin, K.C. Yueh, A.C. Chen (Nantou, Taiwan)

12:30pm-2:00pm: Duodopa for the treatment of severe restless legs syndrome

J. Perez-Perez, B. Pascual-Sedano, A. Campolongo, J. Kulisevsky (Barcelona, Spain)

12:30pm-2:00pm: Dynamic and static posturographic analysis among fallers and non- faller Parkinson’s disease (PD) patients using Neurocom SMART EquiTest

A. Lieberman, C. Frames, A. Deep, M. McCauley, S. Shafer (Phoenix, AZ, USA)

12:30pm-2:00pm: Dysregulated macroautophagy and mitochondrial dynamics in PD with glucocerebrosidase mutations

S.H. Kuo, H. Li, A. Ham, M.M. Cheng, Y. Quan, D. Sulzer, G. Tang (New York, NY, USA)

12:30pm-2:00pm: E326K GBA polymorphism and Parkinson’s disease in Russian population

K.A. Senkevich, M.A. Nikolaev, A.E. Kopytova, T.S. Usenko, I.V. Miliukhina, A.A. Timofeeva, A.F. Yakimovskii, S.N. Pchelina (Saint Petersburg, Russia)

12:30pm-2:00pm: Effect of European physiotherapy guideline for Parkinson´s disease and Microsoft Kinect® adventures games training on postural control, cognition and quality of life: Randomized clinical trial

J.E. Pompeu, K.G. Silva, T.B. Freitas, R.A. Nuvolini, F. Doná, C. Torriani-Pasin, F.F. Ganaça, H.B. Ferraz (Sao Paulo, Brazil)

12:30pm-2:00pm: Effect of genetic variation in SNCA and APOE on cerebrospinal fluid protein levels in patients with Parkinson’s disease and controls

G. Machetanz, K. Lohmann, C.M. Lill, C. Klein, C. Trenkwalder, B. Mollenhauer (Kassel, Germany)

12:30pm-2:00pm: Effect of intra-striatal 6-OHDA lesion on extra-striatal structures in the mouse

B. Becker, M. Demirbas, C. Beyer, S. Tan, M. Kipp (Aachen, Germany)

12:30pm-2:00pm: Effect of L-DOPA on re-emergent tremor in Parkinson’s disease: A neurophysiological assessment

M. Wilken, A. Medina, M.D. Rossi, A.D. Rivero, M. Merello, M. Hallett (Buenos Aires, Argentina)

12:30pm-2:00pm: Effect of marijuana on Essential Tremor: A case report

D.P. Sutherland (Sarasota, FL, USA)

12:30pm-2:00pm: Effect of vibration on motor performance: A new intervention to improve bradykinesia in Parkinson’s disease?

A. Macerollo, C. Palmer, T. Foltynie, P. Korlipara, P. Limousin, M. Edwards, J. Kilner (London, United Kingdom)

12:30pm-2:00pm: Effect of zonisamide on post-traumatic Holmes’ tremor

T. Jo, S. Sekimoto, G. Oyama, N. Izawa, S. Ueno, Y. Shimo, A. Nakajima, M. Nakajima, A. Umemura, H. Arai, N. Hattori (Tokyo, Japan)

12:30pm-2:00pm: Effects of Arachidonyl-2′-chloroethylamide (ACEA), a selective CB1 receptor agonist, in MPTP mouse model of Parkinson’s disease

M. Omidbeigi, S. Asaadi, A. Zali (Tehran, Islamic Republic of Iran)

12:30pm-2:00pm: Efficacy and safety of a L-dopa delivery and monitoring medical device

Y.G. Tirat-Gefen (Fairfax, VA, USA)

12:30pm-2:00pm: Elevated SNCA expression in CD45+ peripheral blood cells in patients with dementia with Lewy bodies

N. Nikolaev, B. Lu.A., P.A. Andoskin, A. Emelyanov, A.E. Kopytova, K.A. Senkevich, I.V. Milyukhina, S.N. Pchelina (Saint-Petersburg, Russia)

12:30pm-2:00pm: Elucidating mechanisms of endogenous disease protection resulting in reduced penetrance in PINK1 deficiency

M. Vos, C. Böhm, C. Klein (Lübeck, Germany)

12:30pm-2:00pm: Endoscopically-documented pharyngeal dystonia due to neuroleptic use without response to alcohol

J.P. Squires, W.L. Severt, M.J. Pitman (New York, NY, USA)

12:30pm-2:00pm: Enteric neurons reveal substantial in vivo mitochondrial changes in Parkinson’s disease

P.M.A. Antony, A.S. Baumuratov, M. Ostaszewski, F. He, L. Salamanca, L. Antunes, J. Weber, L. Longhino, P. Derkinderen, R. Balling, W. Koopman, N. Diederich (Belvaux, Luxembourg)

12:30pm-2:00pm: Epigenome-wide association study of Parkinson’s disease

B. Ritz, Y.H. Chuang, S. Horvath, Y. Bordelon, J. Bronstein (Los Angeles, CA, USA)

12:30pm-2:00pm: ESCRT-0 dysfunction compromises autophagic degradation of protein aggregates and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways

T. Hasegawa, R. Oshima, K. Tamai, N. Sugeno, A. Kikuchi, J. Kobayashi, S. Yoshida, A. Takeda, N. Tanaka, M. Aoki (Sendai, Japan)

12:30pm-2:00pm: Essential tremor: Characterization according to their phenotypes and their association with Parkinsonian signs

J.S. Bestoso, L. Ciancaglini, C.V. Stefani, L.A. di Napoli, J.I. Rojas, D.J. Bauso, E. Cristiano (Caba, Argentina)

12:30pm-2:00pm: Evaluating Parkinsonian motor features via the routine use of consumer electronics – neuroQWERTY

Á. Sánchez-Ferro, C.S. Mendoza, I. Butterworth, M. Matarazzo, P. Montero, R. Trincado, T. Arroyo Gallego, V. Puertas Martín, M.J. Catalán, J.A. Molina, F. Bermejo-Pareja, L. Giancardo (Móstoles, Spain)

12:30pm-2:00pm: Evaluation of kinematic parameters of potential clinical use extracted from Microsoft Kinect V2 motor assessments

K. Otte, B. Kayser, S. Mansow-Model, A.U. Brandt, J. Verrel, T. Schmitz-Hübsch (Berlin, Germany)

12:30pm-2:00pm: Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials

J.P. Seibyl, D. Jennings, K. Marek (New Haven, CT, USA)

12:30pm-2:00pm: Evaluation of the role of oxidative stress in Parkinson’s disease and Parkinson plus syndrome

R. Qadri, M.A. Faiq, M. Behari, V. Goyal, A.K. Mukhopadhyay (New Delhi, India)

12:30pm-2:00pm: Exome sequencing in dementia with Lewy bodies

S.W. Scholz, J.T. Geiger, J. Ding, B. Crane, O. Pletnikova, C. Letson, T.M. Dawson, L.S. Rosenthal, A. Pantelyat, J.R. Gibbs, M. Albert, D.G. Hernandez, A.E. Hillis, A.B. Singleton, D.J. Stone, J.A. Hardy, J.C. Troncoso (Bethesda, MD, USA)

12:30pm-2:00pm: Exome sequencing in the Czech patients with early-onset Parkinson’s disease

D. Kemlink, B. Schormair, O. Fiala, D. Zahorakova, P. Martasek, J. Roth, J. Winkelmann, E. Ruzicka (Praha 2, Czech Republic)

12:30pm-2:00pm: Exosomes-injection to reproduce a mouse model of Parkinson’s disease: A preliminary report

C. Han, J. Huang, K. Ma, Y. Shen, L. Liu, G. Zhang, X. Xu, J. Li, H. Jiang, S. Guo, Y. Xia, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: Expanding the spectrum of ATP1A3 related disorders: Continuum from alternating hemiplegia of childhood to rapid-onset dystonia parkinsonism?

S.A. Rodríguez-Quiroga, D. González-Moron, S.A. Vishnopolska, G.L. Vigo, M. Cordoba, N. Medina, T. Arakaki, N.S. Garretto, M.A. Kauffman (Caba, Argentina)

12:30pm-2:00pm: Expanding the spectrum of PEX10-related peroxisomal biogenesis disorders: Slowly progressive recessive ataxia

M. Renaud, C. Guissart, S. Ferdinandusse, D. Cheillan, O. Lagha-Boukbiza, M. Mallaret, J. Muller, C. Tranchant, M. Anheim, M. Koenig (Strasbourg cedex, France)

12:30pm-2:00pm: Exploring aging-VMAT2 gene-rotenone interactions in a cell model for Parkinson’s disease

H. Jiang, J. Li, C. Han, K. Ma, L. Liu, Y. Shen, L. Wang, S. Guo, Y. Xia, J. Huang, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: Eye movement abnormalities in essential tremor and other neurodegenerative diseases (Parkinson’s disease, spino-cerebellar ataxia, Huntington disease)

M. Wojcik-Pedziwiatr, M. Rudzinska, K. Zajdel, W. Soltan, J. Slawek, A. Szczudlik (Krakow, Poland)

12:30pm-2:00pm: F1 crossbreds of C57BL/6 and CD-1 mice demonstrate resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced nigral neurodegeneration

P.A. Alladi, D. Vidyadhara, H. Yarreiphang, T.R. Raju (Bengaluru, India)

12:30pm-2:00pm: Fahr’s syndrome in a Filipino female with hearing loss and polycystic ovaries: A case report

P.D. Dadgardoust, R.L. Rosales (Manila, Philippines)

12:30pm-2:00pm: Faithful SGCE imprinting in iPSC-derived cortical neurons: An endogenous model system of myoclonus-dystonia

K. Grütz, P. Seibler, A. Weißbach, K. Lohmann, F.A. Carlisle, D.J. Blake, A. Westenberger, C. Klein, A. Grünewald (Lübeck, Germany)

12:30pm-2:00pm: Falls in Parkinson’s disease: Beware the short, slow steps

A. Lieberman, A. Deep, S. Shafer, T. Lockhart (Phoenix, AZ, USA)

12:30pm-2:00pm: Familial Parkinson’s disease in Ireland

D.A. Olszewska, A. McCarthy, B. Magennis, O. Ross, T. Lynch (Dublin, Ireland)

12:30pm-2:00pm: Familial Parkinson’s disease in the Province of Quebec

L.L. Farrell, E. Pourcher, E. Nosova, M. McKenzie, I. Guella, D.M. Evans, C. Déry, M.J. Farrer (Vancouver, BC, Canada)

12:30pm-2:00pm: Familial SPG17/distal hereditary motor neuropathy type V– Complicated hereditary spastic paraplegia with many faces

T. Musacchio, A.K. Zaum, N. Üceyler, C. Sommer, N. Pfeifroth, K. Reiners, E. Kunstmann, J. Volkmann, S. Rost, S. Klebe (Würzburg, Germany)

12:30pm-2:00pm: FBOX07 mutation with juvenile parkinsonism and behavioral disorders

M. Kuzu, F.N. Durmaz, Ç. Ulukan, H. Kaymakçalan, A.O. Çaglayan, C. Akbostanci (Ankara, Turkey)

12:30pm-2:00pm: Floor square size predicts step count of 360° turns in PD patients with freezing

U.M. Fietzek, L. Stuhlinger, A. Plate, A.O. Ceballos-Baumann, K. Bötzel (Munich, Germany)

12:30pm-2:00pm: Frequency of GBA1 and LRRK2 G2019S mutations, and body mass index in Ashkenazi Jews

N. Doan, D. Raymond, R.A. Ortega, J. Ratliff, I. Meijer, J. Squires, S. Buckingham, B. Johannes, A. Vaigast, I. Perera, W.C. Nichols, L. Ozelius, J. Miravite, L. Severt, V. Shanker, N. Lubarr, S. Bressman, R. Saunders-Pullman (New York, NY, USA)

12:30pm-2:00pm: Frontal dysfunction in Tourette syndrome: A PET-FDG study

R. García-Ramos, N. Gonzalez, E. Lopez Valdes, F. Alonso, N. Cabrera, I. Parees, M.J. Catalán, J. Matías-Guíu Antem (Madrid, Spain)

12:30pm-2:00pm: Functional characterisation and the selective vulnerability of SNCA (A30P) patient-derived midbrain dopaminergic neurons to ER stress

P.A. Barbuti, B.F.R. Santos, S. Delcambre, Y. Nonnenmacher, C.D. Obermaier, A. Hummel, K. Hiller, R. Krueger (Belvaux, Luxembourg)

12:30pm-2:00pm: Gait impairment is more than a motor symptom in Parkinson’s disease

H.F. Chan, D.K.W. Chau, T. Fung, Y.F. Cheung, W.C. Fong (Hong Kong, Hong Kong)

12:30pm-2:00pm: Gait initiation in response to emotion-inducing pictures in Parkinson’s disease

L. Avanzino, G. Lagravinese, A. Ravaschio, E. Pelosin, G. Abbruzzese (Genoa, Italy)

12:30pm-2:00pm: Gender-age features of autonomic heart rhythm disturbances in Parkinson’s disease patients

I. Solodovnikova (Odessa, Ukraine)

12:30pm-2:00pm: Gene delivery of AAV2-neurturin for patients with Parkinson’s disease: A meta-analysis

A.G. Almraezy, H. Ahmed, M. Elnenny, A. Negida (Cairo, Egypt)

12:30pm-2:00pm: Gene expression analysis using the Parkinson’s disease map reveals early effects of alpha-synuclein on PD pathogenesis

S. Gebel, A. Ashrafi, P. Garcia, M. Ostaszewski, P. Gawron, L. Vallar, N. Nicot, T. Kaoma, R. Balling, E. Glaab, M. Buttini (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm: Gene network driven probable drug target identification: An in-silico study on Parkinson’s disease

H.N. Singh, J. Pani, K.G. Singh, V. Swarup (Gautam Budh Nagar, India)

12:30pm-2:00pm: Generation and characterization of midbrain organoids from iPSCs of familial Parkinson’s disease

E. Frattini, G. Monzio Compagnoni, S. Salani, P. Rinchetti, M. Nizzardo, M. Baccarin, N. Bresolin, G.P. Comi, S.P. Corti, A. Di Fonzo (Milan, Italy)

12:30pm-2:00pm: Generation of dopaminergic neurons for studying Parkinson’s disease using patient blood cells

D. Ma, W. Zhou, Y. Chao, Y. Zhao, E.K. Tan (Singapore, Singapore)

12:30pm-2:00pm: Generation of human induced pluripotent stem cells carrying a safety bet for cell-based therapy in Parkinson’s disease

Y. Kimura, Y. Kanemura, T. Shofuda, M. Onodera, M. Oda, M. Nakamori, T. Nakano, H. Mochizuki (Osaka, Japan)

12:30pm-2:00pm: Genetic analysis of CHCHD2 gene in Parkinson’s disease in a Taiwanese population

T.S. Fan, H.I. Lin, C.H. Lin, R.M. Wu (Taipei, Taiwan)

12:30pm-2:00pm: Genetic analysis of eighty-seven multiple system atrophy patients

G. Franco, D. Ronchi, I. Trezzi, L. Borellini, F. Del Sorbo, B. Garavaglia, A.E. Elia, G. Ardolino, G. Mora, S. Bonato, N. Bresolin, G.P. Comi, A. Di Fonzo (Milan, Italy)

12:30pm-2:00pm: Genetic Identification of early-onset parkinsonism among Norwegian patients

E.K. Gustavsson, J. Trinh, M. McKenzie, S. Bortnick, J.O. Aasly, M.J. Farrer (Vancouver, BC, Canada)

12:30pm-2:00pm: Genetic risk factors of dementia and psychosis in Parkinson’s disease

T. Oeda, A. Umemura, Y. Mori, S. Tomita, M. Kohsaka, K. Park, K. Inoue, H. Fujimura, H. Hasegawa, H. Sugiyama, H. Sawada (Kyoto, Japan)

12:30pm-2:00pm: Genetic variation near the SNCA gene associates with Parkinson’s disease motor phenotype and progression

C. Cooper, Y. Berlyand, D. Weintraub, S.X. Xie, A. Espay, J. Quinn, K. Edwards, T. Montine, C. Zabetian, A. Chen-Plotkin (Philadelphia, PA, USA)

12:30pm-2:00pm: Genome-wide bioinformatic analysis of Parkinson’s disease: A focus on neuronal health maintenance

R. Qadri, M.A. Faiq, V. Goyal, A.K. Mukhopadhyay (New Delhi, India)

12:30pm-2:00pm: Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease

C.K. Meshul, M.J. Churchill (Portland, OR, USA)

12:30pm-2:00pm: Glucocerebrosidase activity in a cohort of PD patients

I. Trezzi, V. Melzi, G. Franco, L. Borellini, E. Monfrini, A. Bordoni, N. Bresolin, G.P. Comi, A. Di Fonzo (Milan, Italy)

12:30pm-2:00pm: Glutathione status in Parkinson’s disease

L.K. Mischley (Kenmore, WA, USA)

12:30pm-2:00pm: Gustatory function of patients with essential tremor and its correlation with olfactory and cognitive functions

M.G. Senol, H. Tekeli, M. Saglam, E. Arslanoglu (Istanbul, Turkey)

12:30pm-2:00pm: Hemi-stereotypies symptomatic to aneurysm: Differential diagnosis of tardive dyskinesia

D. Rebolledo, P.O. Gonzalez, Z. Rebolledo, A.G.S. Fokine Dotsenko (La Magdalena, Toluca de Lerdo, Mexico)

12:30pm-2:00pm: Hemifacial spasm – Therapeutic assessment of botulinum toxin

H.A.G. Teive, J.P. Matisti, A.D. Kleinfelder, N.B. Galli (Curitiba, Brazil)

12:30pm-2:00pm: Hereditary atypical parkinsonism with novel mutation of the VPS35 and FBXO7 genes

K. Mensikova, T. Bartonikova, L. Mikulicova, R. Vodicka, R. Vrtel, M. Godava, I. Dolinova, M. Vastik, M. Kaiserova, P. Otruba, P. Kanovsky (Olomouc, Czech Republic)

12:30pm-2:00pm: Heterozygous PINK1 p.G411S mutation increases risk for Parkinson’s disease (PD)

W. Springer, A. Puschmann, F.C. Fiesel, M. Ando, T.R. Caulfield, K. Ogaki, M.G. Heckman, R. Hudec, E.D. James, G. Opala, J. Siuda, M. Boczarska-Jedynak, A. Friedman, D. Koziorowski, J.O. Aasly, T. Lynch, G.D. Mellick, M. Mohan, P.A. Silburn, Y. Sanotsky, C. Vilariño-Güell, M.J. Farrer, T. Dawson, Z.K. Wszolek, O.A. Ross (Jacksonville, FL, USA)

12:30pm-2:00pm: High throughput pooled-DNA sequencing of mendelian/susceptibility Parkinson’s disease genes in Spanish population

S. Ortega-Cubero, O. Lorenzo-Betancor, E. Lorenzo, B.A. Benitez, C. Cruchaga, L. Samaranch, M. Diez, J.A. Obeso, M.C. Rodriguez-Oroz, M. Aguilar, M.A. Pastor, P. Pastor (Palencia, Spain)

12:30pm-2:00pm: Histochemical evaluation of the effect of vitamin E on cyanide–induced damage on the prefrontal cortex of Sprague Dawley rats

A.O. Adekeye, P.D. Shallie (Ado-Ekiti, Nigeria)

12:30pm-2:00pm: Histone deacetylase 4 is regulated by microRNA 128 in SH-SY5Y cells of Parkinson’s disease

J. Li, N. Xiong, H. Jiang, L. Liu, C. Han, K. Ma, X. Xu, Y. Shen, Y. Xia, L. Wang, S. Guo, J. Huang, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: How do we clinically distinguish subtypes of myoclonus? A retrospective study

R. Zutt, J.W. Elting, H. van der Hoeven, F. Lange, M.A.J. Tijssen (Groningen, Netherlands)

12:30pm-2:00pm: Human, fly and cellular models of riboflavin transporter neuronopathy

A. Manole, A. Pandraud, M.M. Reilly, J.E.C. Jepson, H. Houlden (London, United Kingdom)

12:30pm-2:00pm: Hyperekplexia secondary to cumulative novel glycine pathway mutations

S. Nandipati, S. Ceulemans, J. Friedman (La Jolla, CA, USA)

12:30pm-2:00pm: Hyperin inhibits lipopolysaccharide-induced microglia activation through p38 and NFκB signaling

X. Zhang, Y.N. Wang, H.H. Fan, R. Yang, S.Y. Li, J.H. Zhu (Wenzhou, People's Republic of China)

12:30pm-2:00pm: ICF-based effects of VIM-DBS on communication in everyday life in patients with essential tremor

M. Hartinger, M. Scholz, D. Mücke, A. Hermes, T.B. Roettger, J. Becker, M. Opitz, T.A. Dembek, I.G. Meister, V. Visser-Vandewalle, M. Grice, L. Timmermann, M.T. Barbe (Berlin, Germany)

12:30pm-2:00pm: Identification of a new biomarker in a mouse model of essential tremor using EEG

V. Duveau, B. Mandé, B. Pouyatos, Y. Roche, C. Roucard (La Tronche, France)

12:30pm-2:00pm: Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein

Z. Alexopoulou, J. Lang, R. Perrett, H.T. Kim, A.L. Goldberg, O. Ansorge, T.A. Fulga, G.K. Tofaris (Oxford, United Kingdom)

12:30pm-2:00pm: Identifying freezing of gait and falls in Parkinson’s disease patients using a body-worn sensor

Y. Okuma, H. Mitoma, M. Yoneyama (Izunokuni, Japan)

12:30pm-2:00pm: IL-6 and motor symptoms in Parkinson’s disease

T. Torgan, T. Baidina, N. Demchuk, M. Danilova (Perm, Russia)

12:30pm-2:00pm: Impact of prolonged temporal discrimination threshold on finger movements of Parkinson’s disease

M.J. Lee, J.S. Son, J.H. Lee, S.J. Kim, C.H. Lyoo, M.S. Lee (Busan, Korea)

12:30pm-2:00pm: Impairments in trunk muscle function influence head and trunk stability during walking in Parkinson’s disease fallers

M.H. Cole, G.A. Naughton, P.A. Silburn (Virginia, Australia)

12:30pm-2:00pm: Implementation of a mobile application in the Luxembourg Parkinson’s study for identification and validation of disease stage and variation

R. Krüger, G. Hipp, M. Kerschenmeyer, P.L. Kolber, A. Trister, C. Suver, V.P. Satagopam, K. Roomp, S.K. Mosch, L. Longhino, A. Schweicher, M. Gantenbein, M. Vaillant, F. Betsou, A. Chioti, R. Schneider, R. Balling, S. Friend (Belvaux, Luxembourg)

12:30pm-2:00pm: Impulse control disorder associates with tyrosine hydroxylase 2 gene variants in Parkinson’s disease patients subject to dopaminergic therapy

I. Legarda, B. Vives, C.A. Beltran-Gomila, B. Ortega-Vila, M. Ruiz, J. Pol-Fuster, C. Vives-Bauza (Palma, Spain)

12:30pm-2:00pm: In idiopathic Parkinson’s disease: The effect of using L-dopa on peripheral nerves

M.E. Temir, F. Genç, Y. Biçer Gömceli, A. Yaman, A. Aybar, E. Karaçay (Antalya, Turkey)

12:30pm-2:00pm: In utero delivery of scAAV9 mediates widespread brain transduction in rats and monkeys: Towards new models of Parkinson’s disease

M. Bourdenx, L. Chansel-Debordeaux, S. Dovero, V. Grouyhier, N. Dutheil, S. Brun, A. Espagna, L. Groc, Q. Li, C. Jimenez, E. Bezard, B. Dehay (Bordeaux, France)

12:30pm-2:00pm: Incidence of waning tremor control in essential tremor patients with deep brain stimulation

M.D. Seier, A. Hiller, C. Murchison (Portland, OR, USA)

12:30pm-2:00pm: Incidental finding of drug-induced movement disorder

G. Avagyan, H. Manvelyan, A. Nazaryan (Yerevan, Armenia)

12:30pm-2:00pm: Increase L-dopa dosage for rest tremor or think about the essential tremor too?

A. Voskanyan, G. Avagyan, E. Khachatryan, K. Harutyunyan, S. Khachaturyan, H. Amirjanyan, H. Manvelyan (Yerevan, Armenia)

12:30pm-2:00pm: Increased anti-MAG autoantibodies titers in Parkinson’s disease

E. Papuc, K. Rejdak (Lublin, Poland)

12:30pm-2:00pm: Increased cellular co-localization of tau fragment 1-368 and alpha-synuclein in two mouse model of Parkinson’s disease

K. Ma, S. Nie, G. Chen, C. Han, X. Guo, Y. Xu, X. Cao (Wuhan, People's Republic of China)

12:30pm-2:00pm: Increased cerebrospinal fluid lactate levels in Parkison’s disease: Is it a proof of mitochondrial inefficiency?

C. Liguori, A. Stefani, E. Olivola, N.B. Mercuri, M. Pierantozzi (Rome, Italy)

12:30pm-2:00pm: Increased energy expenditure in early Parkinson’s disease during exercise

T. Margaliot Kalifa, N. Ziv, H. Bergman, S. Nusair, D. Arkadir (Jerusalem, Israel)

12:30pm-2:00pm: Individualized botulinum toxin type A therapy of bilateral upper limb essential tremor by multi-sensor kinematic technology

O. Samotus, H. Moradi, M. Jog (London, ON, Canada)

12:30pm-2:00pm: Induced pluripotent stem cell-derived cortical neurons as a disease model for X-linked dystonia-parkinsonism

K. Grütz, C. Krause, A. Domingo, L. V Lee, R. Rosales, R.D. Jamora, E. Cutiongco dela Paz, A. Westenberger, C. Klein, P. Seibler (Lübeck, Germany)

12:30pm-2:00pm: Inflammatory profile discriminates clinical subtypes in LRRK2-associated PD

K. Brockmann, C. Schulte, N. Schneiderhan-Marra, A. Apel, C. Pont-Sunyer, D. Vilas, J. Ruiz-Martinez, M. Langkamp, J.C. Corvol, F. Cormier, T. Knorpp, T.O. Joos, A. Bernhard, T. Gasser, C. Marras, B. Schüle, J.O. Aasly, T. Foroud, J.F. Marti-Masso, A. Brice, E. Tolosa, D. Berg, W. Maetzler (Tübingen, Germany)

12:30pm-2:00pm: Influence of high altitude on periodic leg movements during sleep in individuals with restless legs syndrome and healthy controls: A pilot study

A. Stefani, A. Heidbreder, H. Hackner, M. Burtscher, B. Högl (Innsbruck, Austria)

12:30pm-2:00pm: Influence of levodopa on functional brain connectivity in Parkinson’s disease

S. Kobayashi, K. Asano, N. Matsuda, H. Kubo, M. Abe, Y. Ugawa (Fukushima-shi, Japan)

12:30pm-2:00pm: Inhibition of the mitochondrial calcium uniporter (MCU) rescues dopaminergic neurons in pink1-/- zebrafish

B. Oliver, S. Solman, M. Keatinge, M. DaCosta, H. Mortiboys, S. Sugunan, J. Kuznicki (Sheffield, United Kingdom)

12:30pm-2:00pm: Insulin dependent diabetes and hand tremor

S. Khachaturyan, G. Avagyan, K. Harutyunyan, A. Voskanyan, I. Gabrielyan, H. Amirjanyan, H. Manvelyan (Echmiadzin, Armenia)

12:30pm-2:00pm: Integrity of the superior longitudinal fascicle and its relationship with anticipatory postural adjustments in people with Parkinson’s disease and freezing of gait

A.C. de Lima-Pardini, T.Q. Freitas, D.B. Coelho, C.C. Boffino, C. Souza, R. Brandt, E.R. Barbosa, L.A. Teixeira, E. Amaro Jr. (São Paulo, Brazil)

12:30pm-2:00pm: Interest in genetic testing in Parkinson’s disease patients with deep brain stimulation

G. Pal, E. Tam, R. Bhavsar, C. Timms, L. Verhagen, D. Hall, K. Marder (Chicago, IL, USA)

12:30pm-2:00pm: Intracerebroventricular D-galactose injection provokes motor coordination impairment and cerebellar damage in Wistar rats

A.F. Rodrigues, B.S. Zanotto, H. Biasibetti, P. Pierozan, F. Schmitz, E.F. Sanches, D. Delwing Dal Magro, C.A. Netto, A.T.S. Wyse (Brusque, Brazil)

12:30pm-2:00pm: Intracranial calcifications in children and adults: Molecular and phenotypic characterization from a tertiary referral centre

C. Panteghini, M. Carecchio, D. Tonduti, C. Barzaghi, L. Magistrelli, A. Decio, L. Chiapparini, A. Pichiecchio, S. Esposito, C. Pantaleoni, D. Riva, I. Moroni, S. Orcesi, N. Nardocci, B. Garavaglia, Cerebral Calcification Study Group (Milan, Italy)

12:30pm-2:00pm: Intrastriatal injection of ionomycin profoundly changes motor response to L-DOPA and its underlying molecular mechanisms

C. Han, S. Nie, G. Chen, K. Ma, N. Xiong, Z. Zhang, Y. Xu, T. Wang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

12:30pm-2:00pm: Investigating the role of Parkin in mitigating oxidative stress

J.M. Tokarew, D. El Kodsi, J.T. Tomlinson, M.G. Schlossmacher (Ottawa, ON, Canada)

12:30pm-2:00pm: Investigating voice as a biomarker of LRRK2-associated Parkinson’s disease (PD)

S. Arora, N.P. Visanji, T.A. Mestre, T. Ghate, A.E. Lang, M. Little, C. Marras (Birmingham, United Kingdom)

12:30pm-2:00pm: Investigation into the genetic etiology in South African Parkinson’s disease patients

G. Borrageiro, L. Van den Heuvel, S.M.J. Hemmings, S. Seedat, S. Bardien (Cape Town, South Africa)

12:30pm-2:00pm: Investigation of mosaicism for copy number variants in PD brain

C. Proukakis, K. Mokretar, A. Ejaz, A. Soenmez, C. Grace, D. Pease, H. Houlden, J.W. Taanman, A.H. Schapira, E. Nacheva (London, United Kingdom)

12:30pm-2:00pm: Involvement of cerebellothalamocortical pathway in essential tremor and dystonic tremor

P. Panyakaew, H.J. Cho, P. Srivanitchapoom, M. Hallett (Bethesda, MD, USA)

12:30pm-2:00pm: Involvement of peripheral immune system in the pathogenesis of Parkinson’s disease

Y.X. Chao, S.C. Wong, K.J. Puan, J.J.Y. Tai, O. Rötzschke, B. Lee, M. Poidinger, E.K. Tan (Singapore, Singapore)

12:30pm-2:00pm: Is levodopa-induced dyskinesia in Parkinson’s disease associated with increased blood brain barrier permeability and volumetric changes?

O. Segal, D. Last, D. Guez, Y. Mardor, G. Yahalom, O.S. Cohen, S. Benizri, C. Hoffman, S. Hassin-Baer (Ramat Gan, Israel)

12:30pm-2:00pm: Is the assessment of 5 meters of gait with body-worn-sensors enough to recognize Parkinsonian gait?

M.E. Micó Amigo, I. Kingma, A. Kunikoshi, R.V. Lummel, W. Maetzler, J.V. Dieën (Amsterdam, Netherlands)

12:30pm-2:00pm: Is tremor related to celiac disease?

L. Ameghino, M.D. Rossi, D. Cerquetti, M. Merello (Buenos Aires, Argentina)

12:30pm-2:00pm: Isolated eyebrow tremor as an initial presentation form of Parkinson´s disease

E. Lopez Valdes, M. Catalán, R. Garcia-Ramos, P. Montero, I. Parees, F. Alonso (Madrid, Spain)

12:30pm-2:00pm: Isolated finger tremor in Parkinson’s disease and essential tremor

F. Alonso-Frech, H. García-Moreno, P. Montero Escribano, E. López Valdés, M.J. Catalán Alonso, R. García-Ramos García, I. Parees Moreno (Madrid, Spain)

12:30pm-2:00pm: Kinematic analysis of repetitive finger movements and the effects of selegiline and pramipexole in early Parkinson’s disease

G. Leodori, M. Bologna, P. Stirpe, G. Paparella, D. Belvisi, A. Fasano, G. Fabbrini, A. Berardelli (Rome, Italy)

12:30pm-2:00pm: L-dopa-responsive, diurnally fluctuating auricular tremor with tetrahydrobiopterin (BH4) deficiency

N.K. Iwata, H. Shintaku, S. Shibata, K. Takeda, J. Goto (Tokyo, Japan)

12:30pm-2:00pm: Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with idiopathic Parkinson’s disease

J.H. Hong, Y.K. Kim, J.S. Park, J.E. Lee, M.S. Oh, E.J. Chung, J.Y. Kim, Y.H. Sung, C.H. Lyoo, J.H. Lee, D.Y. Kwon, H.S. Kim, H.W. Shin, S.A. Park, I.S. Park, J.S. Kim, P.H. Lee, S.B. Koh, J.S. Baik, S.J. Kim, H.I. Ma, J.W. Kim, Y.J. Kim (Anyang, Korea)

12:30pm-2:00pm: Lance-Adams syndrome with post-hypoxic myoclonus- physiotherapy intervention

B. Cruz (Long Beach, CA, USA)

12:30pm-2:00pm: LC3 deacetylation by SIRT1 is involved in neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson’s disease

Y. Wu, Y. Guo, S. Dong, X. Cui, Y. Feng, W. Zhao (Shanghai, People's Republic of China)

12:30pm-2:00pm: Lessons learned from the Nilotinib trial: Cardio-vascular conditions in parkinsonism

Y. Torres-Yaghi, A. Keys, V. Ellen, S. Ashot, M. Elizabeth, S. Justin, M. Charbel, P. Fernando (Washington, DC, USA)

12:30pm-2:00pm: Levodopa-responsive hereditary spastic paraplegia, SPG35, due to FA2H mutations in siblings

Y. Xing, J.R. Friedman (La Jolla, CA, USA)

12:30pm-2:00pm: Lewy body extracts from Parkinson’s disease brains as models for high-throughput screens of neurotoxicity and α-synuclein spreading from cell-to-cell

E. Bezard, F. Cavaliere, P. Kitchener, E.Y. Pioli, B. Dehay, M. Bourdenx, P. Ramos-Gonzalez, J. Obeso, C. Matute (Bordeaux, France)

12:30pm-2:00pm: Localization and functional study of synaptic vesicle protein synaptogyrin-3 (SYNGR3) on dopaminergic neuronal system

L.F. Li, P.W.L. Ho, H.F. Liu, Z.H.M. Tse, C.S.C. Lam, M.C.T. Leung, M.H.W. Kung, D.B. Ramsden, S.W.L. Ho (Hong Kong, People's Republic of China)

12:30pm-2:00pm: Long term recordings of subthalamic ocillatory activity in patients with Parkinson’s disease

W.J. Neumann, F. Staub, A. Horn, J. Schanda, G.H. Schneider, P. Brown, A.A. Kühn (Berlin, Germany)

12:30pm-2:00pm: Long-duration response to levodopa in Parkinson’s disease is independent of disease duration: A prospective study on de novo patients in Ghana

R. Cilia, E. Cereda, M. Amboni, A. Akpalu, F.S. Sarfo, M. Cham, M. Fabbri, G. Pezzoli (Milan, Italy)

12:30pm-2:00pm: Long-term responsive deep brain stimulation in Tourette syndrome

R.A. Molina, J.B. Shute, P.J. Rossi, E. Opri, K.D. Foote, M.S. Okun, A. Gunduz (Gainesville, FL, USA)

12:30pm-2:00pm: Longitudinal cerebrospinal fluid biomarkers in early Parkinson’s disease and healthy controls

B. Mollenhauer, C.J. Caspell-Garcia, C.S. Coffey, P. Taylor, L.M. Shaw, J.Q. Trojanowski, A. Singleton, M. Frasier, K. Marek, D.R. Galasko (Kassel, Germany)

12:30pm-2:00pm: Longitudinal evaluation of motor and non motor symptoms among LRRK2 risk variants

E.W. Lim, X. Deng, H.H. Li, P. Kumar M, Y.L. Ng, Y.L. Lo, E.K. Tan (Singapore, Singapore)

12:30pm-2:00pm: Longitudinal follow-up of the association of tic disorders with poor academic performance

E. Cubo, C. Gonzalez-Deza, V. Ausin, V. Delgado, S. Saez, X.R. Garcia-Soto, S. Calvo, J. Cordero, J.M. Trejo, J. Macarron, K. Kompoliti (Burgos, Spain)

12:30pm-2:00pm: Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease

S. Hall, Y. Surova, A. Öhrfelt, K. Blennow, H. Zetterberg, O. Hansson (Lund, Sweden)

12:30pm-2:00pm: Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype

I. Huertas Fernandez, S. Jesus, J.A. Lojo, F.J. Garcia Gomez, M. Caceres Redondo, J.M. Oropesa Ruiz, F. Carrillo, L. Vargas Gonzalez, J.F. Martin Rodriguez, P. Gomez Garre, D. Garcia Solis, P. Mir (Sevilla, Spain)

12:30pm-2:00pm: Lrrk2 alleles modify host response to microbial infections

B. Shutinoski, I. Harmsen, M. Hakimi, Y.Y. Zhou, S. Sad, J.J. Tomlinson, E.G. Brown, M.G. Schlossmacher, CLINT Investigators (Ottawa, ON, Canada)

12:30pm-2:00pm: LRRK2 G2019S mutation carrier with an unusual phenotype: Progressive logopenic aphasia

S. López, A. Pozueta, M. Sierra, R. Quirce, P. Sánchez-Juan, I. González-Aramburu, C. Sánchez-Quintana, J.M. Carril, J. Infante (Santander, Spain)

12:30pm-2:00pm: Lymphocytes have a detrimental effect on motor behavior in the AAV1/2 A53T α-synuclein mouse model of Parkinson’s disease

A.A. Karikari, M. Gehmeyr, E. Ribechini, V. Maltese, J. Volkmann, J.M. Brotchie, J.B. Koprich, M.B. Lutz, C.W. Ip (Würzburg, Germany)

12:30pm-2:00pm: Lysosomal alterations in peripheral blood mononuclear cells of Parkinson’s disease patients

N. Papagiannakis, M. Xilouri, C. Koros, M. Stamelou, R. Antonelou, M. Maniati, D. Papadimitriou, M. Moraitou, H. Michelakakis, L. Stefanis (Chaidari, Greece)

12:30pm-2:00pm: Manganese-induced parkinsonism and motor neuron damage- Can there be a relationship?

I. Giorgishvili, N. Lobjanidze, N. Akiashvili, M. Janelidze, M. Beridze (Tbilisi, Georgia)

12:30pm-2:00pm: Medical cannabis for the treatment of Tourette syndrome: A descriptive analysis of 24 patients

S. Arad, L. Bar-Lev Schleider, J. Knaani, H. Shabtai, Y. Balash, A. Ezra, N. Giladi, T. Gurevich (Tel-Aviv, Israel)

12:30pm-2:00pm: MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum

G. Chen, S. Nie, K. Ma, C. Han, Y. Xu, Z. Zhang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

12:30pm-2:00pm: Micro-RNA in cerebrospinal fluid as a biomarker for early diagnosis, differential diagnosis and prognostic marker in Parkinson’s disease

A. Fischbach, A.E. Roser, F. Maass, M. Börger, M. Bähr, I. Zerr, A. Fischer, P. Lingor (Göttingen, Germany)

12:30pm-2:00pm: Microglia P2Y6 receptor is related to Parkinson’s disease and involved in the neuroinflammatory process

X. Yang, Y. Lou, X. Wang, G. Liu, Y. Qian, J. Ding, S. Chen, Q. Xiao (Shanghai, People's Republic of China)

12:30pm-2:00pm: Mild mitochondrial impairment promotes corticostriatal synaptic plasticity alterations in PINK1 heterozygous knockout mice

P. Imbriani, G. Martella, G. Madeo, M. Maltese, V. Vanni, E. Ferraro, E.M. Valente, T. Schirinzi, L. Bonanni, J. Shen, N.B. Mercuri, P. Bonsi, A. Pisani (Rome, Italy)

12:30pm-2:00pm: Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)

H. Shill, A. Agro, E.J. Pappert, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

12:30pm-2:00pm: Mitochondrial cardiolipin couples electron transport between ubiquinone and complex I to rescue PINK1 deficiency

M. Vos, A. Geens, L. Deaulmerie, J. Swerts, K. Craessaerts, P. Seibler, A. Rakovic, B. De Strooper, R. Efremov, V.A. Morais, C. Klein, P. Verstreken (Lübeck, Germany)

12:30pm-2:00pm: Mitochondrial dysfunction in skin fibroblasts from single heterozygous ATP13A2 (PARK9) mutation carriers

J.S. Park, C. Klein, C.M. Sue (St. Leonards, Australia)

12:30pm-2:00pm: Mitochondrial Hsp90 inhibitor G-TTP triggers PINK1/parkin-dependent mitochondrial quality control

F.C. Fiesel, J.D. Elle, H.R. Anneliese, H. Roman, S. Wolfdieter (Jacksonville, FL, USA)

12:30pm-2:00pm: Mitochondrial response precedes intracellular accumulation of α-synuclein in Parkinson’s disease

I. Milenkovic, E. Dassler, M. Weber, G.G. Kovacs (Vienna, Austria)

12:30pm-2:00pm: Mitochondrial-nuclear interplay in single respiratory chain-deficient Parkinson’s disease neurons

A. Grünewald, K.A. Rygiel, P.D. Hepplewhite, C.M. Morris, M. Picard, D.M. Turnbull (Belvaux, Luxembourg)

12:30pm-2:00pm: Mixed tremor with cryptogenic atrophy of dominant hemisphere, diagnostic and treatment challenges

O.E. Turgunkhujaev, A.R. Khashimova (Tashkent, Uzbekistan)

12:30pm-2:00pm: Modulating neuronal activity in dopaminergic neurons to promote their survival

M.A. Bernardi, N. Baffa-Trasci, O. Gershanik, M.E. Avale, J.E. Ferrario (Caba, Argentina)

12:30pm-2:00pm: Modulation of microglia function in the prion-like spreading of α-synuclein in the murine brain

W.M. Wemheuer, P. Garcia, E. Konica, A. Masuch, S. Brioschi, K. Biber, A. Weihofen, H. Kollmus, K. Schughart, D. Coowar, R. Balling, M. Buttini (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm: Modulation of thalamocortical network dynamics via deep brain stimulation in humans with Tourette syndrome

J.B. Shute, P.J. Rossi, E. Opri, R. Molina, C. De Hemptinne, K.D. Foote, M.S. Okun, A. Gunduz (Gainesville, FL, USA)

12:30pm-2:00pm: Molecular landscape of Parkinson’s disease reveals a key role for lipids and lipoproteins

C.J.H.M. Klemann, G.J.M. Martens, M. Sharma, M.B. Martens, O. Isacson, T. Gasser, J.E. Visser, G. Poelmans (Nijmegen, Netherlands)

12:30pm-2:00pm: Monitoring dyskinesia severity using wearable sensor data

J.F. Daneault, F.N. Golabchi, S.I. Lee, G. Vergara-Diaz, G. Ferreira Carvalho, E. Fabara, S. Sapienza, P. Bonato (Charlestown, MA, USA)

12:30pm-2:00pm: Monitoring oxidative stress and progression to cell death: From secretome to blood diagnosis

S.I. Anjo, V.M. Mendes, M. Grãos, B. MAnadas (Cantanhede, Portugal)

12:30pm-2:00pm: mPower: A smartphone-based study of Parkinson’s disease provides personalized measures of disease impact

A.D. Trister, E.C. Neto, B.M. Bot, T. Perumal, A. Pratap, A. Klein, E.R. Dorsey, C.M. Tanner, S.H. Friend (Seattle, WA, USA)

12:30pm-2:00pm: MRI guided high-intensity focused ultrasond for the treatment of essential tremor and Parkinson’s disease: Clinical outcome and radiological findings of unilateral thalamotomy

R. Martínez-Fernandez, J.A. Pineda-Pardo, M. del Álamo, F. Hernández, I. Obeso, S. Casas, P. Pastor, C. Oliver, L. Vela, J.A. Obeso (Madrid, Spain)

12:30pm-2:00pm: Multidisciplinary group program integrating voice and dance movement therapy for Parkinson’s disease patients: Preliminary experience

R. Peled, D. Shpunt, Y. Manor, M. Brozgol, A. Ezra, N. Hezi, R. Hen Simon, J.M. Hausdorff, T. Gurevich (Tel Aviv, Israel)

12:30pm-2:00pm: Muscle selection patterns for injection of onabotulinumtoxinA in adult patients with post-stroke lower-limb spasticity influence outcome: Results from a double-blind, placebo-controlled phase 3 clinical trial

T.H. Wein, A. Esquenazi, A.B. Ward, C. Geis, C. Liu, R. Dimitrova (Montreal, QC, Canada)

12:30pm-2:00pm: Mutant WDR45 links NBIA to impaired autophagy, mitochondrial dysfunction and oxidative stress

M. Dulovic, S. Zittel, A. Rakovic, A. Westenberger, S. Biskup, A. Münchau, C. Klein, P. Seibler (Belgrade, Serbia)

12:30pm-2:00pm: Mutational analysis of GNAL gene in isolated dystonia patients from Spain

P. Gómez-Garre, I. Huertas-Fernández, M.T. Cáceres-Redondo, A. Alonso-Canovas, I. Bernal-Bernal, A. Blanco-Ollero, M. Bonilla-Toribio, J.A. Burguera, M. Carballo, F. Carrillo, M.J. Catalán-Alonso, F. Escamilla-Sevilla, R. Espinosa-Rosso, M.C. Fernández-Moreno, J. García-Caldentey, J.M. García-Moreno, S. Giacometti-Silveira, J. Gutiérrez-García, S. Jesús-Maestre, E. López-Valdés, J.C. Martínez-Castrillo, M.P. Medialdea-Natera, C. Méndez-Lucena, A. Mínguez-Castellanos, M. Moya, J.J. Ochoa-Sepúlveda, T. Ojea, N. Rodríguez, I. Rubio-Agusti, M. Sillero-Sánchez, J. del Val, L. Vargas-González, P. Mir (Seville, Spain)

12:30pm-2:00pm: Myoclonus complicating chickenpox: A case report

F. Imounan, N. Daoudi (Meknes, Morocco)

12:30pm-2:00pm: Myoclonus Dystonia: A report of two rare mutations

A. Mahajan, C. Sidiropoulos (Detroit, MI, USA)

12:30pm-2:00pm: Neurodegeneration and microgliosis are independent of α-synuclein aggregation in a mouse model of "prion-like" α-synuclein speading

P. Garcia, W. Wemheuer, S. Brioschi, A. Masuch, E. Masliah, V. Koziel, T. Pillot, E. Koncina, C. Jaeger, A. Weihofen, R. Balling, K. Biber, M. Buttini (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm: Neurodegeneration with brain iron accumulation (NBIA): Two cases with different subtypes and a rare mutation

N. Sozer Topcular, S. Cagirici, A. Bajrami, E. Demir, H. Akçakaya, V. Yayla (Istanbul, Turkey)

12:30pm-2:00pm: Neurodegenerative disorders with atypical course and cause, diagnostic contribution of genetics and magnetic resonance imaging, two case reports

H. Streitova, M. Balaz (Brno, Czech Republic)

12:30pm-2:00pm: Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2

T. Hatano, A. Okuzumi, K. Kamagata, K. Daida, D. Taniguchi, M. Hori, H. Yoshino, S. Aoki, N. Hattori (Tokyo, Japan)

12:30pm-2:00pm: Neuronal nicotinamide-N-methyltransferase (NNMT) in Parkinson’s disease

K. Schmeisser, A. Parker (Montreal, QC, Canada)

12:30pm-2:00pm: Neurophysiological investigation of brainstem in idiopathic REM sleep behavior disorder (iRBD) through vestibular evoked myogenic potentials (VEMPs)

E.R. de Natale, F. Ginatempo, I. Laccu, B. Mercante, A. Manca, M. Figorilli, M. Puligheddu, F. Deriu (Sassari, Italy)

12:30pm-2:00pm: Next-generation profiling to identify the molecular etiology of Parkinson’s disease dementia

E.D. Driver-Dunckley, J. Corneveaux, D.B. Matt, L. Cuyugan, W. Liang, M. Huentelman, T.G. Beach, C.H. Adler, A. Henderson-Smith, T. Dunckley (Scottsdale, AZ, USA)

12:30pm-2:00pm: Ninjurin 1 gene D110a single nucleotide polymorphism as a genetic marker for nerve damage leprosy patients from South India

A. Sundaramoorthy, S. Keshavarao, A. Valsala Gopalakrishnan (Coimbatore, India)

12:30pm-2:00pm: No RAB39B gene mutations in Chinese familial Parkinson’s disease

J.F. Guo, J.F. Kang, X.X. Yan, B.S. Tang (Changsha, People's Republic of China)

12:30pm-2:00pm: Non-motor symptoms profiles in UK white Caucasian and Asian as well as overseas Thai and East Indian patients with Parkinson’s disease

A. Sauerbier, O. Jitkritsadakul, R. Bhidayasiri, H. Kumar, P. Martinez-Martin, R. Banerjee, M. Kulsum, A. Rizos, G. Harington, L. Perkins, T. Chiwera, D. Trivedi, A. Martin, M. Parry, R. Brown, J. Al-Hashel, W. Kamel, A. Kilany, S. Lim, A. Tan, K. Bhattacharyya, R. Walker, K. Ray Chaudhuri, On behalf of EUROPAR, the MDS Non-Motor PD Study Group and the NILS Group (London, United Kingdom)

12:30pm-2:00pm: Novel PLA2G6 c.1627C>T homozygous mutation and response to DBS-GPi

A.D. Magalhães, L. Correia Guedes, M. Coelho, T. Teodoro, A. Valadas, H. Carvalho, B. Cattoni, J.J. Ferreira (Lisbon, Portugal)

12:30pm-2:00pm: Novel THAP1 missense mutation leading to focal and segmental dystonia

D. Crosiers, C. Van Broeckhoven, P. Cras (Edegem, Belgium)

12:30pm-2:00pm: NREM parasomnias as a marker of cognitive impairment in Parkinson’s disease

B. Minafra, M. Terzaghi, R. Zangaglia, N.G. Pozzi, M. Picascia, R. Cremascoli, E. Sinforiani, N. Vanacore, R. Manni, C. Pacchetti (Pavia, Italy)

12:30pm-2:00pm: Nystagmus in essential tremor

N. Biary, M. Al Zawahmah, W. Khoja, A. Al Abdulsalam (Riyadh, Saudi Arabia)

12:30pm-2:00pm: Nystagmus in harmaline induced tremors in rats and attenuation with ethanol

N. Biary, A. Al Asmari, M. Arshaduddin, M. Al Zawahmah (Riyadh, Saudi Arabia)

12:30pm-2:00pm: Objective data in Parkinson’s disease therapy management – A retrospective analysis of the Parkinson’s kinetigraph (PKG) database

P. Lynch, Y. Zoellner, S. McGregor, M. Home (Minnetonka, MN, USA)

12:30pm-2:00pm: Objective decrement in Parkinson’s disease – A new parameter for the BRAIN tap test

H. Hasan, D.S. Athauda, T. Foltynie, G. Giovannoni, T. Warner, A.J. Lees, A. Noyce (East Riffa, Bahrain)

12:30pm-2:00pm: Objective methods for quantifying the deep brain stimulation (DBS) efficacy in subthalamic-nuclei (STN) neurons with microelectrode recording (MER) technology

V.R. Rama Raju, R.K. Mridula, R. Borgohain, V. Rama Raju (Hyderabad, India)

12:30pm-2:00pm: Objective movement recording in PD patient before and after STN-DBS

D. Flisar, B. Pikš, B. Meglic, Z. Pirtošek, G. Kramberger (Ljubljana, Slovenia)

12:30pm-2:00pm: Oculopalatal myoclonus after stroke

B. Klysz, I. Sarzynska-Dlugosz, A. Czlonkowska, I. Kurkowska-Jastrzebska (Warsaw, Poland)

12:30pm-2:00pm: Olfaction and gray matter volume in Parkinson’s disease. A voxel-based morphometry study

K. Witt, N. Schmidt, O. Granert, L. Paschen, S. Wolff, G. Deuschl (Kiel, Germany)

12:30pm-2:00pm: Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease

A.K. Emelyanov, G.V. Baydakova, P.A. Andoskin, M.A. Nikolaev, K.A. Senkevich, I.V. Milyukhina, A.F. Yakimovskii, A.A. Timofeeva, E.Y. Fedotova, E.P. Nuzhnyi, S.N. Illarioshkin, E.Y. Zakharova, S.N. Pchelina (Saint-Petersburg, Russia)

12:30pm-2:00pm: Opioid K receptor variant delays the onset of dyskinesias in Parkinson’s disease

R. Cilia, R. Asselta, R. Benfante, E. Cereda, D. Vallauri, L. Marabini, D. Fornasari, S. Goldwurm, G. Pezzoli (Milan, Italy)

12:30pm-2:00pm: Opsoclonus myoclonus ataxia syndrome in a seronegative patient with disseminated cryptococcosis: The first case report

K. Sakdisornchai, J. Sringean, O. Jitkritsadakul, R. Bhidayasiri (Bangkok, Thailand)

12:30pm-2:00pm: Optimization of 6-hydroxydopamine animal model of early stage Parkinson´s disease for the assessment of neurorestorative therapies

J.V. Leikas, T.M. Kääriäinen, A.J. Jalkanen, M. Lehtonen, T. Rantamäki, M.M. Forsberg (Kuopio, Finland)

12:30pm-2:00pm: Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study

A. Agro, B. Dzyngel, T. Bilbault, E.J. Pappert (Toronto, ON, Canada)

12:30pm-2:00pm: Orthostatic tremor: A literature review of clinical data

D.E. Bhatti, D. Torres-Russotto (Omaha, NE, USA)

12:30pm-2:00pm: Orthostatic tremor: Disease progression and disability

N. Vijiaratnam, D. Siresena, E. Paul, K.L. Bertram, D.R. Williams (Melbourne, Australia)

12:30pm-2:00pm: Orthostatic tremor: Is deep brain stimulation better than spinal cord stimulation?

H.L. Chiang, Y. Tai, V.S.C. Fung, N. Mahant (Sydney, Australia)

12:30pm-2:00pm: Ortostatic myoclonus: A report of four cases

Z.F. Aldaajani, F.C.F. Chang, N. Mahant, S.D. Kim, V.S.C. Fung (Sydney, Australia)

12:30pm-2:00pm: Paediatric and adult-onset parkinsonism in Chediak-Higashi disease: A new family

M. Carecchio, E. Salsano, A. Legati, C. Lamperti, E. Corsini, B. Garavaglia, D. Pareyson, D. Ghezzi (Milan, Italy)

12:30pm-2:00pm: Parkinson’s disease characteristics in patients with Gaucher’s disease

A. Thaler, A. Mirelman, E. Shimoni, M. Victor, O. Assais, M. Grumberg, T. Gurevich, T. Shiner, M. Gana Weisz, A. Orr Urtreger, N. Giladi (Tel-Aviv, Israel)

12:30pm-2:00pm: Parkinson’s disease motor subtypes show similar deficits in inhibitory control

C.M. Tolleson, M. Turchan, N. van Wouwe, S.A. Wylie (Nashville, TN, USA)

12:30pm-2:00pm: Parkinson’s disease onset on non-dominant side predicts greater motor disability

T.A. Finseth, S. Sillau, B. Berman (Aurora, CO, USA)

12:30pm-2:00pm: Parkinson’s disease-associated Miro1 mutants cause mitochondrial dysfunction

D. Grossmann, D. Scheibner, J. Fitzgerald, W. Mätzler, L. Burbulla, R. Krüger (Belvaux, Luxembourg)

12:30pm-2:00pm: Paroxysmal exercise-induced dystonia within the phenotypic spectrum of ECHS1 deficiency

M. Quadri, M. Skorvanek, S. Olgiati, M. Minneboo, J. Graafland, G.J. Breedveld, R. Bonte, Z. Ozgur, K. Schoonderwoerd, F.W. Verheijen, W.F.J. van Ijcken, H. Fen Chien, E. Reis Barbosa, H.C. Chang, S.C. Lai, T.H. Yeh, C.S. Lu, Y.H. Wu-Chou, A.J.A. Kievit, V. Han, Z. Gdovinova, R. Jech, R.M.W. Hofstra, G.J.G. Ruijter, W. Mandemakers, V. Bonifati (Rotterdam, Netherlands)

12:30pm-2:00pm: Pathophysiological mechanisms of bone mass loss for osteoporosis prevalence in Parkinson’s disease

L.A. Leandro, H.A.G. Teive (Curitiba, Brazil)

12:30pm-2:00pm: Persistent drug-induced parkinsonism with normal dopamine transporter imaging

J.W. Lee, J.Y. Hong, J.S. Oh, I. Lee, J.S. Kim, Y.H. Sohn, P.H. Lee (Wonju, Korea)

12:30pm-2:00pm: Persistent myoclonic dystonia due to SCL2A1 mutation

P.H. McNamara, D. Olszewska, A. McCarthy, J. McKinley, T. McVeigh, T. Lynch (Dublin, Ireland)

12:30pm-2:00pm: Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson’s disease

E.J. Pappert, B. Dzyngel, T. Bilbault, A. Agro (Toronto, ON, Canada)

12:30pm-2:00pm: Phenotype and genotype variability of CACNA1A in a cohort of ataxia in Taiwan

P.Y. Fong, T.H. Yeh, S.C. Lai, C.S. Lu (Taoyuan City, Taiwan)

12:30pm-2:00pm: Phenotypes in Essential Tremor: Gait analysis and imaging study

E. Boutin, T. Witjas, R. Carron, J. Regis, E. Guedj, J.P. Azulay, M. Vaugoyeau (Marseille, France)

12:30pm-2:00pm: Phenotypic characteristics in GBA-associated Parkinson’s disease (PD): A study in a Greek population

A.M. Simitsi, C. Koros, N. Papagiannakis, R. Antonelou, M. Moraitou, H. Michelakakis, M. Stamelou, L. Stefanis (Athens, Greece)

12:30pm-2:00pm: Phosphorylation by GSK-3β enhances binding of metal ion induced tau oligomers to neutral lipid surfaces

G.S. Nuebling, E. Plesch, T. Högen, S. Lorenzl, F. Kamp, A. Giese (Munich, Germany)

12:30pm-2:00pm: Physical training prevents depressive-like behavior and bdnf decrease in an animal model of Parkinson’s disease

T. Tuon, S.S. Valvasori, J.L. Quevedo, C.T. Souza, R.A. Pinho (Criciúma, Brazil)

12:30pm-2:00pm: PINK1-dependent clearance of depolarized mitochondria is driven by the UPS and can occur independently of (macro)autophagy

A. Rakovic, J. Ziegler, C.U. Mårtensson, J. Prasuhn, K. Shurkewitsch, P. König, H.L. Paulson, C. Klein (Luebeck, Germany)

12:30pm-2:00pm: Piper longum L. alkaloids inhibit lipopolysaccharide-stimulated microglial activation and protect nigral dopaminergic neurons

H. Yang, C. Duan (Beijing, People's Republic of China)

12:30pm-2:00pm: Polyethylenimine (PEI) nanoparticle-mediated delivery of siRNA to silence neuronal gene expression of alpha-synuclein in a mouse model of Parkinson’s disease

C. Helmschrodt, A. Bauer, S. Höbel, S. Schöniger, S.A. Fietz, A. Aigner, A. Richter, F. Richter (Leipzig, Germany)

12:30pm-2:00pm: Post-anoxic myoclonus: Timing matters

K.G. Su, A.L. Hiller (Portland, OR, USA)

12:30pm-2:00pm: Post-traumatic rubral tremor – A rare entity

M. Kaur, S. Kushwaha, S. Khosya (New Delhi, India)

12:30pm-2:00pm: Postural and nonmotor disturbances in Parkinson’s disease

A. Pilipovich, V. Golubev, G. Ptimat (Moscow, Russia)

12:30pm-2:00pm: Potential advantages of high resolution lead designs for deep brain stimulation

J. Wu, M. Astrom, G. Molnar (Minneapolis, MN, USA)

12:30pm-2:00pm: Pre-formed fibrils injection worsen pathology caused by AAV-mediated over expression of α-synuclein

L.S. Breger, P. Thakur, O.W. Wan, B. Mattsson, K. Luk, V.M. Lee, J. Trojanowski, A. Björklund (Lund, Sweden)

12:30pm-2:00pm: Premotor phase of PD in two GBA mutation carriers

N. Kresojevic, M. Jankovic, I. Petrovic, V. Dobricic, N. Dragasevic, M. Svetel, L. Brajkovic, V. Kostic (Belgrade, Serbia)

12:30pm-2:00pm: Prescribed gait tests versus continuous monitoring of gait in people with Parkinson’s disease

C. Curtze, J. McNames, M. El-Gohary, J.G. Nutt, M. Mancini, P. Carlson-Kuhta, F.B. Horak (Portland, OR, USA)

12:30pm-2:00pm: Presynaptic dopamine depletion predicts late complications and time of progression to advanced disease in patients with early Parkinson’s disease

R. Djaldetti, L. Greenbaum, M. Lorberboym (Petah Tiqva, Israel)

12:30pm-2:00pm: Prevalence of restless legs syndrome in an atypical Parkinson’s disease population

J.R.P. Zuzuárregui, K. Werbaneth, S. Lee, C. Branson, M.H. Saint-Hilaire, A.D. Hohler (Boston, MA, USA)

12:30pm-2:00pm: Primary progressive aphasia and frontotemporal dementia in an Irish-American family due to a novel progranulin mutation

D.A. Olszewska, A. McCarthy, E.D. Huey, I. Delon, G. Pope, A. Blanco-Campal, T. Lynch (Dublin, Ireland)

12:30pm-2:00pm: Primidone-related connective tissue disorders in essential tremor

C.S.B. Germano, M. Spitz, L.F.R. Vasconcellos (Rio de Janeiro, Brazil)

12:30pm-2:00pm: Propranolol therapy for tardive dyskinesia: A retrospective examination

S.A. Factor, K.A. Armstrong, J.M. Hatcher-Martin (Atlanta, GA, USA)

12:30pm-2:00pm: Protective effects of ATP13A2 in Parkinson’s disease models

S. Martin, S. van Veen, J. Zielich, T. Holemans, C. van den Haute, V. Beakelandt, P. Agostinis, P. Vangheluwe (Leuven, Belgium)

12:30pm-2:00pm: Protein levels of SV2A and VGLUT1 in brain tissue from patients with Parkinson’s disease, dementia with Lewy bodies and Alzheimer’s disease

S. Frykman, M. Oosterhof, M.S. Ahmed, D. Howlet, T. Hortobagyi, P. Francis, D. Årsland (Huddinge, Sweden)

12:30pm-2:00pm: Psychiatric profile in functional (psychogenic) jerky movement disorders

Y.E.M. Dreissen, T.J. van Trier, J.M. Dijk, D.C. Cath, M.A.J. Tijssen (Amsterdam, Netherlands)

12:30pm-2:00pm: Quantification of postural stability in Parkinson’s disease patients utilizing mobile technology

J.L. Alberts, M.M. Koop, S.M. Linder, T. Dey, S.J. Ozinga (Cleveland, OH, USA)

12:30pm-2:00pm: Quantifying daily living transitions in patients with Parkinson’s disease using a body-fixed sensor

J.M. Hausdorff, H. Bernad-Elazari, T. Herman, A. Mirelman, E. Gazit, N. Giladi (Tel Aviv, Israel)

12:30pm-2:00pm: Quantifying turning behavior in Parkinson’s disease patients using mobile technology

M. Miller Koop, S.J. Ozinga, J.L. Alberts (Cleveland, OH, USA)

12:30pm-2:00pm: Quantitative analysis of tremor in patients with cerebellar and brainstem lesions

A. Kovács, Z. Farkas, A. Kamondi (Budapest, Hungary)

12:30pm-2:00pm: Quantitative assessment of advanced therapies in Parkinson’s disease using the Parkinson kinetigraph (PKG)

R.L. Blaze, J. Tan, A.H. Evans (Parkville, Australia)

12:30pm-2:00pm: Quantitative assessment of DBS-induced gait disorder in patients with essential tremor

D. Kroneberg, T. Schmitz-Hübsch, A. Gropp, G.H. Schneider, A.A. Kühn (Berlin, Germany)

12:30pm-2:00pm: Re-emergent tremor in Parkinson’s disease: Epidemiological and clinical features

D. Belvisi, A. Conte, M. Bologna, A. Suppa, M. Costanzo, M.C. Bloise, A. Formica, P. Stirpe, G. Fabbrini, A. Berardeli (Pozzilli, Italy)

12:30pm-2:00pm: Reach-to-grasp impairments of both hands in individuals with Parkinson’s disease

S. Khacharoen, J. Tretriluxana, A. Pisarnpong, P. Chaiyawat (Nakhon Pathom, Thailand)

12:30pm-2:00pm: Reduced lifespan and climbing ability observed in the overexpressing human α-synuclein without heat shock protein CNB115 in Parkinson’s disease drosophila line

M.S. Islam, H.J. Kim, S.S. Hong (Jeonju, Korea)

12:30pm-2:00pm: Reduced thalamo-cortical functional connectivity in asymptomatic LRRK2 mutation carriers

D. Vilas, B. Segura, C. Pont-Sunyer, M.J. Martí, Y. Compta, F. Valldeoriola, H. Baggio, M. Quintana, A. Bayés, J. Hernández-Vara, M. Calopa, M. Aguilar, C. Junqué, E. Tolosa (Barcelona, Spain)

12:30pm-2:00pm: Regulation in speech motor control in ET patients treated with DBS: Kinematics of the lingual and the labial systems

D. Muecke, A. Hermes, M.T. Barbe, T.B. Roettger, N. Henrik, J. Becker, M. Hartinger, I. Meister, V. Visser-Vandewalle, L. Timmermann, M. Grice (Cologne, Germany)

12:30pm-2:00pm: Relationship between Alzheimer’s disease GWAS-linked top hits and risk of Parkinson’s disease with or without cognitive decline: A Chinese population-based study

J.F. Guo, Y.Q. Wang, X.X. Yan, B.S. Tang (Changsha, People's Republic of China)

12:30pm-2:00pm: Relationship of serum ferritin level and tic severity in children with Tourette syndrome

D. Ghosh, E.L. Burkman (Columbus, OH, USA)

12:30pm-2:00pm: Relationships of cognitive functions and psychiatric symptoms with motor phenotypes in patients with untreated early-stage Parkinson’s disease

H. Terashi, Y. Ishimura, T. Taguchi, H. Mitoma, H. Aizawa (Tokyo, Japan)

12:30pm-2:00pm: Relative hypoglycemia induces acute chorea followed by chronic parkinsonism in a diabetic patient on hemodialysis: A case with sequential clinico-radiological correlate

K.J. Lizarraga, D. Adams, L.C. Alexandre, C. Singer (Miami, FL, USA)

12:30pm-2:00pm: Reliability and responsiveness of in-clinic and at-home app-based bradykinesia assessment

D.A. Heldman, E. Urrea Mendoza, L.C. Lovera, D.A. Schmerler, J.P. Giuffrida, A.J. Espay, J.X.O. Garcia, M.E. Mohammad, M.C.U. McFarlane, H.H. Fernandez (Cleveland, OH, USA)

12:30pm-2:00pm: Resetting tremor by single pulse transcranial magnetic stimulation at the motor cortex and the cerebellum in essential tremor and dystonic tremor

P. Panyakaew, H.J. Cho, P. Srivanitchapoom, M. Hallett (Bethesda, MD, USA)

12:30pm-2:00pm: Response to thermal and pain stimulation and genetic variance for pain in patients with Parkinson’s disease – Are they all related?

A. Khlebtovsky, R. Dabby, Y. Rodity, I. Steiner, R. Djaldetti (Petach Tikva, Israel)

12:30pm-2:00pm: Risk of movement disorders with antipsychotic drugs in patients with schizophrenia or depressive disorders

M.V. Rey, L. Molina, B. Recinos, B. Paz, M. Rovelo, F.E. Rodriguez Elias, J. Calderon, A. Arellano, S. Pomata, S. Perez-Lloret, CA-APD Study Team (Buenos Aires, Argentina)

12:30pm-2:00pm: Risk prediction modeling in Parkinson’s disease using genetic and environmental/lifestyle factors

C.M. Lill, Y.H. Chuang, J. Hansen, P.C. Lee, N. Greene, C. Klein, H. Binder, B. Ritz, L. Bertram (Lübeck, Germany)

12:30pm-2:00pm: Role of dopamine and GABA during subthalamic and pallidal deep brain stimulation: Evidence of dopamine release during subthalamic Deep Brain Stimulation

A. Nakajima, Y. Shimo, T. Uka, N. Hattori (Tokyo, Japan)

12:30pm-2:00pm: Role of macroautophagy in regulating microglia-mediated neuroinflammation and dopaminergic neuron injury

M. Jin, L. Hu, C. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: Roles of combined functional catechol-o-methyltransferase genotypes in Chinese Parkinson’s disease: A cross-sectional survey

Y. Qian, X. Yang, S. Xu, J. Liu, Q. Xiao (Shanghai, People's Republic of China)

12:30pm-2:00pm: Safety and efficacy of escalating doses of incobotulinumtoxinA (400-800U): Increasing improvements in disability due to multifocal upper- and lower-limb spasticity

J. Wissel, D. Bensmail, B. Rubin, A. Scheschonka, O. Simon, D.M. Simpson (Berlin, Germany)

12:30pm-2:00pm: Saliva swallowing frequency measured using 24-hours ambulatory impedance-pH monitoring in patients with Parkinson’s disease and drooling

J.G. Kalf, S. Scholten, W. Hopman (Nijmegen, Netherlands)

12:30pm-2:00pm: Same cerebellar atrophy pattern in hyper- and hypokinetic movement disorders due to mitochondrial cytopathy

S.R. Schreglmann, F. Riederer, C. Ganos, G. Kägi, D. Waldvogel, U. Hidding, E. Krasemann, C.R. Baumann, K.P. Bhatia, H.H. Jung, L. Michels (London, United Kingdom)

12:30pm-2:00pm: Selenotranscriptomic analyses identify signature selenoproteins in brain regions in a mouse model of Parkinson’s disease

J.Y. Wang, X. Zhang, Y.L. Ye, H.H. Fan, H.M. Wu, W.H. Cheng, J.H. Zhu (Wenzhou, People's Republic of China)

12:30pm-2:00pm: Sensor based gait analysis: Diagnostic application for apomorphine titration

F. Marxreiter, H. Gassner, J. Barth, J. Schlachetzki, C. Thun, D. Volc, J. Winkler, B. Eskofier, J. Klucken (Erlangen, Germany)

12:30pm-2:00pm: Serum levels of polychlorinated biphenyls, CYP2B6 and neurodegenerative disease in the Faroe Islands

L.L. Farrell, E. Nosova, S. Bech, I. Guella, M.J. Farrer, M.S. Petersen (Vancouver, BC, Canada)

12:30pm-2:00pm: sFIDA: A sensitive diagnostic assay for quantification of α-synuclein aggregates

T. Bujnicki, C. Zafiu, O. Bannach, D. Willbold (Jülich, Germany)

12:30pm-2:00pm: Sleep in essential tremor patients: A polysomnographic study

O. Dogu, S. Ozal, H. Kaleagasi (Mersin, Turkey)

12:30pm-2:00pm: Sleep motor activity in amyotrophic lateral sclerosis

M. Puligheddu, P. Congiu, D. Aricò, F. Rundo, F. Marrosu, G. Gioi, E. Costantino, G. Borghero, M.L. Fantini, R. Ferri (Monserrato, Italy)

12:30pm-2:00pm: Sleep related disorders in subtypes of patients with Parkinson’s disease in the Tomsk region, Russia

M.A. Nikitina, I.A. Zhukova, V.M. Alifirova, N.G. Zhukova, O.P. Izhboldina, J.S. Mironova, M.A. Titova, N.G. Brazovskaya, S.E. Sukhanov (Tomsk, Russia)

12:30pm-2:00pm: SMPD1 mutations, acid-sphingomyelinase activity and α-synuclein accumulation in Parkinson’s disease

Z. Gan-Or, V. Mallett, O. Tavassoly, Y. Dauvilliers, C. Leblond, A. Ambalavanan, S. Laurent, S. Strong, D. Spiegelman, A. Dionne-Laporte, C. Liong, O. Levy, S. Fahn, C. Waters, P. Mazzoni, S. Kuo, W. Chung, B. Ford, K. Marder, U. Kang, P. Wolf, P. Oliva, X. Zhang, L. Clark, P. Dion, E. Fon, N. Dupre, G. Rouleau, R. Alcalay (Montreal, Canada)

12:30pm-2:00pm: SOD1 aggregation: A pathological link between Parkinson’s disease and amyotrophic lateral sclerosis?

B.G. Trist, K.M. Davies, S. Genoud, V. Smoothy, G.M. Halliday, S. Roudeau, A. Carmona, L. Perrin-Verdugier, R. Ortega, K.L. Double (Sydney, Australia)

12:30pm-2:00pm: Sodium butyrate attenuates rotenone-induced neurodegeneration via enhancing autophagy and preventing α-synuclein aggregation

L. Liu, C. Han, K. Ma, X. Xu, J. Huang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: Sonographic investigation of Pisa syndrome in Parkinson’s disease

J. Shiraishi, T. Okazaki, M. Mizuba, K. Kajiwara, S. Saeki, R. Matsugaki, T. Takei, T. Uozumi (Fukuoka, Japan)

12:30pm-2:00pm: Spastic gait and mechanical energy recovery in children with hereditary spastic paraplegia

V. Maltese, S. Klebe, A. Marzegan, M. Dipaola, J. Volkmann, C.A. Frigo, P. Cavallari, I.U. Isaias (Wuerzburg, Germany)

12:30pm-2:00pm: SPAsticity in PractiCE (SPACE) – An international, observational study of botulinum toxin type A in spasticity

J. Wissel, J. Harriss, O. Simon, K. Sternberg, N. Roche, C. Cantú-Brito, S. Khatkova, P. Säterö (Berlin, Germany)

12:30pm-2:00pm: Spatial accuracy and reliability of the Microsoft Kinect V2 in the assessment of joint movement in comparison to marker-based motion capture (Vicon)

K. Otte, B. Kayser, S. Mansow-Model, A.U. Brandt, J. Verrel, T. Schmitz-Hübsch (Berlin, Germany)

12:30pm-2:00pm: Specificity and sensitivity of F-waves parameters in diagnosis of RLS/WED

P. Congiu, M.L. Fantini, G. Milioli, P. Tacconi, M. Figorilli, G. Gioi, B. Pereira, F. Marrosu, L. Parrino, M. Puligheddu (Monserrato, Italy)

12:30pm-2:00pm: Speed and severity of toxicity induced by pre-formed α-synuclein fibrils in rat brain is enhanced by α-synuclein overexpression

P. Thakur, L. Breger, B. Mattsson, K. Luk, V.M. Lee, J. Trojanowski, A. Björklund (Lund, Sweden)

12:30pm-2:00pm: Stabilometry characteristics as objective Parkinson’s disease progression biomarkers

I.V. Miliukhina, T.V. Sergeev, E.V. Gracheva, A.V. Kudrevatykh, M.D. Didur (Saint-Petersburg, Russia)

12:30pm-2:00pm: Staging and clinical correlates of cortical thinning in Parkinson’s disease

H. Wilson, F. Niccolini, C. Pellicano, P. Piccini, M. Politis (London, United Kingdom)

12:30pm-2:00pm: Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [¹⁸F]MNI-659 PET imaging

D.S. Russell, D.L. Jennings, O. Barret, G.D. Tamagnan, D. Alagille, J.P. Seibyl, K.L. Marek (New Haven, CT, USA)

12:30pm-2:00pm: Structural and functional signature of primary orthostatic tremor

C. Gallea, T. Popa, E. Roze, S. Lehéricy, S. Meunier, M. Vidailhet (Paris, France)

12:30pm-2:00pm: Study on association between physical and genetics role in essential tremor – A case control study

K. Kalimuthu, C. Ramachandran, M. Kadarkarai, V. Savariar (Coimbatore, India)

12:30pm-2:00pm: Substantia nigra α4β2 nicotinic cholinergic receptor expression correlates with tremor in Parkinson’s disease

M. Muller, R. Albin, N. Bohnen (Ann Arbor, MI, USA)

12:30pm-2:00pm: Substantial motor and non-motor symptoms in children and adults with classical galactosemia and organic acidurias

A. Kuiper, M.A. Coenen, W. Eggink, M.A.J. Tijssen, T.J. De Koning (Groningen, Netherlands)

12:30pm-2:00pm: Subthalamic nucleus activity during virtual reality provoked lower limb freezing in a patient with Parkinson’s disease and freezing of gait

M.J. Georgiades, M. Gilat, J.M. Shine, J. McMaster, N. Mahant, S.J.G. Lewis (Sydney, Australia)

12:30pm-2:00pm: Survey of telemedicine use among MDS members

A. Hassan, E.R. Dorsey, E. Cubo, C.G. Goetz, B.R. Bloem, M. Guttman, S.L. Heath, M. Katz, M. Spinder, C.M. Tanner, Z. Mari, A. Pantelyat, J.A. Bajwa, N.B. Galifianakis, E.M. Gatto (Rochester, MN, USA)

12:30pm-2:00pm: Symptomatic palatal and respiratory tremor with ataxia following fourth ventricle epidermoid cyst removal

B.R. Barton, B. Barton (Chicago, IL, USA)

12:30pm-2:00pm: Synaptic homeostasis in Parkinson’s disease: An high-density EEG study in different stage of the disease

S. Galati, S. Sarasso, C. Moeller, A. Kalein-Lang, C. Staedler (Lugano, Switzerland)

12:30pm-2:00pm: Systematic review and meta-analysis of randomized controlled trials to evaluate placebo response in restless legs syndrome

F.B. Rodrigues, M. Silva, G.S. Duarte, R. Camara, R. Fernandes, D. Abreu, J. Costa, J.J. Ferreira (Lisboa, Portugal)

12:30pm-2:00pm: Systematic review of autosomal recessive parkinsonism using the MDGene database protocol

C. Hartmann, A. Mashychev, A. Westenberger, A. Domingo, J. Hampf, S. Schaake, H. Zehnle, C. Marras, L. Bertram, M. Kasten, K. Lohmann, C.M. Lill, C. Klein (Lübeck, Germany)

12:30pm-2:00pm: TAF1 and its isoforms is underexpressed in different endogenous models of X-linked dystonia-parkinsonism

A. Domingo, K. Grütz, P. Seibler, P. Capetian, L.V. Lee, R. Rosales, R.D. Jamora, A. Westenberger, A. Rakovic, C. Klein (Lübeck, Germany)

12:30pm-2:00pm: Technology use habits and preferences of a population with Parkinson’s disease and their care partners

J.M. Dean (Boulder, CO, USA)

12:30pm-2:00pm: Testing feasibility and utility of remote data capture technology to assess Parkinson’s disease

J. Carter, N. Hellmers, A. Hanineva, C. Henchcliffe (New York, NY, USA)

12:30pm-2:00pm: The contribution of the subthalamic nucleus in gait initiation of subjects with Parkinson’s disease

C. Palmisano, G. Arnulfo, N.G. Pozzi, A. Canessa, A. Leporini, C.A. Frigo, G. Pezzoli, F. Steigerwald, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)

12:30pm-2:00pm: The correlation between N30 SEP and motor function in Parkinson’s disease

S.Y. Kang, Y.J. Kim, Y.H. Sohn, H.I. Ma (Hwaseong, Korea)

12:30pm-2:00pm: The distinguishing clinical features of rapid-onset-parkinson-dystonia (RDP) syndrome due to ATP1A3 mutations

I.A. Meijer, R.A. Ortega, D. Raymond, N. Lubarr, V. Shanker, W.L. Severt, S. Bressman, L. Ozelius, R. Saunders-Pullman (New York, NY, USA)

12:30pm-2:00pm: The effect of STN-DBS on movement initiation control is modulated by the noradrenergic system: Evidence of an interaction from a combined pharmacological/DBS/EEG study

C. Spay, M. Albares, S. Thobois, E. Broussolle, P. Boulinguez, B. Ballanger (Bron, France)

12:30pm-2:00pm: The effect of uni- and bilateral thalamic deep brain stimulation on speech in patients with essential tremor: Acoustics and intelligibility

J. Becker, T.B. Roettger, M. Hartinger, D. Mücke, A. Hermes, J. Pochmann, T.A. Dembek, J. Wirths, N. Allert, V. Visser-Vandewalle, I.G. Meister, M. Grice, L. Timmermann, M.T. Barbe (Cologne, Germany)

12:30pm-2:00pm: The effects of viral priming on neurotoxin induced neurodegeneration and synapse dysfunction in cell culture models relevant to Parkinson’s disease

L.K. Olsen, E. Dowd, D. McKernan (Galway, Ireland)

12:30pm-2:00pm: The epigenetic regulation of HIF-1α by SIRT1 in MPP+ treated SH-SY5Y cells

Y. Wu, S. Dong, Y. Guo, Y. Feng, X. Cui, S. Kuo, T. Liu (Shanghai, People's Republic of China)

12:30pm-2:00pm: The Faroese Parkinson’s diseases research program-Multifactorial analyses of a complex syndrome

M.S. Petersen, S. Bech, E. Nosova, L.L. Farrell, I. Guella, D. Evans, B. Ritz, J. Aasly, M.J. Farrer (Tórshavn, Faroe Islands)

12:30pm-2:00pm: The French experience of liver transplantation for severe neurological forms of Wilson disease

A. Poujois, R. Sobesky, W. Meissner, E. de Medeiros, C. Vanlemmens, A.S. Brunet, E. Broussolle, J.C. Duclos-Vallée, F. Woimant (Paris, France)

12:30pm-2:00pm: The impact of levodopa and apomorphine on beta- and gamma-oscillations in cortico-basal ganglia circuits in experimental parkinsonism

J. Kühn, J.K. Haumesser, P.J. Magill, A.A. Kühn, V.V. Nikulin, C. van Riesen (Berlin, Germany)

12:30pm-2:00pm: The inflammatory burden of tic onset in a paediatric cohort: A preliminary study

A. Capuano, F. Nicita, M. Angeloni, F. Vigevano (Rome, Italy)

12:30pm-2:00pm: The interrater variability in clinical assessment of post-hypoxic myoclonus

J.C. van Zijl, M. Beudel, J.W.J. Elting, B.M. de Jong, J. van der Naalt, W.M. van den Bergh, A.O. Rossetti, M.A.J. Tijssen, J. Horn (Groningen, Netherlands)

12:30pm-2:00pm: The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease

J.E. Ferrario, S. Sanz-Blasco, M. Bordone, A. Damianich, A. Bernardi, G. Gomez, I. Taravini, E. Avale, O. Gershanik (Buenos Aires, Argentina)

12:30pm-2:00pm: The method of biofeedback training for the patients with Parkinson’s disease

I.S. Goursky, S.A. Likhachev, V.V. Vashchylin (Minsk, Belarus)

12:30pm-2:00pm: The phenotypic and genetic features of myoclonus-dystonia in six Saudi Arabian kindreds

S.A. Bohlega, A. Aldakheel, T. Alkhairallah, A. Alkhani, M. Almuhaizea, F. Alotaibi (Riyadh, Saudi Arabia)

12:30pm-2:00pm: The relevance of movement disorders gene panels in clinical practice: How many patients are we sorting out?

C. Barzaghi, C. Panteghini, M. Carecchio, A. Legati, V. Monti, C. Reale, F. Invernizzi, B. Garavaglia (Milan, Italy)

12:30pm-2:00pm: The role of non-steroidal anti-inflammatory use in symptomatic and asymptomatic LRRK2 G2019S mutation carriers

K.A. Wyman-Chick, M.J. Barrett, S.A. Sperling, C.A. Manning (Charlottesville, VA, USA)

12:30pm-2:00pm: The small GTP-binding protein Rhes influences midbrain dopaminergic neurons: Behavioral and biochemical studies

A. Pinna, F. Napolitano, G. Costa, P.F. Porceddu, L. Contu, J. Wardas, M.A. Casu, A. Usiello, M. Morelli (Cagliari, Italy)

12:30pm-2:00pm: The spectrum of CNS hyperexcitability in gluten-related disorders

M. Hadjivassiliou, G.D. Rao, P. Sarrigiannis (Sheffield, United Kingdom)

12:30pm-2:00pm: The temporal relationship between premonitory sensations and tics compared to obsessions

V.C. Brandt, C. Beck, J. Hermanns, T. Bäumer, B. Zurowski, S. Anders, A. Münchau (Lübeck, Germany)

12:30pm-2:00pm: The visible leg tremor at standing is always orthostatic tremor?

E. Oh, J.G. Lim, Y.S. Kim (Daejeon, Korea)

12:30pm-2:00pm: Three distinct cases of methamphetamine induced movement disorders

T.A. Clark, J. Kraakevik (Portland, OR, USA)

12:30pm-2:00pm: Tick disorders in children and differential diagnosis with progressive diseases of the nervous system

D. Aminova, K. a (Tashkent, Uzbekistan)

12:30pm-2:00pm: Tics exacerbations in middle-aged and older adults with Tourette syndrome: A case series

D. Robakis, D. Machado, E. Penney, E.D. Louis (New Haven, CT, USA)

12:30pm-2:00pm: Timing control of gait in essential tremor patients vs. age-matched controls

A.K. Rao, E.D. Louis, A.K. Rao (New York, NY, USA)

12:30pm-2:00pm: To new method of tremor assessment

A.V. Boika (Minsk, Belarus)

12:30pm-2:00pm: Topiramate responsive adult-onset opsoclonus myoclonus ataxia syndrome

Y. Degirmenci, H. Kececi (Duzce, Turkey)

12:30pm-2:00pm: Toward a new biomarker on Parkinson’s disease: Study of alpha synuclein on upper enteric system by endoscopy

N. Ben Ali, S. Mrabet, S. Hawet, R. Debbiche, S. Belal (Tunis, Tunisia)

12:30pm-2:00pm: Towards a responsive deep brain stimulation for the treatment of essential tremor

E. Opri, J. Shute, R. Molina, M. Okun, A. Gunduz, K. Foote (Gainesville, FL, USA)

12:30pm-2:00pm: Transcriptional profile of blood leukocyte in Parkinson’s disease patients after multi-modal exercise and tai chi training

L. Jin, Y. Hu, T. Zhang, K. Zhang, Z. Nie, F. Chen, Q. Cai, S. Li (Shanghai, People's Republic of China)

12:30pm-2:00pm: Transient myoclonic state in the elderly: A new entity in the classification of myoclonus

T. Hashimoto, T. Doden, H. Sato (Matsumoto, Japan)

12:30pm-2:00pm: Transient parkinsonism during pregnancy in patient heterozygous for Gaucher’s disease: Case report

S. Patel, K. Appleby, H. Fernandez (Cleveland, OH, USA)

12:30pm-2:00pm: Treatment of OFF episodes in Parkinson’s disease: An evaluation of patient and caregiver insights

E.J. Pappert, N. deGruyther, A. Agro (Toronto, ON, Canada)

12:30pm-2:00pm: Treatment of OFF episodes in Parkinson’s disease: An evaluation of physician practices

E.J. Pappert, A. Agro, N. deGruyther (Toronto, ON, Canada)

12:30pm-2:00pm: Tremor amplitude detected by three-dimensional optical device provides good correlation to clinical rating scale

K.H. Chen, P.C. Lin, Y.J. Chen, B.S. Yang, C.H. Lin, R.M. Wu (Hsin-Chu, Taiwan)

12:30pm-2:00pm: Tremor frequency by iPhone® applications: Correlation with EMG analysis

R. Araújo, M. Pereira, A. Matos, L. Negrão, A. Morgadinho (Coimbra, Portugal)

12:30pm-2:00pm: Tremor-recording methods and related quantitative tremor parameters in Parkinson’s disease

A. Kovács, Z. Farkas, A. Kamondi (Budapest, Hungary)

12:30pm-2:00pm: Triple X syndrome: Are tremors part of its phenotype?

X. Garcia, M.E. Mohammad, H. Fernandez, I. Itin (Cleveland, OH, USA)

12:30pm-2:00pm: Turkish version of the Johns Hopkins restless legs syndrome quality of life questionnaire (RLS-QoL): Validity and reliability study

S. Güler, F.N. Turan (Edirne, Turkey)

12:30pm-2:00pm: Two cases of parkinsonism with atypical genetics

J.A. Ribeiro, F. Moreira, J. Beato-Coelho, A.S. Morgadinho, M.R. Almeida, C. Januário (Coimbra, Portugal)

12:30pm-2:00pm: Two new cases of a novel ovario-leukodystrophy related to AARS2 mutation from Korea

H.J. Yang, J.M. Lee, J.H. Kwon, S.T. Lee, H.J. Kim, B. Jeon (Ulsan, Korea)

12:30pm-2:00pm: Two siblings with action myoclonus renal failure syndrome

M. Tábuas-Pereira, J. Durães, J. Tomás, A. Gouveia, C.S. Miranda, M.C. Macário (Coimbra, Portugal)

12:30pm-2:00pm: Two-step induction of dopaminergic neurons – Differentiation of leukapharesis-derived mesenchymal stem cells

S.I. El-Jaafary, M.M. Abdel-Dayem, N.M. Salama, H. Gabr, A.S. Abdelhafiz, Z.M. Ismail (Cairo, Egypt)

12:30pm-2:00pm: Unconventional chaperone inhibits alpha-synuclein amyloid formation by promoting off-pathway aggregation

J. Bieschke, E. Illes-Toth, M. Shah, N. Wu, S. Verzini, P. Selenko, E. Wanker (Saint Louis, MO, USA)

12:30pm-2:00pm: Urate and homocysteine: Changes in motor and cognitive symptoms in newly diagnosed Parkinson’s disease

I.J. Sleeman, R. Lawson, A. Yarnall, G. Duncan, F. Johnston, T. Khoo, D. Collerton, J.P. Taylor, D. Burn (Newcastle upon Tyne, United Kingdom)

12:30pm-2:00pm: Using wavelet coherence analysis to distinguish between tremor types

G. Kramer, M.A.J. Tijssen, N.M. Maurits, J.W. Elting (Groningen, Netherlands)

12:30pm-2:00pm: Vagus nerve stimulation as a novel treatment strategy for Parkinson’s disease

A. Farrand, R. Gregory, K. Helke, S. Hays, V. Hinson, H. Boger (Charleston, SC, USA)

12:30pm-2:00pm: Validation of an electronic motor diary for patients with Parkinson’s disease

A. Medina, D. Cerquetti, F. Nanni, M. Rossi, M. Merello (Buenos Aires, Argentina)

12:30pm-2:00pm: Valproate-associated parkinsonism – A critical review of the literature

F. Brugger, K.P. Bhatia, F.M.C. Besag (St. Gallen, Switzerland)

12:30pm-2:00pm: Vascular degeneration in Parkinson’s disease

J. Guan, P. Yang, R.L.M. Faill, M. Dragunow, H.J. Waldvogel (Auckland, New Zealand)

12:30pm-2:00pm: Video-based tremor analysis via Kinect® System in comparison to accelerometric and electromyographical tremor detection

F. Heinrich, T. Schmitz-Hübsch, T. Ellermeyer, S. Mansow-Model, A. Lipp (Berlin, Germany)

12:30pm-2:00pm: Vitamin D in early Parkinson’s disease

I.M. Sleeman, T. Aspray, S. Coleman, G. Duncan, T.K. Khoo, I. Schoenmakers, L. Rochester, D.J. Burn, A.J. Yarnall (Newcastle, United Kingdom)

12:30pm-2:00pm: Vitamin D receptor polymorphisms and Parkinson’s disease in a Korean population: Revisited

W. Jang, J.S. Kim (Gangneung, Korea)

12:30pm-2:00pm: Wrist reveals the fall risk in activities of daily living

T. Pozaic, R. Foell, A.K. Grebe, W. Stork (Waiblingen, Germany)

12:30pm-2:00pm: Young-onset Parkinson’s disease in two siblings with compound heterozygosity for two rare parkin mutations

H. Apaydin, A. Gündogdu-Eken, A. Gündüz, M. Tütüncü, B.Ç. Poyraz, A.N. Basak (Istanbul, Turkey)

12:00pm-1:30pm: [18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer’s disease

J.B. Rowe, P. Vázquez Rodríguez, Y.T. Hong, R.J. Borchert, S. Sami, W.R. Bevan-Jones, S.P. Jones, R. Arnold, A. Surendranathan, E. Mak, S. Li, T. Fryer, J. O'Brien, L. Passamonti (Cambridge, United Kingdom)

12:00pm-1:30pm: In vivo evaluation of tau pathologies in patient with progressive supranuclear palsy and healthy subjects with [¹¹C]PBB3-PET

H. Endo, H. Shimada, Y. Kimura, M. Ichise, M. Ono, H. Shinotoh, F. Niwa, S. Kitamura, K. Takahata, S. Hirano, S. Koga, D.W. Dickson, N. Sahara, M. Yamada, M. Higuchi, T. Toda, T. Suhara (Chiba, Japan)

12:00pm-1:30pm: 99mTc-TRODAT-1 SPECT findings in a patient with sporadic Creutzfeldt-Jakob disease

G. Fabiani, S.C.G. Scremin, H.A.G. Teive (Campina Grande do Sul, Brazil)

12:00pm-1:30pm: A case of misdiagnosed Parkinson’s disease (PD)

I. Gabrielyan, K. Harutyunyan, G. Avagyan, H. Amirjanyan, A. Voskanyan, S. Khachaturyan, H. Hambardzumyan, A. Nazaryan, H. Manvelyan (Yerevan, Armenia)

12:00pm-1:30pm: A cognitive fMRI study of non-manifesting LRRK2 and GBA carriers

A. Thaler, N. Bregman, A. Mirelman, T. Gurevich, M. Gana-Weiss, A. Orr-Urtreger, T. Hendler, N. Giladi (Tel-Aviv, Israel)

12:00pm-1:30pm: A comparison of self-report and performance-based balance measures to predict recurrent falls in people with Parkinson’s disease: A cohort study

L.R.S. Almeida, G.T. Valenca, N.N. Negreiros, E.B. Pinto, J. Oliveira-Filho (Salvador, Brazil)

12:00pm-1:30pm: A cross-sectional study in spinocerebellar ataxia type 12 (SCA-12) patients from a tertiary care center in Eastern India

S. Chatterjee, R. Banerjee, B. Mondal, M.U. Kulsum, K. Chatterjee, S.S. Jha, P. Chatterjee, S. Choudhury, S.S. Anand, H. Kumar (Kolkata, India)

12:00pm-1:30pm: A health cost analysis for Huntington disease in Peru

G. Silva-Paredes, M. Cornejo-Olivas, M. Inca-Martinez, K. Espinoza-Huertas, A. Vishnevetsky, P. Mazzetti, R. Urbanos-Garrido (Lima, Peru)

12:00pm-1:30pm: A largest case series study of spinocerebellar ataxia type 2(SCA2) from India: Do SCA2 clinical subtypes exists?

A.K. Srivastava, A.K. Sonakar, S. Shakya, V. Suroliya, A. Takkar, I. Ahmad, R.K. Singh, I. Singh, D. Vibha, G. Shukla, V. Goyal, K. Prasad, A. Garg, M. Faruq (New Delhi, India)

12:00pm-1:30pm: A longitudinal study of functional deterioration of primary olfactory cortex in early-stage Parkinson’s disease

J. Wang, Z. Mosher, T. Subramanian, Q.X. Yang (Hershey, PA, USA)

12:00pm-1:30pm: A new tool to stage Parkinson’s disease PDCS (Parkinson’s disease composite scale): A pilot study on behalf of the European Parkinson’s disease association (EPDA)

F. Stocchi, P. Martinez-Martin, F.G. Radicati (Rome, Italy)

12:00pm-1:30pm: A novel causal mutation for spinocerebellar ataxia 19/22 (SCA19)

C.M. Testa, V. Norris, J. Hoder, V. Hagood, R. Lewandowski, G.N. Tseng (Richmond, VA, USA)

12:00pm-1:30pm: A proposed Parkinson’s disease neuropsychological battery (PNB)

L.L. van Wanrooij, J. Hoogland, J.G. Goldman, G. Stebbins, G.J. Geurtsen, D. Weintraub (Amsterdam, Netherlands)

12:00pm-1:30pm: A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval

D. Stamler, E. Offman, M. Bradbury, L. De Boer (La Jolla, CA, USA)

12:00pm-1:30pm: A step forward to the future: UPDRS kinematic measures for telemedicine

G. Albani, C. Azzaro, F. Parisi, C. Ferraris, M. Giuberti, L. Contin, D. Pianu, L. Pradotto, V. Cimolin, N. Cau, M. Galli, R. Nerino, G. Ferrari, A. Mauro (Piancavallo, Italy)

12:00pm-1:30pm: A technological solution for monitoring Parkinson’s disease: A patient-based perspective on necessity, usability and acceptability

S. Couth, E. Poliakoff, J. Vega, C. Jay, S. Harper, R. Almutiry, T.F. Cootes, A.M. Ramsay, S.A. Kotz (Manchester, United Kingdom)

12:00pm-1:30pm: A unique phenotype associated with anti-GAD antibodies

A.P. Mentreddi, S. Chitnis, P. Khemani (Dallas, TX, USA)

12:00pm-1:30pm: Abnormal findings in polisomnographic records of patients with spinocerebellar ataxia type 2 (SCA2)

A. Zanatta, A.C.d.S. Crippa, F.M.B. Germiniani, H.A.G. Teive (Curitiba, Brazil)

12:00pm-1:30pm: Abnormal intrinsic brain activity reveals neural correlates of impaired cognitive function in early stage of Huntington’s disease (HD): A resting-state fMRI study

W. Liu, J. Yang, K. Chen, C. Luo, J.M. Burgunder, Q. Gong, H. Shang (Chengdu, People's Republic of China)

12:00pm-1:30pm: Accuracy of clinical diagnosis of dementia with Lewy bodies: A systematic review and meta-analysis

G. Rizzo, S. Arcuti, M. Copetti, M. Alessandria, R. Savica, A. Fontana, R. Liguori, G. Logroscino (Bologna, Italy)

12:00pm-1:30pm: Acute cerebellar degeneration as the first manifestation of Sjögren syndrome: A case report

R. Maciel, S. Camargos, F. Cardoso (Belo Horizonte, Brazil)

12:00pm-1:30pm: Affective theory of mind in Parkinson’s disease

A.M. Hammad, S. Ghozy, S.I. El-Jaafary (Cairo, Egypt)

12:00pm-1:30pm: Alterations in muscle synergies in early stage Parkinson’s disease

J.F. Daneault, G. Vergara-Diaz, C. Adans-Dester, G. Ferreira-Carvalho, V.C.K. Cheung, P. Bonato (Charlestown, MA, USA)

12:00pm-1:30pm: Altered brain activation in complex walking conditions in patients with Parkinson’s disease

I. Maidan, K. Rosenberg-Katz, Y. Jacob, N. Giladi, J.E. Deutsch, A. Mirelman, J.M. Hausdorff (Tel Aviv, Israel)

12:00pm-1:30pm: Altered cerebello-thalamo-cortical pathway in Huntington’s disease

J.F. Martín-Rodríguez, M. Gómez-Crespo, M.T. Cáceres-Redondo, L. Vargas-González, F.J. Palomar, P. Porcacchia, P. Álvarez de Toledo, J.M. Oropesa-Ruiz, F. Carrillo, I. Huertas-Fernández, S. Jesús, P. Mir (Seville, Spain)

12:00pm-1:30pm: Altered resting-state functional interhemispheric connectivity in Parkinson’s disease

X. Dan, S. Lin, A. Liu, Z. Wang, M.J. McKeown, P. Chan (Beijing, People's Republic of China)

12:00pm-1:30pm: Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): Updated week 8 results for the switch cohort

V. Sung, D. Stamler, D.O. Claassen (Birmingham, AL, USA)

12:00pm-1:30pm: Ambulatory assessment of tremor

M. Horne, S. O'Connor, P. Churchward, T. Perera, M. Braybrook (Parkville, Australia)

12:00pm-1:30pm: Analysis of cognitive disorders of Parkinson’s disease (PD) in the comparative aspect

S. Lukmonov, D. Tolibov, A. Sobirov, F. Yunusov, D. Jalilov, K. Abdukhalimova, A. Kalendarev (Tashkent, Uzbekistan)

12:00pm-1:30pm: Analysis of factors associated with cognitive and functional performance in Parkinsonian with normal mini-mental state examination

R. Breder, M.A.A. Leite, M.C.A. Ribas, M. Orsini (Niterói, Brazil)

12:00pm-1:30pm: Anhedonia and its correlation with clinical aspects in Parkinson’s disease

H. Nagayama (Tokyo, Japan)

12:00pm-1:30pm: Anti-GAD antibody cerebellar ataxia mimicking multiple system atrophy

J.B. Parmera, L.S.V. Schneider, R.G. Cury, M.M. Simabukuro, L.H.M. Castro, E.R. Barbosa (São Paulo, Brazil)

12:00pm-1:30pm: Anxiety and cognition are associated with dopaminergic dysfunction in de novo Parkinson’s disease

M. Picillo, G. Santangelo, R. Erro, A. Cozzolino, M. Amboni, C. Vitale, P. Barone, M.T. Pellecchia (Baronissi, Italy)

12:00pm-1:30pm: Anxiety and parkinsonism signs in idiopathic REM sleep behavior disorder

F. Escudier, R.B. Postuma, P.A. Bourgouin, J. Montplaisir, J.F. Gagnon (Montreal, QC, Canada)

12:00pm-1:30pm: Apolipoprotein E genotypes in Brazilian patients with Parkinson’s disease and their correlation with cognitive performance assessed by MoCA

M.M.C.M. Brito, R.S.J. Silva, V. Tumas, I.F. Mata, C.Z. Zabetian (Ribeirão Preto, Brazil)

12:00pm-1:30pm: Apraxia in Parkinson’s disease

M. Tábuas-Pereira, P. Correia, F. Moreira, A. Morgadinho, C. Januário (Coimbra, Portugal)

12:00pm-1:30pm: Are clinical certainty ratings helpful in the diagnosis of Parkinson’s disease?

H.V. Gupta, S.H. Mehta, J.G. Hentz, H.A. Shill, E. Driver-Dunckley, M.N. Sabbagh, C.M. Belden, B.N. Dugger, T.G. Beach, G.E. Serrano, L.I. Sue, C.H. Adler (Scottsdale, AZ, USA)

12:00pm-1:30pm: Are limbic and cognitive effects on balance in Parkinson’s disease equal?

K.A. Ehgoetz Martens, C.G. Ellard, Q.J. Almeida (Camperdown, Australia)

12:00pm-1:30pm: Arterial spin labeling perfusion MRI compensate for other diagnostic tools in evaluation of Parkinson’s disease with dementia

K. Abe, T. Hayashi, N. Akiyama, M. Yamamoto, M. Fujita (Nishinomiya, Japan)

12:00pm-1:30pm: Assessment of brainstem function with blink reflex variations in Parkinson’s disease

D. Weise, C. Pargac, J.J. Rumpf, C. Fricke, J. Classen (Leipzig, Germany)

12:00pm-1:30pm: Assessment of cognitive-motor interference during an upper extremity motor task in Parkinson’s disease

P.J.M. Bank, J. Marinus, J.H. de Groot, J.J. van Hilten, C.G.M. Meskers (Leiden, Netherlands)

12:00pm-1:30pm: Assessment of humor in Parkinson’s disease and the effect of deep brain stimulation

A. Greuel, C.J. Lewis, F. Maier, R. Dano, S. Heintz, W. Ruch, C. Eggers (Cologne, Germany)

12:00pm-1:30pm: Assessment of subclinical cerebellar involvement in progressive supranuclear palsy using SUIT based volumetric analysis

A. Lenka, L. George, K.R. Jhunjhunwala, S.A. Pasha, S. Mangalore, J. Saini, R. Yadav, P.K. Pal (Bangalore, India)

12:00pm-1:30pm: Association between cognitive status and mobility performance in dual task condition in patients with Parkinson’s disease

S.M.A.A. Pompeu, T.B. Freitas, K.G. Silva, C. Torriani-Pasin, F. Doná, J.E. Pompeu (São Paulo, Brazil)

12:00pm-1:30pm: Association between urine protein/creatinine ratio and cognitive dysfunction in Parkinson’s disease

Y.S. Oh, J.S. Kim, K.S. Lee (Seoul, Korea)

12:00pm-1:30pm: Association or causation? Orthostatic hypotension and cognitive impairment in α-synucleinopathies: A systematic review

S.J. Udow, A.E. Lang, M. Masellis (Toronto, ON, Canada)

12:00pm-1:30pm: Attention and dopamine: Increased distractibility in Parkinson’s disease

C. Warden, S. YorkWilliams, N. Ahn, D. Everling, K.L. Poston (Stanford, CA, USA)

12:00pm-1:30pm: Attention to action: Common to both conversion (psychogenic) and Parkinsonian (neurogenic) motor speech disorders

S. Sapir (Haifa, Israel)

12:00pm-1:30pm: Automatic event-detection for the neurophysiological evaluation of voluntary and involuntary movements

D. Benninger, J. Rechenmann, N. Chao, J. del R. Millan, R. Chavarriaga (Lausanne, Switzerland)

12:00pm-1:30pm: Autosomal recessive ataxia due to ANO10 mutations; full and novel phenotypic data in an Irish pedigree

P. Bogdanova-Mihaylova, N. Austin, M.D. Alexander, L. Cassidy, S.M. Murphy, R.A. Walsh (Dublin, Ireland)

12:00pm-1:30pm: Balance in patients with newly diagnosed Parkinson´s disease – A three year follow-up of a cohort in Northern Sweden

C. Johansson, E. Johansson, G.M. Johansson, B. Lindström, L. Forsgren (Sävar, Sweden)

12:00pm-1:30pm: Baseline physical activity may influence exercise-induced changes in cognitive function in Parkinson’s disease

R. Chow, C.R.A. Silveira, B.N. Intzandt, E. Beck, Q.J. Almeida (Waterloo, ON, Canada)

12:00pm-1:30pm: Behavioral and neuroimaging effects of LSVT-BIG and conventional physiotherapy in Parkinson’s disease

F. Schaible, F. Schwartz, T. v. Eimeren, C. Eggers (Köln, Germany)

12:00pm-1:30pm: Beneficial effect of L-theanine against 3-nitropropionic acid induced neurotoxicity in rats: Possible role of neurotransmitters and nitric oxide

P. Kumar, S. Jamwal (Moga, India)

12:00pm-1:30pm: Biochemical evaluation in patients with suspected ataxia related to CoQ10 deficiency

J.L.H. Pedroso, F.G. Ravagnani, M.H. Barros, L.R. Sanches, F.R. Picosse, T.O. Lopes, P.C. Aguiar, M. Chiaratti, C.H. Macabelli, J.H. Arita, M.R. Masruha, O.G. Barsottini, C.C. Ferreiro-Barros (Sao Paulo, Brazil)

12:00pm-1:30pm: Blinded video assessment of subtle Parkinsonian signs in PREDICT-PD participants

A.J. Noyce, A. Schrag, J. Masters, J.P. Bestwick, G. Giovannoni, A.J. Lees (London, United Kingdom)

12:00pm-1:30pm: Botulinum toxin treatment of freezing of gait in Parkinson’s disease patients as reflected in functional magnetic resonance imaging of leg movement

M. Vaštík, P. Hok, P. Hluštík, P. Kanovský, Z. Tüdös (Olomouc, Czech Republic)

12:00pm-1:30pm: Bradykinesia, low monthly income and current employment are associated with depression in patients with Parkinson’s disease: Results of a study from Sri Lanka

M.R. Withana, T.B. Herath, C. Rodrigo, C. Gamage, R. Gamage (Colombo, Sri Lanka)

12:00pm-1:30pm: Brain iron levels in Parkinson’s disease by postmortem and MRI measurements: A systematic review and meta-analysis

J.Y. Wang, Q.Q. Zhuang, L.B. Zhu, H. Zhu, T. Li, X. Zhang, J.H. Zhu (Wenzhou, People's Republic of China)

12:00pm-1:30pm: Brain mechanisms underlying visual processing in Parkinson’s disease

I. Rektorova, N. Elfmarkova, M. Gajdos, R. Marecek, S. Rapcsak (Brno, Czech Republic)

12:00pm-1:30pm: Brain network imaging findings in multiple system atrophy with cognitive decline

K. Hara, H. Watanabe, E. Bagarinao, K. Kawabata, N. Yoneyama, R. Ohdake, K. Imai, M. Masuda, T. Yokoi, T. Tsuboi, M. Ito, N. Atsuta, M. Katsuno, G. Sobue (Nagoya, Japan)

12:00pm-1:30pm: CAG repeat length and weight loss in pre-manifest Huntington’s disease

C.F. Kutz, L.J. Adams (Colorado Springs, CO, USA)

12:00pm-1:30pm: CAG repeats number of ATXN7 in SCA7 patients and normal population in Japan

Y. Adachi, R. Shimoyama (Matsue, Japan)

12:00pm-1:30pm: Can quantitative analysis of the “finger-to-nose test” discern between EOA and other conditions of coordination impairment?

O.E. Martinez Manzanera, T. Lawerman, D.A. Sival, N. Maurits (Groningen, Netherlands)

12:00pm-1:30pm: Cancer in Machado Joseph disease patients – Low frequency as a cause of death

L.B. Jardim, G.N. Souza, N. Kersting, T.A. Gonçalves, D. Pacheco, M.L. Saraiva-Pereira, J.A. Saute (Porto Alegre, Brazil)

12:00pm-1:30pm: Catechol-o-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson’s disease

Y. Zhang, Y. Zhang, K. Nie, S. Feng, L. Wang, J. Zhao, Z. Huang, L. Wang (Guangzhou, People's Republic of China)

12:00pm-1:30pm: Cerebellar ataxia and pregnancy

N. Hidarilak, T. Yacoubian (Birmingham, AL, USA)

12:00pm-1:30pm: Cerebellar GABA in essential tremor and dystonic tremor: A MR spectroscopy study

P. Panyakaew, H.J. Cho, S. Horovitz, M. Hallett (Bethesda, MD, USA)

12:00pm-1:30pm: Cerebellar GABA-A receptor activity is inversely correlated with gait speed in Parkinson’s disease

N.I. Bohnen, K.A. Frey, R.A. Koeppe, P.J.H. Scott, M.L.T.M. Muller (Ann Arbor, MI, USA)

12:00pm-1:30pm: Cerebellar gray matter alterations in Huntington disease: A voxel-based morphometry study

P. Azevedo, R. Guimarães, L. Piovesana, C. Piccinin, M.C. Arci, L. Villany, L. Campos, G. Pinheiro, J. Zuiane, A. Amato Filho, F. Cendes, Í. Lopes-Cendes, A. D'Abreu (Campinas, Brazil)

12:00pm-1:30pm: Cerebrospinal fluid biomarkers in Parkinson’s disease and associated cognitive impairment

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

12:00pm-1:30pm: Changes in motor symptoms of Parkinson’s disease: 2-year follow-up of 735 cases

P. Martinez-Martin, C. Rodriguez-Blazquez, A. Rizos, K.R. Chaudhuri, NILS, EUROPAR and MDS Non-Motor PD Study Groups (Madrid, Spain)

12:00pm-1:30pm: Changes of brain structure and cognition in individuals with possible prodromal Parkinson’s disease

M. Heldmann, J. Heeren, L. Rauch, C. Klein, T.F. Münte, M. Kasten, N. Brüggemann (Lübeck, Germany)

12:00pm-1:30pm: Characteristics of drop outs in a longitudinal study on individuals at risk for a neurodegenerative disorder

U. Suenkel, S. Heinzel, A.K. von Thaler, F. Metzger, G.W. Eschweiler, I. Liepelt-Scarfone, W. Maetzler, D. Berg (Tübingen, Germany)

12:00pm-1:30pm: Characterization and quantitative analysis of prelemniscal radiations in Parkinson´s disease

M.G. Garcia-Gomar, I. Vaca-Palomares, M. Esqueda, J. Soto, J.D. Tournier, L. Concha, F. Velasco (Queretaro, Mexico)

12:00pm-1:30pm: Children with intractable temporal and extratemporal seizures: Correlation of the MR spectroscopy and EEG findings in the surgical planning

M.M. Arnaout, S.S. Desoky, I.A. Lebda, A.A. Bessar, M.I. Fathy, E.H. Zidan, H.A. Hassan (Zagazig, Egypt)

12:00pm-1:30pm: Chorea-acanthocytosis: The first described clinical case in Ukraine

Y.O. Trufanov (Kyiv, Ukraine)

12:00pm-1:30pm: Choreoathetosis associated with cervical dystonia as clinical presentation of thyrotoxicosis: A rare condition

S.C.B. Casagrande, S.M.C.d.A. e Silva (São Paulo, Brazil)

12:00pm-1:30pm: Circulatory levels of BDNF correlate with cognitive deficits in people with Parkinson’s disease

H. Khalil, M.A. Alomari, O.F. Khabour, A. Al-Hieshan, J.A. Bajwa (Irbid, Jordan)

12:00pm-1:30pm: Clinical and analytical validation of novel autosomal recessive ataxia mutations identified from whole exome sequencing

S. Shakya, R. Kumari, A.K. Srivastava, D. Dash, A. Takkar, I. Singh, A. Garg, M. Mukerji, M. Faruq (New Delhi, India)

12:00pm-1:30pm: Clinical and behavioral features in carriers of intermediate length alleles of HTT gene. A case series of Mexican population

M.A. Ramírez-García, D.J. Dávila-Ortiz de Montellano, P. Yescas-Gómez, A. Ochoa-Morales, C. Boll, M.E. Alonso-Vilatela (Mexico City, Mexico)

12:00pm-1:30pm: Clinical and imaging characteristics of spinocerebellar ataxia type 14 defined in a German multi-center sample

T. Schmitz-Hübsch, S. Lux, A.U. Brandt, P. Bauer, E. Schlapakow, S. Greschus, H. Gärtner, M.E. Kirlangic, V. Gras, D. Timmann, M. Synofzik, N. Shah, L. Schöls, U. Kopp, T. Oberwahrenbrock, H. Zimmermann, C. Pfueller, E.M. Kadas, M. Rönnefarth, A. Grosch, M. Endres, T. Klockgether, K. Amunts, F. Paul, S. Doss, M. Minnerop (Berlin, Germany)

12:00pm-1:30pm: Clinical and instrumental gait analysis study of fear of falling in Parkinson’s disease patients

P.C. Gordon, J.B. Ferraz, L.M. Medeiros, L.F.R. Oliveira, D.K. Amado, A.M. Lima Neto, M.S.G. Rocha (Sao Paulo, Brazil)

12:00pm-1:30pm: Clinical and neuroimaging correlations in early manifest Huntington’s disease patients: Default mode network properties according to resting-state functional MRI

Y.A. Seliverstov, E.V. Seliverstova, S.A. Klyushnikov, R.N. Konovalov, S.N. Illarioshkin (Moscow, Russia)

12:00pm-1:30pm: Clinical presentation and genetic characteristics of Huntingtons disease in Croatia: Thirty years of experience

M. Relja, I. Jurjevic, K. Blazina, V. Miletic, N. Klepac (Zagreb, Croatia)

12:00pm-1:30pm: Clinico-genetic correlation in Indian spinocerebellar ataxia (SCA1) patients

A. Takkar, I. Ahmed, S. Shakya, V. Suroliya, R. Singh, A. Sonkar, A.K. Srivastava, M. Faruq (New Delhi, India)

12:00pm-1:30pm: Co-occurrence of two triplet repeat associated SCA mutations: A dilemma in clinical diagnosis, prognosis and genetic counselling and clinical significance

A.K. Srivastava, S. Shkaya, M. Faruq, V. Suroliya, V. Goyal, K. Prasad (New Delhi, India)

12:00pm-1:30pm: Cognition and amyloid biomarker status in non-demented patients with Parkinson’s disease patients (PD) with or without subjective cognitive decline (SCD)

I. Liepelt-Scarfone, F. Klumpp, W. Maetzler, S. Nussbaum, M. Timmers, G. Salvadore, M. Albers, K. Michaelis, Z. Tkaczynska, J. Streffer, D. Berg (Tübingen, Germany)

12:00pm-1:30pm: Cognitive and behavioral problems in children and adolescents with myoclonus dystonia

M.A. Coenen, H. Eggink, H. van den Berg, J.M. Spikman, M.A. Tijssen (Groningen, Netherlands)

12:00pm-1:30pm: Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension

K.E. McDonell, C.A. Shibao, I. Biagginoi, D. Robertson, D.O. Claassen (Nashville, TN, USA)

12:00pm-1:30pm: Cognitive and psychiatric outcome 3 years after bilateral deep brain stimulation of the globus pallidus pars interna versus subthalamic nucleus for Parkinson’s disease

J.A. Boel, V.J.J. Odekerken, G.J. Geurtsen, B.A. Schmand, M. Figee, R.J. de Haan, P. van den Munckhof, P.R. Schuurman, R.M.A. de Bie, The NSTAPS Study Group (Amsterdam, Netherlands)

12:00pm-1:30pm: Cognitive complaint in Parkinson’s disease patients with normal cognition

R.F. Purri, L. Brennan, J. Rick, L. Chahine, N. Dahodwala, A. Chen-Plotkin, J.E. Duda, J.F. Morley, R.S. Akhtar, J.Q. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

12:00pm-1:30pm: Cognitive deficits in Parkinson’s disease: A preliminary study of neuropsychological profiles

R.J. Giannaula, P.G. Sanz, J.C. Maiques, M.B. Seijas, M.J. González Aguilar, L. Grasso (Buenos Aires, Argentina)

12:00pm-1:30pm: Cognitive development in individuals with mild Parkinsonian signs

S. Lerche, K. Brockmann, I. Wurster, A. Pilotto, U. Sünkel, V. Herbst, B. Brixx, A.K. von Thaler, F. Metzger, G. Eschweiler, W. Maetzler, D. Berg (Tübingen, Germany)

12:00pm-1:30pm: Cognitive function and self-reported depressive symptoms in a population-based cohort to study non-motor-symptoms of Parkinson’s disease

E.J. Vollstedt, K. Hückelheim, S. Tunc, J. Hampf, C. Kritzinger, M. Kasten, C. Klein (Luebeck, Germany)

12:00pm-1:30pm: Cognitive impairment in Huntington’s disease

N. Kamble, N. Netravathi, K. Kumar, S. Jain, P.K. Pal (Bangalore, India)

12:00pm-1:30pm: Cognitive profile of Filipino patients with X-linked dystonia parkinsonism

J.E.C. Bautista, R.D.G. Jamora, L.K. Ledesma, L.V. Lee, R.L. Rosales, C.C.E. Diesta, A. Domingo (Quezon City, Philippines)

12:00pm-1:30pm: Coin rotation as strongest predictor of buttoning in Parkinson’s: A multicenter study demonstrating the everyday impact of limb-kinetic apraxia

T. Foki, T. Vanbellingen, C. Lungu, W. Pirker, S. Bohlhalter, T. Nyffeler, J. Kraemmer, D. Haubenberger, F.P.S. Fischmeister, E. Auff, M. Hallett, R. Beisteiner (Vienna, Austria)

12:00pm-1:30pm: Combined effects of visual and auditory cues on gait initiation in Parkinson’s disease

T. Hashimoto, H. Sato (Matsumoto, Japan)

12:00pm-1:30pm: Combined imaging markers increase accuracy when predicting real life disease onset in Huntington’s disease

S.L. Mason, R. Daws, R.A. Barker, A.D. Hampshire (Cambridge, United Kingdom)

12:00pm-1:30pm: Communication and language skills in Huntington’s disease

Y. Manor, D. Shpunt, S. Naor, L. Frydman, A. Gad, A. Ezra, A. Migirov, J. Knaani, A. Socher, T. Gurevich (Tel-Aviv, Israel)

12:00pm-1:30pm: Comparative analysis of clinical and neuroimaging features of parkinsonism and dementia of Alzheimer’s type

D. Tolibov, G. Rakhimbaeva (Tashkent, Uzbekistan)

12:00pm-1:30pm: Comparative analysis of upper limb motor function and articulation disorder in Parkinson’s disease

E. Ruzicka, J. Rusz, T. Tykalova, K. Zarubova, R. Krupicka, R. Jech (Prague, Czech Republic)

12:00pm-1:30pm: Comparative study of the substantia nigra echogenicity and 123-I ioflupane SPECT in patients with REM behavior disorder

J. Mašková, P. Dušek, D. Školoudík, K. Kupka, K. Šonka, V. Ibarburu Lorenzo Y Losada, J. Kubinyi, E. Ruzicka (Praha 2, Czech Republic)

12:00pm-1:30pm: Comparative study patients with different clinical forms of Parkinson’s disease

N.D. Demchuk, T.V. Yakovleva, Y.V. Karakulova (Perm, Russia)

12:00pm-1:30pm: Comparison of change in the UPDRS verses MDS-UPDRS in a population of Parkinson’s disease (PD) patients treated with deep brain stimulation (DBS)

S.S. Wang, N.B. Galifianakis, M. San Luciano, P.S. Larson, P.A. Starr, N. Ziman, J.L. Ostrem (San Francisco, CA, USA)

12:00pm-1:30pm: Comparison of DAT and DOPA PET tracer for assessing severity and progression in patients with Parkinson’s disease

W. Li, N.P. Lao-Kaim, A.A. Roussakis, A. Martin-Bastida, C. Loane, N. Valle-Guzman, Z. Kefalopoulou, M. Politis, T. Foltynie, R.A. Barker, P. Piccini (London, United Kingdom)

12:00pm-1:30pm: Comparison of DAT scan, cardiac MIBG scintigraphy, and cerebrospinal fluid 5HIAA levels in Parkinsonian syndrome

R. Sengoku, M. Yamazaki, D. Kaneda, Y. Nishina, A.M. Tokumaru, S. Murayama (Tokyo, Japan)

12:00pm-1:30pm: Comparison of mental practice and proprioceptive neuromuscular facilitation in sisters with cerebellar atrophy

C. Bedeschi, D. Guedes, D. Ambrosano (Barueri, Brazil)

12:00pm-1:30pm: Comparison of Test Your Memory (TYM) and Montreal Cognitive Assessment (MoCA) measures in Parkinson’s disease

E.J. Henderson, H. Chu, D.M. Gaunt, A.L. Whone, Y. Ben-Shlomo, V. Lyell (Bristol, United Kingdom)

12:00pm-1:30pm: Comparison of the utility of three cognitive scales for MDS Level-I diagnosis of mild cognitive impairment in Parkinson’s disease: MoCA, PD-CRS and ACE-III

R. Fernandez-Bobadilla, J. Pagonabarraga, J.A. Matias-Guiu, S. Martínez-Horta, A. Horta-Barba, J. Marin-Lahoz, J. Perez-Perez, B. Pascual-Sedano, H. Bejr-Kasem, A. Campolongo, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm: Compensation strategies for gait in Parkinson’s disease

S.C. Lidstone, A. Fasano, M. Hallett, A. Nieuwboer, E. Ruzicka, B.A. Bloem (Toronto, ON, Canada)

12:00pm-1:30pm: Computer uses and difficulties in Parkinson’s disease

Z. Katsarou, M. Plotnik, G. Zeilig, A. Gottlieb, R. Kizony, S. Bostantjopoulou (Thessaloniki, Greece)

12:00pm-1:30pm: Consolidation of learning and memory in Parkinson’s disease

M.E. Sharp, K. Duncan, K. Foerde, R. Kahane, D. Shohamy (New York City, NY, USA)

12:00pm-1:30pm: Construct validity of Moca test in a sample of patients with Parkinson´s disease in Bogotá and Cali – Colombia

B.E. Muñoz, O. Bernal, A. Castillo, J.L. Orozco (Cali, Colombia)

12:00pm-1:30pm: Coping styles and their influence on outcomes in Parkinson’s disease

K.M. Sundvick, F. Kassam, N. Dispirito, E. Book, S. Cresswell (Vancovuer, BC, Canada)

12:00pm-1:30pm: Core set of measures of balance for people with multiple sclerosis and cerebellar ataxia

S.J. Winser, C.M. Smith, L.A. Hale, L.S. Claydon, S.L. Whitney, B. Klatt, J. Mottershead, I. Zaydan, R. Heyman, S. Winser (Dunedin, New Zealand)

12:00pm-1:30pm: Corpus callosum thickness and area in Parkinson’s disease

I.O. Bledsoe, D. Merkitch, G. Stebbins, B. Bernard, J.G. Goldman (Chicago, IL, USA)

12:00pm-1:30pm: Correlation analysis for postural instability and autonomic dysfunction in patients with Parkinson’s disease

S. You, S.H. Lim, H. Lee, H.A. Kim (Dague, Korea)

12:00pm-1:30pm: Correlation between neuro-behavioral symptoms, cognition and gait in patients with dementia with Lewy bodies (DLB)

B. Tousi, L. Mourany (Cleveland, OH, USA)

12:00pm-1:30pm: Correlation between self-perceived balance confidence, postural control, gait and quality of life of individuals with Parkinson’s disease

J.E. Pompeu, K.G. Silva, T.B. Freitas, F. Doná, C. Torriani-Pasin, R.A. Nuvolini (São Paulo, Brazil)

12:00pm-1:30pm: Cortical atrophy in cognitively impaired Parkinson’s disease patients

M.M. Almuqbel, T.R. Melzer, D.J. Myall, M.R. MacAskill, L. Livingston, K. Wood, T.L. Pitcher, R.J. Keenan, J.C. Dalrymple-Alford, T.J. Andrson (Christchurch, New Zealand)

12:00pm-1:30pm: Cortical excitability in patients with Parkinson’s disease on levodopa carbidopa intestinal gel thereapy

S.D. Kim, S. Vucic, N. Mahant, M.C. Kiernan, V.S.C. Fung (Sydney, Australia)

12:00pm-1:30pm: Cortical grey matter atrophy in the motor system in Friedreich ataxia: The IMAGE-FRDA study

I. Harding, L. Selvadurai, L. Corben, M. Stagnitti, E. Storey, G. Egan, M. Delatycki, N. Georgiou-Karistianis (Melbourne, Australia)

12:00pm-1:30pm: Cortical phase amplitude coupling (PAC) identifies patterns in clinical states of Parkinson’s disease (PD) using magnetoencephalography (MEG)

E. Peña, S.A. Mian, L. Rosedahl, F.A.I. Mohammed, T.M. Mohammad, M.D. Johnson, J.A. Bajwa (Minneapolis, MN, USA)

12:00pm-1:30pm: Cortical thinning associated with mild cognitive impairment in Parkinson’s disease

S. Galantucci, F. Agosta, T. Stojkovic, I. Petrovic, E. Stefanova, E. Canu, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)

12:00pm-1:30pm: Cortico-striatal functional connectivity in the premanifest and manifest period of Huntingtons disease measured with high-field functional magnetic resonance imaging

M. Kronenbuerger, J. Hua, C.A. Ross (Baltimore, MD, USA)

12:00pm-1:30pm: Critical path for Parkinson’s II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson’s disease

D.T. Stephenson, S. Arneric, D. Babcock, P. Cole, T. Comery, M.F. Gordon, D. Grosset, D. Hill, S.Z. Imam, C.R. Jarecke, V. Kern, D. Matthews, R. Meibach, K. Romero, A. Roach, D. Russell, J. Seibyl, P. Sherwin, B.A. Sieber, L. Slicker, C. Sur, K. Marek (Tucson, AZ, USA)

12:00pm-1:30pm: CSF inflammatory and cell death biomarkers in Huntington’s disease – An exploratory cross-sectional study

F.B. Rodrigues, L. Byrne, S.J. Tabrizi, H. Zetterberg, E. Wild (London, United Kingdom)

12:00pm-1:30pm: Cytokines in CSF and plasma as potential biomarkers for PD cognitive impairment

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

12:00pm-1:30pm: DAT SPECT data of Parkinson’s disease patients with and without REM Sleep Pathology: A report from the DeNoPa cohort

M.L. Muntean, D. Leucuta, B. Mollenhauer, C. Trenkwalder, F. Sixel-Döring (Göttingen, Germany)

12:00pm-1:30pm: Decline in drawing ability associated with frontal dysfunction after subthalamic nucleus deep brain stimulation in Parkinson’s disease

S. Hirano, S. Furukawa, M. Asahina, T. Yamamoto, T. Uchiyama, Y. Yamanaka, Y. Higuchi, T. Horikoshi, T. Uno, N. Saeki, S. Kuwabara (Chiba, Japan)

12:00pm-1:30pm: Deep brain stimulation of the dentate nucleus improves ataxia and modulates cortical excitability

C.C. França, M.J. Teixeira, D. Ciampi de Andrade, R. Galhardoni, V.R. Barboza, V. Silva, G. Lepski, E.R. Barbosa, R.G. Cury (São Paulo, Brazil)

12:00pm-1:30pm: Defective visual perception in patients with Parkinson’s disease: The impairment of preattentive visual processing in the normal intellectual patients

Y. Higashi, T. Tabuchi, M. Tabata, E. Mori (Himeji, Japan)

12:00pm-1:30pm: Deficits in sensorimotor networks in functional movement disorders: A graph-theory based network analysis

C.W. Maurer, K. LaFaver, S. Tinaz, M. Hallett, S.G. Horovitz (Bethesda, MD, USA)

12:00pm-1:30pm: Dementia in Parkinson’s disease: Is male gender a risk factor?

E. Cereda, R. Cilia, C. Klersy, C. Siri, A. Colombo, B. Pozzi, E. Reali, A.L. Zecchinelli, C.B. Mariani, S. Tesei, M. Canesi, G. Sacilotto, N. Meucci, M. Zini, I.U. Isaias, M. Barichella, E. Cassani, S. Glodwurm, G. Pezzoli (Pavia, Italy)

12:00pm-1:30pm: Demographic and phenotypic comparison of Huntington’s disease in Europe and North America: Data from REGISTRY and COHORT, two prospective observational cohort studies

M. Orth, J. Bronzova, C. Tritsch, R. Dorsay, J.M. Burgunder, A. Gemperli (Ulm, Germany)

12:00pm-1:30pm: Density of metabotropic glutamate receptors subtype 1 in de novo patients with Parkinson’s disease using ¹¹C-ITMM PET

M. Mishina, M. Suzuki, K. Ishii, M. Sakata, K. Wagetsuma, K. Ishibashi, J. Toyohara, M.R. Zhang, K. Kimura, K. Ishiwata (Kawasaki, Japan)

12:00pm-1:30pm: Depression and clinical progression in spinocerebellar ataxias

S.H. Kuo, R.Y. Lo, K.P. Figueroa, S.M. Pulst, S. Perlman, G. Wilmot, C. Gomez, J. Schmahmann, H. Paulson, V.G. Shakkottai, S. Ying, T. Zesiewicz, K. Bushara, M. Geschwind, G. Xia, T. Ashizawa, S.H. Subramony (New York, NY, USA)

12:00pm-1:30pm: Depressive disorders in Parkinson’s disease and Alzheimer’s disease

D. Tolibov, G. Rakhimbaeva (Tashkent, Uzbekistan)

12:00pm-1:30pm: Detecting brainstem changes in Parkinson’s disease using quantitative MRI

C. Lambert, A. Lutti, B. Draganski, T. Foltynie (London, United Kingdom)

12:00pm-1:30pm: Detection of primary olfactory cortex dysfunction in early-stage Parkinson’s disease

J. Wang, T. Subramanian, Q.X. Yang (Hershey, PA, USA)

12:00pm-1:30pm: Development of a tool for assessment of embarrassment due to dystonia

R. Verma, K.S. Anand (New Delhi, India)

12:00pm-1:30pm: Developmental movement patterns resemble movement disorder features in healthy babies and toddlers

M.J. Kuiper, R. Brandsma, R.J. Lunsing, H. Eggink, H. Burger, H.J. Ter Horst, A.F. Bos, D.A. Sival (Groningen, Netherlands)

12:00pm-1:30pm: Diagnosis and management of dementia with Lewy bodies: Influence of concomitant cerebrovascular disease

A. Chimagomedova, E. Vasenina, O. Levin (Moscow, Russia)

12:00pm-1:30pm: Diagnostic accuracy of common bedside ataxia examination tests

R. Thompson, P. Woolman, D.E. Bhatti, A. Hellman, J.M. Bertoni, D. Torres-Russotto (Omaha, NE, USA)

12:00pm-1:30pm: Diagnostic performance of the Spanish version of the 19-items wearing-off questionnaire in Mexican patients with PD

D. Cruz-Fino, A. Alvarado-Bolaños, M. Rodríguez-Violante, A. Cervantes-Arriaga (Mexico City, Mexico)

12:00pm-1:30pm: Diagnostic reliability of clinical symptoms in patients with incomplete manifestation of the triad of parkinsonism compared to 18F-DOPA PET-CT MRI imaging

C. Peralta, T. Soto Depetris, A. Perez, F. Biafore, J. Gili, A. Valda, D. Menna, M. Aguilar, H. Corradini, M. Bastianello (Caba, Argentina)

12:00pm-1:30pm: Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration: Results of a large international multicenter study of 3206 patients (the QUALPD study)

M. Skorvanek, P. Martinez-Martin, N. Kovacs, I. Zezula, M. Rodriguez-Violante, J.C. Corvol, P. Taba, K. Seppi, O. Levin, A. Schrag, T. Foltynie, M. Alvarez-Sanchez, T. Arakaki, Z. Aschermann, I. Aviles-Olmos, E. Benchetrit, C. Benoit, A. Bergareche-Yarza, A. Cervantes-Arriaga, A. Chade, F. Cormier, V. Datieva, D.A. Gallagher, N. Garretto, Z. Gdovinova, O. Gershanik, M. Grofik, V. Han, J. Huang, L. Kadastik-Eerme, M.M. Kurtis, G. Mangone, J.C. Martinez-Castrillo, A. Mendoza-Rodriguez, M. Minar, H.P. Moore, M. Muldmaa, C. Mueller, B. Pinter, W. Poewe, K. Rallmann, E. Reiter, C. Rodriguez-Blazquez, C. Singer, B.C. Tilley, P. Valkovic, C.G. Goetz, G.T. Stebbins (Kosice, Slovakia (Slovak Republic))

12:00pm-1:30pm: Diffusion tensor imaging in Parkinson’s disease: Review and meta-analysis with clinical considerations and neuroimaring parameters

C. Atkinson-Clement, S. Pinto, A. Eusebio, O. Coulon (Aix-en-Provence, France)

12:00pm-1:30pm: Diffusion tensor imaging of corticospinal tract, cingulum and corpus callosum in Parkinson’s disease (PD) patients

R. Guimarães, B. Campos, L. Campos, L. Piovesana, P. Azevedo, A. D'Abreu, F. Cendes (Campinas, Brazil)

12:00pm-1:30pm: Diffusion tensor imaging of the corticospinal tract differentiates Parkinson’s disease (PD) patients from controls

R. Guimaraes, B. Campos, L. Campos, L. Piovesana, P. Azevedo, A. D'Abreu, F. Cendes (Campinas, Brazil)

12:00pm-1:30pm: Diffusion tensor metrics of thalamic degeneration and postural instability in Parkinson’s disease

M. Petrou, C. Davatzikos, M. Muller, R. Koeppe, R. Albin, K. Frey, N. Bohnen (Ann Arbor, MI, USA)

12:00pm-1:30pm: Disability is an independent predictor of falls and recurrent falls in people with Parkinson’s disease without a history of falls: A one-year prospective study

L.R.S. Almeida, C. Sherrington, N.E. Allen, S.S. Paul, G.T. Valenca, J. Oliveira-Filho, C.G. Canning (Salvador, Brazil)

12:00pm-1:30pm: Disease-related variables effect on depression and anxiety level in Parkinson’s patients

T. Uyar, D. Sarikaya Varlik, A. Ercan, O.C. Cenker, I. Gungor Dogan (Rize, Turkey)

12:00pm-1:30pm: Disrupted hubs in functional brain networks in subtype-specific Parkinson’s disease

L. Ma, H. Chen, T. Feng (Beijing, People's Republic of China)

12:00pm-1:30pm: Disrupted motor memory in Parkinson’s disease

S. Voets, J.S. Brittain, M. Panouilleres, C. Miall, N. Jenkinson (Birmingham, United Kingdom)

12:00pm-1:30pm: Disruption of functional connectivity in Parkinson’s disease patients presenting phonemic fluency impairment

K. Kawabata, H. Watanabe, E. Bagarinao, N. Yoneyama, K. Hara, R. Ohdake, K. Imai, M. Masuda, T. Yokoi, T. Tsuboi, M. Ito, N. Atsuta, M. Katsuno, G. Sobue (Nagoya, Japan)

12:00pm-1:30pm: Does cognitive decline contribute to poorer quality of life in incident Parkinson’s disease? A three year follow up

R.A. Lawson, A.J. Yarnall, G.W. Duncan, D.P. Breen, T.K. Khoo, C.H. Williams-Gray, R.A. Barker, D. Collerton, J.P. Taylor, D.J. Burn (Newcastle upon Tyne, United Kingdom)

12:00pm-1:30pm: Does dopamine affect the selection of stepping actions in PD?

E. Mallia, C. Stummer, J. Rothwell, B.R. Bloem, V. Weerdesteyn (London, United Kingdom)

12:00pm-1:30pm: Does repetitive transcranial magnetic stimulation (rTMS) affect cognitive function in Parkinson’s disease by modulating high-frequency brain oscillations: A magnetoencephalography (MEG) study

I. Buard, J. Shattuck, B.M. Kluger (Aurora, CO, USA)

12:00pm-1:30pm: Dopamine and task-dependent evolution of oscillatory activity in the subthalamic nucleus (STN) and coupling between the STN local field potential and muscle activity in Parkinson’s disease

U. Ramirez Pasos, R. Reese, F. Steigerwald, M. Reich, C. Matthies, I. Isaias, J. Volkmann (Wuerzburg, Germany)

12:00pm-1:30pm: Dopamine modulates learning conflicting action-valence associations in Parkinson’s disease

N.C. van Wouwe, D.O. Claassen, J.S. Neimat, S.A. Wylie (Nashville, TN, USA)

12:00pm-1:30pm: Dopamine reduces Parkinson’s tremor through increased thalamic inhibition

M.F. Dirkx, H.E. den Ouden, E. Aarts, M. Timmer, B.R. Bloem, I. Toni, R.C. Helmich (Nijmegen, Netherlands)

12:00pm-1:30pm: Dopaminergic and metabolic network activities in onset-related subtypes of Parkinson’s disease: A dual-tracer positron emission tomography study

F.T. Liu, J.J. Ge, J.J. Wu, Z.T. Ding, C.T. Zuo, J. Wang (Shanghai, People's Republic of China)

12:00pm-1:30pm: Dopaminergic and non-dopaminergic effects on instrumented timed up and go test in patients with Parkinson’s disease

V. Dibilio, A. Nicoletti, G. Mostile, S. Toscano, A. Luca, L. Raciti, R. Vasta, C.E. Cicero, D. Contrafatto, M. Zappia (Catania, Italy)

12:00pm-1:30pm: Dopaminergic drug management in Parkinson’s disease: Gait and language function show correlation during treatment

H. Murakami, A. Futamura, T. Kuroda, S. Ishigaki, M. Kezuka, K. Ono, M. Kawamura (Tokyo, Japan)

12:00pm-1:30pm: Dopaminergic medication affects choice bias in Parkinson’s disease

A.J.M. van Nuland, R.C.G. Helmich, M. Dirkx, H. Zach, B.R. Bloem, I. Toni, R. Cools, H.E.M. den Ouden (Nijmegen, Netherlands)

12:00pm-1:30pm: Dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behaviour disorder

R. De Marzi, K. Seppi, B. Högl, C. Müller, C. Scherfler, A. Stefani, A. Iranzo, E. Tolosa, J. Santamarìa, E. Gizewski, M. Schocke, C. Kremser, W. Poewe (Innsbruck, Austria)

12:00pm-1:30pm: Dropped head syndrome in parkinsonism: Two treatable etiologies not to miss

P. Termsarasab, S.J. Frucht (New York, NY, USA)

12:00pm-1:30pm: DTI in Parkinson’s disease: Asymmetric progression

L. Chan, K. Ng, C. Yeoh, H. Rumpel, E. Tan (Singapore, Singapore)

12:00pm-1:30pm: Dynamic dopamine transporter images are helpful for diagnosing parkinsonism

K. Abe, K. Fukushima, T. Katuura, K. Kitajima, Y. Maeda, K. Hahiskawa, H. Yoshikawa (Nishinomiya, Japan)

12:00pm-1:30pm: Dyskinesias-reduced-self-awareness and theory of mind in Parkinson’s disease: A novel frame of interpretation

S. Palermo, M. Amanzio, M. Zibetti, L. Lopiano (Turin, Italy)

12:00pm-1:30pm: Dysphagia in early stage Huntington’s disease (HD) – Pilot observations from a multimodal imaging study

I. Trender-Gerhard, E. Michou, A. Gerhard, D. Craufurd, S. Hamdy, K. Herholz (Manchester, United Kingdom)

12:00pm-1:30pm: Dysregulations of GABAergic neurotransmission in Huntington’s disease brain

Y.T. Hsu, Y.G. Chang, H.M. Chen, Y. Chern (Taichung, Taiwan)

12:00pm-1:30pm: Early clinical features of paraneoplastic cerebellar degeneration: Diagnostic outcomes of adult onset cerebellar ataxia

J. Zhang, Z. Xu, J.Y.H. Chai, L. Tan (Beijing, People's Republic of China)

12:00pm-1:30pm: Early grey matter changes in structural covariance networks in Huntington’s disease

E.M. Coppen, J. van der Grond, A. Hafkemeijer, S.A.R.B. Rombouts, R.A.C. Roos (Leiden, Netherlands)

12:00pm-1:30pm: EARLYSTIM: STN-DBS alleviates behavioural side effects of dopamine replacement therapy when compared to best medical treatment

E. Lhommée, W. Lars, C. Virginie, K. Witt, F. Maier, L. Tonder, L. Timmermann, T. Hälbig, F. Pineau, F. Durif, T. Witjas, J.L. Houeto, P. Krack (Grenoble, France)

12:00pm-1:30pm: Effect of rivastigmine in Parkinson’s disease dementia – A logitudinal observational study

S. Raha, L. Ebenezer (Bridgend, United Kingdom)

12:00pm-1:30pm: Effectiveness of duodenal levodopa/carbidopa infusion gel (LCIG) therapy on the neuropsychiatric disturbances of advanced Parkinson’s disease (EDIS study)

M.J. Catalan, P. Montero, J. Herreros, J.M. Arbelo, P. Martinez-Martin (Madrid, Spain)

12:00pm-1:30pm: Effectiveness of Levodopa responsiveness of Blink reflex recovery: An objective method to differentiate Parkinsonian syndromes

C. Gaddipati, M. Umaiorubahan, C.U. Velmurugendran, V. Shankar (Chennai, India)

12:00pm-1:30pm: Effects of a 12-week exercise program on cognition in Parkinson’s disease

J.C. Johnson, A.L. Svitak, M.T. Farrell, S.C. Mosch, F. Yu, E.D. Parker, L.R. Hanson (Saint Paul, MN, USA)

12:00pm-1:30pm: Effects of age and gender on brainstem MR-planimetry

S. Mangesius, A. Hussl, E. Reiter, B. Pinter, F. Krismer, C. Scherfler, C. Müller, A. Djamshidian, M. Schocke, W. Poewe, K. Seppi (Innsbruck, Austria)

12:00pm-1:30pm: Effects of dual task on upper extremity function and postural control in patients with Parkinson’s disease

S.M.A.A. Pompeu, B.R.B. Moraes, J.E. Pompeu (São Paulo, Brazil)

12:00pm-1:30pm: Effects of gender, age and hyposmia on cognitive functions in healthy elderly individuals at risk for Parkinson’s disease: Results from the TREND study

S. Heinzel, U. Suenkel, F.G. Metzger, E. Schaeffer, B. Roeben, R. Yilmaz, S. Lerche, K. Brockmann, A.K. von Thaler, I. Liepelt-Scarfone, G.W. Eschweiler, A.J. Fallgatter, W. Maetzler, D. Berg (Tübingen, Germany)

12:00pm-1:30pm: Effects of zonisamide on dementia with Lewy bodies (DLB): A post-hoc analysis of phase 2 study for parkinsonism in DLB patients

M. Murata, M. Nakamura, H. Maruyama (Tokyo, Japan)

12:00pm-1:30pm: Emotional facial EMG responses are affected in Huntington’s disease

C.C. Kordsachia, I. Labuschagne, J. Stout (St. Kilda, Australia)

12:00pm-1:30pm: Emotional modulation of the startle reflex in essential tremor: Evidence of altered cerebellar input into limbic circuitry?

J.A. Lafo, A.E. Mikos, B.M. Scott, M.S. Okun, D. Bowers (Gainesville, FL, USA)

12:00pm-1:30pm: Empowering Parkinson’s patients to declare pain: A multicenter report of the use of the first Parkinson’s pain questionaire (King’s PD pain quest)

A.M. Rizos, P. Martinez-Martin, S. Pal, R. Sophia, C. Carroll, D. Martino, C. Falup-Pecurariu, B. Kessel, T. Andrews, D. Paviour, A. Sauerbier, A. Martin, M. Parry, L. Perkins, D. Trivedi, T. Chiwera, P. Odin, A. Antonini, K. Ray Chaudhuri, On behalf of EUROPAR, The IPMDS Non-Motor PD Study Group (London, United Kingdom)

12:00pm-1:30pm: Enroll-HD: A global clinical research platform for Huntington’s disease

T.A. Mestre, C. Fitzer-Attas, J. Giuliano, B. Landwehrmeyer, C. Sampaio (Ottawa, Canada)

12:00pm-1:30pm: Epidemiology and economic burden of falls and fractures in patients with Huntington’s disease

D.O. Claassen, P. Donga, S. Rajagopalan, L.M. De Boer, B. Carroll, S. Gandhi (Nashville, TN, USA)

12:00pm-1:30pm: Esophageal involvement in multiple system atrophy

T. Shimohata, H. Taniguchi, H. Nakayama, K. Hori, M. Inoue, M. Nishizawa (Niigata, Japan)

12:00pm-1:30pm: European pediatric normative values for the scale for assessment and rating of ataxia (SARA)

T.F. Lawerman, R. Brandsma, R.J. Lunsing, J.G.M. Burgerhof, D.A. Sival, On behalf of the Childhood Ataxia and Cerebellar Study Group of the European Pediatric Neurology Society, N. Barisic, P. Baxter, E. Bertini, L. Blumkin, V. Brankovic, G.E. Calabro, C.E. Catsman-Berrevoets, D. Craiu, B. Dan, A. Dica, T. Franciskovic, J. Gburek-Augustat, S. Grunt, H. Hartley, F. Kammoun, C. Kennedy, M.J. Kuiper, I. Lehman, A. Lustenberger, F. Mancini, M. Mirabelli-Badenier, E. Mulder-den Hartog, M. Steinlin, M. Synofzik, C.C. Triki, E.M. Valente, G. Vasco, A. Zekavica (Groningen, Netherlands)

12:00pm-1:30pm: Evaluating bradykinesia: How many finger taps are needed?

E. Ruzicka, R. Krupicka, K. Zarubova, J. Rusz, R. Jech, D. Stanek, Z. Szabo (Praha, Czech Republic)

12:00pm-1:30pm: Evaluating quantitative EEG (QEEG) measures to differentiate between Parkinson’s disease (PD) patients and healthy individuals

M. Chaturvedi, F. Hatz, U. Gschwandtner, V. Roth, P. Fuhr (Basel, Switzerland)

12:00pm-1:30pm: Evaluating swallowing function in patients with Huntington disease enrolled in the first-HD study

S.A. Frank, D.O. Claassen, S. Janicki, D. Oakes, D. Stamler, V. Sung, C. Vaughn, C.M. Testa, On behalf of First-HD HSG Investigators (Boston, MA, USA)

12:00pm-1:30pm: Evaluating the effects of deep brain stimulation (DBS) in mice with spinocerebellar ataxia (SCA1)

V. Vedam-Mai, K. McFarland, Q. Zhang, H. Kim, R. Nathu, S. Kurtovic, K. Savery, T. Ashizawa, M.S. Okun (Gainesville, FL, USA)

12:00pm-1:30pm: Evaluating the natural history of prodromal PD in the PARS cohort

D. Jennings, A. Siderowf, M. Stern, K. Marek, PARS Study Investigators (New Haven, CT, USA)

12:00pm-1:30pm: Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6

T. Xie, D. Appelbaum, J. Bernard, M. Padmanaban, Y. Pu, C. Gomez (Chicago, IL, USA)

12:00pm-1:30pm: Evaluation of quality of life (QOL), patient- and clinician-reported outcomes with deutetrabenazine treatment of chorea in Huntington disease in first-HD

C.M. Testa, D.O. Claassen, D. Oakes, D. Stamler, V. Sung, S. Frank, On behalf of the First-HD HSG Investigators (Richmond, VA, USA)

12:00pm-1:30pm: Evaluation of the surface based measures to discriminate progressive supranuclear palsy from corticobasal syndrome

N. Upadhyay, A. Suppa, M.C. Piattella, F.D. Stasio, C. Colonnese, C. Colosimo, A. Berardelli, P. Pantano (Rome, Italy)

12:00pm-1:30pm: Evidence of striatal dopaminergic dysfunction Sydenham’s chorea in remission with (99m)Tc-TRODAT-1 SPECT

R. Maciel, D. Maia, C.F. de Lima, F. Cardoso (Belo Horizonte, Brazil)

12:00pm-1:30pm: Excessive daytime sleepiness is mediated by loss of caudate dopaminergic function in Parkinson’s disease

T. Yousaf, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

12:00pm-1:30pm: Executive function and verbal fluency in patients with Parkinson’s disease

A.F. Barbosa, M.C. Voos, C.O. Souza, J. Chen, H.F. Chien, D.V. Francato, E.R. Barbosa, L.L. Mansur (São Paulo, Brazil)

12:00pm-1:30pm: Exploring structural covariance networks of gray matter in Parkinson’s disease

L.J. de Schipper, J. van der Grond, J. Marinus, J.J. van Hilten (Leiden, Netherlands)

12:00pm-1:30pm: Exploring the brainstem functions in cervical dystonia

P. Tocco, M.C. Tozzi, S. Monaco, L. Bertolasi (Verona, Italy)

12:00pm-1:30pm: Extensive bilateral basal ganglia and cerebellar calcification in Fahr’s syndrome after thyroidectomy

T. Uyar, K. Paksoy, C. Çokluk (Rize, Turkey)

12:00pm-1:30pm: Eye tracking-based measurement of cognitive functions in patients with neurodegenerative diseases

H. Schmitz-Peiffer, K. Linse, W. Rüger, M. Joos, M. Löhle, A. Storch, A. Hermann (Dresden, Germany)

12:00pm-1:30pm: Facial expressivity in Parkinson’s disease (PD) via an examination of smiling behavior: Preliminary findings

D.L. McCabe, A.D. Bono, R.J. Stafford, A.I. Dumer, K.A. Scorpio, J.L. Spielman, R. Bind, L.O. Ramig, J.C. Borod (New York, NY, USA)

12:00pm-1:30pm: Factors related to psychotic symptoms in patients with Parkinson’s disease

B. Tserensodnom (Ulaanbaatar, Mongolia)

12:00pm-1:30pm: Fall prediction in Parkinson’s disease based on motor dual-tasking: Evidence from the prospective MODEP study

S. Heinzel, M. Maechtel, S.E. Hasmann, M.A. Hobert, T. Heger, D. Berg, W. Maetzler (Tübingen, Germany)

12:00pm-1:30pm: Fast and simple non-invasive screening tool for mitochondrial changes in Huntington’s disease

P. Dušek, M. Rodinová, I. Lišková, E. Trefilová, Z. Ellederová, J. Klempír, J. Roth, H. Hansíková (Prague, Czech Republic)

12:00pm-1:30pm: Feasibility and effectiveness of a low-threshold psychoeducative group-intervention for depression in Parkinson’s disease

K. Linse, M. Fauser, C. Ossig, A. Hermann, A. Storch (Dresden, Germany)

12:00pm-1:30pm: Fiberoptic endoscopic evaluation of swallowing findings in patients with Machado-Joseph disease

J.L. Pedroso, G.L.A. Diaféria, S.W. Park, L. Haddad, F.L.M. Haddad, O.P. Barsottini (São Paulo, Brazil)

12:00pm-1:30pm: Fifteen years of clinical trials in Huntington’s disease: Too many clinical trial failures

A.M. Travessa, F.B. Rodrigues, T.A. Mestre, C. Sampaio, J.J. Ferreira (Lisboa, Portugal)

12:00pm-1:30pm: Fractionating apathy – Effort, reward and impulsivity mechanisms in Parkinson’s and Huntington’s disease

C. O'Callaghan, S. Mason, C. Williams-Gray, R. Barker, B. Sahakian, T. Robbins (Cambridge, United Kingdom)

12:00pm-1:30pm: Fragile X-associated tremor/ataxia syndrome in two female patients

L. Hvizdosova, M. Kaiserova, K. Mensikova, P. Kanovsky (Olomouc, Czech Republic)

12:00pm-1:30pm: Freezing of gait (FOG) in PD: Is electroencephalography (EEG) a gateway to elucidating the pathophysiology?

T. Munteanu, E.J. Baird, C. Fearon, S.M. Waechter, C. McDonnell, J. Gallego, B. Quinlivan, I. Killane, J.S. Butler, T. Lynch, R.B. Reilly (Dublin, Ireland)

12:00pm-1:30pm: Freezing of gait in extrapontine myelinolysis

Y.N. Kwon, D. Lee, T.B. Ahn (Jindo-gun, Korea)

12:00pm-1:30pm: Freezing of gait in Parkinson’s disease: A stopping deficit?

K. Smulders, D.S. Peterson, M. Mancini, J.G. Nutt, F.B. Horak, B.W. Fling (Portland, OR, USA)

12:00pm-1:30pm: Freezing of gait is associated with more fear of falling avoidance behavior and less participation in daily physical activity

M.R. Landers, B. Poston, J. Nash, J. Longhurst (Las Vegas, NV, USA)

12:00pm-1:30pm: Frequency of echogenic abnormality of the substantia nigra is increased in methamphetamine users

J.J. Rumpf, J. Albers, C. Fricke, D. Weise, J. Classen (Leipzig, Germany)

12:00pm-1:30pm: Frontal cortex grey matter integrity determines motor improvement after STN-DBS in patients with Parkinson’s disease

M. Muthuraman, G. Deuschl, C. Riedel, J. Volkmann, S. Groppa (Mainz, Germany)

12:00pm-1:30pm: Frontal lobe white matter atrophy correlates with disability in spastic paraplegia type 11 (SPG11)

I. Faber, A.R.M. Martinez, T.T.J. Rezende, R.F. Casseb, C.M. Lourenço, W. Marques Jr, J.L. Pedroso, O.G.P. Barsottini, I.T. Lopes-Cendes, M.C. França Jr (Campinas, Brazil)

12:00pm-1:30pm: Functional connectivity alterations in Parkinson’s disease patients with impulsive control disorders

A. Campabadal, B. Segura, H.C. Baggio, M.J. Marti, F. Valldeoriola, Y. Compta, C. Uribe, A.I. Garcia-Diaz, A. Abos, C. Junque (Barcelona, Spain)

12:00pm-1:30pm: Functional connectivity during resting state in Parkinson’s disease patients with and without mild cognitive impairment

O. Monchi, A. Nagano-Saito, A. Hanganu, S. Jobert, B. Mejia-Constain, C. Degroot, A.L. Lafontaine, H. Chertkow, A. Tam, P. Orban, P. Bellec, O. Monchi (Calgary, AB, Canada)

12:00pm-1:30pm: Functional connectivity underpinnings of fatigue in “drug-naïve” patients with Parkinson’s disease

A. Giordano, R. De Micco, G. Caiazzo, A. Russo, M. Cirillo, F. Esposito, G. Tedeschi, A. Tessitore (Naples, Italy)

12:00pm-1:30pm: Functional connectome organization is altered in PD patients with mild cognitive impairment

S. Galantucci, F. Agosta, I. Stankovic, S. Basaia, T. Stojkovic, E. Stefanova, E. Canu, A. Meani, V.S. Kostic, M. Filippi (Milan, Italy)

12:00pm-1:30pm: Functional deficits during response inhibition improve after dopaminergic medication for Parkinson

C. Vriend, J.P. Trujillo, N.J.H.M. Gerrits, H.W. Berendse, Y.D. van der Werf, O.A. van den Heuvel (Amsterdam, Netherlands)

12:00pm-1:30pm: FYN expression is associated with regulatory region genetic variation

L.M. Bekris, J.A. Zahratka, Y. Shao, M. Shaw, K. Todd, M. Khrestian, J.B. Leverenz (Cleveland, OH, USA)

12:00pm-1:30pm: GAA expansion with clinic/urodynamic findings in Friedreich’s ataxia with LUTS

P.N.S. Almeida, A.F.A. Musegante, U. Barroso (Salvador, Brazil)

12:00pm-1:30pm: Gait and cognition: Mapping the global and discrete relationships in ageing and neurodegenerative disease

R. Morris, S. Lord, J. Bunce, D. Burn, L. Rochester (Newcastle-Upon-Tyne, United Kingdom)

12:00pm-1:30pm: GAITRite comparison between Parkinson’s disease stages

W. Deeb, D. Martinez-Ramirez, J. Giugni, M. Okun, C. Hass (Gainesville, FL, USA)

12:00pm-1:30pm: Gender and age-based differential item functioning (DIF) analysis of MDS-UPDRS

C.G. Goetz, L. Wang, G.T. Stebbins, B.C. Tilley, S. Luo (Chicago, IL, USA)

12:00pm-1:30pm: Gender differences in DLB: frequency, clinical presentation and treatment

S. Garcia-Ptacek, M.G. Kramberger, D. Aarsland (Huddinge, Sweden)

12:00pm-1:30pm: Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson’s disease

I. Huertas Fernandez, S. Jesus, F.J. Garcia Gomez, J.A. Lojo, I. Bernal Bernal, M. Bonilla Toribio, J.F. Martin Rodriguez, D. Garcia Solis, P. Gomez Garre, P. Mir (Sevilla, Spain)

12:00pm-1:30pm: Globus pallidus interna oscillatory activity differentiates tics from voluntary movements and the Parkinsonian resting state

J. Jimenez-Shahed, I. Telkes, A. Viswanathan, N.F. Ince (Houston, TX, USA)

12:00pm-1:30pm: Gray/white matter contrast loss correlates with clinical severity and visuospatial impairment in Parkinson’s disease patients

C. Uribe, B. Segura, H.C. Baggio, M.J. Marti, F. Valldeoriola, Y. Compta, A.I. Garcia-Diaz, A. Campabadal, A. Abos, C. Junque (Barcelona, Spain)

12:00pm-1:30pm: Grey matter atrophy associated with the progression of cognitive decline in Parkinson’s disease (PD)

M. Chondrogiorgi, L.G. Astrakas, A.K. Zikou, M.I. Argyropoulou, S. Konitsiotis (Ioannina, Greece)

12:00pm-1:30pm: Handwriting in Parkinson′s disease: Systematic review and preliminary study

C. Simonet, A.J. Noyce, H. Ling, A.J. Lees, T.T. Warner (Segovia, Spain)

12:00pm-1:30pm: Head drop in patient with Parkinson’s disease as an alert of upcoming myasthenic chrisis

V. Vuletic (Zagreb, Croatia)

12:00pm-1:30pm: Heart rate variability to differentiate dementia with Lewy bodies from Alzheimer’s disease in patients with mild cognitive impairment

J. Yoon, S.M. Lee, J.M. Hong (Suwon, Korea)

12:00pm-1:30pm: Hemifacial spasm: Objective computation of vertebrobasilar vascular sinuosity

L. Chan, E.C. Edmond, S.X.L. Sim, H. Li, E. Tan (Singapore, Singapore)

12:00pm-1:30pm: Hereditary spastic paraplegia caused by heterozygous AFG3L2 and SPG7 mutations

C.D. Stephen, J.D. Schmahmann (Boston, MA, USA)

12:00pm-1:30pm: How do cognitive profiles differ in patients with Parkinson’s disease with cognitive decline in comparison to patients remaining cognitively stable? Preliminary results of a 3 years follow-up study

A. Meyer, U. Gschwandtner, V. Cozac, F. Hatz, P. Fuhr (Basel, Switzerland)

12:00pm-1:30pm: How do we make mistakes diagnosing movement disorders?

J. Rosales, N. Larripa, C.A. Del Carpio, S.A. Rodríguez-Quiroga, L. Assante, J. Cassen, T. Arakaki, N.S. Garretto (Caba, Argentina)

12:00pm-1:30pm: How does cognition affect reaching in Parkinson’s disease?

J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty (Leeds, United Kingdom)

12:00pm-1:30pm: How does preprocessing affect estimation of causal information transfer in the human brain?

I. Weber, E. Florin, F. Jung, M. von Papen, L. Timmermann (Cologne, Germany)

12:00pm-1:30pm: Huntington disease phenocopies or misdiagnosis: A black South African cohort

F.K. Baine, A. Krause (Johannesburg, South Africa)

12:00pm-1:30pm: Illusional perception in Parkinson’s disease

C. Ding, C. Palmer, J. Hohwy, G. Youssef, B. Paton, N. Tsuchiya, J. Stout, D. Thyagarajan (Clayton, Australia)

12:00pm-1:30pm: Imitation of hand movements in Parkinson’s disease: A comparison with visual cueing

J. Bek, E. Gowen, S. Vogt, T. Crawford, E. Stack, J. Dick, E. Poliakoff (Manchester, United Kingdom)

12:00pm-1:30pm: Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists

M.E. Mohammad, J.A. Vizcarra, K. O'Donnell, S. Patel, X. Garcia, X.X. Yu, K. Vlastaris, K. Sutton, H.H. Fernandez (Cleveland, OH, USA)

12:00pm-1:30pm: Impact of chronic LD treatment on metabolism, blood flow and blood-brain barrier permeability in the 6-OHDA rat model

R.P. Lerner, Z. Bimpisidis, V. Jourdain, T. Chaly, M. Hellman, K. Graf, V. Dhawan, S. Dewey, A. Cenci, D. Eidelberg (Manhasset, NY, USA)

12:00pm-1:30pm: Impact of datscan on clinical decision making: diagnosis and management of clinically uncertain Parkinsonian syndromes

J.R. Isaacson, N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

12:00pm-1:30pm: Impact of sociodemographic and clinical characteristics on cognition of individuals with Parkinson’s disease

M.R. Olchik, A. Ayres, M. Ghisi, A.F.S. Schuh, C.R.M. Rieder (Porto Alegre, Brazil)

12:00pm-1:30pm: Impact of white matter hyperintensity on motor compensation in Parkinson’s disease

J.J. Lee, Y. Lee, S.J. Chung, P.H. Lee, Y.H. Sohn (Seoul, Korea)

12:00pm-1:30pm: Impaired cerebellum to motor cortex associative plasticity in Parkinson’s disease

M.K. Lu, C.M. Chen, J.R. Duann, C.H. Tsai (Taichung, Taiwan)

12:00pm-1:30pm: Impaired cube copy on the MOCA indicates worse performance in several cognitive domains in Parkinson´s disease

C. Gasca-Salas, M. Cohn, J.A. Pineda, J.A. Obeso (Madrid, Spain)

12:00pm-1:30pm: Impaired eye voice coordination in spinocerebellar degeneration while reading aloud

Y. Terao, S. Tokushige, S. Terada, T. Sasaki, M. Hamada, S. Tsuji, Y. Ugawa (Tokyo, Japan)

12:00pm-1:30pm: Impaired temporal coupling of action and perception in Parkinson’s disease

E. Pretegiani, N. Vanegas-Arroyave, E. FitzGibbon, M. Hallett, L.M. Optican (Bethesda, MD, USA)

12:00pm-1:30pm: Impairment of decision-making processes in patients with Parkinson’s disease during a strategic game

A.C. Parr, B.C. Coe, G. Pari, D.P. Munoz (Kingston, ON, Canada)

12:00pm-1:30pm: Improvement of saccade amplitude by the STN DBS and visual target eccentricity

A. Yugeta, Y. Terao, Y. Ugawa (Tokyo, Japan)

12:00pm-1:30pm: Improving clinical detection of balance deficits in individuals with Parkinson’s disease with and without freezing of gait and the effects of dopaminergic replacement therapy

K.A. Ehgoetz Martens, C.G. Ellard, Q.J. Almeida (Camperdown, Australia)

12:00pm-1:30pm: Impulse control disorder in early Parkinson’s disease: Follow-up study

V. Markovic, I. Stankovic, I. Petrovic, T. Stojkovic, M. Jecmenica-Lukic, A. Tomic, V. Kostic (Belgrade, Serbia)

12:00pm-1:30pm: Impulse control disorder in Parkinson’s disease is not related to lower cognitive performance

J. Marin-Lahoz, R. Fernandez-Bobadilla, J. Pagonabarraga, S. Martinez-Horta, B. Pascual-Sedano, J. Perez-Perez, H. Bejr-Kasem, A. Gironell, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm: Impulsive action tendencies in GPi DBS Parkinson’s patients

D. Martinez-Ramirez, C.S. Little, J.P. Chapman, S. Carbunaru, J.C. Giugni, M.W. Vasquez, F. Chai, R. Walz, A. Sririam, K. Kanoff, S.A. Wylie, M.S. Okun (Gainesville, FL, USA)

12:00pm-1:30pm: Impulsive-compulsive behaviors in patients with Parkinson’s disease and demographically-comparable group of healthy controls

M.A. Nikitina, I.A. Zhukova, V.M. Alifirova, N.G. Zhukova, O.P. Izhboldina, J.S. Mironova, M.A. Titova, N.G. Brazovskaya, S.E. Sukhanov (Tomsk, Russia)

12:00pm-1:30pm: In vivo MRI detection of Parkinson’s disease associated degeneration in the lateral ventral tier of substantia nigra pars compacta

D.E. Huddleston, J. Langley, J. Sedlacik, K. Boelmans, S.A. Factor, X. Hu (Atlanta, GA, USA)

12:00pm-1:30pm: Increased cortical control of gait in patients with Parkinson’s disease and freezing of gait

G.J. Revuelta, C. Chan, S. Jenkins, J. Jensen, L. Bonilha (Charleston, SC, USA)

12:00pm-1:30pm: Increasing placebo response in Parkinson’s disease through apomorphine pre-conditioning

E. Frisaldi, E. Carlino, L. Giudetti, A. Pampallona, M. Zibetti, M. Lanotte, L. Lopiano, F. Benedetti (Turin, Italy)

12:00pm-1:30pm: Independent validation of the quality of life in essential tremor questionnaire (QUEST)

N. Kovács, A. Makkos, M. Kovács, J. Janzsky (Pécs, Hungary)

12:00pm-1:30pm: Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the FIRST-HD and TETRA-HD trials

D.O. Claassen, B. Carroll, L.M. De Boer, E. Wu, R. Ayyagari, S. Gandhi, D. Stamler (Nashville, TN, USA)

12:00pm-1:30pm: Inferring the causal interplay of motor related brain areas in the aging brain: A dynamic causal modeling (DCM) approach

F. Jung, P. Löhrer, F. Nettersheim, I. Weber, T.A. Dembek, C. Huber, E.A. Pelzer, M. Tittgemeyer, L. Timmermann (Cologne (Köln), Germany)

12:00pm-1:30pm: Inferring the coupling of motor related brain areas during paced finger tapping in Parkinson’s patients

V. Seeger, F. Jung, L. Schneider, T.A. Dembek, P. Reker, N. Apetz, M. Tittgemeyer, L. Timmermann (Cologne, Germany)

12:00pm-1:30pm: Influence of different spike sorting algorithms on the detection of single unit spiking activity in the subthalamic nucleus of patients with Parkinson’s disease

J. Sukiban, R. Pauli, T.A. Dembek, I. Weber, F. Jung, N. Voges, M. Denker, S. Gruen, L. Timmermann (Cologne, Germany)

12:00pm-1:30pm: Influence of lateral wedges on postural control in patient with Parkinson’s disease

J. Park, J. Yoon, W. Jang, J.S. Kim, J. Youn, E.S. Oh (Busan, Korea)

12:00pm-1:30pm: Instrumented quantitative study of movement and gait in Parkinson’s disease clinical subtypes

P.C. Gordon, J.B. Ferraz, L.M. Medeiros, L.F.R. Oliveira, D.K. Amado, A.M. Lima Neto, M.S.G. Rocha (Sao Paulo, Brazil)

12:00pm-1:30pm: Interleaved pro- and anti-saccade performance in Huntington’s disease

I. Vaca-Palomares, J. Fernandez-Ruiz, B. Coe, D.P. Munoz (Kingston, ON, Canada)

12:00pm-1:30pm: Interrelation between gait impairment with cognitive disturbances in patients with Parkinson’s disease

K. Stepanchenko (Kharkiv, Ukraine)

12:00pm-1:30pm: Intraoperative localization of beta band and high-frequency oscillations within the subthalamic nucleus

B.C.M. van Wijk, A. Pogosyan, T. Foltynie, M.I. Hariz, P. Limousin, L. Zrinzo, P. Brown, V. Litvak (London, United Kingdom)

12:00pm-1:30pm: Investigating the relationship between reaction time and cognition in Parkinson’s disease

J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty (Leeds, United Kingdom)

12:00pm-1:30pm: Investigation of driving ability to drive safely in patients with Parkinson’s disease by interview

R. Ando, C. Yamazaki, H. Iwaki, H. Yabe, N. Nishikawa, M. Nagai, K. Nakashima, M. Nomoto, Safe Driving Study Group of Japan (Tohon, Japan)

12:00pm-1:30pm: iPad-based preassessment questionnaires are feasible in a Parkinson’s service

B. Mohamed, E.L. Lane, E.C. Thomas, M. Landwehr, C.W. Ngu, J. Butler, K. Williams, M. Wardle (Cardiff, United Kingdom)

12:00pm-1:30pm: Iron accumulation and volume loss in the extrapyramidal motor system in Friedreich ataxia: The IMAGE-FRDA study

I. Harding, M. Delatycki, L. Corben, P. Raniga, M. Stagnitti, E. Storey, N. Georgiou-Karistianis, G. Egan (Melbourne, Australia)

12:00pm-1:30pm: Iron accumulation in a Wilson disease patient: Longitudinal 7T MRI and transcranial sonography study

P. Dusek, D. Skoloudik, J. Maskova, T. Huelnhagen, R. Bruha, D. Zahorakova, T. Niendorf, E. Ruzicka, S.A. Schneider, J. Wuerfel (Prague, Czech Republic)

12:00pm-1:30pm: Is Apple Watch a new hope for patients with Parkinson’s disease?

H. Ohtsubo, H. Iwaki, R. Andou, T. Tsujii, H. Babe, N. Nishikawa, M. Nagai, M. Nomoto (Tohon, Japan)

12:00pm-1:30pm: Is it just a coincidence? Three new cases of Parkinson’s disease associated with myasthenia gravis

G. Sciacca, A. Nicoletti, E. Reggio, G. Mostile, M. Zappia (Catania, Italy)

12:00pm-1:30pm: Is the defective gait automaticity associated to deficiencies in implicit learning in patients with Parkinson’s disease?

M.E.P. Piemonte, A.F. Helene, B. Monte, E.N. Guelfi, E. Okamoto, C. Vargas, J.A. Galves (Sao Paulo, Brazil)

12:00pm-1:30pm: Is the selection of stepping impaired in PD in ON state?

C. Stummer, E. Mallia, J. Rothwell, B.R. Bloem, V. Weerdesteyn (Nijmegen, Netherlands)

12:00pm-1:30pm: Isolated micrographia following stroke

P. Montero Escribano, M.J. Catalán Alonso, F. Alonso French, E. López Valdés, R. García Ramos, I. Parees Moreno (Madrid, Spain)

12:00pm-1:30pm: Juvenile chorea: Diagnostic criterias, prediction of movement disorders

M.D. Sanoeva, N.A. Mansurova, M. Avezova (Bukhara, Uzbekistan)

12:00pm-1:30pm: Lessons-experienced in the creation of a global public-private consortium with the goal of advancing treatments that hold most potential for delayed disease progression in Parkinson’s disease – Critical path for Parkinson’s (CPP)

V.D. Kern, D.T. Stephenson, K. Romero, E. Avilés, S.T. Broadbent, S.P. Arneric, L. Barbieri, S. Ford, A. Roach (Tucson, AZ, USA)

12:00pm-1:30pm: Levodopa impairs learning in healthy young adults: Implications for Parkinson’s disease

P.A. MacDonald, A. Vo, K.N. Seergobin (London, ON, Canada)

12:00pm-1:30pm: Levodopa induced dyskinesia and nicotinergic α4β2 acetylcholin receptor density: A multi-tracer imaging study

J. Brumberg, S. Küsters, G. Marotta, M.M. Reich, F. Steigerwald, A. Buck, J. Volkmann, S. Samnick, I.U. Isaias (Würzburg, Germany)

12:00pm-1:30pm: Long term prognosis of functional motor disorders, a case-control follow-up study

J. Gelauff, L. Ludwig, A. Carson, M. Tijssen, J. Stone (Groningen, Netherlands)

12:00pm-1:30pm: Long-term impact of lead poisoning on neurologic function in children and adolescents

N.T. Boyd, M.J. Kuiper, R. Brandsma, T.F. Lawerman, R.J. Lunsing, F. Serrano, C. Olivera, D.A. Sival (Groningen, Netherlands)

12:00pm-1:30pm: Longterm outcome of cognition following subthalamic deep brain stimulation in Parkinson´s disease

D. Gruber, C. Lisa, A. Kuehn, U. Kopp, G.H. Schneider, A. Kupsch (Beelitz-Heilstätten, Germany)

12:00pm-1:30pm: Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington’s disease gene carriers

H. Wilson, F. Niccolini, S. Haider, T. Reis Marques, G. Pagano, C. Coello, S. Natesan, S. Kapur, E.A. Rabiner, R.N. Gunn, S.J. Tabrizi, M. Politis (London, United Kingdom)

12:00pm-1:30pm: Magnetic resonance imaging and pyramidal impairment in Huntington disease

A. Sanguinetti, S. Lescano, M. Cesarini, J. Etcheverry, E. Gatto (Buenos Aires, Argentina)

12:00pm-1:30pm: Magnetic resonance imaging in spinocerebellar ataxias: A systematic review

J.A. Saute, E. Reckziegel, M.C. França Jr, T.J.R. Ribeiro, L.M. Vedolin, L.B. Jardim, A.A. Klaes (Porto Alegre, Brazil)

12:00pm-1:30pm: Magnetic resonance imaging of nigrosome-1 in the diagnosis of early Parkinson’s: Initial results of the Parkinson’s magnetic imaging repository (PaMIR)

S.T. Schwarz, Y. Xing, A. Martin Bastida, C. Lakmali Sugathapala, M. Silverdale, J. Mclean, R. Jampana, N. Bajaj, D. Burn, P. Piccini, D. Grosset, D.P. Auer (Nottingham, United Kingdom)

12:00pm-1:30pm: Maintenance of balance function in patients with HD treated with deutetrabenazine, as measured by Berg balance test (BBT) in First-HD

D.O. Claassen, D. Oakes, D. Stamler, V. Sung, C.M. Testa, S. Frank, On behalf of the First-HD HSG Investigators (Nashville, TN, USA)

12:00pm-1:30pm: Manual MRI morphometry in Parkinsonian syndromes

L. Möller, J. Kassubek, M. Südmeyer, R. Hilker, E. Hattingen, K. Egger, F. Amtage, G. Respondek, M. Stamelou, A. Schnitzler, W.H. Oertel, S. Knake, H.J. Huppertz, G.U. Höglinger (Marburg, Germany)

12:00pm-1:30pm: May substantia nigra volume asymmetry be an indicator of motor asymmetry in Parkinson’s disease? A retrospective analysis

N.F. Durmaz, M. Yorubulut, C.M. Akbostanci (Ankara, Turkey)

12:00pm-1:30pm: Memory compensation strategies in patients with Parkinson’s disease

C.C. Walton, J.Y.Y. Szeto, L. Mowszowski, S.J.G. Lewis, S.L. Naismith (Sydney, Australia)

12:00pm-1:30pm: Metabolic brain changes related to specific cognitive impairment in non-demented Parkinson’s disease patients

M. Trošt, S. Brezovar, C.C. Tang, D. Eidelberg, N. Zupancic Kriznar, M. Gregoric Kramberger, P. Tomše, Z. Pirtošek (Ljubljana, Slovenia)

12:00pm-1:30pm: Mild cognitive impairment in Parkinson’s disease: Impact on caregiver outcomes

J.Y.Y. Szeto, M. Gilat, C.C. Walton, L. Mowszowski, S.L. Naismith, S.J.G. Lewis (Sydney, Australia)

12:00pm-1:30pm: Mild cognitive impairment is linked with white matter degeneration in the cortico-subcortical tracts in patients with Parkinson’s disease

A. Hanganu, J.C. Houde, V.S. Fonov, C. Degroot, B. Mejia-Constain, A.L. Lafontaine, V. Soland, S. Chouinard, L.D. Collins, M. Descoteaux, O. Monchi (Calgary, Canada)

12:00pm-1:30pm: Mirror movements in Moebius syndrome: Mirroring beyond movements

H.J.S. Cho, P. Panyakaew, M. Hallett (Bethesda, MD, USA)

12:00pm-1:30pm: MMSE and MoCA feasibility in Parkinson’s disease and dementia with Lewy bodies: A multicenter 1-year follow-up study

R. Biundo, L. Weis, S. Bostantjopoulou, E. Stefanova, C. Falup-Pecurariu, M.G. Kramberger, G. Geurtsen, A. Antonini, D. Weintraub, D. Aarsland (Venice, Italy)

12:00pm-1:30pm: Modeling dementia with Lewy bodies using patient-derived neurons

D.H. Adamowicz, J. Mertens, D.P. Salmon, D.R. Galasko, S. Roy, F.H. Gage (La Jolla, CA, USA)

12:00pm-1:30pm: Modelling spinocerebellar ataxia 15 with iPS cell derived neurons

S. Wiethoff, C. Arber, S. Wray, Y. Zhi, R. Patani, H. Henry (London, United Kingdom)

12:00pm-1:30pm: Modulation of local field potentials during gait in the STN of patients with Parkinson’s disease

F. Hell, J.H. Mehrkens, A. Plate, K. Bötzel (München, Germany)

12:00pm-1:30pm: Monoaminergic biomarkers of cognitive decline in Parkinson’s disease and Lewy body dementia

S. van der Zee, Y. Vermeiren, T. Aerts, D. van Dam, M.J. Gerritsen, J.M. Spikman, T. van Laar, P.P. de Deyn (Groningen, Netherlands)

12:00pm-1:30pm: Motor cortex neuroplasticity and learning following high-intensity interval exercise

J.P. Coxon, E. Stavrinos (Melbourne, Australia)

12:00pm-1:30pm: Motor function restoration during REM sleep behavioral disorder in Parkinson’s disease: A vídeo-polysomnography study

P. Bugalho, T. Lampreia, R. Miguel, M. Mendonça, A. Caetano, R. Barbosa (Lisbon, Portugal)

12:00pm-1:30pm: Motor subtypes in Parkinson’s disease are distinguished by alterations in morphology and white matter integrity

G. Vervoort, I. Leunissen, M. Firbank, E. Heremans, E. Nackaerts, W. Vandenberghe, A. Nieuwboer (Leuven, Belgium)

12:00pm-1:30pm: Movement disorders are the common signs as the first neurological deficit in cases with spinocerebellar ataxia type 2 (SCA2)

N. Miyaue, R. Ando, T. Iwaki, H. Yabe, N. Nishikawa, M. Nagai, H. Takashima, M. Nomoto (Ehime, Toohn City, Japan)

12:00pm-1:30pm: Movement disorders in diabetes – Report of two cases

H. Sienkiewicz-Jarosz, G. Witkowski, M. Restel, D. Ryglewicz (Warszawa, Poland)

12:00pm-1:30pm: Movement execution but not preparation modulates somatosensory temporal discrimination thresholds in healthy subjects

A. Conte, D. Belvisi, N. Manzo, F. Barone, M. Tartaglia, N. Upadhyay, M. Bologna, A. Berardelli (Rome, Italy)

12:00pm-1:30pm: Movement related beta oscillatory activity during self-paced wrist movement in the human subthalamic nucleus

P. Zhuang, R. Chen, M. Hallett, Q. Cui, Y. Zhang, J. Li, Y. Li (Beijing, People's Republic of China)

12:00pm-1:30pm: MRI diagnostics child cerebral palsy with symptomatic epilepsy

D. Aminova (Tashkent, Uzbekistan)

12:00pm-1:30pm: MRI signatures of the brain of Parkinson’s disease and idiopathic REM sleep behavioral disorder subjects

P. Tuite, S. Mangia, P. Burton, A. Svatkova, I. Nestrasil, A. Sierra Lopez, K. Shmueli, L. Eberly, M. Howell, S. Michaeli (Minneapolis, MN, USA)

12:00pm-1:30pm: Multi-modal imaging in Parkinson’s disease patients with freezing of gait

J.M. Hall, C. O'Callaghan, J.M. Shine, M. Gilat, C.C. Walton, K.A. Ehgoetz Martens, A.A. Moustafa, S.J.G. Lewis (Milperra, Australia)

12:00pm-1:30pm: Multicenter report of clinical use of a non-motor symptom questionnaire for craniocervical dystonia: The DNMS quest

L. Klingelhoefer, M. Kaiser, D. Martino, L. Perkins, M. Wienecke, A. Sauerbier, R. Untucht, D. Trivedi, K. Mammadova, T. Chiwera, A. Rizos, P. Martinez-Martin, H. Reichmann, K.R. Chaudhuri (Dresden, Germany)

12:00pm-1:30pm: Multimodal imaging assessment of nigrostriatal pathway in Parkinson’s disease using 11C-PE2I PET and neuromelanin-sensitive MR

A. Martin-Bastida, N.P. Lao-Kaim, A.A. Roussakis, W. Li, M. Politis, N. Valle-Guzman, Z. Kefalopoulou, G. Paul, H. Widner, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

12:00pm-1:30pm: Natural history of saccadic abnormalities in spinocerebellar ataxia 2: Implications to designing future clinical trials

R. Rodríguez-Labrada, L. Velázquez-Pérez, G. Auburger, U. Ziemann, Y. Vazquez-Mojena, N. Canales-Ochoa (Holguín, Germany)

12:00pm-1:30pm: Negative emotional signals impair isometric force control in Parkinson’s disease

R.L. Blakemore, M.R. MacAskill, R. Shoorangiz, T.J. Anderson (Christchurch, New Zealand)

12:00pm-1:30pm: Neural mechanisms underlying step initiation failure in patients with Parkinson’s disease and freezing of gait

M. Gilat, M. Georgiades, J.M. Shine, K.A. Ehgoetz Martens, C.C. Walton, J.M. Hall, S.J.G. Lewis (Sydney, Australia)

12:00pm-1:30pm: Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson’s disease: A resting state functional MRI study

M.C. Wen, S.Y.E. Ng, H.S.E. Heng, Y. Chao, L.L. Chan, E.K. Tan, L.C.S. Tan (Singapore, Singapore)

12:00pm-1:30pm: Neuro-cognitive domain related to conversion of Parkinson’s disease dementia

S.M. Cheon, S.Y. Lee, J.W. Kim (Busan, Korea)

12:00pm-1:30pm: Neuroanatomical correlates of apathy in non-demented and non-depressed Parkinson’s disease

S. Martinez-Horta, F. Sampedro, J. Pagonabarraga, R. Fernandez-Bobadilla, J. Marin-Lahoz, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm: Neuroleptic medication is associated with a worse health status in the years prior to treatment, but have the potential for normalization

P. Schmidt, F. Cubillos, T. Simuni, C. Marras, T. Davis, E.C. Nelson, M.S. Okun (Miami, FL, USA)

12:00pm-1:30pm: Neurologic phenotipic variability in spinocerebelar ataxia hype 2 (SCA2)

T.L. Monte, C.L. Lucas, S. Amanda, R. Estela, A. Marina, M.L.S. Pereira, J.L. Pedroso, O. Barsotini, F.R. Vargas, P. Fernanda, R. Castilho, L.B. Jardim (Porto Alegre, Brazil)

12:00pm-1:30pm: Neuromelanin in Parkinson’s disease: A 3 T MRI study

S. Pietracupa, A. Martin-Bastida, N.L. Kaim, S. Schwarz, D. Auer, A. Berardelli, P. Piccini (Rome, Italy)

12:00pm-1:30pm: Neuromelanin-MRI of substantia nigra subregions in Parkinson’s disease

L. Borellini, G. Franco, P. Trujillo, P. Summers, A. Di Fonzo, D.O. Claassen, A. Costa (Milan, Italy)

12:00pm-1:30pm: Neuron specific protein S100B and cognitive impairment in various forms parkinsonism

R.J. Matmurodov, K.M. Khalimova, N.S. Rashidova, U. Ergashev, O. Turgunhojayev (Tashkent, Uzbekistan)

12:00pm-1:30pm: Neurophysiological evidence of posterior-cortical alterations in premanifest Huntington’s: An event-related brain potentials study of face and face-like objects processing

S. Martinez-Horta, J. Perez-Perez, A. Horta-Barba, R. Fernandez-Bobadilla, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm: Neuroprotective potential of L-theanine against excitotoxic neuronal death induced by quinolinic acid: Possible neurotransmitters and nitric oxide modulation mechanism

S. Jamwal, P. Kumar (Moga, India)

12:00pm-1:30pm: Neuropsychiatric, personality and non-motor correlates of impulse control disorders in recent onset Parkinson’s disease

D.M.A. Swallow, M.A. Lawton, K.A. Grosset, N. Malek, N. Bajaj, R.A. Barker, Y. Ben-Shlomo, D.J. Burn, T. Foltynie, J. Hardy, H.R. Morris, N. Williams, N.W. Wood, D.G. Grosset, PRoBaND Collaborators (Glasgow, United Kingdom)

12:00pm-1:30pm: Neuropsychological assessment in a cohort of patients with Parkinson’s disease

C. Juri, W. Uslar, H. Farias, M. Vasquez (Santiago, Chile)

12:00pm-1:30pm: Neuropsychological correlates of impulse control disorders and punding in Parkinson´ s disease

G. Santangelo, F. Falco, M. Vicidomini, R. Allocca, P. Barone, C. Vitale (Caserta, Italy)

12:00pm-1:30pm: Neuropsychological subgroups in non-demented Parkinson’s disease: A latent class analysis

L. Brennan, K. Devlin, S.X. Xie, D. Mechanic-Hamilton, B. Tran, H. Hurtig, A. Chen-Plotkin, L. Chahine, J.F. Morley, J.E. Duda, D.R. Roalf, N. Dahodwala, J. Rick, J.Q. Trojanowski, P.J. Moberg, D. Weintraub (Philadelphia, PA, USA)

12:00pm-1:30pm: Neuropsychology and magnetic resonance correlation in Parkinson´s disease mild cognitive impairment: Case-control study

L.F.R. Vasconcellos, M. Adachi, D. Greca, M. Cruz, A.L. Malak, H. Charchat-Fichman, J.S. Pereira (Rio de Janeiro, Brazil)

12:00pm-1:30pm: Nigrostriatal degeneration and serum BDNF levels in patients with “de novo” untreated Parkinson’s disease

G. Marti, N. Saez, M. Corominas, G. Cuberas, C. Lorenzo, O. De Fabregues, J. Alvarez-Sabin, M. Casas, J. Hernandez (Barcelona, Spain)

12:00pm-1:30pm: Novel PET Tracers of alpha-synuclein for the diagnosis of Parkinson’s disease

E. Tsika, A. Davranche, J. Molette, E. Gabellieri, S. Papin, S. Nampally, H. Kroth, D. Lowe, A. Pfeifer, A. Muhs (Lausanne, Switzerland)

12:00pm-1:30pm: Novel variants in the SACS gene in a first Central-Eastern European family with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)

M. Schinwelski, M. Krygier, J. Slawek, M. Zuk, M. Rydzanicz, A. Walczak, P. Stawinski, A. Konkel, M. Sildatke-Bauer, R. Ploski, J. Limon (Gdansk, Poland)

12:00pm-1:30pm: Objective, unobtrusive assessment of bradykinesia in Parkinson’s disease

P.J.M. Bank, J. Marinus, J.H. de Groot, C.G.M. Meskers, J.J. van Hilten (Leiden, Netherlands)

12:00pm-1:30pm: Occurrence and pattern of cognitive deficits in prodromal Parkinson’s disease

C. Pausch, J. Spiegel, F.A. Wollenweber, C. Bayer, U. Dillmann, K. Fassbender, S. Behnke (Homburg Saar, Germany)

12:00pm-1:30pm: Olfaction analysis in spinocerebellar ataxia type 10 and type 3 comparing with healthy controls and PD

M. Moscovich, A. Moro, R. Munhoz, H.G. Teive, L.S. Moryiama (Curitiba, Brazil)

12:00pm-1:30pm: Olfactory performance and resting state functional connectivity in non-demented drug naïve patients with Parkinson’s disease

M. Sunwoo, J.H. Ham, J.Y. Hong, Y.H. Sohn, P.H. Lee (Seongnam, Korea)

12:00pm-1:30pm: Onset-related subtypes of Parkinson’s disease differ in the patterns of striatal functional connectivity: A resting-state functional MRI study

Y. Hou, J. Yang, C. Luo, R. Ou, W. Song, Q. Gong, H. Shang (Chengdu, People's Republic of China)

12:00pm-1:30pm: Optic nerve integration as a visuospatial cognitive predictor in Parkinson’s disease

J.J. Lee, Y. Lee, S.J. Chung, Y.H. Sohn, P.H. Lee (Seoul, Korea)

12:00pm-1:30pm: Optogenetic silencing of locus coeruleus activity in mice impairs cognitive flexibility in an attentional set-shifting task

K. Janitzky, M. Lippert, A. Engelhorn, J. Tegtmeier, J. Goldschmidt, H.J. Heinze, F.W. Ohl (Magdeburg, Germany)

12:00pm-1:30pm: Overlapping corticobasal syndromes: The many faces of the Armstrong criteria

A. Pilotto, W. Maetzler, M. Synofzik, E. Schaeffer, C. Schulte, M.A. Hobert, K. Srulijes, T. Gasser, D. Berg (Tübingen, Germany)

12:00pm-1:30pm: Pain-motor integration in the primary motor cortex in Parkinson’s disease

A. Suppa, C. Leone, F. Di Stasio, A. Biasiotta, L. Marsili, S. La Cesa, A. Di Santo, G. Fabbrini, G. Cruccu, A. Berardelli (Rome, Italy)

12:00pm-1:30pm: Pallidal DBS and pallidotomy alter cortical synchronization in Parkinson’s disease

S. Miocinovic, C. De Hemptinne, A. Miller, J.L. Ostrem, P.A. Starr (San Francisco, CA, USA)

12:00pm-1:30pm: Pantotenate kinase associated neurodegeneration (PKAN): Proposal for a clinical rating scale

A. Darling, C. Garrido, S. Aguilera, M. Tomas-Vila, I. Gaston, M. Madruga, L. González-Gutiérrez, J. Ramos-Lizana, M. Pujol, K. Tustin, J.P. Lin, L. Martorell, C. Tello, V. Lupo, C. Espinos, L. Stefanis, L. Sanz, F. Gutiérrez, P.J. Garcia, L. Vela, T. Temudo, R. Pons, M.J. Martí, B. Pérez-Dueñas (Barcelona, Spain)

12:00pm-1:30pm: Parkinson’s disease associated psychosis: Prevalence and risk factors

A. Dutt, H. Kumar, M. Mukherjee, M.U. Kulsum, C. Sengupta (Kolkata, India)

12:00pm-1:30pm: Parkinson’s disease patients with onset in right side have a worse cognitive prognosis

T. Poliakova, I. Zerr, O. Levin (Belgorod, Russia)

12:00pm-1:30pm: Parkinson’s disease-linked mutation in DNAJC13 causes specific trafficking defect in endosomal pathway

S. Yoshida, T. Hasegawa, R. Oshima, J. Kobayashi, N. Sugeno, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

12:00pm-1:30pm: Participation in cognitively-stimulating activities and computer use are associated with better cognitive performance in Parkinson’s disease independent from nigrostriatal dopaminergic and cortical cholinergic degenerations

J.L.B. Bohnen, M.L.T.M. Muller, J.D.J. Haugen, N.I. Bohnen (Ann Arbor, MI, USA)

12:00pm-1:30pm: Patient reported outcomes in Parkinson’s disease (PRO-PD) rating scale validation

L.K. Mischley (Kenmore, WA, USA)

12:00pm-1:30pm: Perception of time in music in Parkinson´s disease – Processing of musical syntax compensates rhythmic deficits

D. Bellinger, E. Altenmüller, J. Volkmann (Wuerzburg, Germany)

12:00pm-1:30pm: Performance in Montreal cognitive assessment and functional independence in Parkinsonian with normal mini-mental state examination

R. Breder, M.A.A. Leite, B.L. Pessoa, C.O. Vilaça (Niterói, Brazil)

12:00pm-1:30pm: Peripheral insulin sensitivity and body composition alterations in early stage Machado Joseph disease

J.A. Saute, S.N. Gabriele, C.B. Haas, V.R. Torrez, A.W. Brochier, G.V. Furtado, T.C. Gheno, A.D. Russo, T.L. Monte, A. Schumacher-Schuh, R. D´Avila, K.C. Donius, R.M. Castilhos, D.O. Souza, M.L. Saraiva-Pereira, V.L. Torman, S.A. Camey, C.R.M. Rieder, L.V.C. Portela, L.B. Jardim (Porto Alegre, Brazil)

12:00pm-1:30pm: Persistent hemichorea and caudate atrophy in untreated diabetic striatopathy

B. Krishnaiah, E. Lucassen, M.C. Stahl (Hershey, PA, USA)

12:00pm-1:30pm: Personality and addictive behaviours in prodromal and early Parkinson’s disease

F. BaigBM, M. Lawton, M. Rolinski, C. Ruffmann, J. Klein, K. Nithi, D. Okai, Y. Ben-Shlomo, M.T.M. Hu (Oxford, United Kingdom)

12:00pm-1:30pm: PET examination of the monoamine transporter with 11C-beta-CIT

M. Tábuas-Pereira, F. Oliveira, A. Moreira, M. Sousa, F. Moreira, C. Januário, A. Abrunhosa, M. Castelo-Branco (Coimbra, Portugal)

12:00pm-1:30pm: PET imaging of tau pathology in progressive supranuclear palsy

S. Coakeley, S.S. Cho, P. Rusjan, A. Graff-Guerrero, R. Chen, A.E. Lang, L. Kalia, E. Slow, S. Houle, A.P. Strafella (Toronto, ON, Canada)

12:00pm-1:30pm: Phenomenology and therapeutic strategies in a series of patients with chorea-acanthocytosis

C. Estevez-Fraga, M. Matarazzo, R. Rigual, P. Garcia Ruiz, L. Vela, M. Kurtis, A. Minguez, R. Luquin, I.J. Posada Rodriguez, M.C. Rodriguez-Oroz, J. García de Yébenes, J.C. Martínez-Castrillo, J.L. López-Sendón (Madrid, Spain)

12:00pm-1:30pm: Phenotypic insights into ADCY5-associated disease

F.C.F. Chang, A. Westenberger, R.C. Dale, M. Smith, H.S. Pall, B. Perez-Duenas, P. Grattan-Smith, R.A. Ouvrier, N. Mahant, B.C. Hanna, M. Hunter, J.A. Lawson, C. Max, R. Sachdev, E. Meyer, D. Crimmins, D. Pryor, J.G.L. Morris, A. Munchau, D. Grozeva, K.J. Carss, L. Raymond, M.A. Kurian, C. Klein, V.S.C. Fung (Wentworthville, Australia)

12:00pm-1:30pm: Phenotypic spectrum and longitudinal outcome of Parkinson’s disease patients with psychosis

M.S. Nanjunda Swamy, M.M. Abbas, S.T. Govindappa, P. Basu, R. Ramanathan, U.B. Muthane (Bangalore, India)

12:00pm-1:30pm: Piperine potentiates neuroprotective effect of curcumin in MPTP model of Parkinson’s disease in rats: Impact on neurochemical modulation

S. Singh, P. Kumar (Moga, India)

12:00pm-1:30pm: Pisa syndrome in a drug-naive Parkinson’s disease patient

P. Solla, A. Cannas, M.M. Mascia, M. Mancino, D. Picciau, R. Farris, G. Orofino, L. Cugusi, L. Polizzi, F. Marrosu (Monserrato (Cagliari), Italy)

12:00pm-1:30pm: Plasma ceramides and glucosylceramides predict cognitive decline among cognitively normal Parkinson’s disease patients

M.M. Mielke, C.E. Hagen, R. Savica, J.A. Syrjanen, X.M.T. Persson, C. Schulte, R. Dodel, M. Balzer-Geldsetzer, J.B. Schulz, K. Reetz, U. Wullner, A. Spottke, A. Storch, H.U. Wittchen, O. Riedel, E. Kalbe, S. Graber-Sultan, T. Gasser, D. Berg, I. Liepelt-Scarfone (Rochester, MN, USA)

12:00pm-1:30pm: Predicting incident impulse control disorder behaviour in Parkinson’s disease patients using a clinical-genetic model

J. Kraemmer, K. Smith, D. Weintraub, V. Guillemot, M.A. Nalls, F. Cormier, I. Moszer, A. Brice, A.B. Singleton, J.C. Corvol (Paris, France)

12:00pm-1:30pm: Predictive performance of EEG theta spectral power over developing dementia in Parkinson’s disease

V.V. Cozac, M. Chaturvedi, U. Gschwandtner, F. Hatz, A. Meyer, K. Nowak, R. Sturzenegger, P. Fuhr (Basel, Switzerland)

12:00pm-1:30pm: Predictors of dementia in Parkinson’s disease: A population-based cohort study

A. Keener, K. Paul, A. Folle, J. Bronstein, B. Ritz (Los Angeles, CA, USA)

12:00pm-1:30pm: Predictors of quality of life in Huntington’s disease. A longitudinal observational study

A. Brás, F. Júlio, M. Sousa, F. Blanco, C. Januário (Coimbra, Portugal)

12:00pm-1:30pm: Predictors of recurrent falls in people with Parkinson’s disease and development of a predictive tool

L.R.S. Almeida, G.T. Valenca, N.N. Negreiros, E.B. Pinto, J. Oliveira-Filho (Salvador, Brazil)

12:00pm-1:30pm: Predominant motor neuron involvement in autosomal recessive SYNE1 ataxia

W. Nachbauer, A. Schossig, C. Fauth, W. Poewe, S. Boesch (Innsbruck, Austria)

12:00pm-1:30pm: Preliminary findings of MR imaging of the entire spinal cord in Friedreich’s ataxia

K. Reetz, S. Romanzetti, I. Dogan, M.L. Macel, D. Timmann, I.A. Giordano, T. Klockgether, J.B. Schulz (Aachen, Germany)

12:00pm-1:30pm: Presenting symptoms and cognitive profile in Lewy body dementia: A series of cases

B. Minafra, G.M.D. Toscano, M. Picascia, R. Zangaglia, N.G. Pozzi, M. Terzaghi, R. Manni, E. Sinforiani, C. Pacchetti (Pavia, Italy)

12:00pm-1:30pm: Prevalence of depression and dementia in Parkinson’s disease

A. Kalendarev, F. Yunusov, G. Rakhimbaeva (Tashkent, Uzbekistan)

12:00pm-1:30pm: Prevalence of depression in Parkinson’s disease patients

A.M. Weldehana (Addis Ababa, Ethiopia)

12:00pm-1:30pm: Prevalence of impulse control disorders among adult Filipino patients with idiopathic Parkinson’s disease seen at a tertiary center in Manila

J.K.P. de Guzman, A.D. Yap, C.L. Go (Manila, Philippines)

12:00pm-1:30pm: Prodromal criteria of spinocerebellar type 2: Lessons for physiopathology, natural history and therapeutical trials

L. Velázquez-Pérez, R. Rodríguez-Labrada, N. Canales-Ochoa, J. Fernandez-Ruiz, J. Medrano-Montero, Y. Vazquez-Mojena, G. Auburger, U. Ziemann (Holguín, Cuba)

12:00pm-1:30pm: Profile of depressive symptoms in Parkinson’s disease patients and a population-based elderly cohort

K. Hückelheim, E.J. Vollstedt, S. Tunc, J. Hampf, J. Graf, V. Tadic, C. Klein, M. Kasten (Lübeck, Germany)

12:00pm-1:30pm: Prognostic factors of motor symptoms in Parkinson’s disease using neuromelanin imaging and the relationship with (123)I-FP-CIT-SPECT

A. Okuzumi, T. Hatano, K. Kamagata, M. Hori, S. Aoki, N. Hattori (Tokyo, Japan)

12:00pm-1:30pm: Program evaluation empowerment of people with Huntington’s disease (HD) and their families: Using goal attainment scaling (GAS)

D. Alburquerque, N. Rojas, S. Tapia, P. Reyes, C. Silva, P. Chana-Cuevas (Santiago, Chile)

12:00pm-1:30pm: Progression of motor subtypes in Huntington’s disease: A six-year follow-up

M. Jacobs, E.P. 't Hart, R.A.C. Roos (Leiden, Netherlands)

12:00pm-1:30pm: Progressive ataxia and palatal tremor: A case report

G. Fabiani, J. Yared, H.A.G. Teive (Campina Grande do Sul, Brazil)

12:00pm-1:30pm: Progressive atrophy of parahippocampal gyrus correlates with Hoehn & Yahr stages of Parkinson’s disease: A voxel based morphometric study

P.K. Pal, R.M. Naduthota, L. George, K. Jhunjhunwala, J. Saini, R.D. Bharath, A. Lenka, R. Yadav (Bangalore, India)

12:00pm-1:30pm: Prolonged cerebellar syndrome after Legionnaire’s disease

B.R. Barton (Chicago, IL, USA)

12:00pm-1:30pm: Pronounced beta oscillations are a characteristic of the cortico-basal ganglia loop of subacute and chronic animal models of Parkinson´s disease

C. van Riesen, J.K. Haumesser, J. Kühn, A. Kühn, M.H. Beck (Berlin, Germany)

12:00pm-1:30pm: Psychiatric manifestations in the initial motor stage of Parkinson’s disease

I. Stankovic, E. Stefanova, A. Tomic, M. Jecmenica Lukic, V. Markovic, N. Kresojevic, I. Petrovic, M. Svetel, V.S. Kostic (Belgrade, Serbia)

12:00pm-1:30pm: Psychogenic movement disorder in cerebellar atrophy

P. Sommer, D. Földy, O. Khalifa, E. Fertl (Vienna, Austria)

12:00pm-1:30pm: Psychosis in Huntington’s disease

J. Perez-Perez, S. Martinez-Horta, M. Carceller, J. Pagonabarraga, A. Horta, R. Fernandez-Bobabilla, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm: Quantifiable changes in cortical visual processing in patients with Parkinson’s disease but no cognitive impairment

R.S. Weil, B. Bahrami, D.S. Schwarzkopf, H. Burn, J.D. Warren, H.R. Morris (London, United Kingdom)

12:00pm-1:30pm: Rapid eye movement sleep behavior disorder symptoms correlate with domains of cognitive impairment in Parkinson’s disease

J.R. Zhang, J. Chen, Z.J. Yang, H.J. Zhang, Y.T. Fu, Y. Shen, P.C. He, C.J. Mao, C.F. Liu (Suzhou, People's Republic of China)

12:00pm-1:30pm: Recruitment of single subthalamic neurons for kinematic control of hand and feet movements employs different strategies

A. Tankus, A. Mirelman, N. Giladi, I. Fried, J.M. Hausdorff (Tel-Aviv, Israel)

12:00pm-1:30pm: Refined basal ganglia model accounting for GPi modulation of thalamic tonic and burst modes

M.S. Baron, D. Kumbhare (Richmond, VA, USA)

12:00pm-1:30pm: Relation between personality trait and depression in Parkinson’s disease

A. Kumon, Y. Kobayashi, M. Saruwatari, N. Kawashima, K. Hasegawa (Sagamihara, Japan)

12:00pm-1:30pm: Relation between the clinical features and the standardized heart to mediastinum ratio in cardiac metaiodobenzylguanidine imaging in patients with Parkinson’s disease: A multicenter cross-sectional study

T. Osada, Y. Morita, K. Ohta, S. Nogawa, K. Takahashi, K. Yamaguchi, D. Yasutomi, M. Seki, Y. Nihei, S. Iwasawa, N. Suzuki (Tokyo, Japan)

12:00pm-1:30pm: Relationship between freezing and pedunculopontine nucleus’ size in Parkinson’s disease: Semi quantitative analysis based on MRI with modified FGATIR sequence

S. Chen, M. Tir, P. Monet, J.M. Constans, O. Godefroy, M. Lefranc, P. Krystkowiak (Amiens, France)

12:00pm-1:30pm: Relationship between sensory augmentation and exercise routine in the improvement in balance and gait in a patient with lithium-induced ataxia

M.D. Maldonado (Santiago, Chile)

12:00pm-1:30pm: Relationship of MDS-UPDRS non-motor symptoms to cognitive functioning in patients with Parkinson’s disease

B.A. Bernard, D. Carns, G.T. Stebbins, J.G. Goldman, C.G. Goetz (Chicago, IL, USA)

12:00pm-1:30pm: Reliability of a newly developed protocol for fiberoptic endoscopic evaluation of swallowing in Parkinson’s patients (PARK-FEES)

J.A. Simons, S. von Clarmann, T. Warnecke (Lübeck, Germany)

12:00pm-1:30pm: Reliability of verbal and written trail test for individuals with Parkinson’s disease: Is it a good cognitive test?

M.R. Olchik, M. Ghisi, A. Freiry, A.F.S. Schuh, C.R.M. Rieder (Porto Alegre, Brazil)

12:00pm-1:30pm: Repeat size and X-inactivation in the clinical phenotype of fragile X premutation carrier sisters: A familial case series

D.A. Hall, E. Robertson, J.A. O'Keefe, A.G. Hadd, L. Zhou, E. Berry-Kravis (Chicago, IL, USA)

12:00pm-1:30pm: Research of vestibular evoked myogenic potentials (VEMP) in the diagnosis of postural instability in Parkinson’s disease

O.A. Alenicova, S.A. Likhachev (Minsk, Belarus)

12:00pm-1:30pm: Response inhibition in Parkinson’s disease

J. Kim, K. Zhang, M.A.I.U.A. Cruadhlaoich, S. YorkWilliams, V. Menon, K.L. Poston (Stanford, CA, USA)

12:00pm-1:30pm: Resting state functional connectivity in olfactory network in de novo Parkinson’s disease

S. Marino, L. Bonanno, F. Caminiti, F. Corallo, V. Lo Buono, S. De Salvo, G. Di Lorenzo, P. Bramanti (Messina, Italy)

12:00pm-1:30pm: Resting-state functional connectivity of subthalamic nucleus in different phenotypes of Parkinson’s disease

Z. Wang, H. Chen, H. Ma, L. Ma, T. Wu, T. Feng (Beijing, People's Republic of China)

12:00pm-1:30pm: Retrieval action verbs is impaired in Parkinson´s disease patients using a sentence completion task

E. Herrera, R. Pérez, M. González-Nosti (Gijón, Spain)

12:00pm-1:30pm: Reward insensitivity differentiates apathy from depression in Parkinson’s disease

K. Muhammed, M. Ben Yehuda, D. Drew, S. Manohar, T. Chong, G. Tofaris, M. Bogdanovic, G. Lennox, M. Hu, M. Husain (Oxford, United Kingdom)

12:00pm-1:30pm: Risk factors of wearing-off phenomenon in Parkinson’s disease in Japan

J. Fukae, S. Ouma, K.I. Kashihara, N. Hattori, Y. Tsuboi (Fukuoka, Japan)

12:00pm-1:30pm: Scores and dimensions to assess cognitive impairment in Parkinson’s disease

I. Liepelt-Scarfone, S. Gräber, A. Pilotto, D. Blum, M. Fruhmann Berger, D. Berg (Tübingen, Germany)

12:00pm-1:30pm: Screening for neuropsychiatric symptoms in Parkinson’s disease

M.J. Barrett, S.A. Sperling, B.B. Shah, J.L. Flanigan, G.F. Wooten, M.B. Harrison, C.A. Manning (Charlottesville, VA, USA)

12:00pm-1:30pm: Screening for SLC25A46 mutations in familial and sporadic ataxic patients

S. Efthymiou, C. Bettencourt, H. Houlden (London, United Kingdom)

12:00pm-1:30pm: Screening of posterior cortical dysfunction in early Parkinson’s disease with mild cognitive impairment as an approach to select patients at higher risk for developing dementia

H. Bejr-Kasem, J. Pagonabarraga, R. Fernandez-Bobadilla, J. Perez-Perez, J. Marin-Lahoz, B. Pascual-Sedano, S. Martínez-Horta, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm: Selective activation of excitatory cell groups in the medial medulla differentially affects spatial-temporal gait parameters

A. Worley, S. Luks, V. VanderHorst (Boston, MA, USA)

12:00pm-1:30pm: Self-perception of daily performance in relation to motor performance in advanced Parkinson’s disease – Case studies

J. Jansa, B. Piks, D. Flisar, M. Gregoric Kramberger, Z. Pirtosek (Ljubljana, Slovenia)

12:00pm-1:30pm: Self-reported cognitive complaints and neuropsychological performance in idiopathic REM sleep behavior disorder

P.A. Bourgouin, F. Escudier, L. Bernier-Lalonger, R.B. Postuma, J. Montplaisir, J.F. Gagnon (Montreal, QC, Canada)

12:00pm-1:30pm: Sensitivity of people with Parkinson’s to different intensities of emotions (SPiEs)

J. Wincenciak, D.J. Burn, L.S. Delicato (Newcastle upon Tyne, United Kingdom)

12:00pm-1:30pm: Sensory and motor aspects of rhythmic entrainment in Parkinson’s disease

E.S. te Woerd, R. Oostenveld, F.P. de Lange, P. Praamstra (Nijmegen, Netherlands)

12:00pm-1:30pm: Severe striatal and pallidal atrophy in early disease stages of X-linked dystonia-parkinsonism

H. Hanßen, M. Heldmann, R.L. Rosales, A. Domingo, A. Münchau, T. Bäumer, D. Rasche, V. Tronnier, T.F. Münte, L.V. Lee, C. Klein, N. Brüggemann (Lübeck, Germany)

12:00pm-1:30pm: Shape and volume abnormalities relate to motor abilities in idiopathic rapid eye movement sleep behavior disorder

S. Rahayel, C. Bedetti, R.B. Postuma, J. Montplaisir, S. Brambati, J. Carrier, O. Monchi, J.F. Gagnon (Montreal, QC, Canada)

12:00pm-1:30pm: Simultaneous symptomatic onset of Parkinson’s disease and myasthenia gravis

P. Kumar, T.M. Biller, A.M. Kurzweil, K. Kiprovski, J.E. Fleisher (New York, NY, USA)

12:00pm-1:30pm: Single unit activity of globus pallidus during voluntary movements in patients with cervical dystonia

A.S. Sedov, A.A. Tomskiy, A.V. Dekopov, R.S. Medvednik, S.V. Zvorikina (Moscow, Russia)

12:00pm-1:30pm: Single unit activity of medial thalamus during goal-directed motor and cognitive behavior in patients with cervical dystonia

U.N. Semenova, D.A. Devetiarov, R.S. Medvednik, A.S. Sedov (Moscow, Russia)

12:00pm-1:30pm: Single-subject FDG PET patterns and cognitive dysfunctions in Parkinson’s disease

A. Pilotto, E. Premi, S.P. Caminiti, L. Presotto, R. Turrone, A. Alberici, B. Paghera, B. Borroni, D. Perani, A. Padovani (Brescia, Italy)

12:00pm-1:30pm: Social cognition assessment in progressive supranuclear palsy: The cognitive interface with frontotemporal dementia

E.P.F. Resende, P. Caramelli, F.E.C. Cardoso, H.C. Guimarães, M. Hornberger, M. Bertoux, A.L. Teixeira, L. Cruz de Souza (Belo Horizonte, Brazil)

12:00pm-1:30pm: Specific in-patient’s rehabilitation improves postural and gait instability in Huntington’s disease

L. Brabcová, J. Roth, O. Horácek, M. Kolárová, H. Bozková, J. Rusz, P. Košková, K. Lísalová, F. Jancok, J. Klempír, E. Ruzicka, H. Brozová (Beroun, Czech Republic)

12:00pm-1:30pm: Spectral analysis of rapid eye movement (REM) sleep as a potential marker of neurodegenerative disease in REM sleep behavior disorder

J. Rodrigues Brazète, J.F. Gagnon, R.B. Postuma, P.A. Bourgouin, D. Petit, J. Montplaisir (Montreal, QC, Canada)

12:00pm-1:30pm: Speech prosody impairment predicts cognitive decline in Parkinson’s disease

I. Rektorova, J. Mekyska, E. Janousova, M. Kostalova, M. Mrackova, I. Eliasova, D. Berankova, R. Marecek (Brno, Czech Republic)

12:00pm-1:30pm: Spinocerebellar ataxia 17: First observation in Russia

S.A. Klyushnikov, D.A. Prikhodko, N.Y. Abramycheva, M.Y. Krasnov, S.N. Illarioshkin (Moscow, Russia)

12:00pm-1:30pm: Sporadic cerebellar ataxia associated with hypogonadotropic hypogonadism and PNPLA6 gene mutation. Case report in a Brazilian patient

H.A.G. Teive, C.L. Boguszewski, S. Raskin, C. Buck, S.B. Seminara (Curitiba, Brazil)

12:00pm-1:30pm: Stage dependent alteration of cortical excitability in patients with hepatic encephalopathy

S.J. Groiss, M. Butz, T. Baumgarten, N.D. Füllenbach, D. Häussinger, A. Schnitzler (Düsseldorf, Germany)

12:00pm-1:30pm: Staging of cognitive impairment: Validation of a novel cognitive score with [¹⁸F]FDG-PET

D. Blum, M. Reimold, W. Maetzler, C. la Fougère, G. Reischl, D. Berg, I. Liepelt-Scarfone (Tübingen, Germany)

12:00pm-1:30pm: Standardized assessment of camptocormia in idiopathic Parkinson’s disease

T. Schmidt, G. Ebersbach, G. Doreen (Beelitz-Heilstätten, Germany)

12:00pm-1:30pm: Strategies for a high quality data in an observational longitudinal study: Enroll-HD experience

N. Gonçalves, D. Abreu, R. Lobo, J. Giuliano, T. Mestre, J.J. Ferreira, C. Fitzer-Attas, B. Landwehrmeyer, C. Sampaio (Lisbon, Portugal)

12:00pm-1:30pm: Striatal molecular alterations in Huntington’s disease gene expansion carriers: A systematic review and meta-analysis of PET studies

F. Niccolini, G. Pagano, P. Fusar-Poli, A. Wood, L. Mrzljak, C. Sampaio, M. Politis (London, United Kingdom)

12:00pm-1:30pm: Structural connectivity networks in prodromal and clinical Huntington’s disease

C. Sanchez-Castañeda, H. Baggio, U. Sabatini, F. Squitieri, C. Junque (Barcelona, Spain)

12:00pm-1:30pm: STUB1/CHIP mutations cause Gordon Holmes syndrome as part of widespread multisystemic neurodegeneration: Evidence from novel mutations

S.N. Hayer, K. Smets, B. Bender, T. Deconinck, S. Züchner, L. Schöls, R. Schüle, P. De Jonghe, J. Baets, M. Synofzik (Tübingen, Germany)

12:00pm-1:30pm: Study of striatal dopamine transporter function in Alzheimer’s disease with parkinsonism

T. Yamamoto, A. Miyake, K. Ikeda, T. Furuya, T. Mitsufuji, Y. Ito, T. Sasaki, K. Takahashi, N. Tamura, I. Matsunari, A. Nobuo (Iruma-gun, Japan)

12:00pm-1:30pm: Sub-acute rapidly progressive cerebellar ataxia – A case of JC virus associated granule cell neuronopathy (GCN)

V.K. Palmadottir, J.A. Gold, N. Vora, C.W. Kilbane (Stanford, CA, USA)

12:00pm-1:30pm: Substantia nigra hyperechogenicity in Mexican patients with Parkinson’s disease

C.Y. Rodriguez-Garza, A. Anaya-Escamilla, R. Pinales-Razo, I. Estrada-Bellmann, C.R. Camara-Lemarroy (Monterrey, Mexico)

12:00pm-1:30pm: Substantia nigra hyperechogenicity in Parkinson´s disease motor phenotypes

T. Toomsoo, A.H. Pool, I. Liepelt–Scarfone, L. Kadastik-Eerme, T. Asser, D. Berg, P. Taba (Tallinn, Estonia)

12:00pm-1:30pm: Subthalamic neurons encode reward hypersensitivity and loss hyposensitivity in Parkinson’s patients with impulse control disorders

P.J. Rossi, A. Gunduz, M.S. Okun (Gainesville, FL, USA)

12:00pm-1:30pm: Suicide attempts and Huntington’s disease: Perseveration, not just impulsivity

O.C. Roman, J.G. Stovall, D.O. Claassen (Nashville, TN, USA)

12:00pm-1:30pm: Suppression of dyskinesia in Parkinson’s disease by electrical stimulation of dorsal subthalamic nucleus tissue

H.A.C. Wark, G.H. Duffley, C.R. Butson, L.E. Schrock (Salt Lake City, UT, USA)

12:00pm-1:30pm: Sustained effects of cerebellar transcranial direct current stimulation in patients with ataxia: A randomized, double blind, sham-controlled study

V. Dell'Era, A. Benussi, M. Cosseddu, A. Padovani, B. Borroni (Brescia, Italy)

12:00pm-1:30pm: Swallowing disorders characteristics and the relation to cognitive level, disease duration and disease severity in patients with Huntington’s disease

Y. Manor, D. Shpunt, N. Avniel, S. Assa, Y. Torner, A. Gad, A. Ezra, J. Knaani, A. Socher, Y. Oestriecher-Kedem, T. Gurevich (Tel Aviv, Israel)

12:00pm-1:30pm: Symptom progression in a large cohort of Parkinson’s disease cases in a clinical practice setting

K. Markopoulou, A. Premkumar, B. Schoneburg, S. Walters, R. Frigerio, M. Szela, D.M. Maraganore (Glenview, IL, USA)

12:00pm-1:30pm: Synaptic biomarkers for cognitive decline in Lewy body dementias and Alzheimer’s disease. A mass spectrometry approach

E. Bereczki, R.M.M. Branca, P.T. Francis, J.H. Baek, J. Lehtio, D. Aarsland (Huddinge, Sweden)

12:00pm-1:30pm: Targeted over-expression with AAV-mediated human α-synuclein in a rat model of Parkinson’s disease – Validation of novel fine motor functional effects

R. Pussinen, T. Ahtoniemi, T. Huhtala, O. Kontkanen, A. Nurmi (Kuopio, Finland)

12:00pm-1:30pm: Tau pathology in Huntington’s disease: A brief in vivo PET-imaging report

K. Giehl, K. Reetz, I. Dogan, C. Werner, J.B. Schulz, A. Drzezga, T. van Eimeren (Köln, Germany)

12:00pm-1:30pm: Tau PET in Parkinson syndromes. A new diagnostic tool?

J. Hammes, G.N. Bischof, K. Giehl, Ö. Onur, A. Drzezga, T. Klockgether, T. van Eimeren (Cologne, Germany)

12:00pm-1:30pm: Technology use and impulse control disorders (ICDs) in patients with Parkinson’s disease (PD)

E.A. Byrd, C.M. Tanner, C.A. Racine, N.B. Galifianakis (San Francisco, CA, USA)

12:00pm-1:30pm: Temporal course of the total motor score in Huntington disease

P. Auinger, T.J. Felong, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulos, C. Venuto, R. Dorsey (Rochester, NY, USA)

12:00pm-1:30pm: Temporal course of the UHDRS chorea score in Huntington disease

T.J. Felong, P. Auinger, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulos, C. Venuto, R. Dorsey (Rochester, NY, USA)

12:00pm-1:30pm: Temporal working memory deficit in Parkinson’s disease

B. Degos, I. Ameqrane, S. Rivaud-Péchoux, P. Pouget, M. Missal (Paris, France)

12:00pm-1:30pm: Testing candidate transcriptional biomarkers of asymtpomatic and symptomatic stages in spinocerebellar ataxia type 3 (SCA3)

M. Raposo, C. Bettencourt, M. Lima (Ponta Delgada, Portugal)

12:00pm-1:30pm: The aetiology of idiopathic late onset cerebellar ataxia

R. Barbosa, M. Mendonça, T. Lampreia, P. Bugalho (Lisboa, Portugal)

12:00pm-1:30pm: The alterations in behavioral memory for prolongation disease duration in patients with Parkinson’s disease

M. Saruwatari, Y. Kobayashi, A. Kumon, K. Hasegawa (Sagamihara, Japan)

12:00pm-1:30pm: The assessment of quality of life in patients with early and moderately advanced Huntington disease

N. Szejko, L. Milanowski, A. Gogol, Z. Jamrozik, P. Janik (Warsaw, Poland)

12:00pm-1:30pm: The association between structural brain connectivity with plasma APO-A1 levels in Parkinson’s disease: Connectometry approach

F. Rahmani, M.H. Aarabi (Tehran, Islamic Republic of Iran)

12:00pm-1:30pm: The cerebral structural and functional signatures of impulse control disorder in Parkinson’s disease

F. Imperiale, F. Agosta, E. Canu, V. Špica, M. Jecmenica, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)

12:00pm-1:30pm: The clinical characteristics of Lewy body disease showed autonomic failures preceding motor signs

A. Miyake, T. Yamamoto, K. Ikeda, T. Furuya, M. Takashi, Y. Ito, Y. Nakazato, N. Tamura, N. Araki (Irumagun Moroyama Town, Japan)

12:00pm-1:30pm: The clinical significance of brain microbleed in Alzheimer’s disease patients with Parkinsonian signs

J.Y. Ahn, H.T. Kim (Seoul, Korea)

12:00pm-1:30pm: The cognitive profile of idiopathic REM sleep behavior disorder

L. Bernier-Lalonger, F. Escudier, P.A. Bourgouin, R.B. Postuma, J. Montplaisir, J.F. Gagnon (Montreal, QC, Canada)

12:00pm-1:30pm: The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale

L.S. Croll, K.M. Montgomery, C.V. Kulick, M.J. Nirenberg (New York, NY, USA)

12:00pm-1:30pm: The effect of an eight-week mindfulness training intervention on emotion related brain activation in people with Parkinson’s disease

B.A. Pickut, W. Van Hecke, P. Cras, E. Kerckhofs, S. Vanneste, D. Crosiers, P. Marien, P.M. Parizel (Grand Rapids, MI, USA)

12:00pm-1:30pm: The effect of anodal transcranial direct current stimulation (tDCS) on sequential motor skill learning in persons with Parkinson’s disease

E. Kerckhofs, N. Deroost (Brussels, Belgium)

12:00pm-1:30pm: The effect of dopamine on global versus specific inhibitory control in Parkinson’s disease

D. Kuebler, H. Schroll, R. Eva, A. Diepold, C. Meyer, A. Kuhn (Berlin, Germany)

12:00pm-1:30pm: The effect of dopaminergic therapy on stimulus-response learning and decision-making in Parkinson’s disease using fMRI

P.A. MacDonald, N.M. Hiebert, K.N. Seergobin, A.M. Owen (London, ON, Canada)

12:00pm-1:30pm: The effect of statin use on cognition in Parkinson’s disease

B.L. Deck, J. Rick, S.X. Xie, A. Chen-Plotkin, J.E. Duda, J.F. Morley, L.M. Chahine, N. Dahodwala, R.S. Akhtar, J.Q. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

12:00pm-1:30pm: The effects of deep brain stimulation for Parkinson’s disease on cognition and perceived quality of life: Preliminary results from an Ecuadorian sample

M.B. Jurado Noboa, R. Santibañez Vásquez, J. Achi, M. Navarrete, C. Mawyin (Guayaquil, Ecuador)

12:00pm-1:30pm: The effects of gait and balance training on walking economy in early and mid stage Huntington’s disease

J.L. Kubica, J. Szymura, E. Mirek, M. Filip, M. Wiecek, M. Maciejczyk, M. Rudzinska, U. Pustulka-Piwnik, J. Stozek, S. Pasiut (Krakow, Poland)

12:00pm-1:30pm: The efficacy of quantitative ^99mTc-TRODAT-1 SPECT in diagnosis of aged patients with Parkinson’s disease

C.F. Lee, C.Y. Wei, G.U. Huang, I.J. Chen, B. Hsu (Changhua, Taiwan)

12:00pm-1:30pm: The evaluation of metabolic differences by using 18F-FDG-PET/CT in demented and non demented Idiophatic Parkinson’s disease patients

S. Altinayar, M. Bakir, Y. Demirtas, Y. Kaplan (Malatya, Turkey)

12:00pm-1:30pm: The feasibility of measuring fatigability in early-stage Parkinson’s disease using functional MRI

Y. Xing, N. Bajaj, S.T. Schwarz, D.P. Auer (Nottingham, United Kingdom)

12:00pm-1:30pm: The improvement of a tardive diskinesia movements by inline skating

S.C.B. Casagrande, R.G. Cury, A.C.d.L. Pardini, D.B. Coelho, C.d.O. Souza, T.G. de Oliveira, M.G.d.S. Ghilardi, E.R. Barbosa, E.T. Fonoff (Sao Paulo, Brazil)

12:00pm-1:30pm: The interactive walkway: Towards assessing gait-environment interactions in a clinical setting

D.J. Geerse, M. Roerdink, B. Coolen, J. Marinus, J.J. van Hilten (Leiden, Netherlands)

12:00pm-1:30pm: The International Parkinson and Movement Disorder Society – non-motor rating scale (MDS-NMS): Results from the cognitive pre-testing and phases 1 and 2 of an international validation

K. Ray Chaudhuri, D. Weintraub, A. Schrag, P. Martinez-Martin, On behalf of EUROPAR, The MDS Non-Motor PD Study Group (London, United Kingdom)

12:00pm-1:30pm: The movement disorder associated with NMDAR-antibody encephalitis: An expert-rater video study

J.A. Varley, K.P. Bhatia, R.C. Dale, V. Fung, T. Granata, M.A.J. Tijssen, A. Lang, J.P. Lin, M. Lim, T. Lynch, N. Nardocci, K.D. Sethi, S.R. Irani (Oxford, United Kingdom)

12:00pm-1:30pm: The nucleocytoplasmic transport of ataxin-3 as pathogenic mechanism in spinocerebellar ataxia type 3

T. Schmidt, A. Sowa, I.M. Martins, M. Abedi, Z. Wang, J. Schmidt, H. Tricoire, O. Riess (Tübingen, Germany)

12:00pm-1:30pm: The patient’s perspective: The effect of dopamine on Parkinson symptoms

H. Zach, M.F. Dirkx, J.W. Pasman, B.R. Bloem, R.C. Helmich (Vienna, Austria)

12:00pm-1:30pm: The patterns of olfactory function in Parksinson’s disease patients with mild cognitive impairment

J.W. Park, H.K. Yoon, M.H. Park, D.Y. Kwon (Ansan, Korea)

12:00pm-1:30pm: The position of the conus medullaris and the prevalence of isolated lipoma of filum terminale in Parkinson’s disease

H. Mori, K. Shindo (Kurashiki, Japan)

12:00pm-1:30pm: The practicalities of freezing of gait assessment methods

C. Stummer, E. Mallia, B. Debû, B.R. Bloem, M.U. Ferraye (Nijmegen, Netherlands)

12:00pm-1:30pm: The pull test in healthy subjects: Quantitative, posturographic and electromyographic analysis

J.R. Pérez-Sánchez, B. De La Casa-Fages, A. Contreras, J.M. Velázquez, A. Muñoz-González, F. Grandas (Madrid, Spain)

12:00pm-1:30pm: The regulation of ASIC1a on dopamine release and its implication in the pathogenesis of Parkinson’s disease

Y. Jing, L. Sha, L. Chunfeng, W. Fen (SuZhou, People's Republic of China)

12:00pm-1:30pm: The relationship among clinical features, DAT scintigraphy and MIBG cardiac scintigraphy in patients with Parkinson’s disease

J. Ebina, T. Sekiguchi, M. Takahashi, A. Inaba, S. Orimo (Tokyo, Japan)

12:00pm-1:30pm: The relationship between cognitive aspects (education status, executive function and verbal fluency) and motor aspects (balance and gait) in patients with Parkinson’s disease

C.O. Souza, M.C. Voos, H.F. Chien, D.V. Francato, A.F. Barbosa, J.M. Greve, E.T. Fonoff, E.R. Barbosa (Sao Paulo, Brazil)

12:00pm-1:30pm: The relationship between cognitive task and postural stability in the early stages of Parkinson’s disease

M. Demirkiran, M. Erdem (Adana, Turkey)

12:00pm-1:30pm: The relationship between impulse control disorders and dyskinesia in Parkinson´s disease: The ALTHEA study

R.J. Vorovenci, L. Weis, R. Biundo, A. Antonini (Venice, Italy)

12:00pm-1:30pm: The role of cathepsin L involved in the activation of microglia and Parkinson’s disease

S. Xu, X. Yang, H. Zhang, Y. Qian, Q. Xiao (Shanghai, People's Republic of China)

12:00pm-1:30pm: The role of depression in suicidal ideation in a sample of patients with Parkinson’s disease

M.M. Dumitru (Iasi, Romania)

12:00pm-1:30pm: The role of neuroinflammation in the development of Parkinson’s disease dementia

A. Kouli, R. Vuono, R.A. Barker, C.H. Williams-Gray (Cambridge, United Kingdom)

12:00pm-1:30pm: The role of striatal dopaminergic terminals in early de novo PD patients with speech impairment

S. Polychronis, G. Pagano, M. Politis (London, United Kingdom)

12:00pm-1:30pm: The role of the frontal lobe in complex walking among healthy older adults and patients with Parkinson’s disease: An fNIRS study

A. Mirelman, I. Maidan, F. Nieuwhof, H. Bernad-Elazari, M.F. Reelick, B.R. Bloem, N. Giladi, J.E. Deutsch, J.A.H.R. Claassen, J.M. Hausdorff (Tel Aviv, Israel)

12:00pm-1:30pm: The scale for assessment and rating of ataxia in early onset ataxia; always a reliable biomarker?

R. Brandsma, T.F. Lawerman, M.J. Kuiper, I.J. Lunsing, H. Burger, D.A. Sival (Groningen, Netherlands)

12:00pm-1:30pm: The spectrum of abnormal movements and predictors of outcome in anti-NMDA receptor encephalitis in Thai patients

K. Suksuchano, M. Apiwattanakul (Bangkok, Thailand)

12:00pm-1:30pm: The value of multi-slice computed tomography angiography in diagnosis of intracranial circulation in patients with vascular parkinsonism

M. Ataniyazov, G. Rakhimbaeva, K. Ataniyazova (Tashkent, Uzbekistan)

12:00pm-1:30pm: THK-5351 tau-tracer uptake in patients with clinically diagnosed progressive supranuclear palsy

S. Schönecker, M. Brendel, J. Havla, G. Höglinger, K. Bötzel, A. Danek, A. Rominger, J. Levin (Munich, Germany)

12:00pm-1:30pm: Three-dimensional cytoarchitecture of the basal ganglia: Clinical applications of a computational pipeline for histology to MRI registration

E.J.L. Alho, M. Alegro, R.L. Deus, R.P. Reis, L.T. Grinberg, J.F. Pereira Jr, L. Zöllei, E. Amaro Jr., H. Heinsen, E.T. Fonoff (Sao Paulo, Brazil)

12:00pm-1:30pm: TMS-EEG markers of inhibitory deficits in Huntington’s disease

E. Casula, I. Mayer, S. Tabrizi, J. Rothwell, M. Orth (Rome, Italy)

12:00pm-1:30pm: Tracking Parkinson’s disease over 2-6 years with MRI

T.R. Melzer, D.J. Myall, M.R. MacAskill, L. Livingston, T.L. Pitcher, K. Wood, R.J. Keenan, J.C. Dalrymple-Alford, T.J. Anderson (Christchurch, New Zealand)

12:00pm-1:30pm: Tractographic patterns of effective pallidal DBS in DYT-6 Dystonia: A case study

L. Huang, N. Vanegas-Arroyave, K.A. Zaghloul, M. Hallett, S.G. Horovitz, C. Lungu (Bethesda, MD, USA)

12:00pm-1:30pm: Tractography study of individuals with mutation for Huntington’s disease in symptomatic and pre-symptomatic phases

R.A. Saba, J. Yared, T. Doring, V. Borges, L.B. Barcelos, H.B. Ferraz (São Paulo, Brazil)

12:00pm-1:30pm: Transcranial sonography and cognitive dysfunction in Parkinson’s disease

S. Behnke, A. Pilotto, I. Liepelt-Scarfone, R. Yilmaz, C. Pausch, S. Dieterich, I. Posner, J. Spiegel, U. Dillmann, M. Unger, B. Schmidl, J. Bürmann, K. Fassbender, D. Berg (Homburg Saar, Germany)

12:00pm-1:30pm: Transcranial sonography of the substantia nigra and its correlation with iron metabolism and c-reactive protein in Parkinson’s disease

X. Yang, J. Liu, Y. Qian, S. Xu, Q. Xiao (Shanghai, People's Republic of China)

12:00pm-1:30pm: Transcranial static magnetic field stimulation (tSMS) decreases motor cortex excitability in Parkinson’s disease OFF but not ON medication

M. Dileone, M. Carrasco-López, J. Segundo-Rodriguez, L. Mordillo-Mateos, N. López-Aristegui, F. Alonso-Frech, M. Catalan-Alonso, J. Obeso, A. Oliviero, G. Foffani (Madrid, Spain)

12:00pm-1:30pm: Transient hemiballismus in a fast jet pilot

T. Coysh, D.P. Breen, P. Hodkinson (Stevenage, United Kingdom)

12:00pm-1:30pm: Treatment and diagnosis with the use of neuropsychological scale in patients with posttraumatic subcortical Parkinsonian dementia

R.R. Umarov, N.G. Sokhibnazarov (Tashkent, Uzbekistan)

12:00pm-1:30pm: Treatment with the use of the PD-specific scales for patients suffering from subcortical Parkinsonian dementia

N.G. Sokhibnazarov, F.K. Shermukhamedova (Tashkent, Uzbekistan)

12:00pm-1:30pm: Ultra high field magnetic resonance imaging of nigrosome 1 is a biomarker of new onset and premotor Parkinson’s disease

M.A. Brodsky, J.M. Pollock, J. Grinstead, D. Lahna, D. Pettersson, W.D. Rooney (Portland, OR, USA)

12:00pm-1:30pm: Unilateral subthalamotomy in Parkinson´s disease: Cognitive and neuropsychiatric effects and correlation with lesion size

I. Obeso, E. Casabona, R. Rodríguez-Rojas, N. Pavón, R. Macías, M.L. Bringas, J.A. Obeso, M. Jahanshahi (Madrid, Spain)

12:00pm-1:30pm: Use of dementia rating scale-II (DRS-II) total score in PD deep brain stimulation (DBS) candidacy determination

M.J. Sollman, J.G. Hesse, B.C. Sachs, J.F. Cook (Winston-Salem, NC, USA)

12:00pm-1:30pm: Utility of the Mayo sleep questionnaire in predicting final autopsy diagnosis of alpha-synucleinopathy

D. Shprecher, J. Hentz, C. Adler, B. Dugger, H. Shill, E. Driver-Dunkley, S. Mehta, M. Sabbagh, C. Belden, R. Savica, L. Sue, T. Beach (Sun City, AZ, USA)

12:00pm-1:30pm: Utility of the Montreal cognitive assessment for screening of mild cognitive impairment and dementia associated with Parkinson’s disease in a Colombian hospital

S.C. Cerquera Cleves, S.J. Romero Vanegas, F. Cruz Sanabria, C. Ruiz de Sánchez, F.F. Pretelt Burgos (Bogotá, Colombia)

12:00pm-1:30pm: Validation of the Hebrew version of the International Parkinson and Movement Disorder Society—unified Parkinson’s disease rating scale (MDS-UPDRS)

J. Zitser, A. Bar David, H. Shabtai, A. Ezra, M. Brozgol, C. Peretz, A. Rozenberg, T. Herman, G.T. Setbbins, C.G. Goetz, B.C. Tilley, S.T. Luo, L. Wang, N. Giladi, T. Gurevich (Tel Aviv, Israel)

12:00pm-1:30pm: Validation of the Seoul-instrumental activity of daily living in the detection of dementia in Parkinson’s disease

S.J. Kim, E.J. Chung (Busan, Korea)

12:00pm-1:30pm: Validity and reliability of the Turkish version of the scales for outcomes in Parkinson’s disease-autonomic questionnaire (SCOPA-AUT)

H. Yasar, M.G. Senol, S. Tasdemir, U.H. Ulas, S. Alay (Ankara, Turkey)

12:00pm-1:30pm: Verbal fluency deficits in essential tremor patients: Underlying structural changes

E.A. Pelzer, C. Nelles, D.J. Pedrosa, L. Burghaus, C. Eggers, C. Melzer, M. Tittgemeyer, L. Timmermann (Cologne, Germany)

12:00pm-1:30pm: Verbatim patient-reported outcomes and trails making test B (TMT-B) performance in the REACH2HD trial

J.L. Purks, A. Zeymo, N.M. Shara, K.E. Anderson, I. Shoulson (Washington, DC, USA)

12:00pm-1:30pm: Vestibular evoked myogenic potentials as biomarkers for non-motor symptoms of Parkinson’s disease

A. Shalash, D. Hassan (Cairo, Egypt)

12:00pm-1:30pm: Viewer responses to a virtual reality simulation of Parkinson’s disease psychosis

J.G. Goldman, G.T. Stebbins, D. Fredericks, M. Upchurch (Chicago, IL, USA)

12:00pm-1:30pm: Visual hallucination and pattern of brain degeneration in Parkinson’s disease

W.W. Lee, E.J. Yoon, J.Y. Lee, S.W. Park, Y.K. Kim (Seoul, Korea)

12:00pm-1:30pm: Visual hallucinations and executive dysfunction in Charles Bonnet syndrome: Preliminary findings from SHAPED

D.H. Ffytche, F. D'Antonio, R. Pinto, D. Collerton, J.P. Taylor, D.J. Burn, R. Barker, D. Aarsland, R. Howard (London, United Kingdom)

12:00pm-1:30pm: Visual hallucinations may serve as a possible predictor for Parkinson’s disease dementia

Y.P. Chang, Y.H. Yang, C.L. Lai, L.M. Liou (Kaohsiung, Taiwan)

12:00pm-1:30pm: Visual vs. automated analysis of [123I]FP-CIT SPECT scans in patients with parkinsonism

E. Mäkinen, J. Joutsa, J. Johansson, M. Mäki, M. Seppänen, V. Kaasinen (Turku, Finland)

12:00pm-1:30pm: Volition and action control in Parkinson’s disease patients with impulsive-compulsive behaviour disorders

L. Ricciardi, P. Haggard, L. de Boer, C. Sorbera, M.P. Stenner, F. Morgante, M.J. Edwards (London, United Kingdom)

12:00pm-1:30pm: Volumetry of the olfactory bulbs and tracts in the differential diagnosis of neurodegenerative parkinsonisms

M. Menendez Gonzalez, E. Suárez-Sanmartin, C. García, M. Blázquez Estrada (Mieres, Spain)

12:00pm-1:30pm: What predicts Parkinson’s disease? Hyposmia, MIBG SPECT, DAT SPECT and the PD-specific metabolic pattern

S.K. Meles, D. Vadasz, R.J. Renken, K.M. Eggert, E. Sittig-Wiegand, C. Depboylu, V. Ries, G. Mayer, K. Reetz, S. Overeem, A. Pijpers, H. Höffken, M. Luster, K. Kesper, W. Oertel, K.L. Leenders (Groningen, Netherlands)

12:00pm-1:30pm: When and why patients with Parkinson’s disease become bed ridden

K. Kashihara, M. Kitayama, T. Hamaguchi (Okayama, Japan)

12:00pm-1:30pm: “Words untold”

P.M. Iyer, B. McGuiness, J. Scott, S. Manning, A. Chalisseri, D. Olszewska, M. Farrell, T. Lynch (Dublin, Ireland)

12:00pm-1:30pm: A case of hemifacial spasm with a right-sided pontine meningioma that resolved with PICA loop vascular decompression surgery

E.M. Feinstein, S.J. Frucht (New York, NY, USA)

12:00pm-1:30pm: A case with posttraumatic functional shoulder dyskinesia

S. Tezcan, M. Demirci, M.C. Akbostanci (Ankara, Turkey)

12:00pm-1:30pm: A clinical trials ‘charter’ to improve communication about, recruitment to and retention in Parkinson’s clinical trials

C. Carroll, I. Tom, M. Helen, S. Jon (Plymouth, United Kingdom)

12:00pm-1:30pm: A combined therapeutic approach in the management of abnormal postures in Parkinson’s disease

S. Di Martino, E. Unti, C. Tramonti, S. Mazzucchi, U. Bonuccelli, B. Rossi, R. Ceravolo, C. Chisari (Pisa, Italy)

12:00pm-1:30pm: A community organizing approach to identify and address the barriers to healthcare for XDP patients in Panay Island, Philippines

G.M. Solinap, A.C. Aguil, P.B. Acuna, L.V. Lee, N. Sharma (Charlestown, MA, USA)

12:00pm-1:30pm: A comparison of deep brain stimulation and continuous intrajejunal levodopa infusion in advanced Parkinson’s disease: The INVEST study

D. van Poppelen, R.M.A. de Bie, J.M. Dijk (Amsterdam, Netherlands)

12:00pm-1:30pm: A comparison of standards of care in Parkinson’s disease between a general neurology clinic and a specialist movement disorders clinic based on the UK NICE guidelines

S.M. Yap, M.O. Dablouk, S. O'Sullivan (Dublin, Ireland)

12:00pm-1:30pm: A computational model of iron transport between the blood circulation and the brain

V. Tjendana-Tjhin, S. Mitchell, E.A. Milward, M.J. Chappell, J.F. Collingwood (Coventry, United Kingdom)

12:00pm-1:30pm: A cross-linguistic approach to speech intelligibility in people with PD

Y. Kim, Y. Choi (Baton Rouge, LA, USA)

12:00pm-1:30pm: A crossover study of pretarsal and preseptal injections of botulinum toxin type A (BTX-A) in the treatment of hemifacial spasm and blepharospasm

A. Choolam, K. Kulkantrakorn, P. Lolekha (Pathumthani, Thailand)

12:00pm-1:30pm: A double blind investigation of efficacy and safety of incobotulinumtoxinA in Parkinson’s disease tremor- A customized injection approach

S.O. Mittal, R. Rostami, D.G. Machado, D. Richardson, B. Jabbari (Cleveland, OH, USA)

12:00pm-1:30pm: A double-blind randomized controlled trial of cognitive training for freezing of gait in Parkinson’s disease

C.C. Walton, L. Mowszowski, J.M. Shine, M. Gilat, J.M. Hall, C. O'Callaghan, A.J. Muller, M. Georiades, J.Y.Y. Szeto, K.A. Ehgoetz Martens, S.L. Naismith, S.J.G. Lewis (Sydney, Australia)

12:00pm-1:30pm: A dynamic causal model of the superior colliculus: Inhibitory activity increases with the temporal discrimination threshold

B. Quinlivan, R. Moran, E. McGovern, S. Narasimham, I. Beiser, L. Williams, O. Killian, R. Beck, S. O'Riordan, J.S. Butler, M. Hutchinson, R.B. Reilly (Dublin, Ireland)

12:00pm-1:30pm: A functional magnetic imaging study of the response in the superior colliculus to looming stimuli in cervical dystonia patients and their relatives

E.M. Mc Govern, S. Narasimham, O. Killian, I. Beiser, L. Williams, B. Quinlivan, J.S. Butler, S. O'Riordan, R.B. Reilly, M. Hutchinson (Dublin, Ireland)

12:00pm-1:30pm: A healthy volunteer phase 1 study of RE-024, a potential phosphopantothenate replacement therapy for patients with pantothenate kinase-associated neurodegeneration (PKAN)

R.D. Marshall, A. Harring-Abbott, K. Lucey, K. Leach, M. Beconi, J. Hunt, H. Plotkin (San Diego, CA, USA)

12:00pm-1:30pm: A heterozygous splicing mutation c.823-10G>T at the intron9/exon 10 of the MAPT gene in an Irish family with FTDP- 17

E.M. Fallon, D.A. Olszewska, C. McGuigan, I. Delon, F. Brett, B. Lawlor, M. Hutchinson, M. Hutton, T. Lynch (Dublin, Ireland)

12:00pm-1:30pm: A multi-centre European comparative survey of advanced therapies (infusion and deep brain stimulation) in Parkinson’s disease

A.M. Rizos, P. Martinez-Martin, P. Reddy, M. Silverdale, K. Ashkan, A. Antonini, D. Calandrella, P. Odin, T. Henriksen, N. Bryndum, A. Glad, M.G. Kramberger, Z. Pirtošek, M. Trošt, T. van Laar, R. Katzenschlager, H.S. Dafsari, L. Timmermann, A. Storch, H. Reichmann, K. Ray Chaudhuri, On behalf of EUROPAR, The IPMDS Non-Motor PD Study Group (London, United Kingdom)

12:00pm-1:30pm: A national case study of virtual care visits for Parkinson’s disease (RACE-PD): Interim assessment of participant and investigator experiences

R. Korn, H.T. Keenan, T. Felong, S. Goldenthal, S. Kanchana, H. Schwarz, S. Sharma, K. Andrzejewski, E.A. Stevenson, R. Barbano, G. Kang, K. Rizer, A. Shukla, M.J. Dodge, C. Tanner, M. Katz, R. Rodriguez, N. Galifianakis, W. Zhu (Rochester, NY, USA)

12:00pm-1:30pm: A new test for the measuring hand functions in Parkinson’s disease: Psychometric evaluation of the squares test

E. Goz, F. Soke, A. Genc, B. Donmez Colakoglu, P. Keskinoglu (Izmir, Turkey)

12:00pm-1:30pm: A phase II, pragmatic, randomized clinical trial on a high-intensity exercise and fall prevention boot camp for Parkinson’s disease: Feasibility and safety

M.R. Landers, J.W. Navalta (Las Vegas, NV, USA)

12:00pm-1:30pm: A phase II, pragmatic, randomized clinical trial on a high-intensity exercise and fall prevention boot camp for Parkinson’s disease: Signal of efficacy

M.R. Landers, J.W. Navalta (Las Vegas, NV, USA)

12:00pm-1:30pm: A randomized clinical trial of atomoxetine treatment for mild cognitive impairment (MCI) in Parkinson’s disease (PD)

V.K. Hinson, J. Elm, A. Delambo, T. Turner (Charleston, SC, USA)

12:00pm-1:30pm: A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients

K. Kieburtz, C.W. Olanow, Y. Cohen, S. Oren (Rochester, NY, USA)

12:00pm-1:30pm: A rapid chemical-genetic screen utilising impaired movement phenotypes in caenorhabditis elegans

K. Schmeisser, Y.F. Ghassemi, C. Maios, A. Parker (Montreal, QC, Canada)

12:00pm-1:30pm: A survey of impulse control disorders in Chinese patients with Parkinson’s disease and literature review

Q. Xiao, X. Wang, Y. Tan, M. Wei (Shanghai, People's Republic of China)

12:00pm-1:30pm: Abnormal motor sequence representation in dystonia

M.J. Jaynes, J.W. Mink (Rochester, NY, USA)

12:00pm-1:30pm: AbobotulinumtoxinA for cervical dystonia: A meta-analysis of injection practices across 5 countries

R. Trosch, V.P. Misra, P. Maisonobe, S. Om (Farmington Hills, MI, USA)

12:00pm-1:30pm: AbobotulinumtoxinA for cervical dystonia: International treatment patterns

T.M. Chung, C. Colosimo, V.P. Misra, D. Charles, P. Maisonobe, S. Om (São Paulo, Brazil)

12:00pm-1:30pm: Active movement discrimination of the ankle in Parkinson’s disease

H.E. Teasdale, E.A. Preston, G. Waddington (Canberra, Australia)

12:00pm-1:30pm: Activities of daily living and motor scores of the UPDRS in fluctuating Parkinson’s disease patients treated with opicapone

J. Ferreira, A. Lees, O. Rascol, T. Müller, A. Santos, I. Oliveira, N. Lopes, J.F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

12:00pm-1:30pm: Acute admissions in people with Parkinson’s – More than just frailty

N. Leopold, B. Mohamed, C. Thomas (Cardiff, United Kingdom)

12:00pm-1:30pm: Acute movement disorders in Tunisian childhood

H. Benrhouma, H. Klaa, A. Nasri, I. Kraoua, I. Turki (Tunis, Tunisia)

12:00pm-1:30pm: ADCY5 screening in paediatric-onset hyperkinetic movement disorders: Report of three new Italian families

M. Carecchio, N.E. Mencacci, G. Zorzi, F. Zibordi, C. Fusco, A. Iodice, L. Veneziano, C. Barzaghi, L. 'RBibo, N. Wood, B. Garavaglia, N. Nardocci (Milan, Italy)

12:00pm-1:30pm: Adenosine A2A receptor antagonist istradefylline might have efficacy to fatigue and depression in some patients of Parkinson’s disease

H. Ito, T. Kamei (Fujisawa, Japan)

12:00pm-1:30pm: ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study

R. Pahwa, C.M. Tanner, R.A. Hauser, P. Nausieda, D.D. Truong, K. Hull, P. Agarwal, R. Johnson, A.E. Ruby, N.L. McClure, M.J. Stempien (Kansas City, KS, USA)

12:00pm-1:30pm: Adult onset Niemann-Pick type C: 24 month follow-up on miglustat

B. Elibol, F. Ozkinay, H. Onder (Ankara, Turkey)

12:00pm-1:30pm: Altered inter-hemispheric functional coordination in primary blepharospasm

J. Yang, C. Luo, W. Song, Q. Wei, R. Ou, Y. Hou, Q. Gong, H. Shang (Chengdu, People's Republic of China)

12:00pm-1:30pm: Alternating hemiplegia of childhood: Movement disorders and epilepsy due to mutuations in ATP1A3

A.P. Kleinert-Altamirano, M.O. Fiesco-Roa, K. Brockmann, E. Liebermann-Hernández, C. Marques-Lourenco (Tuxtla Gutiérrez, Mexico)

12:00pm-1:30pm: Amelioration of αLPHA-synuclein aggregation and motor behavior deficits by apocyanin in intranigral lipopolysaccharide induced animal model of Parkinson’s disease

B. Nehru, N. Sharma (Chandigarh, India)

12:00pm-1:30pm: AMP kinase regulates ligand-gated K-ATP channels in substantia nigra dopamine neurons

S.W. Johnson, Y. Wu, A.C. Munhall, K.Z. Shen (Portland, OR, USA)

12:00pm-1:30pm: An atypical case of adult-onset, levodopa-responsive, paroxysmal dystonia

V.N. Holiday (Portland, OR, USA)

12:00pm-1:30pm: An ongoing phase 2, multi-centre, open-label, study of WTX101 in Wilson disease patients – Early observations

A. Czlonkowska, K.H. Weiss, A. Ala, F. Askari, D. Nicholl, M.L. Schilsky (Warsaw, Poland)

12:00pm-1:30pm: An update on genotype-phenotype correlation in X-linked dystonia-parkinsonism (XDP/DYT3)

M.E. Dy, C.M. De Gusmao, M.E. Talkowski, T.J. Multhaupt-Buell, L.R. Paul, C. Bragg, N. Sharma (Boston, MA, USA)

12:00pm-1:30pm: AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, W.K.D. Ko, Q. Li, A. Crossman, E. Bezard, S. Hogg (Manchester, United Kingdom)

12:00pm-1:30pm: AntiParkinsonian effects of the “radiprodil and tozadenant” combination in MPTP-treated marmosets

A. Michel, J.M. Nicolas, S. Rose, M. Jackson, P. Colman, W. Briône, D. Sciberras, P. Muglia, D. Scheller, M. Citron, P. Downey (Braine L'Alleud, Belgium)

12:00pm-1:30pm: AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia

L. Kadastik-Eerme, N. Taba, P. Taba (Tartu, Estonia)

12:00pm-1:30pm: Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany

D. Maessen, G. Ebersbach, L. Timmermann, A. Ceballos-Baumann (Düsseldorf, Germany)

12:00pm-1:30pm: Applicability study of a multitask cognitive and motor exercise program for individuals with Parkinson´s disease: The COGWEB CNS Move Program

J. Domingos, D. Peralta, R. Loureiro, C. Ribeiro, V.T. Cruz, J. Ferreira (Torres Vedras, Portugal)

12:00pm-1:30pm: Apraclonidine in blepharospasm

J. Jankovic, D. Vijayakumar, S. Wijemanne (Houston, TX, USA)

12:00pm-1:30pm: Apraclonidine in the treatment of ptosis

S. Wijemanne, D. Vijayakumar, J. Jankovic (Houston, TX, USA)

12:00pm-1:30pm: Aquatic physical therapy: Functional motor skills in people with Parkinson’s disease

V.L. Israel, B. Yamaguchi, V.L. Israel (Curitiba, Brazil)

12:00pm-1:30pm: Are Parkinson’s disease futility studies futile?

B.C. Tilley, J. Elm (Houston, TX, USA)

12:00pm-1:30pm: Are we speaking the same language? A pilot study to evaluate the agreement in clinical phenotyping of children with cerebral palsy

H. Eggink, D. Kremer, O.F. Brouwer, M.F. Contarino, M.E. van Egmond, A. Elema, K. Folmer, J.F. van Hoorn, L.A. van de Pol, V. Roelfsema, M.A.J. Tijssen (Groningen, Netherlands)

12:00pm-1:30pm: Assessing vestibular function in individuals with cervical dystonia and the effects of botulinum toxin treatment

K.L. Andrzejewski, A. Owens, M.T. Bull, K.M. Biglan, S. Kanchana, J.W. Mink, R. Barbano (Rochester, NY, USA)

12:00pm-1:30pm: Assessment of need for treatment with botulinum toxin type A in cervical dystonia patients

C.L. Vaughan, G.T. Stebbins, C.L. Comella (Charleston, SC, USA)

12:00pm-1:30pm: Assessment of oral hygiene status before and after the use of powered tooth brush in patients with Parkinson’s diseases

F. Pullishery, F.M. Kuyyadi (Malappuram, India)

12:00pm-1:30pm: Association analysis of NALCN polymorphisms rs1338041 and rs61973742 in a Chinese population with isolated cervical dystonia

Q. Zhou, J. Yang, B. Cao, Y. Chen, Q. Wei, R. Ou, W. Song, B. Zhao, Y. Wu, H. Shang (Chengdu, People's Republic of China)

12:00pm-1:30pm: Association of amyotrophic lateral sclerosis with basal ganglia impairment

D. Mirzaeva, A. Prokhorova, B. Muinjanov, P. Deleyn (Tashkent, Uzbekistan)

12:00pm-1:30pm: Association of Parkinson’s disease with essential tremor

D. Aygun (Samsun, Turkey)

12:00pm-1:30pm: Association of the DRD2 (CA) n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response of dopamine agonists

S. Xu, J. Liu, X. Yang, Y. Qian, Q. Xiao (Shanghai, People's Republic of China)

12:00pm-1:30pm: Atypical presentation of psychogenic movement disorder with jaw-opening dystonia: Two cases reports

W.T. Yoon (Seoul, Korea)

12:00pm-1:30pm: Auditory cues during obstacle crossing increase gait asymmetry in neurologically health individuals but not in people with Parkinson’s disease

M.B. Pestana, L.T.B. Gobbi, L. Simieli, D. Orcioli-Silva, A.M. Baptista, V.S. Beretta, P.C.R. Santos, T. Penedo, V.I.A. Pereira, F.A. Barbieri (Rio Claro, Brazil)

12:00pm-1:30pm: Autophagic modulation by rosuvastatin prevent rotenone induced neurotoxicity as an in vitro model of Parkinson’s disease

W. Jang (Gangneung, Korea)

12:00pm-1:30pm: Axial prominent, delayed onset dystonia in cerebral palsy: Highlights on a distinct phenotype with favorable outcome following deep brain stimulation

L. Cif, V. Gonzalez Martinez, E. Sanrey, E. Nerrant, M. Ros, F. Cyprien, E. Chan Seng, T. Roujeau, P. Coubes (Montpellier, France)

12:00pm-1:30pm: Balance and gait disturbances in Parkinson’s disease patients with falls and freezing of gait

J. Stozek, M. Rudzinska, S. Bukowczan, A. Szczudlik (Cracow, Poland)

12:00pm-1:30pm: Balance training in individual’s with Parkinson’s disease: Therapist-supervised vs. home-based exercise programmes

E.M. Atterbury, K.E. Welman (Stellenbosch, South Africa)

12:00pm-1:30pm: Beliefs and knowledge on Parkinson’s disease (PD) among people with PD, the public and traditional healers in Western Cape, South Africa

J. Mokaya, J. Carr (Tygerberg, South Africa)

12:00pm-1:30pm: Best supportive care or palliative care for late stage Parkinsonian syndromes?

S. Lorenzl, C. Richinger, C. Schmotz, G. Nübling (Salzburg, Austria)

12:00pm-1:30pm: Beta – blockers worsen vascular parkinsonism in patients with concomitant coronary heart disease

A. Turakhonov, S. Dadajonov, R. Sadikov, R. Khodjaev, S. Nurov (Tashkent, Uzbekistan)

12:00pm-1:30pm: Beyond 30 years of Parkinson’s disease: A comprehensive characterization of long-surviving patients

A. Romagnolo, M.G. Rizzone, F. Dematteis, M. Zibetti, A. Merola, L. Rizzi, E. Montanaro, C.A. Artusi, M. Lanotte, L. Lopiano (Turin, Italy)

12:00pm-1:30pm: Biochemical features of lipids spectrum in blood in patients with Parkinson’s disease

Z.A. Akbarkhodjaeva, F. Saidvaliev (Tashkent, Uzbekistan)

12:00pm-1:30pm: Biseptol a new antiParkinsonian agent?

K. Karpinska, V. Smolanka (Uzhgorod, Ukraine)

12:00pm-1:30pm: Blindfolded balance training in patients with Parkinson’s disease: A sensory-motor strategy to improve the gait

A. Peppe, S. Bonnì, M. Fabio, K. Giacomo, A. Martino Cinnera, M. Tramontano, C. Caltagirone (Rome, Italy)

12:00pm-1:30pm: Body position during sleep in patients with Parkinson’s disease (PD): A sensor-based analysis

J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

12:00pm-1:30pm: Botulinum neurotoxin type A versus anticholinergics for cervical dystonia in adults – 2016 Cochrane movement disorders group systematic review update

F.B. Rodrigues, G.S. Duarte, R.E. Marques, M. Castelão, J.J. Ferreira, P. Moore, J. Costa (Lisboa, Portugal)

12:00pm-1:30pm: Botulinum neurotoxin type A versus placebo for hemifacial spasm in adults – 2016 Cochrane movement disorders group systematic review update

M. Castelão, F.B. Rodrigues, R.E. Marques, G.S. Duarte, J.J. Ferreira, P. Moore, J. Costa (Lisboa, Portugal)

12:00pm-1:30pm: Botulinum neurotoxins type A versus B for cervical dystonia in adults – 2016 Cochrane movement disorders group systematic review update

M. Castelão, G.S. Duarte, F.B. Rodrigues, R.E. Marques, J.J. Ferreira, P. Moore, J. Costa (Lisboa, Portugal)

12:00pm-1:30pm: Botulinum toxin A injections changes sensorimotor network activations in cervical dystonia to state more related to physiological condition

M. Nevrly, P. Hlustik, P. Otruba, P. Hok, Z. Tudos, P. Kanovsky (Olomouc, Czech Republic)

12:00pm-1:30pm: Botulinum toxin in cerebral palsy children with gait disorder: Different therapy approaches

G.S. Pilina (Izhevsk, Russia)

12:00pm-1:30pm: Botulinum toxin type A therapy for blepharospasm – Update of a Cochrane systematic review and meta-analysis

R.E. Marques, G.S. Duarte, F.B. Rodrigues, M. Castelão, J.J. Ferreira, P. Moore, J. Costa (Lisboa, Portugal)

12:00pm-1:30pm: Botulinum toxin type B therapy for cervical dystonia – 2015 update of a Cochrane systematic review and meta-analysis

R.E. Marques, G.S. Duarte, F.B. Rodrigues, M. Castelão, J.J. Ferreira, P. Moore, J. Costa (Lisboa, Portugal)

12:00pm-1:30pm: Brain networks revealed by resting state functional MRI in familial and sporadic primary dystonia

K. Fujita, A. Vo, D. Eidelberg (Manhasset, NY, USA)

12:00pm-1:30pm: Can hospital admissions predict mortality in Parkinson’s?

B. Mohamed, N. Leopold, C. Thomas (Cardiff, United Kingdom)

12:00pm-1:30pm: Can treadmill training facilitate the dual-task gait in Parkinson’s disease?

A.V.C. Sousa, L.M.M. Santiago, R.E.O. Silva, A.P. Spaniol, D.A. Oliveira, É.R.V.P. Galvão, T.S. Ribeiro, A.R.R. Lindquist (Natal, Brazil)

12:00pm-1:30pm: Categories of psychogenic movement disorders to functional blepharospasm

J. Gazulla (Zaragoza, Spain)

12:00pm-1:30pm: Cerebellar learning and its modifiability by alcohol in myoclonus-dystonia

A. Weissbach, E. Werner, T. Bäumer, D. Timmann, N. Brüggemann, V. Tadic, C. Klein, A. Münchau (Lübeck, Germany)

12:00pm-1:30pm: Cervical dystonia and quality of life

S. Tomic, I. Petkovic, T. Pucic, S. Juric, S. Butkovic Soldo (Osijek, Croatia)

12:00pm-1:30pm: Cervical dystonia associated to Wallenberg syndrome

I. Parees, M. Romeral, D. Mayo, D. Toledo, M.E. Garcia, J. Matias-Guiu, A. Marcos, J. Porta-Etessam (Madrid, Spain)

12:00pm-1:30pm: Cervical dystonia preceding Parkinson´s disease – Continuum – coincidence or epiphenomenon–Report of 3 cases

J. Walch, G. Kägi (St. Gallen, Switzerland)

12:00pm-1:30pm: Changes in handwriting following repetitive transcranial magnetic stimulation over pre-motor cortex in Parkinson’s disease

A.Y. Son, M.C. Biagioni, E. Pirraglia, A. DiRocco (New York, NY, USA)

12:00pm-1:30pm: Changes of speech after neurostimulation for Parkinson’s disease with early fluctuations: A 2-years randomized controlled trial (earlystim-speech)

S. Pinto, A. Nebel, R. Espesser, J. Rau, P. Maillochon, O. Krack, K. Knudsen, A. Ghio, O. Niebuhr, Y. Agid, M. Schüpbach, G. Deuschl (Aix-en-Provence, France)

12:00pm-1:30pm: Characterization of European longitudinal cohort studies in Parkinson’s disease – Report of the JPND working group BioLoC-PD

S. Lerche, I. Liepelt-Scarfone, G. Alves, P. Barone, S. Behnke, Y. Ben-Shlomo, H. Berendse, D. Burn, R. Dodel, D. Grosset, M. Hu, M. Kasten, R. Krüger, W. Maetzler, B. Mollenhauer, W. Oertel, U. Walter, K. Wirdefeldt, D. Berg (Tübingen, Germany)

12:00pm-1:30pm: Chewing-induced blepharospasm in Parkinson’s disease

E. Sasse, L.F. Vasconcellos, M. Spitz (Rio de Janeiro, Brazil)

12:00pm-1:30pm: Classification and recommendation of nonpharmacological therapies for Parkinson’s disease

T.T.C. Capato, C.H. Fen, E.R. Barbosa (São Paulo, Brazil)

12:00pm-1:30pm: Clinical and biological predictors of time to initiation of symptomatic therapy in early Parkinson’s disease

T. Simuni, J. Long, C. Caspell-Garcia, C.S. Coffey, S. Lasch, C. Tanner, D. Jennings, K. Kieburtz, K. Marek, On behalf of the PPMI Investigators (Chicago, IL, USA)

12:00pm-1:30pm: Clinical and molecular features of DYT1 primary dystonia in a Peruvian population

M. Inca-Martinez, K. Milla-Neyra, C.C. Cosentino, N. Mori, V. Marca, M. Flores, E. Guevara-Silva, Y. Nuñez-Coronado, C.M. Vasquez, L. Torres-Ramirez, P. Mazzetti, M. Cornejo-Olivas (Lima, Peru)

12:00pm-1:30pm: Clinical benefits of vestibular rehabilitation in neurodegenerative diseases

B.S. Zeigelboim, G.B. Santos, H.A.G. Teive, M.I.R. Severiano, C.M. Porto (Curitiba, Brazil)

12:00pm-1:30pm: Clinical characteristics and natural history of oromandibular dystonia

L. Scorr, S. Factor, H. Jinnah (Atlanta, GA, USA)

12:00pm-1:30pm: Clinical characterization of pramipexole induced edema in Parkinson’s disease (PD). Is it always the best option discontinue the treatment?

E. Urrea-Mendoza, F.J. Revilla (Greenville, SC, USA)

12:00pm-1:30pm: Clinical course and treatment of 6 children with GNAO1 mutations causing a severe, life-threatening chorea

A. Robichaux-Viehoever, A. Ananth, Y.M. Kim, A. Hanson-Kahn, R. Cox, G. Enns, J. Strober, M. Willing, B. Schlaggar, J. Bernstein, Y. Wu (San Francisco, CA, USA)

12:00pm-1:30pm: Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

12:00pm-1:30pm: Clinical effects of pallidal stimulation in dystonia are quantitatively related to intracortical inhibition

A. Fecíková, V. Cejka, V. Capek, F. Ruzicka, V. Bocek, D. Štastná, I. Štetkárová, D. Urgošík, R. Jech (Praha, Czech Republic)

12:00pm-1:30pm: Clinical outcomes of pallidal and subthalamic nucleus deep brain stimulation in isolated cranial and cranio-cervical dystonia

N.S. Luthra, K.A. Dodenhoff, M. San Luciano, M.M. Volz, S.L. Heath, P.A. Starr, J.L. Ostrem (San Francisco, CA, USA)

12:00pm-1:30pm: Clinical profile of patients with writer’s cramp

H.S. Kaleagasi, O. Dogu (Mersin, Turkey)

12:00pm-1:30pm: Cognitive behavioural thrapy and adiunctive physical therapy for functional movement disorders

R. Erro, M. Tinazzi, C. Dallocchio (London, United Kingdom)

12:00pm-1:30pm: Cognitive effects of AG-0029 in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard, S. Hogg (Manchester, United Kingdom)

12:00pm-1:30pm: Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard (Manchester, United Kingdom)

12:00pm-1:30pm: Colonic α-synuclein: A potential diagnostic biomarker in Parkinson’s disease

C. Ruffmann, I. Poggiolini, N. Bengoa-Vergniory, F. Baig, M. Rolinski, J. Klein, M.T. Hu, R. Wade-Martins, J. Alegre-Abarrategui, L. Parkkinen (Oxford, United Kingdom)

12:00pm-1:30pm: Combinative therapy of memantine and galantamine hydrobromide as a tool of choice for the treatment of vascular parkinsonism with early appearance of dementia symptoms

A. Turakhanov, S. Dadajonov, R. Sadikov, R. Khodjaev, S. Nurov (Tashkent, Uzbekistan)

12:00pm-1:30pm: Combined pallidal and thalamic stimulation for multifocal primary dystonia with prominent writers’ cramp

A. Wloch, M. Abdallat, G. Lütjens, C. Schrader, J.K. Krauss (Hannover, Germany)

12:00pm-1:30pm: Combined stimulation of STN and SNr for resistant freezing of gait in Parkinson’s disease (STN+SNr) – A multicenter randomized controlled trial

D. Weiss, G. Naros, C. Meisner, R. Krüger, A. Gharabaghi (Tübingen, Germany)

12:00pm-1:30pm: Comparing quality of PD care in a comprehensive clinic to specialist care

S.A. Factor, L.P. Prizer, F.C. Goldstein, L.M. Trotti, A. Hermida, C. Vaughan (Atlanta, GA, USA)

12:00pm-1:30pm: Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease

C. Mahapatra, R. Manchanda (Mumbai, India)

12:00pm-1:30pm: Conjugal Parkinson´s disease – Real or chance?

B. Balint, R. Erro, F. Brugger, A. Batla, E. Antelmi, C. Ganos, K.P. Bhatia (London, United Kingdom)

12:00pm-1:30pm: Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa

R. Shaltiel-Karyo, E. Zawoznik, I. Weinstock, M. Nemas, Y. Caraco, P.A. LeWitt, S. Oren, O. Yacoby-Zeevi (Rehovot, Israel)

12:00pm-1:30pm: Contributions of sensorial feedback to gait in Parkinson’s disease

F.A. Barbieri, L.T.B. Gobbi, P.C.R. Santos, R. Vitório, L. Simieli, D. Orcioli-Silva, M.B. Pestana, C.M. Fiorelli, Q. Almeida (Bauru, Brazil)

12:00pm-1:30pm: Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice

S.J. LoRusso, B. Ouyang, B.R. Barton (Chicago, IL, USA)

12:00pm-1:30pm: Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns

J. Morgan, M. Stacy, R. Rubens, S. Khanna, S. Gupta (Augusta, GA, USA)

12:00pm-1:30pm: Copper chelation efficacy of alginate/chitosan based D-penicillamine nanoparticles in rat model of non-Wilsonian brain copper toxicosis

A. Pal, B.R. Thapa, R.K. Vasishta, R. Prasad (Chandigarh, India)

12:00pm-1:30pm: Correlation between Parkinson’s disease and malignant tumors

E. Binaghi, M.M. Mascia, P. Solla, M. Meloni, R. Farris, D. Ciaccio, G. Orofino, F. Marrosu, A. Cannas (Cagliari, Italy)

12:00pm-1:30pm: Coupling between visual information and body sway in people with Parkinson’s disease

C.F. Cruz, L.A.O.A. Nóbrega, E. Okamoto, M.E.P. Piemonte, J.A. Barela (São Paulo, Brazil)

12:00pm-1:30pm: Creatine for patients with Parkinson’s disease: A meta-analysis

A. Attia, H. Ahmed, M. Morsi, K. Awad, M. Elnenny, E. Ghanem, A. Negida (Cairo, Egypt)

12:00pm-1:30pm: Creativity related to dopaminergic treatment. A multicenter study

P.J. Garcia Ruiz, J.C. Martinez Castrillo, L. Vela (Madrid, Spain)

12:00pm-1:30pm: Creutzfeldt-Jakob disease presenting predominantly with movement disorder: A case report

A.A. Sann, M.M. Zaw, T.L. Choie (Yangon, Myanmar)

12:00pm-1:30pm: Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease

K. Romero, D. Burn, M. Hu, A. Yarnell, C. Williams Gray, K. Marek, D. Grosset, M. Sutherland, M. Isaac, A. Bhattaram, V. Sinha, M.F. Gordon, P. Muglia, L. Slicker, W. Hirst, M. Facheris, J. Posener, M. Bani, B. Corrigan, R. Schindler, K. Tsai, T. Nicholas, J. Cedarbaum, J. Gallagher, S. Ford, E. Avilex, V. Kern, S. Arneric, D. Stephenson, A. Roach (Tucson, AZ, USA)

12:00pm-1:30pm: CSF level of chromogranin A in amyotrophic lateral sclerosis

M. Kaiserova, P. Otruba, K. Mensikova, Z. Grambalova, H. Prikrylova Vranova, J. Mares, D. Stejskal, P. Kanovsky (Olomouc, Czech Republic)

12:00pm-1:30pm: Curcumin supplementation improves motor dysfunction in lipopolysaccharide induced Parkinon’s disease model: Possible biochemical, neurochemical and immunohistochemical alterations in rats

N. Sharma, B. Nehru (Chandigarh, India)

12:00pm-1:30pm: Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital

K. Nalamada, J. Cosgrove, P. Duggan-Carter, S. Jamieson, J. Alty (Leeds, United Kingdom)

12:00pm-1:30pm: DBS outcomes in a mixed cohort of dystonia: A single center experience

O. Saeed, I. Haq, S.B. Tatter, A.W. Laxton, T. Wilson, M. Siddiqui (Winston Salem, NC, USA)

12:00pm-1:30pm: Deep brain stimulation in three patients with dystonia and severe cerebellar atrophy

V. Gonzalez, L. Cif, E. Sanrey, E. Nerrant, F. Cyprien, M. Ros, E. Chanseng, T. Roujeau, P. Coubes (Montpellier, France)

12:00pm-1:30pm: Deep brain stimulation of the locomotor mesencephalic region in rats with lesioned sensorimotor cortex: A model of functional motor recovery after stroke

F. Fluri, M.K. Schuhmann, C. Kleinschnitz, J. Volkmann (Würzburg, Germany)

12:00pm-1:30pm: Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson’s disease patients with motor fluctuations

C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

12:00pm-1:30pm: Development of a human neuroblastoma model of pantothenate kinase-associated neurodegeneration

A. Di Marco, G. Auciello, A. Vecchi, D. Vignone, M.R. Battista, E. Bracacel, F. Bonelli, E. Nizi, E. Monteagudo, M. Beconi (Pomezia, Italy)

12:00pm-1:30pm: Development of a nanoherbaceutical containing natural L-DOPA from mucuna pruriens for the prevention and treatment of Parkinson’s disease in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced animal model

P.C. Bhatt, V. Kumar (New Delhi, India)

12:00pm-1:30pm: Development of a nanoherbaceutical formulation containing compound extracts from huperzia serrata, mucuna pruriens and withania somnifera for the prevention and treatment of Parkinson’s disease

V. Kumar, P.C. Bhatt (Allahabad, India)

12:00pm-1:30pm: Development of hyperkinesias after long term pallidal stimulation for dystonia

A. Wloch, G. Lütjens, C. Schrader, M. Manu, C. Blahak, J.K. Krauss (Hannover, Germany)

12:00pm-1:30pm: Diagnostic value of a new coronal examination plane in transcranial nigral sonography and of additional M-mode tremor frequency determination for the differentiation of idiopathic Parkinson’s disease and essential tremor

L. Tönges, R. Daniel, D. Woitalla, S. Muhlack, R. Gold, C. Krogias (Bochum, Germany)

12:00pm-1:30pm: Diaphragmatic dystonia in a patient that presents with Meige syndrome and disordered breathing

N. Licking, B. Farro (Portland, OR, USA)

12:00pm-1:30pm: Differences in physicians’ understanding of biologic and biosimilar medicines in the USA and Europe

A.L. Molinari, H.L. Gewanter, M. Reilly, D. Charles (Washington, DC, USA)

12:00pm-1:30pm: Differences in processing proprioceptive input from the neck muscles may explain the benefit from sensory tricks in patients with idiopathic cervical dystonia

F. Brugger, A. Peters, D. Georgiev, G. Kägi, B. Balint, K.P. Bhatia, B.L. Day (St. Gallen, Switzerland)

12:00pm-1:30pm: Differential clinical outcomes in unifocal vs. multifocal premotor rTMS for Parkinson’s disease: A randomized trial

M.C. Biagioni, A.Y. Son, S. Agarwal, G. Dacpano, M. Brys, P. Kumar, A. Cucca, J. Singleton-Garvin, R. Gilbert, A. Quartarone, A. DiRocco (New York, NY, USA)

12:00pm-1:30pm: Differential effects of tango, treadmill, and stretching interventions on gait in people with Parkinson’s disease

M.E. McNeely, R.P. Duncan, G.M. Earhart (St. Louis, MO, USA)

12:00pm-1:30pm: Digitally captured Archimedes spiral indices correlate with clinical assessment of dystonia severity

J.B. Ratliff, A. Mirallave, R. Ortega, A. Glickman, Q. Yu, D. Raymond, S. Bressman, S. Pullman, R. Saunders-Pullman (New York, NY, USA)

12:00pm-1:30pm: Direct comparisons for botulinum neurotoxins in movement disorders

R. Maggio, S. Lalli, A. Albanese (Rozzano, Italy)

12:00pm-1:30pm: DIRECT DBS: A prospective, multi-center clinical trial with blinding for a directional DBS lead

J. Volkmann, S. Chabardes, G.K. Steinke, S. Carcieri, N. Van Dyck (Wuerzberg, Germany)

12:00pm-1:30pm: Disruption of cerebellar connectivity in cervical dystonia

P. Filip, B. Martin (Brno, Czech Republic)

12:00pm-1:30pm: Distinguishing pseudo-dystonia from dystonia: A case series

L.E. Katus, S.J. Frucht (New York, NY, USA)

12:00pm-1:30pm: Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

12:00pm-1:30pm: Diverse effects of alpha-synuclein fibrils on various neuron cell lines, using different buffers

F. Aliakbari, D. Morshedi, A.A. Shabani, H. Mohammad Beigi, A. Tayaranian Marvian, P. Shariati, S.A. Shojaosadati, A.A. Saboury (Semnan, Islamic Republic of Iran)

12:00pm-1:30pm: Do predictors of good response to deep brain stimulation in primary cervical movement disorders exist?

E. Sanrey, V. Gonzalez, L. Cif, F. Cyprien, E. Borgeais, J. Perez, M. Ros, P. Coubes (Montpellier, France)

12:00pm-1:30pm: Does distance walked after two minutes predict total 6 minute walk test distance in people with Parkinson’s disease?

R.P. Duncan, M.E. McNeely, G.M. Earhart (Saint Louis, MO, USA)

12:00pm-1:30pm: Does physical exercise influence the cognitive domains that predict dementia in Parkinson’s disease?

C.R.A. Silveira, E.A. Roy, B.N. Intzandt, Q.J. Almeida (Waterloo, ON, Canada)

12:00pm-1:30pm: Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson’s disease center

S. Patel, X. Garcia, M.E. Mohammad, X.X. Yu, K. Vlastaris, K. O'Donnell, K. Sutton, H.H. Fernandez (Cleveland, OH, USA)

12:00pm-1:30pm: Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy

A. Tóth, H. Nagy, S. Funk, A. Takáts (Budapest, Hungary)

12:00pm-1:30pm: Dopaminergic medication effect on speech in Parkinson’s disease: A kinematic study

T.E. Tong, M.L. Ng, N. Yan (Hong Kong, Hong Kong)

12:00pm-1:30pm: Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke

A. Azimov, R. Sadykov, G. Rakhimbaeva, S. Dadajonov, O. Azizova (Tashkent, Uzbekistan)

12:00pm-1:30pm: Dosing of abobotulinumtoxinA and muscle selection in patients with simple patterns of cervical dystonia

V.P. Misra, R. Trosch, S. Om, P. Maisonobe (London, United Kingdom)

12:00pm-1:30pm: Drug safety in the pharmacotherapy of Parkinson’s disease

S. Müller-Rebstein, C. Trenkwalder, J. Ebentheuer, C. Culmsee, G. Höglinger (Kassel, Germany)

12:00pm-1:30pm: Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease

M. Tomiyama, Y. Funamizu, T. Kon, R. Haga, T. Ueno, H. Nishijima, A. Arai, C. Suzuki, J.I. Nunomura, M. Baba (Aomori, Japan)

12:00pm-1:30pm: Duodenal levodopa infusion: Safety and efficacy in a 6 years outpatient follow-up

S. Simoni, N. Tambasco, E. Sacchini, P. Nigro, F. Ripandelli, P. Calabresi (Perugia, Italy)

12:00pm-1:30pm: Duodopa treatment experience in Oradea

M. Sabau, L. Botnaru, A. Badea, C. Dudas (Oradea, Romania)

12:00pm-1:30pm: Duration of levodopa treatment and prevalence of osteoporosis in patients with Parkinson’s disease

S.H. Guptha (Peterborough, United Kingdom)

12:00pm-1:30pm: Dynamic prediction for multiple repeated measures and event time data: An application to Parkinson’s disease

S. Luo, J. Wang (Houston, TX, USA)

12:00pm-1:30pm: Dystonia after peripheral nerve injury in DYT1 transgenic rats

S. Knorr, K. Grundmann-Hauser, J. Volkmann, C.W. Ip (Wuerzburg, Germany)

12:00pm-1:30pm: Dystonia-deafness syndrome caused by beta -actin gene mutation and the effect of pallidal deep brain stimulation

H. Eggink, M.E. van Egmond, M.C. Schönherr, C.C. Verschuuren-Bemelmans, T.J. de Koning, M.J.C. van Dijk, M.A.J. Tijssen (Groningen, Netherlands)

12:00pm-1:30pm: Dystonia, myoclonus, and tremor without epilepsy associated with a mutation in STXBP1

L.S. Tochen, C. Applegate, H.S. Singer (Baltimore, MD, USA)

12:00pm-1:30pm: Dystonia, tremor, and dystonic tremor

A.R. Rosen, A.G. Shaikh, H.A. Jinnah (Atlanta, GA, USA)

12:00pm-1:30pm: DYT16/PRKRA founder mutation causes childhood-onset generalized dystonia in a family from southern Italy

M. Quadri, S. Olgiati, M. Sensi, F. Gualandi, E. Groppo, V. Rispoli, J. Graafland, G.J. Breedveld, G. Fabbrini, A. Berardelli, V. Bonifati (Rotterdam, Netherlands)

12:00pm-1:30pm: DYT2 dystonia – Too rare to be found?

V. Dobricic, N. Kresojevic, A. Marjanovic, A. Tomic, M. Svetel, I. Novakovic, V. Kostic (Belgrade, Serbia)

12:00pm-1:30pm: Early retirement and loss of income among X linked dystonia parkinsonism (XDP / DYT3) patients in Capiz, Roxas City Philippines

P.J.B. Acuna, C.L. Go (Boston, MA, USA)

12:00pm-1:30pm: ECG-based cardiopulmonary coupling for sleep stability assessment in patients with amyotrophic lateral sclerosis

S. Mariani, P. Congiu, G. Milioli, G. Gioi, G. Borghero, F. Marrosu, R.J. Thomas, A.L. Goldberger, M. Puligheddu (Boston, MA, USA)

12:00pm-1:30pm: EEG Spectral power changes prior to non-epileptic seizures: A pilot study

A.M. Meppelink, I. Parees, M. Beudel, S. Little, M. Edwards (Groningen, Netherlands)

12:00pm-1:30pm: Effect of botulinum toxin on the non-motor symptoms of dystonia

E. Shakweh, R. Pearce, N. Pavese (London, United Kingdom)

12:00pm-1:30pm: Effect of dopamine and L-3,4 – dihydroxyphenylalanine in treatment of experimental parkinsonism

M.U. Kulmanova (Tashkent, Uzbekistan)

12:00pm-1:30pm: Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia

W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, M. Sanchez, W. Shanahan (New York, NY, USA)

12:00pm-1:30pm: Effect of outside influences on the therapeutic benefits of botulinum toxin injections

D.C. Taylor, P.A. LeWItt, P. Kaminski (Royal Oak, MI, USA)

12:00pm-1:30pm: Effect of over(exaggerated) articulation technique in voice and speech of individuals with Parkinson’s disease with deep brain stimulation

G.L.A. Diaféria, F.A.M. Bento, M. Padovani, E.T. Fonoff, M.S. Behlau (São Paulo, Brazil)

12:00pm-1:30pm: Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study

P.A. LeWitt, M.I. Freed, M. Leinonen, A. Sedkov, H. Murck (West Bloomfield, MI, USA)

12:00pm-1:30pm: Effect of pharmacist-led interventions on motor symptoms and quality of life in Parkinson’s patients: A pilot study

C. Stuijt, T.V. Laar (Groningen, Netherlands)

12:00pm-1:30pm: Effect of repeated intravenous amantadine infusions in patients with Parkinson’s disease

A. Khlebtovsky, I. Steiner, R. Djaldetti, T. Treves (Petach Tikva, Israel)

12:00pm-1:30pm: Effect of right DLPFC-repetitive transcranial magnetic stimulation (rTMS) on tardive dyskinesia in patients with psychosis

S. Lavania, A. Pattojoshi, A.H. Khan, S. Lavania (Agra, India)

12:00pm-1:30pm: Effectiveness of a multidisciplinary PD clinic in improving quality of life

H.F. Chan, D.K.W. Chau, T. Fung, I. Chan, Y.F. Cheung, W.C. Fong (Hong Kong, Hong Kong)

12:00pm-1:30pm: Effectiveness of Lee Silverman voice treatment big on improving gait and quality of life in Parkinson’s disease patients after STN-DBS

V.V.P. Kagita, N.N. Mohd, A.K. Puligopu, R.M. Kandadai, M.A. Kanikannan, S. Jabeen, R. Borgohain (Hyderabad, India)

12:00pm-1:30pm: Effectivity and safety of rotigotine transdermal patch on motor and cognitive dysfunctions in Parkinson’s disease with dementia and dementia with Lewy bodies

K. Ohta, Y. Kujuro, T. Osada, T. Toguchi, Y. Shinohara (Tokyo, Japan)

12:00pm-1:30pm: Effects of cerebellar theta-burst stimulation on arm and neck movement kinematics in patients with focal dystonia

M. Bologna, G. Paparella, A. Fabbrini, G. Leodori, L. Rocchi, M. Hallett, A. Berardelli (Pozzilli, Italy)

12:00pm-1:30pm: Effects of combined repetitive transcranial magnetic stimulation and treadmill training on gait performance in Parkinson’s disease

C.L. Chung, M.K.Y. Mak (Hong Kong, Hong Kong)

12:00pm-1:30pm: Effects of exercise intervention on balance and gait performance, and balance confidence in people with Parkinson’s disease – A meta-analysis

M.K. Mak, I.S. Wong-Yu (Hong Kong, People's Republic of China)

12:00pm-1:30pm: Effects of levodopa on adaptation of reactive stepping in people with Parkinson’s disease

F.B. Horak, B. Dijstra, J.G. Nutt, D.S. Paterson (Portland, OR, USA)

12:00pm-1:30pm: Effects of movement rate and amplitude on repetitive finger motion in people with Parkinson’s disease and freezing of gait

M.P. Pereira, S. Vercruysse, E. Heremans, A. Nieuwboer (Leuven, Belgium)

12:00pm-1:30pm: Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, E. Valadez, Y. Torres-Yaghi, R. Falconer, R. Mills, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

12:00pm-1:30pm: Effects of plantar automated mechanical stimulation (AMPS) on motor symptoms of patients with advanced Parkinson’s disease: Preliminary data of a double blind randomized clinical trial

L. Bartolomei, M. Malaguti, A. Pastore, G.M. Minicuci, N. Bonetto, S. Ferrari, M. Pellegrini (Vicenza, Italy)

12:00pm-1:30pm: Effects of pyridostigmine bromide vs. fludrocortison in the treatment of orthostatic hypotension in Parkinson’s disease

S.R. Schreglmann, F. Büchele, M. Sommerauer, L. Epprecht, G. Kägi, S. Hägele-Link, O. Götze, L. Zimmerli, D. Waldvogel, C.R. Baumann (London, United Kingdom)

12:00pm-1:30pm: Effects of safinamide in patients with Parkinson’s disease measured by Parkinson’s KinetiGraphTM

I. Suttrup, V. Zentsch, J. Schroeder, T. Warnecke (Muenster, Germany)

12:00pm-1:30pm: Effects of the biodex stability system training on balance, gait and fatigue in Parkinson’s disease

G. Singh, R. Pahwa, K.E. Lyons, Y. Colgrove, N.K. Sharma (Troy, NY, USA)

12:00pm-1:30pm: Effects of videogame step training on gait adaptability in people with Parkinson´s disease – A randomized controlled trial

M.J.D. Caetano, J.C. Menant, C.G. Canning, J. Song, D. Schoene, M. Brodie, S.R. Lord (Sydney, Australia)

12:00pm-1:30pm: Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial

K. Hannink, L. ter Brake, A. Wertenbroek, K. Movig, J. van der Palen, L. Dorresteijn (Enschede, Netherlands)

12:00pm-1:30pm: Efficacy and safety of abobotulinumtoxinA in craniocervical dystonia and hemifacial spasm

A. Jesic, D. Stefanovic, N. Delibasic, J. Radanov, M. Cvijanovic (Victoria, Seychelles)

12:00pm-1:30pm: Efficacy and safety of tetrabenazine in hyperkinetic movements disorders- An observational study

R. Miguel, M. Mendonça, R. Barbosa, F. Ladeira, T. Lampreia, J. Vale, P. Bugalho (Lisbon, Portugal)

12:00pm-1:30pm: Efficacy of 4845 botulinum toxin (BoNT) treatment cycles, and clinical strategies after a failed cycle

P. Tanvijit, A.P. Moore (Bangkok, Thailand)

12:00pm-1:30pm: Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia

S.H. Isaacson (Boca Raton, FL, USA)

12:00pm-1:30pm: Efficacy of long-term treatment with istradefylline and analysis of the expression of A2A receptor protein and post-transcriptional DNA methylation

N. Kanzato, K. Nakachi, T. Naka, M. Higa, S. Mochizuki, Y. Miyamae (Okinawa Prefecture, Haebaru-cho, Japan)

12:00pm-1:30pm: Efficiency of carotid endarterectomy in vascular parkinsonism in patients with stenotic carotid artery disease

M. Ataniyazov, G. Rakhimbaeva, K. Ataniyazova (Tashkent, Uzbekistan)

12:00pm-1:30pm: Eight weeks of home-based balance training not as effective as therapist-based during dual tasks

E.M. Atterbury, K.E. Welman (Stellenbosch, South Africa)

12:00pm-1:30pm: Electromyographic and kinematic patterns in runner’s dystonia

O.F. Ahmad, P. Ghosh, C. Lungu, B. Karp, C. Stanley, K. Alter (Bethesda, MD, USA)

12:00pm-1:30pm: Elemental profiles as biomarkers for diagnosis and disease progression of Parkinson’s disease

F. Maass, M. Börger, A. Fischbach, B. Michalke, M. Bähr, I. Zerr, P. Lingor (Göttingen, Germany)

12:00pm-1:30pm: Endoscopic-guided injection of botulinum toxin into the longus capitis muscle and into the obliquus superior part of the longus colli muscle in dystonic antecaput

G. Reichel, A. Stenner, H. von Sanden, L. Herrmann, C. Feja, S. Löffler (Zwickau, Germany)

12:00pm-1:30pm: Engrailed enhances dopamine synthesis in healthy dopaminergic neurons

D. Alvarez-Fischer, M. Baaske, F. Vulinovic, J. Fuchs, P. Seibler, A. Rakovic, A. Prochiantz, C. Klein (Lübeck, Germany)

12:00pm-1:30pm: Epidemiological and clinical profile of essential blepharospasm and its response to treatment with TBA over a 11-year period

J.R.R. Manoel, U.C. Júnior, D.P. Nones, F.M.B. Germiniani, H.A.G. Teive (Curitiba, Brazil)

12:00pm-1:30pm: Epidemiological investigation of yips among Golfers in Japan

Y. Gon, M. Mihara, S. Kawamura, K. Nakata, D. Kabata, A. Shintani, H. Mochizuki (Suita, Japan)

12:00pm-1:30pm: Establishment of InMotion, an independent, fee-free community center for persons with movement disorders

D.E. Riley, K.M. Jaffe, J.Z. Peters (Warrensville Heights, OH, USA)

12:00pm-1:30pm: European physiotherapy guideline for Parkinson’s disease: Information for neurologists

D.L.M. Radder, M.J. Faber, N.M. de Vries, B.R. Bloem, S.H.J. Keus (Nijmegen, Netherlands)

12:00pm-1:30pm: Evaluation of droxidopa dosing and clinical response in 50 consecutive patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension

S.H. Isaacson, S. Brillman, N. Chhabria (Boca Raton, FL, USA)

12:00pm-1:30pm: Evaluation of impulse control disorders in fluctuating Parkinson’s disease patients under opicapone treatment

N. Lopes, J. Ferreira, A. Lees, T. Müller, H. Reichmann, H. Gama, A. Santos, C. Oliveira, J.F. Rocha, P. Soares-da-Silva (Coronado, Portugal)

12:00pm-1:30pm: Evaluation of respiratory and depression levels of patients with Parkinson’s disease

E.E. Okuyucu, O. Canbay, E. Dogru, I. Huzmeli, N. Katayifci, F. Duman, N.C. Korkmaz, B. Yucekaya, E. Seker (Hatay, Turkey)

12:00pm-1:30pm: Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia

W. Wen, K. Kishnani, S. Ramaswamy, S. Piscitelli (New York, NY, USA)

12:00pm-1:30pm: Exercise-induced adaptive neuroplasticity in the MPTP mouse model of Parkinson’s disease

C.J.H.M. Klemann, G. Poelmans, G.J.M. Martens, J.E. Visser (Nijmegen, Netherlands)

12:00pm-1:30pm: Exome sequencing reveals homozygous mutations in SACS, ATCAY, and MCOLN1 in three Pakistani families with complex dystonia

H. Manzoor, N. Brüggemann, F. Hinrichs, H.M.J. Hussain, M. Wajid, T. Bäumer, A. Münchau, S. Naz, K. Lohmann (Lahore, Pakistan)

12:00pm-1:30pm: Experience of pallidal deep brain stimulation (DBS) in dystonia at a tertiary care centre in India

D. Srinivas, R. Yadav, K. Jhunjhunwala, P. Pal (Bangalore, India)

12:00pm-1:30pm: Experience with utilization of rytary in the clinical setting

Y. Kianirad, T. Simuni, C. Zadikoff, D. Bega, M. Afshari, S. Jonnalagadda (Chicago, IL, USA)

12:00pm-1:30pm: Expiratory muscle training for the impaired loudness of speech in Parkinson’s disease: An open-label study

S. Tomita, T. Oeda, A. Umemura, M. Kohsaka, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Kyoto, Japan)

12:00pm-1:30pm: Exploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progression

N. Lopes, J. Ferreira, A. Lees, W. Poewe, H. Reichmann, A. Santos, C. Oliveira, J.F. Rocha, P. Soares-da-Silva (Porto, Portugal)

12:00pm-1:30pm: Exploring hospitalizations and visits to the emergency room of patients with Parkinson’s disease: A ten years’ follow-up

M.T. Montojo, Y. Macias, M. ÁLvarez, C. Martín, L. Borrega, L. Vela (Alcorcón, Spain)

12:00pm-1:30pm: Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease

A. Ashrafi, M. Buttini, P. Garcia, A. del Sol, E. Glaab (Esch-sur-Alzette, Luxembourg)

12:00pm-1:30pm: Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease

S. Gupta, S. Khanna, S. Kell, R. Rubens (Hayward, CA, USA)

12:00pm-1:30pm: Factors affecting the cardiac sympathetic denervation in autopsy confirmed dementia with Lewy bodies

M. Takahashi, T. Uchihara, M. Yoshida, K. Wakabayashi, A. Kakita, H. Takahashi, S. Toru, T. Kobayashi, S. Orimo (Tokyo, Japan)

12:00pm-1:30pm: Factors associated with falling in early, treated Parkinson’s disease: The NET-PD LS1 cohort

K.L. Chou, J.J. Elm, C.L. Wielinski, D.K. Simon, M.J. Aminoff, C.W. Chadwick, G.S. Liang, R.A. Hauser, L. Sudarsky, C.C. Umeh, T. Voss, J. Juncos, J.Y. Fang, J.T. Boyd, I. Bodis-Wollner, M. Zoltan, J.C. Morgan, A.M. Wills, S.L. Lee, S.A. Parashos, On behalf of the NINDS NET-PD Investigators (Ann Arbor, MI, USA)

12:00pm-1:30pm: Fall status and stepping response: Individuals with PD are differently influenced by side-affected

B.N. Intzandt, E. Beck, M.P. Pereira, Q.J. Almeida (Waterloo, ON, Canada)

12:00pm-1:30pm: Falls and frailty predicate escalating care needs in Parkinson’s disease

B. Mohamed, C. Thomas, H. Shukla, S. Aithal (Cardiff, United Kingdom)

12:00pm-1:30pm: Familial cortical myoclonic tremor with epilepsy in Chinese population: Clinical and neurophysiologic features in nine pedigrees from People’s Republic of China

Z. Cen, C. Huang, H. Yin, F. Xie, X. Lu, Z. Ouyang, Y. Lou, X. Qiu, Z. Wang, J. Xiao, M. Ding, W. Luo (Hangzhou, People's Republic of China)

12:00pm-1:30pm: Feasibility and preliminary efficacy of a telehealth approach to group tango instruction for people with Parkinson’s disease

K.J. Seidler, R.P. Duncan, M.E. McNeely, M.E. Hackney, G.M. Earhart (St. Louis, MO, USA)

12:00pm-1:30pm: Feasibility of implementing a long-term mobile device program in PD patients

L.R. Bataille, L.D. Herron, M. Afek, I. Feldman, C. Admati, S. Chowdhury (New York, NY, USA)

12:00pm-1:30pm: Feasibility, safety and effects of a group intervention based on European physiotherapy guideline for Parkinson´s disease

J.E. Pompeu, T.B. Freitas, R.A. Nuvolini, K.G. Silva, F. Doná, R.A. Andreotti, N.A. Mazzini, M.G.R. Almeida, C. Torriani-Pasin (Sao Paulo, Brazil)

12:00pm-1:30pm: Features of the quality of life and related disorders in patients with focal dystonia

Z.A. Akbarkhodjaeva, G.S. Rakhimbaeva (Tashkent, Uzbekistan)

12:00pm-1:30pm: Fighting Freezing of gait in Parkinson’s disease: Effect of a phase-dependent tactile biofeedback

M. Mancini, K. Smulders, G. Harker, A.C. Fortaleza, J.G. Nutt, F.B. Horak (Portland, OR, USA)

12:00pm-1:30pm: Finding an optimal lead trajectory for a better stimulated volume in movement disorder therapy

J. Perez, L. Cif, V. Gonzalez, E. Sanrey, F. Cyprien, P. Coubes (Montpellier, France)

12:00pm-1:30pm: Finger tapping-related brain activation and impact of cerebellar theta-burst stimulation in cervical dystonia patients

T.M. Odorfer, G.A. Homola, J. Volkmann, D. Zeller (Wuerzbuerg, Germany)

12:00pm-1:30pm: Fox insight wear ecosystem: using mobile technology and cloud-based computing to support PD research

I. Feldman, M. Afek, L. Bataille (Gedera, Israel)

12:00pm-1:30pm: Frequency and types of dystonia in Wilson’s disease patients

K. Dziezyc, T. Litwin, G. Chabik, A. Czlonkowska (Warsaw, Poland)

12:00pm-1:30pm: Frequency of falls in nursing homes for neurodegenerative diseases

C. Godinho, J.M. Domingos, A.S. Pereira, M. Duarte, J.J. Ferreira (Lisboa, Portugal)

12:00pm-1:30pm: Functional characterization of the upstream start codon in the GCH1 gene

L.C. Jones, E. Davila, L.K. Goode, P.G. Bhide, I. Armata (Tallahassee, FL, USA)

12:00pm-1:30pm: Gait and anthropometric characteristics of patients with Parkinson’s disease seen in a Nigerian tertiary hospital

A.O. Ogundele, M.O. Olaogun, M.A. Komolafe (Ile-Ife, Nigeria)

12:00pm-1:30pm: Gaze evoked blepharospasm

P.P. Urban (Hamburg, Germany)

12:00pm-1:30pm: Gender-dependent behavioral and biochemical differences in the A53T genetic mouse model of Parkinson’s disease

G. Costa, M.J. Sisalli, L. Contu, A. Scorziello, M. Morelli (Cagliari, Italy)

12:00pm-1:30pm: Glial cells and iron accumulation in the brain of the Zitter rat

T. Kadowaki, H. Lassmann, S. Ueda, C. Schuh, K. Hirata (Mibu, Japan)

12:00pm-1:30pm: Global implementation of efficacious voice treatment for Parkinson’s disease: LSVT LOUD: Germany®

T. Brauer, H. Penner, P. Benecke, C. Fox, L. Ramig (Mainz, Germany)

12:00pm-1:30pm: Group climate in the voice therapy of patients with Parkinson’s disease

G.L.A. Diaféria, P.B. Takaki, G. Madazio, C. Pacheco, M.S. Behlau (São Paulo, Brazil)

12:00pm-1:30pm: Has iCare PD started in Singapore?

S.H.X. Liew, C. Cyq, N. Jcf, K. Sym, R.C.L. Ong (Singapore, Singapore)

12:00pm-1:30pm: Healthcare burden of Parkinson’s disease

M. Tagliati, A.T. Connolly (Los Angeles, CA, USA)

12:00pm-1:30pm: Heterozygous TUBB4A knock-out impairs mitochondrial motility in human neuronal model of DYT4

V. Krajka, F. Vulinovic, P. Seibler, K. Lohmann, C. Klein, A. Rakovic (Luebeck, Germany)

12:00pm-1:30pm: Highlighting the spectrum of practice in the routine management of cervical dystonia with botulinum neurotoxin-A: Baseline injection practice data from MetaCD

R. Trosch, V.P. Misra, S. Om, P. Maisonobe (Farmington Hills, MI, USA)

12:00pm-1:30pm: Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature

R.W.K. Borgemeester, G.F.H. Diercks, M.L.A. Schuttelaar, T. van Laar (Groningen, Netherlands)

12:00pm-1:30pm: Home care program for patients with Parkinson’s disease – A Singapore experience

H.L. Ng, W. Li, S. Abdul Karim, K.Y. Tay, W.L. Au, L.C.S. Tan (Singapore, Singapore)

12:00pm-1:30pm: Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial

S. Muzerengi, R.L. Woolley, C. Rick, N. Ives, F. Dowling, R. Gray, C.E. Clarke, PD MED Collaborative Group (Birmingham, United Kingdom)

12:00pm-1:30pm: How accurate is the prediction of driving ability in a Parkinson’s clinic setting?

C. Thomas, R. Amin, B. Mohamed (Cardiff, United Kingdom)

12:00pm-1:30pm: How satisfied are cervical dystonia patients with their botulinum toxin treatment? Findings from an international observational study

V.P. Misra, C. Colosimo, D. Charles, T.M. Chung, P. Maisonobe, S. Om (London, United Kingdom)

12:00pm-1:30pm: Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo

A. Weihofen, H. Patel, C. Huy, C. Liu, I. Combaluzier, S. Mueller-Steiner, N. Cavegn, L. Strobel, T.M. Engber, K.J. Rhodes, C. Hock, R.M. Nitsch, F. Montrasio, J. Grimm, A. Dunah, P.H. Weinreb (Cambridge, MA, USA)

12:00pm-1:30pm: Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease

L. Zhang, M. Wang, J. Zhu, Y. Pan, J. Dong (Nanjing, People's Republic of China)

12:00pm-1:30pm: Impaired processing of visuo-spatial information in cervical dystonia patients

C.J. Amlang, C. Hubsch-Bonneaud, S. Rivaud-Pechoux, S. Mehdi, A. El Helou, Y. Trotter, J.B. Durand, P. Pouget, M. Vidailhet (Berlin, Germany)

12:00pm-1:30pm: Impaired response times to luminance stimuli in dystonia patients indicate disordered superior colliculus processing

L. Williams, J.S. Butler, B. Quinlivan, A. Molloy, E. McGovern, I. Beiser, M. Thirkettle, S. O'Riordan, P. Redgrave, R. Reilly, M. Hutchinson (Dublin, Ireland)

12:00pm-1:30pm: Improved motor functioning of people with Parkinson’s disease following dance intervention

S.M. Simone, K.A. Beben, S.E. Maguire, C. Noudga, K.L.M. Martin, G.N. Luabeya, P. Dhami, R.J. Bar, J.F. DeSouza (Toronto, ON, Canada)

12:00pm-1:30pm: Improvement in posture, pain, and cardiac autonomic function in a prospective study of osteopathic manipulative medicine and physical therapy for camptocormia in Parkinson’s disease

J.D. Mancini, D.M. Pasternack, N. Caruana, A. Leder (Old Westbury, NY, USA)

12:00pm-1:30pm: Improvement of foot progression in cervical dystonia using osteopathic manipulative medicine

J.D. Mancini, Z. Oliff, A. LaRosa, S. Mody, R. Abu-Sbaih, A. Leder (Old Westbury, NY, USA)

12:00pm-1:30pm: Improvement of freezing of gait with intestinal levodopa infusion in advanced Parkinson’s disease patients

M. Zibetti, S. Angrisano, F. Dematteis, A. Romagnolo, A. Merola, L. Lopiano (Torino, Italy)

12:00pm-1:30pm: Improvement of levodopa induced foot dystonia with 60 Hz frequency subthalamic- deep brain stimulation

J.P. Battista, R.A. Ramdhani (New York, NY, USA)

12:00pm-1:30pm: Improvement of post-stroke fixed dystonia of upper and lower limb following DBS of internal capsule: Report of two cases

G. Messina, V. Levi, R. Cordella, I. Dones, A. Franzini (Milan, Italy)

12:00pm-1:30pm: Improving drug discovery using brain oscillations as biomarkers of Parkinson’s disease

B. Pouyatos, S.J. Perry, D.E. Grigoriadis, R. Maury, C. Bouyssières, C. Roucard, V. Duveau, Y. Roche (La Tronche, France)

12:00pm-1:30pm: Improving provision of Parkinson’s disease exercise classes

C. Carroll, P. Pujara, J. Rideout (Plymouth, United Kingdom)

12:00pm-1:30pm: Improving the experience of diagnosis in Parkinson’s disease

C. Carroll, B. Blight, V. Evans, N. Hawkes, J. Davis (Plymouth, United Kingdom)

12:00pm-1:30pm: In-vivo free-water imaging and functional connectivity in a knock-in mouse model of DYT1 dystonia

J.C. DeSimone, M. Febo, P. Shukla, E. Ofori, L.M. Colon-Perez, Y. Li, D.E. Vaillancourt (Gainesville, FL, USA)

12:00pm-1:30pm: Incidence and etiologies of pediatric asterixis

B.R. Aravamuthan, J.L. Waugh (Boston, MA, USA)

12:00pm-1:30pm: Incidence of fragility fractures in people with parkinsonism [PwP] – A 5 year retrospective observational study

S. Aithal, C. Thomas, S. Raha, H. Shukla, L. Ebenezer, R. Sequeria, B. Mohamed (Caerphilly, United Kingdom)

12:00pm-1:30pm: Influence of treadmill gait training with additional load on motor function, postural instability and history of falls for individuals with Parkinson’s disease: A randomized clinical trial

L.C.L. Trigueiro, A.V.C. Sousa, G.L. Gama, T.S. Ribeiro, L.G.L.M. Ferreira, C.R. Simão, É.R.V.P. Galvão, E.M.G.S. Silva, C.G. Júnior, A.R.R. Lindquist (Natal, Brazil)

12:00pm-1:30pm: Inhibition of cathepsin D enhances the autophagy lysosome pathway dysfunction and α-synuclein aggregation in experimental parkinsonism

L. Li, Y.P. Yang, L. Gao, Y. Song, Z. Liang (Suzhou, People's Republic of China)

12:00pm-1:30pm: Inhibition of glucosylceramide synthase reduces pathology and improves cognition in synucleinopathy murine models

L. Shihabuddin, C. Viel, J. Clarke, H. Park, J.C. Dodge, J. Marshall, B. Wang, S.H. Cheng, S.P. Sardi (Framingham, MA, USA)

12:00pm-1:30pm: Interdisciplinary allied health care in a southern Brazil service

V.L. Israel, B. Yamaguchi, V.L. Israel (Curitiba, Brazil)

12:00pm-1:30pm: International differences in the baseline characteristics and clinical management of cervical dystonia patients presenting for botulinum toxin treatment in routine practice

D. Charles, T.M. Chung, V.P. Misra, C. Colosimo, S. Om, P. Maisonobe (Nashville, TN, USA)

12:00pm-1:30pm: Investigating the plastic effects of rapid paired associative stimulation in dystonia

V.F.M. Ramos, P. Srivanitchapoom, S. Pandey, A. Holmes, S. Kukke, R. Paine, N. Thirugnanasanbandam, N. Dang, M. Hallett (Bethesda, MD, USA)

12:00pm-1:30pm: Investigation of head tremor in cervical dystonia: Novel application of virtual reality head mounted display, the oculus rift

I.M. Beiser, B. Quinlivan, E. McGovern, L.J. Williams, S. Narasimham, O. Killian, R. Beck, G. Colvert, S. O'Riordan, J.S. Butler, R.B. Reilly, M. Hutchinson (Dublin, Ireland)

12:00pm-1:30pm: Investigation of the influence of the parieto-premotor network on the motor cortex in writer’s cramp using transcranial magnetic stimulation

J.E. Park, P. Mathew, M. Villegas, P. Srivanitchapoom, M. Hallett (Bethesda, MD, USA)

12:00pm-1:30pm: Is physiotherapy an effective for treatment of Parkinson’s disease?!

R. Agzamov, S. Tursunov, G. Rakhimbaeva, F. Yunusov, D. Lutfullaeva, J. Olimov, A. Kalendarev, K. Abdukhalimova, R. Mirzaev (Tashkent, Uzbekistan)

12:00pm-1:30pm: KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia

S.A. Factor, R.A. Hauser, S. Siegert, G.S. Liang, C.F. O'Brien (Atlanta, GA, USA)

12:00pm-1:30pm: Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry

W. Poewe, T. Kimber, B. Bermans, P. Odin, A. Antonini, O. Bajenaru, K. Onuk, A. Yegin, L. Bergmann, K.R. Chaudhuri (Innsbruck, Austria)

12:00pm-1:30pm: Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry

K.R. Chaudhuri, Z. Pirtosek, B. Pickut, W. Poewe, F. Valldeoriola, L. Defebvre, R. Jech, P. Odin, C. Winkler, J. Szasz, K. Onuk, A. Yegin, L. Bergmann, A. Antonini (London, United Kingdom)

12:00pm-1:30pm: Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience

E. Pekkonen, J. Lyytinen, O. Lindström, L. Kylänpää, M. Udd (Helsinki, Finland)

12:00pm-1:30pm: Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study

M. Senek, D. Nyholm (Uppsala, Sweden)

12:00pm-1:30pm: Levodopa, placebo and rotigotine change biomarker levels for oxidative stress

S. Muhlack, M. Kinkel, L. Herrmann, L. Tönges, T. Müller (Bochum, Germany)

12:00pm-1:30pm: Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study

P. Havránková, J. Klempír, M. Fialová, A. Rezková, J. Petrtýl, V. Capek, E. Ruzicka, J. Roth, R. Jech (Praha, Czech Republic)

12:00pm-1:30pm: Levodopa/carbidopa intestinal gel, neuropathy, and B-vitamins – Is there an association?

S. Löns, E. Chorbadgieva, A. Kleimann, D. Dressler, C. Schrader (Hannover, Germany)

12:00pm-1:30pm: Localization of basal ganglia and thalamic damage in dyskinetic cerebral palsy

B.R. Aravamuthan, J.L. Waugh (Boston, MA, USA)

12:00pm-1:30pm: Long-latency somatosensory evoked potentials of the subthalamic nucleus

C. Trenado, S. Elben, L. Friggemann, S. Gruhn, S. Groiss, J. Vesper, A. Schnitzler, L. Wojtecki (Düsseldorf, Germany)

12:00pm-1:30pm: Long-term comparative outcomes of functional neurosurgical procedures for treatment of secondary hemidystonia

W.O. Contreras Lopez, A.R.C. Azevedo, M.G. Guilardi, M. San Martin Sepulveda, R.C.R. Martinez, M.J. Teixeira, E.T. Fonoff (São Paulo, Brazil)

12:00pm-1:30pm: Long-term effects of a short inpatient rehabilitation course and peer support in dystonia

K. Martikainen, S. Kinos, R. Marttila (Turku, Finland)

12:00pm-1:30pm: Long-term effects of levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease patients: Dutch multicenter retrospective cohort study

H.R. Moes, J. Groenendal-Laurensse, M. Drent, G. Tissingh, T. van Laar (Groningen, Netherlands)

12:00pm-1:30pm: Long-term effects of pallidal DBS in patients with primary dystonia

P. Krause, S. Völzmann, A. Kupsch, G.H. Schneider, A. Kühn (Berlin, Germany)

12:00pm-1:30pm: Long-term results of pallidal deep brain stimulation in a cohort of eight children with isolated dystonia assessed by blinded video rating

P. Krause, K. Lauritsch, A. Lipp, A. Horn, B. Weschke, A. Kupsch, K. Kiening, G.H. Schneider, A. Kühn (Berlin, Germany)

12:00pm-1:30pm: Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients

R.L. Rodriguez, C. Zadikoff, A.J. Espay, V.S.C. Fung, C. Hall, W.Z. Robieson, K. Chatamra, S. Eaton, M.F. Facheris, J. Benesh (Orlando, FL, USA)

12:00pm-1:30pm: Loss of heart rate variability in ALS: Time and frequency domain assessment

P. Congiu, G. Milioli, G. Borghero, G. Gioi, F. Marrosu, M. Puligheddu, A.L. Goldberger, S. Mariani (Monserratoo, Italy)

12:00pm-1:30pm: Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity

C.H. Lin, H.I. Lin, M.L. Chen, T.T. Lai, L.P. Cao, M.J. Farrer, R.M. Wu, C.T. Chien (Taipei, Taiwan)

12:00pm-1:30pm: May early introduction of dopaminergic agonists improve simptoms after ischemic stroke? The interim report

J. Kobal, Z. Melik, K. Cankar (Ljubljana, Slovenia)

12:00pm-1:30pm: Medication use patterns vary across expert Parkinson’s disease clinics

P. Schmidt, F. Cubillos, T. Simuni, C. Marras, T. Davis, E.C. Nelson (Miami, FL, USA)

12:00pm-1:30pm: Medicinal cannabis for Parkinson’s disease: A survey of practices, beliefs, and attitudes among providers at NPF centers of excellence

D. Bega, T. Simuni, M.S. Okun, P. Schmidt (Chicago, IL, USA)

12:00pm-1:30pm: Mental simulation of whole-body movements in patients with isolated cervical dystonia

M. Esposito, C. Vitale, F. Falco, S. Corvino, R. Allocca, S. Peluso, G. Santangelo, M. Conson (Naples, Italy)

12:00pm-1:30pm: Mind the gap: Temporal discrimination and cervical dystonia

A. Sadnicka, C. Daum, C. Cordivari, K.P. Bhatia, J.C. Rothwell, S. Manohar, M.J. Edwards (London, United Kingdom)

12:00pm-1:30pm: Minimizing levodopa titration period for Parkinson’s disease (PD)

I. Thomas, M. Alam, D. Nyholm, M. Senek, J. Westin (Falun, Sweden)

12:00pm-1:30pm: Mobile decision support system for nurse managment of deep brain stimulation

G. Duffley, D. Martinez, J. Krueger, B. Lutz, M.S. Okun, C.R. Butson (Salt Lake City, UT, USA)

12:00pm-1:30pm: Motor fluctuations in relation to plasma concentrations following a single-dose of levodopa/carbidopa microtablets in advanced Parkinson’s disease

M. Senek, H. Askmark, S.M. Aquilonius, F. Bergquist, R. Constantinescu, A. Ericsson, S. Lycke, A. Medvedev, M. Memedi, F. Ohlsson, J. Spira, J. Westin, D. Nyholm (Uppsala, Sweden)

12:00pm-1:30pm: Motor phenotype classification in moderate to advanced PD: Data from the BioFIND study

L. Luo, H.F. Andrews, J.G. Goldman, R.N. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, A. Amara, S. Frank, A. Rudolph, C. Casaceli, K. Gwinn, M. Sutherland, C. Kopil, L. Vincent, M. Frasier, U.J. Kang (New York, NY, USA)

12:00pm-1:30pm: Motor variability and learning indices in DYT1 dystonia

A. Sadnicka, A. Stevenson, J.C. Rothwell, K.P. Bhatia, J. Galea, M.J. Edwards (London, United Kingdom)

12:00pm-1:30pm: Motor-related brain changes associated with acute administration of trihexyphenidyl in patients with cervical dystonia

R.G. Burciu, E. Ofori, P. Shukla, J.W. Chung, J. DeSimone, C.W. Hess, N.R. McFarland, A. Wagle Shukla, M.S. Okun, D.E. Vaillancourt (Gainesville, FL, USA)

12:00pm-1:30pm: MRI abnormalities and EEG patterns of symptomatic epilepsy in children with cerebral palsy

K. Aminov (Tashkent, Uzbekistan)

12:00pm-1:30pm: Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III

B.L. Greco, T. Simuni, J. Lowell, K.C. Hodgeman, S. Sharma, C.A. Marshall, J. Denmark, W. Galpern, J.L. Goudreau, C. Meuiner, C. Sia, C.A. Thomas, D. Young, K.M. Biglan (Rochester, NY, USA)

12:00pm-1:30pm: Multi-parameter imaging in hemidystonia responsive to GPi deep brain stimulation

C. Sidiropoulos, S. Bowyer, A. Zillgitt, P.A. LeWitt, H. Bagher-Ebadian, E. Davoodi-Bojd, J.M. Schwalb, H. Soltanian-Zadeh (West Bloomfield, MI, USA)

12:00pm-1:30pm: Multicentre retrospective chart review of patients treated with incobotulinumtoxinA to evaluate sustained efficacy and tolerability in converted and de-novo conditions

M.S. Jog, R.M. Jog, A. Tewari, D. Hobson, D. Stewart, D. King (London, ON, Canada)

12:00pm-1:30pm: Multidisciplinary Parkinson rehabilitation in the Netherlands: The effectiveness of points of Parkinson (POP)

E.T. Steendam-Oldekamp, W.A.W.F. Rutgers, T. van Laar (Groningen, Netherlands)

12:00pm-1:30pm: ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump

R. Shaltiel-Karyo, Y. Tsarfati, E. Zawoznik, I. Weinstock, M. Nemas, A. Rubinski, Y.S. Schiffenbauer, A. Nyska, O. Yacoby-Zeevi (Rehovot, Israel)

12:00pm-1:30pm: Neck proprioception is impaired in patients with idiopathic cervical dystonia

J. De Pauw, R. Mercelis, A. Hallemans, S. Michiels, S. Truijen, P. Cras, W. De Hertogh (Antwerp, Belgium)

12:00pm-1:30pm: Negative dystonia of the palate: Mutation in the THAP1 (DYT6) gene found in a 42 years old patient

S. Grimaldi, E. Boutin, D. Robert, A. Lagier, D. Korchia, H. Soma, J.P. Azulay (Marseille, France)

12:00pm-1:30pm: Neural plasticity and freezing of gait: Stepping through the FoG

B.W. Fling, M. Mancini, P. Carlson-Kuhta, L.A. King, K. Smulders, D.S. Peterson, N. Pal, J.G. Nutt, F.B. Horak (Portland, OR, USA)

12:00pm-1:30pm: Neuroprotection effect of an endogenous amine, 1MeTIQ against disturbances in dopamine release induced by the neurotoxin, 6-OHDA: In vivo microdialysis study

A. Wasik, I. Romanska, L. Antkiewicz-Michaluk (Krakow, Poland)

12:00pm-1:30pm: Neuroprotective and antidepressant-like effects of the endogenous amines from tetrahydroisoquinoline group TIQ and 1MeTIQ in the animal model of depressive disorder: Behavioral and neurochemical studies in the rat

L.R. Antkiewicz-Michaluk (Krakow, Poland)

12:00pm-1:30pm: New therapeutic algorithm for abnormal posture in Parkinson’s disease and related disorders

Y. Mukai, Y. Furusawa, Y. Aoshima, H. Todo, Y. Hama, C. Matsumoto, N. Wakasugi, Y. Mizuno, T. Kawazoe, Y. Saitoh, T. Sakamoto, M. Murata (Tokyo, Japan)

12:00pm-1:30pm: Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

12:00pm-1:30pm: Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

C. Moussa, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, F. Pagan (Washington, DC, USA)

12:00pm-1:30pm: Non-motor symptoms evaluation in idiopathic cervical dystonia

N. Novaretti, V. Tumas (Ribeirão Preto, Brazil)

12:00pm-1:30pm: Novel mutations identified in dopamine transporter deficiency syndrome

J. Ng, J. Zhen, K. Erreger, N.C. Oien, S. Mohammed, J.P. Linn, J. Muntadas, I. Denzler, A. Garcia Cazorla, R. Artuch, S. Pope, S.J.R. Heales, A. Galli, M.E.A. Reith, M.A. Kurian (London, United Kingdom)

12:00pm-1:30pm: Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease

E. Tsika, A. Davranche, E. Gabellieri, S. Nampally, J. Molette, S. Papin, H. Kroth, A. Pfeifer, D. Lowe, A. Muhs (Lausanne, Switzerland)

12:00pm-1:30pm: Novel training based on declarative memory cues improves gait perfromance in patients with Parkinson’s disease: A randomized clinical trial

M.E.P. Piemonte, E. Okamoto, K.R. Cardoso, T.P. Oliveira, C.S. Miranda, M. Pikel, F. Mendes, G.F. Xavier (Sao Paulo, Brazil)

12:00pm-1:30pm: Nursing diagnoses and interventions in rehabilitation related to antiParkinsonian pharmacotherapy

M.H.S. Tosin, B.G.R.B. Oliveira, T.R. Garcia (Rio de Janeiro, Brazil)

12:00pm-1:30pm: Objective measurement in clinical care of patients with Parkinson’s disease

M. Horne, K. Kotschet, M. Braybrook (Parkville, Australia)

12:00pm-1:30pm: Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch

N. Fixler, L. Reitblat, A. Wagner, S. Cohen, M. Afek, P. Bonato, J.F. Daneault, N. Golabchi, S. Moore, A. Patel, C. Cho, L. Bataille (Petach Tikva, Israel)

12:00pm-1:30pm: Ocular flutter in alcohol withdrawal syndrome

K.P. Frei, M. Dastjerdi, F.B. Pedouim, L.H. Sovory, K. Dashtipour (Loma Linda, CA, USA)

12:00pm-1:30pm: Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

N.K. Majbour, N.N. Vaikath, K.D. Dijk, M. Ardah, C.E. Teunissen, H.W. Berendse, W.D.J. Berg, O.M.A. El-Agnaf (Amsterdam, Netherlands)

12:00pm-1:30pm: Onset and stabilization of opicapone treatment effects in fluctuating Parkinson’s disease patients: Exploratory by-week efficacy analysis of pooled phase III studies

A. Lees, J. Ferreira, H. Reichmann, E. Tolosa, A. Santos, C. Oliveira, I. Oliveira, N. Lopes, J.F. Rocha, P. Soares-da-Silva (London, United Kingdom)

12:00pm-1:30pm: Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies

A. Lees, J. Ferreira, T. Müller, F. Stocchi, C. Oliveira, A. Santos, N. Lopes, J.F. Rocha, P. Soares-da-Silva (London, United Kingdom)

12:00pm-1:30pm: Orientation of attention affects onset of head saccades: A novel representation of the Posner cueing effect

I.M. Beiser, B. Quinlivan, E. McGovern, L.J. Williams, S. Narasimham, O. Killian, R. Beck, S. O'Riordan, J.S. Butler, R.B. Reilly, M. Hutchinson (Dublin, Ireland)

12:00pm-1:30pm: Osmotic demyelination syndrome with dystonia and parkinsonism responsive to dopaminergic therapy

L.E. Katus, S.J. Frucht (New York, NY, USA)

12:00pm-1:30pm: Osteopathic manipulative treatment in Parkinson’s disease: Preliminary results of a double blind sham-controlled cross-over study

S. Varanese, L. Cicchitti, G. Travaglini, V. Carafa, N. Modugno, S. Spinelli, F. Marsicano, M. Mistichelli, F. Marsicano, F. Giorgini, M. Verzella (Pozzilli, Italy)

12:00pm-1:30pm: Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms

B. Magennis, E.A. Donlon, E.M. Fallon, T. Lynch (Dublin, Ireland)

12:00pm-1:30pm: Painful legs and moving toes (PLMT) treatment with topic capsaicin: A case report

F.S. Tensini, T.S. Tensini, H.A.G. Teive (Curiitba, Brazil)

12:00pm-1:30pm: Pallidal deep brain stimulation improves dystonia in Woodhouse-Sakati syndrome

J.Y. Chen, J.L. Ostrem, B. Lee, P. Starr, A. Viehoever (San Francisco, CA, USA)

12:00pm-1:30pm: Pallidal low frequency activity correlates with dystonic symptoms in patients with cervical dystonia

W.J. Neumann, J. Huebl, C. Brücke, C. Slentz, G.H. Schneider, A.A. Kühn (Berlin, Germany)

12:00pm-1:30pm: Pallidal versus subthalamic stimulation for PD: Beyond the motor effects

M.G. dos Santos Ghilardi, R.G. Cury, R.C.R. Martinez, M.J. Teixeira, E.R. Barbosa, E.T. Fonoff (Sao Paulo, Brazil)

12:00pm-1:30pm: Parietal hand pseudodystonia: Significant functional gains with ultrasound-guided botulinum toxin treatments

P. Pita Lobo, C. Costa (Amadora, Portugal)

12:00pm-1:30pm: PARK-OMM – An osteopathic manipulative medicine protocol to improve motor function and balance in Parkinson’s disease

S. Yao, K. de Vries, J. DiFrancisco-Donoghue, J. Mancini, M.K. Jung, G. Cheriyan, S. Curtis, A. Leder (Old Westbury, NY, USA)

12:00pm-1:30pm: Parkinson patient reported outcomes of voice and communication pre, post and 6 months following LSVT LOUD® and LSVT ARTIC

A.E. Halpern, L.O. Ramig, K. Freeman, J.L. Spielman (Denver, CO, USA)

12:00pm-1:30pm: Parkinson’s disease (PD) quality improvement measures (QIM) and outcomes study

J. Martello, L. Shulman, M. Armstrong, S. Reich (Baltimore, MD, USA)

12:00pm-1:30pm: Parkinsonian symptoms in patients with cervical dystonia treated with bilateral pallidal deep brain stimulation: A controlled study

D. Georgiev, P. Mahlknecht, F. Brugger, S. Vinke, A. Zacharia, T. Grover, L. Zrinzo, M. Hariz, K.P. Bhatia, M. Jahanshahi, E. Tripoliti, G.M. Hariz, T. Foltynie, P. Limousin (Ljubljana, Slovenia)

12:00pm-1:30pm: Parkinsonism due to hypermanganism in the background of cirrhosis and recovery by CaNaEDTA

B. Elibol, H. Onder, G.Y. Cakmakli, E.S. Topcuoglu (Ankara, Turkey)

12:00pm-1:30pm: Participant feedback in the PREDICT-PD study

C.W. Osborne, J. Bestwick, G. Giovannoni, A.J. Lees, A. Schrag, A. Noyce (London, United Kingdom)

12:00pm-1:30pm: Pathological findings from two Parkinson’s disease patients after intraputaminal GDNF infusion

T.R. Yamasaki, V.D. Smith, Y. Ai, D.M. Gash, P.T. Nelson, G.A. Gerhardt, J.T. Slevin (Lexington, KY, USA)

12:00pm-1:30pm: Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias

S.J. Sherman, T. Falk (Tucson, AZ, USA)

12:00pm-1:30pm: Patient experiences following Parkinson’s disease treatment with inhaled levodopa: Results from a Phase 2b study

P. LeWitt, A. Niyazov, A. Sedkov, H. Murck, A. Guo (West Bloomfield, MI, USA)

12:00pm-1:30pm: Patient satisfaction with flexible botulinum toxin injection intervals – Preliminary results of a telephone survey

C. Linder, S. Macher, E. Auff, T. Sycha (Vienna, Austria)

12:00pm-1:30pm: PD COMM Pilot: A pilot randomised controlled trial of Lee Silverman voice treatment (LSVT) versus NHS speech and language therapy versus no intervention in Parkinson’s

C.M. Sackley, S. Patel, R. Woolley, N.J. Ives, C.E. Rick, F. Dowling, K. Wheatley, C. Smith, M. Brady, C.E. Clarke (London, United Kingdom)

12:00pm-1:30pm: Perception of the visual vertical is not impaired in patients with idiopathic cervical dystonia

J. De Pauw, R. Mercelis, W. Saeys, S. Truijen, P. Cras, W. De Hertogh (Antwerp, Belgium)

12:00pm-1:30pm: PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program

J.P. Hubble, B. Fisher, K. Lyons, C. McLean, G. Petzinger, R. Pahwa (Louisville, KY, USA)

12:00pm-1:30pm: Peri-operative dopaminergic replacement protocol with rotigotine in Parkinson’s disease patients

L. Abraira del Fresno, L. Ispierto, A.M. Crespo, T. Canento, D. Vilas, M. Gonzalez, F. Sala, L. Morató, J. Sánchez-Ojanguren, R. Álvarez (Barcelona, Spain)

12:00pm-1:30pm: Peripheral neuropathies in Parkinson’s disease during levodopa-carbidopa intestinal gel treatment: Results from a long-term prospective follow-up study

A. Romagnolo, A. Merola, M. Zibetti, A. Bernardini, D. Cocito, C.A. Artusi, F. Dematteis, S. Angrisano, M.G. Rizzone, L. Lopiano (Turin, Italy)

12:00pm-1:30pm: Pharmacokinetic profile of ONO-2160/CD (levodopa prodrug/carbidopa) in animal and human

M. Nomoto, M. Nagai, N. Nishikawa, K. Yano, Y. Kagamiishi, M. Akisada, S. Saito, M. Yuba, T. Koyanagi, A. Takeda (Tohon Ehime, Japan)

12:00pm-1:30pm: Phenomenology of idiopathic adult-onset truncal dystonia

D.J. Ehrlich, S.J. Frucht (New York, NY, USA)

12:00pm-1:30pm: Physical therapy, a third wheel in the management of Parkinson’s disease

M.V. Alvarez, M. Rodriguez (San Antonio, TX, USA)

12:00pm-1:30pm: Physiological and biomechanical responses of people with Parkinson’s during Zumba Gold®: Effects of dance styles and number of sessions

A. Delextrat, J. Bateman, P. Esser, N. Targen, H. Dawes, M.A. Delextrat (Oxford, United Kingdom)

12:00pm-1:30pm: Physiotherapy can reduce the decline in functioning according to ICF framework in patients in early stage of Parkinson’s disease evolution

E.T.N. Guelfi, E. Okamoto, F.B. Tarallo, J.C. Elmauer, R.R. Fermino, V.F. Giangiardi, P. Yuki, E.P. Piemonte (São Paulo, Brazil)

12:00pm-1:30pm: Pilot study on the long lasting effectivness of an integrated tailored sensory-motor rehabilitation program associated with BoNTA in cervical dystonia

A. Castagna, M. Ramella, A. Crippa, L. Sciumè, G. Giacobbi, C. Corrini, D. Anastasi, A. Montesano (Milano, Italy)

12:00pm-1:30pm: Pisa syndrome in Parkinson’s disease: A mobile orfixed deformity?

E.I. Giyazitdinova, B.T. Muinjonov, G.S. Rakhimbaeva, Y.A. Musaeva, F.K. Shermukhamedova (Taskent, Uzbekistan)

12:00pm-1:30pm: Pre-pulse inhibition of blink reflex in cervical dystonia

M. Kiziltan, O. Öztürk, A. Gündüz (Istanbul, Turkey)

12:00pm-1:30pm: Preclinical evaluation of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesias: Is it a ‘chemical’ DBS?

T. Falk, M.J. Bartlett, T. Ye, L.B. Lazarus, M.L. Heien, S.L. Cowen, S.J. Sherman (Tucson, AZ, USA)

12:00pm-1:30pm: Predicting medication reduction in Parkinson’s disease patients after deep brain stimulation

S.A. Dodwell, C.E. Ashton, D.K. Simon, D. Tarsy, E. Papavassiliou, R. Alterman, L. Shih (Boston, MA, USA)

12:00pm-1:30pm: Predicting risk of sarcopenia in people with Parkinson’s disease

A.P.C. Loureiro, B. Yamaguchi, I.L.P. Villegas, M.P. Ferreira, V.L. Israel (Curitiba, Brazil)

12:00pm-1:30pm: Predicting therapeutic effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease

J.B. Rowe, C. Rae, C. Nombela, T. Ham, P. Vazquez, I. Coyle-Gilchrist, C.R. Housden, B.J. Sahakian, T.W. Robbins, Z. Yes (Cambridge, United Kingdom)

12:00pm-1:30pm: Predictive validity of statistical models of Parkinson’s disease progression

A. Mendes, A. Gonçalves, N. Vila-Chã, M. Calejo, I. Moreira, J. Fernandes, J. Damásio, A. Bastos-Lima, S. Cavaco (Porto, Portugal)

12:00pm-1:30pm: Predictors of onabotulinumtoxinA treatment response in patients with cervical dystonia

J. Jankovic, S. Marc, A. Aubrey (Houston, TX, USA)

12:00pm-1:30pm: Prevalence of orthostatic hypotension after a low subacute levodopa dose in patients with parkinsonism

G. Calandra-Buonaura, L. Sambati, I. Gessaroli, A. Turrini, R. Terlizzi, G. Giannini, P. Guaraldi, P. Cortelli (Bologna, Italy)

12:00pm-1:30pm: Priapism and hypersexuality associated with rotigotine in an elderly Parkinsonian patient: A case report

A. Cannas, M. Meloni, M.M. Mascia, P. Solla, G. Orofino, R. Farris, D. Ciaccio, E. Binaghi, F. Marrosu (Nuoro, Italy)

12:00pm-1:30pm: Probable REM sleep behaviour disorder and detrusor overactivity in primary cervical dystonia- A case report

S.L. Bhadran, M.G.J. Jacob, S. Kripal (Thrissur, India)

12:00pm-1:30pm: Profile of urgent care visits in movement disorders

J.T. Lazarus, V.D. Sharma, L. Scorr, S. Factor (Atlanta, GA, USA)

12:00pm-1:30pm: Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents

M.J. Matos, D. Viña, F. Rodríguez-Enríquez, S. Vilar, L. Santana, E. Uriarte (Santiago de Compostela, Spain)

12:00pm-1:30pm: Progressive encephalomyelitis with rigidity and myoclonus (PERM) in an intellectually disabled patient initially misdiagnosed as neuroleptic malignant syndrome (NMS)

Z. Xu, K. Prasad, T. Yeo (Singapore, Singapore)

12:00pm-1:30pm: Proprioceptive training as a means to enhance sensorimotor function in Parkinson’s disease

N. Elangovan, P. Tuite, J. Konczak (Minneapolis, MN, USA)

12:00pm-1:30pm: Pseudodystonic upper limb secondary to thalamic lesions: Usefulness of ultrasound-guided botulinum toxin treatment

C. Costa, P. Pita Lobo (Amadora, Portugal)

12:00pm-1:30pm: Psychiatric co-morbidity is highly prevalent in idiopathic cervical dystonia and significantly influences health-related quality of life: Results of a controlled study

M. Smit, A. Kuiper, V. Han, V.C.R. Jiawan, G. Douma, B. van Harten, J.M.T.H. Oen, M.E. Pouwels, H.J.G. Dieks, A.L. Bartels, M.A.J. Tijssen (Groningen, Netherlands)

12:00pm-1:30pm: Psychiatric disorders and personality traits in patients with functional dystonia

A. Tomic, M. Svetel, I. Petrovic, N. Dragasevic Miskovic, D. Pesic, M. Mitkovic, A. Potrebic, N. Kresojevic, V.S. Kostic (Belgrade, Serbia)

12:00pm-1:30pm: Psychogenic gait disorders in children – Report of 2 cases

S. Lorenzl, M. Kranz (Hausham, Germany)

12:00pm-1:30pm: Psychogenic non-epileptic seizures among patients with temporal lobe and other epilepsies: Phenomenology and EEG correlates

B.D. Wissel, A.K. Dwivedi, T.E. Gaston, F.J. Rodriguez-Porcel, D. Al Jaafari, J.L. Hopp, A. Krumholz, Y. Wang, S.M.A. van der Salm, D.M. Andrade, F. Borlot, B.D. Moseley, J.L. Cavitt, S. Williams, J. Stone, W.C. LaFrance Jr, J.P. Szaflarski, A.J. Espay (Cincinnati, OH, USA)

12:00pm-1:30pm: Quantitative measurements of deficit type and severity in focal embouchure dystonia

A.E. Morris, S.D. Anderson, J.W. Mink (Rochester, NY, USA)

12:00pm-1:30pm: Randomised trial comparing dopamine agonist, MAOB inhibitor and COMT inhibitor as adjuvant therapy in later Parkinson’s disease (PD)

C.E. Clarke, S. Patel, N. Ives, C. Rick, A. Gray, C. Jenkinson, E. McIntosh, K. Wheatley, A. Williams, R. Gray (Birmingham, United Kingdom)

12:00pm-1:30pm: Randomized controlled trial protocol: Balance training with rhythmical cues to improve and maintain balance control in Parkinson’s disease

T.T.C. Capato, J. Tornai, V.F. Gianguiagi, R.R. Firmino, E.R. Barbosa, M.E. Piemonte (São Paulo, Brazil)

12:00pm-1:30pm: Rasagiline treatment for sleep disorders in Parkinson’s disease (RaSPar) – Double-blinded, randomized, placebo-controlled, placebo run-in-phase, polysomnography clinical trial

W. Schrempf, M. Fauser, K. Otto, M. Wienecke, C. Ossig, S. Brown, A. Maass, M.D. Brandt, U. Schwanebeck, X. Graehlert, H. Reichmann, A. Storch (Dresden, Germany)

12:00pm-1:30pm: RE-024: A potential phosphopantothenate replacement therapy in 2 patients with pantothenate kinase-associated neurodegeneration (PKAN)

P. Roa, P. Stoeter, E. Perez, M. Santana (Santo Domingo, Dominican Republic)

12:00pm-1:30pm: RE-024: Mechanism of action and efficacy in non-clinical models

M. Beconi, E. Monteagudo, A. Di Marco, S. Malancona, D. Elbaum, S. Harper (San Diego, CA, USA)

12:00pm-1:30pm: Real world conversion of levodopa to a novel extended release levodopa preparation: Determining predictors and dose ratios

W. Ondo, P. Coss, M. Christie (Houston, TX, USA)

12:00pm-1:30pm: Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease

J.T. Butler, D. Isaacs, C. Tolleson, R. Pierce, T. Davis (Nashville, TN, USA)

12:00pm-1:30pm: Real-time ultrasound for automated analysis and visualization of neck muscles in cervical dystonia

C. Kobylecki, M.A. Silverdale, R. Cunningham, P. Harding, I.D. Loram (Salford, United Kingdom)

12:00pm-1:30pm: Recent result of indicative evaluation for deep brain stimulation of Parkinson’s disease patients

H. Saiki, S. Matsumoto (Osaka, Japan)

12:00pm-1:30pm: Reflex saccades changes can estimate long-term symptom progression in DBS STN and MED Parkinson’s disease patients (PD)

S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

12:00pm-1:30pm: Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations

C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

12:00pm-1:30pm: Relationship between balance, trunk impairment and hand function in Parkinson’s disease

B. Donmez Colakoglu, F. Soke, A. Genc, P. Keskinoglu (Izmir, Turkey)

12:00pm-1:30pm: Relationship of muscular strength with cardiovascular function in Parkinson’s disease

M.A. Alomari, H. Khalil, O.F. Khabour, E. Dersieh, J.A. Bajwa (Irbid, Jordan)

12:00pm-1:30pm: Reliability of the sensory organization test to predict falls in individuals with Parkinson’s disease

T.E. Apoznanski, S. Yao, M.K. Jung, J. DiFrancisco-Donoghue (Old Westbury, NY, USA)

12:00pm-1:30pm: Results of the German registry of pediatric deep brain stimulation in patients with childhood-onset dyskinetic movement disorders (GEPESTIM)

A. Koy, W. Milena, K.A.M. Pauls, A.A. Kühn, P. Krause, J. Hübl, G.H. Schneider, G. Deuschl, R. Erasmi, D. Falk, J.K. Krauss, G. Lütjens, A. Schnitzler, L. Wojtecki, J. Vesper, R. Korinthenberg, V.A. Coenen, V. Visser-Vandewalle, M. Hellmich, L. Timmermann (Cologne, Germany)

12:00pm-1:30pm: Risk factors associated with postural changes in Parkinson’s disease

A. Khlebtovsky, O. Keret, Y. Rodity, G. Tsvetov, I. Slutzcki-Shraga, F. Benninger, R. Djaldetti (Petach Tikva, Israel)

12:00pm-1:30pm: Risk factors for premature withdraw from the LS-1 PD study

J.Y. Fang, S. Luo, M. Huang, R.B. Dewey, R. Hauser, G. Chen (Nashville, TN, USA)

12:00pm-1:30pm: Robust sensorimotor deficits in a knock-in mouse model of primary torsion dystonia

F. Richter, J. Gerstenberger, A. Bauer, C. Helmschrodt, A. Richter (Leipzig, Germany)

12:00pm-1:30pm: Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia

G. Gangarossa, M. Guzman, V. Prado, M. Prado, S. Daumas, S. El Mestikawy, E. Valjent (Paris, France)

12:00pm-1:30pm: Role of the nurse coordinator within a unit for treatment of neuro-surgical behaviours and abnormal movements

E. Borgeais, C. Fournera, I. Creff, P. Coubes (Montpellier, France)

12:00pm-1:30pm: Rotigotine transdermal patch in Chinese patients with advanced Parkinson’s disease: A randomized, double-blind study

Z. Zhang, M. Asgharnejad, H. Xue, E. Surmann, L. Bauer (Beijing, People's Republic of China)

12:00pm-1:30pm: Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up

B.J. Snow, E. Mulroy, M. Simpson, L. Macdonald, A. Bok, K. Taylor, J. Han, K. Durbin (Auckland, New Zealand)

12:00pm-1:30pm: Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis

N. Elsagheer, H. Ahmed, A. Attia, K. Awad, E. Ezzat, M. Abd Elaleem Aziz, A. Negida (Beni Suef, Egypt)

12:00pm-1:30pm: Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations

R. Pahwa, P. LeWitt, A. Corbin, R. Batycky, H. Murck (Kansas City, KS, USA)

12:00pm-1:30pm: Safety of nelotanserin in a randomized placebo-controlled phase 2 study

W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, S. Piscitelli, M. Sanchez, W. Shanahan (New York, NY, USA)

12:00pm-1:30pm: Safety of opicapone in fluctuating Parkinson’s disease patients: Results of the 1-year extension of study BIPARK I

A. Santos, J. Ferreira, A. Lees, F. Stocchi, O. Rascol, N. Lopes, H. Gama, J.F. Rocha, P. Soares-da-Silva (Porto, Portugal)

12:00pm-1:30pm: Safety, pharmacokinetics, and efficacy of levodopa prodrug ONO-2160/CD: A study in patients with Parkinson’s disease

M. Nomoto, M. Nagai, N. Nishikawa, Y. Kagamiishi, K. Yano, M. Akisada, S. Saito, M. Yuba, A. Takeda (Tohon Ehime, Japan)

12:00pm-1:30pm: Sarcopenia and dynapenia in patients with parkinsonism

E. Cassani, E. Cereda, G. Pinelli, L. Iorio, A. Valentino, C. Pusani, V. Ferri, C. Bolliri, M. Pasqua, G. Frazzitta, M. Barichella, G. Pezzoli (Milano, Italy)

12:00pm-1:30pm: Seated balance is impaired in patients with idiopathic cervical dystonia

J. De Pauw, R. Mercelis, A. Hallemans, G. Van Gils, S. Truijen, P. Cras, W. De Hertogh (Antwerp, Belgium)

12:00pm-1:30pm: Selective M4 antagonism potentiates L-DOPA-induced dyskinesia in MPTP-treated common marmosets

D. Klisko, R. Fisher, L. Lincoln, P. Jenner, S. Rose (London, United Kingdom)

12:00pm-1:30pm: Self-perception of vocal handicap in Parkinson’s disease

A.K. Silbergleit, J. Wall, L. Schultz, J. Peacock, P.A. LeWitt (West Bloomfield, MI, USA)

12:00pm-1:30pm: Sensor-based motor state detection in Parkinson’s disease to approach personalized therapy delivery

L.P. Roncoroni, M. Scholten, I. Hanci, A. Gharabagi, D. Weiss (Tübingen, Germany)

12:00pm-1:30pm: Sensorimotor gray matter changes in professional brass players with and without Embouchure dystonia

T.A. Mantel, C. Dresel, E. Altenmüller, A. Jochim, G. Gora-Stahlberg, C. Zimmer, B. Haslinger (Munich, Germany)

12:00pm-1:30pm: Sensorimotor impairments and the excitability of spinal cord in lead intoxicated rat during development and a potent restorative effect of curcumin

H. Benammi, O. El Hiba, H. Gamrani (Marrakesh, Morocco)

12:00pm-1:30pm: Sensory gating and inhibition in dystonia

E. Antelmi, R. Erro, L. Rocchi, R. Liguori, M. Tinazzi, J. Rothwell, K. Bhatia (Bologna, Italy)

12:00pm-1:30pm: Sensory tricks in cervical dystonia

A. Gündüz, A.D. Elmali, G.S. Koçak, N. Uzun Adatepe, F. Karaali-Savrun, M. Kiziltan (Istanbul, Turkey)

12:00pm-1:30pm: Sensory tricks in primary blepharospasm and cervical dystonia

S. Pandey, G. Soni, N. Sarma (New Delhi, India)

12:00pm-1:30pm: Serum level of vitamin D3 in patients with neurodegenerative diseases compared to healthy adults and its correlation with the years spent from the initial diagnosis

A.N. Taravari (Skopje, Macedonia)

12:00pm-1:30pm: Significant improvement of adult-onset dystonia with cannabinoids-based oromucosal spray

M. Aguilar, S. Romero, L. Molina Porcel, P. Pastor (Terrassa, Spain)

12:00pm-1:30pm: Smell perception and judgement in PD patients: Results of a study designed, conducted, analysed and reported by PD patients

J. Stamford (London, United Kingdom)

12:00pm-1:30pm: Spectrum of acute movement disorders in a pediatric movement disorder clinic; Malaysian experience

T.A. Tajudin (Johor, Malaysia)

12:00pm-1:30pm: Speech and voice range profile in patients with Parkinson’s disease with deep brain stimulation: Preliminary data

G.L.A. Diaféria, A.E. Dias, M.J. Carvalho, R. Cury, E.R. Barbosa, E.T. Fonoff (São Paulo, Brazil)

12:00pm-1:30pm: Status of NPF-QII after six years: Updates to the dataset

F. Cubillos, E.C. Nelson, T. Simuni, C. Marras, M. Rafferty, T. Davis, P. Schmidt (Miami, FL, USA)

12:00pm-1:30pm: STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort

T. Simuni, K.M. Biglan, J. Lowell, K. Hodgeman, B. Greco, R. Rockhill, D. Oakes (Chicago, IL, USA)

12:00pm-1:30pm: Stiff person syndrome

P. Dosekova, G. Krastev, J. Haring, R. Lackovic (Trnava, Slovakia (Slovak Republic))

12:00pm-1:30pm: Stiff person syndrome: Case series

E. Sasse, G. Amorelli, M. Spitz, C.S.B. Germano, L.F. Vasconcellos (Rio De Janeiro, Brazil)

12:00pm-1:30pm: STN-DBS in Parkinson’s disease with early motor complications – A 10 year follow-up

J. Muellner, F. Pineau, D. Maltête, J.L. Houeto, M.L. Welter, S. Navarro, P. Cornu, C. Bernasconi, Y. Agid, M. Schuepbach (Bern, Switzerland)

12:00pm-1:30pm: Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)

F. Kerwood, C. Kenney, K. Kieburtz, W. Olanow, C. Resburg, J. Krishnaswami, S. Bandak (San Francisco, CA, USA)

12:00pm-1:30pm: Striatal and pedunculopontine nucleus diffusion tensor imaging in cervical dystonia

K. Mente, A. Holmes, D. Urbano, M. Hallett, S.G. Horovitz (Bethesda, MD, USA)

12:00pm-1:30pm: Striatal postsynaptic dysfunction in X-linked dystonia-parkinsonism is associated with disease progression

N. Brüggemann, R.L. Rosales, J.L. Waugh, A.J. Blood, A. Domingo, M. Heldmann, R.D. Jamora, A. Münchau, L.V. Lee, I. Buchmann, C. Klein (Lübeck, Germany)

12:00pm-1:30pm: STRONG VOICE: Design of a multisite, open-label, longitudinal registry for patients with neurogenic dysphonia/dysphagia treated with vocal fold augmentation

K.D. Sethi, A. Verma, C.A. Rosen, C.H. Adler, C.J. Bassich, T.L. Carroll, M.D. Stacy (Raleigh, NC, USA)

12:00pm-1:30pm: Structural and connectivity changes after botulinum neurotoxin therapy in blepharospasmus and hemifacial spasm

C.V. Chirumamilla, G. Deuschl, K.E. Zeuner, M. Muthuraman, S. Groppa (Mainz, Germany)

12:00pm-1:30pm: Structural and functional brain network alterations in psychogenic dystonia

E. Sarasso, F. Agosta, A. Tomic, S. Basaia, M. Svetel, G. Mandic-Stojmenovic, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)

12:00pm-1:30pm: Structural organization of the brain connectome in patients with psychogenic dystonia

S. Basaia, F. Agosta, A. Tomic, E. Sarasso, M. Svetel, S. Galantucci, V.S. Kostic, M. Filippi (Milano, Italy)

12:00pm-1:30pm: Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece

G.A. Tagaris, A. Skafida, D. Athanasopoulos, E. Trachani, S. Tsiara (Athens, Greece)

12:00pm-1:30pm: Subthalamic deep brain stimulation vs. intraduodenal levodopa infusion: A long-term retrospective comparative study

A. Merola, A.J. Espay, A. Romagnolo, A. Bernardini, M. Rosso, K.J. Espay, L. Rizzi, M. Zibetti, M. Lanotte, L. Lopiano (Torino, Italy)

12:00pm-1:30pm: Subtle sensory abnormalities in patients with segmental and cervical dystonia detected by quantitative sensory testing

L. Paracka, F. Wegner, C. Blahak, M. Abdallat, M. Karst, D. Dressler, J.K. Krauss (Hannover, Germany)

12:00pm-1:30pm: Successful treatment of movement disorders after resection of midbrain cavernous malformations: Report of two cases

A. Smolanka, V. Smolanka, K. Karpinska, M. Dovhanych, T. Havryliv (Uzhhorod, Ukraine)

12:00pm-1:30pm: Suggested criteria for patient selection for therapy with carbidopa/levodopa enteral suspension (CLES)

R.L. Rodriguez, T. Green, F. Rossi, A. Khaku, J. Slevin (Orlando, FL, USA)

12:00pm-1:30pm: Supplement use in PD is associated with delayed initiation of dopaminergic therapy

L. Chahine, S. Xie, K. Smith, C. Scordia, R. Purri, C. Linder, J. Duda, N. Dahodwala (Philadelphia, PA, USA)

12:00pm-1:30pm: Swallowing difficulties in patients with Parkinson’s disease and Parkinsonian syndromes

Y.O. Trufanov (Kyiv, Ukraine)

12:00pm-1:30pm: Switching double-blind opicapone, entacapone or placebo to open-label opicapone: Efficacy results of the 1-year extension of study BIPARK I

J. Ferreira, A. Lees, E. Tolosa, W. Poewe, A. Santos, N. Lopes, J.F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

12:00pm-1:30pm: Symptoms of dystonia in a mouse with mutation in Lamb1

K.J. Sweadner, Y.B. Liu, A. Tewari, J. Salameh, A. Brashear, L.J. Ozelius, K. Khodakhah (Boston, MA, USA)

12:00pm-1:30pm: Syndrome of dystonia-parkinsonism is a complication of cyclosporine A treatment and may be irreversible

P. Miklavcic, S. Avcin, J. Jazbec, T. Vipotnik Vesnaver, B. Todorova, M. Trost, M. Kojovic (Ljubljana, Slovenia)

12:00pm-1:30pm: Synergistic effects of physical therapy and botulinum toxin in primary cervical dystonia

W. Hu, V. Rundle-Gonzalez, S.J. Kulkarni, L. Almeida, M. Okun, A. Wagle Shukla (Gainesville, FL, USA)

12:00pm-1:30pm: Systematic literature review of quetiapine for hallucinosis / psychosis in Parkinson’s disease (PD)

K. Dashtipour, J.J. Chen, L. Massihi, S. Tashiro, K. Frei (Loma Linda, CA, USA)

12:00pm-1:30pm: Systems biological approach to Parkinson’s disease- Uncovering effects of PD on the synapse

K.F. Heil, O. Sorokina, J.D. Armstrong, J. Hellgren Kotaleski (Edinburgh, United Kingdom)

12:00pm-1:30pm: Taking specialist clinics into community nursing homes

T. Williams, S. Mahon, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

12:00pm-1:30pm: Targeting PDE7 by the small molecule S14: A potential disease-modifying Parkinson�s disease therapy ready to start clinical trials

A. Martinez, C. Gil, D. Lopez Ribas, E. Cunchillos, J. Domenech, M. Sarasa (Madrid, Spain)

12:00pm-1:30pm: Tear fluid as potential biomarker for the diagnosis of Parkinson’s disease

M. Börger, S. Funke, F. Maaß, A. Fischbach, M. Bähr, F. Grus, P. Lingor (Göttingen, Germany)

12:00pm-1:30pm: Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease

T. Willows, N. Dizdar, D. Nyholm, H. Widner, P. Grenholm, U. Schmiauke, A. Urbom, K. Groth, J. Larsson, J. Permert, S. Kjellander (Huddinge, Sweden)

12:00pm-1:30pm: Temporal discrimination threshold and the menstrual cycle

E.M. Mc Govern, E. O'Connor, I. Beiser, L. Williams, J.S. Butler, B. Quinlivan, R. Reilly, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

12:00pm-1:30pm: Temporal dynamics of pallidal low-frequency oscillations in dystonia

D.A.I. Pina-Fuentes, J.C. van Zijl, J.W. Elting, G. Drost, J.M. van Dijk, M.A. Tijssen, M. Beudel (Groningen, Netherlands)

12:00pm-1:30pm: Testing for the “whack-a-mole” sign in the movement disorders clinic

J.E. Park, C. Maurer, M. Villegas, M. Hallett (Bethesda, MD, USA)

12:00pm-1:30pm: The anatomical basis of genetic dystonia: A multimodal MRI study

E. Sarasso, F. Agosta, A. Tomic, S. Basaia, N. Dragasevic, M. Svetel, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)

12:00pm-1:30pm: The application of mobile health technology to increase physical activity in persons with Parkinson’s disease

T.D. Ellis, T.R. DeAngelis, K. Hendron, J.T. Cavanaugh, N. Sullivan, L. Goehring, C.A. Thomas, M. Saint-Hilaire, N.K. Latham (Boston, MA, USA)

12:00pm-1:30pm: The clinical benefit of pallidal stimulation in dystonia is related to the electrode position in the medio-lateral direction

R. Jech, A. Fecíková, D. Štastná, T. Serranová, D. Urgošík, F. Ruzicka (Prague 2, Czech Republic)

12:00pm-1:30pm: The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson’s disease: Experience from a case report

R. González-Maldonado, R. González-Redondo, C.G. DiCaudo (Granada, Spain)

12:00pm-1:30pm: The CNS moving voice program: Implementation of a dual voice and physical exercise program for Parkinson’s disease: An applicability study

R. Loureiro, J. Domingos, D. Peralta, J. Dean, J. Ferreira (Lisbon, Portugal)

12:00pm-1:30pm: The communicative effectiveness survey-revised (CESR): An objective measure of communicative participation for people with Parkinson’s disease

N.J. Donovan (Baton Rouge, LA, USA)

12:00pm-1:30pm: The correlation between dietary fiber, fluid intake and constipation in patients with Parkinson’s disease

N. Kawashima, A. Tabata, A. Kumon, K. Miyashita, A. Sato, H. Onuma, S. Nakamura, E. Horiuchi, K. Hasegawa (Fujisawa, Japan)

12:00pm-1:30pm: The differentiated treatment of Parkinson’s disease in patients with concomitant diabetes mellitus(DM) type 2

F.S. Akhmedova, M.K.U. Tukhtamishev (Tashkent, Uzbekistan)

12:00pm-1:30pm: The effect of daytime working for development of sleep apnea in office workers

D.M. Sultonov, U.N. Vokhidov (Tashkent, Uzbekistan)

12:00pm-1:30pm: The effect of improved nutritional status on psychiatric features and quality of life in Parkinson’s disease patients

N. Ongun, C. Erdogan, E. Degirmenci, L.S. Bir (Denizli, Turkey)

12:00pm-1:30pm: The effect of levodopa-carbidopa intestinal gel on activities of daily living: Results from the observational MONOTREAT study in advanced Parkinson’s disease patients

R. Krüger, P. Lingor, T. Doskas, J. Henselmans, E.H. Danielsen, O. de Fabregues, A. Stefani, S.C. Sensken, J.C. Parra Riaza, K. Onuk, A. Yegin (Tübingen, Germany)

12:00pm-1:30pm: The effect of Mozart piano sonata on Parkinsonian tremor, rigidity and bradykinesia

A. Shoeybi, N. Olfati (Mashhad, Islamic Republic of Iran)

12:00pm-1:30pm: The effect of walking speed on postural stability in Parkinson’s disease fallers

M.H. Cole, M. Sweeney, Z.J. Conway, T.D. Blackmore, P.A. Silburn (Virginia, Australia)

12:00pm-1:30pm: The effectiveness of deep brain stimulation on dystonia: A meta-analysis

A.K.D. Antonio, E.A. Barcelon, P.M.D. Pasco (Manila, Philippines)

12:00pm-1:30pm: The effects of intensive speech treatment on intelligibility in Spanish dysarthria secondary to Parkinson’s disease

G. Moya-Gale, E. Levy (New York, NY, USA)

12:00pm-1:30pm: The efficacy of tremor detection and suppression device in intractable rest tremor in patients with Parkinson’s disease

O. Jitkritsadakul, C. Thanawattano, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

12:00pm-1:30pm: The high prevalence of pain among patients with X linked dystonia parkinsonism

P.J.B. Acuna, C.L. Go (Boston, MA, USA)

12:00pm-1:30pm: The impact of STN DBS on kinetic tremor in Parkinson’s disease patients

S. Szlufik, M. Szumilas, J. Dutkiewicz, D. Koziorowski, T. Mandat, E. Slubowska (Warsaw, Poland)

12:00pm-1:30pm: The influence of cerebellar transcranial direct current stimulation on skill acquisition in Parkinson’s disease

L. Lima de Albuquerque, K. Fischer, S. Jalene, M.R. Landers, B. Poston (Las Vegas, NV, USA)

12:00pm-1:30pm: The Luxembourg Parkinson’s study: Integrating the Lewy body composite risk score into a longitudinal study

M. Kerschenmeyer, P. Kolber, G. Hipp, K. Roomp, S.K. Mosch, A. Schweicher, L. Longhino, M. Falz, V.P. Satagopam, M. Gantenbein, M. Vaillant, F. Betsou, A. Chioti, R. Schreiner, R. Krüger (Belval, Luxembourg)

12:00pm-1:30pm: The neurosteroid dehydroepiandrosterone sulfate (DHEAS) reverses the dopaminergic deficiencies in mild hepatic encephalopathy: A possible therapeutic issue for the management of parkinsonism in cirrhotic patients

O. El Hiba, H. Gamrani (Marrakesh, Morocco)

12:00pm-1:30pm: The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA

W.H. Oertel, C. Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, H. Mueller, M.M. Unger, K.M. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

12:00pm-1:30pm: The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

12:00pm-1:30pm: The Parkinson progression marker initiative (PPMI) – Developing a comprehensive longitudinal biomarker dataset

Parkinson Progression Marker Initiative (New Haven, CT, USA)

12:00pm-1:30pm: The potential therapeutic effect of intranasal administration of stem cells in rotenone model of Parkinson’s disease in mice

M. El-Gamal, M. Salama, M. Sobh, M. Emam, A. Abdalla, A. Lotfy, D. Sabry, M. El-Qotb, M. Sobh (Mansoura, Egypt)

12:00pm-1:30pm: The prevalence of non- motor symptoms in dystonia

P.M. de Carvalho Aguiar, F.P. da Silva-Junior, S.M. Azevedo Silva, E.R. Barbosa, V. Borges, M.S.G. Rocha, J.C.P. Limongi, H.B. Ferraz (Sao Paulo, Brazil)

12:00pm-1:30pm: The role and underlying mechanisms of BAG3 in regulating autophagy in PC12 cells

Y.P. Yang, Y.L. Cao, C.J. Mao, F. Wang, L.F. Hu, C.F. Liu (Suzhou, People's Republic of China)

12:00pm-1:30pm: The role of acoustic salience in acoustic cueing and sound-based motor rehabilitation

B.G. Schultz, S.A. Kotz (Maastricht, Netherlands)

12:00pm-1:30pm: The role of active rehabilitation measures, for maintaining the quality of life of patients after stroke with movement disorders in the general practice conditions

G. Sadullaeva (Tashkent, Uzbekistan)

12:00pm-1:30pm: The role of proprioceptive deficits as a mechanism of gait impairments in postural instability and gait disorder Parkinson’s disease subtype

M.P. Pereira, P.H.S. Pelicioni, Q.J. Almeida, L.T.B. Gobbi (Leuven, Belgium)

12:00pm-1:30pm: The sense of agency is altered in cervical dystonia

C. Delorme, E. Roze, D. Grabli, J.M. Mayer, B. Degos, M. Vidailhet, Y. Worbe (Paris, France)

12:00pm-1:30pm: The serum response factor SRF protect dopamine (DA) neurons in Parkinson’s disease partially by mediate autophagy through a beclin 1-dependent pathway

X. Cheng (Suzhou, People's Republic of China)

12:00pm-1:30pm: The systemic synuclein sampling study (S4)

D. Jennings, C. Coffey, T. Beach, T. Foroud, C.H. Adler, B. Mollenhauer, J. Seibyl, D. Ecklund, S. Lasch, V. Arnedo, C. Kopil (New Haven, CT, USA)

12:00pm-1:30pm: The unfolded protein response pathway as a possible therapeutic target for the synucleinopathies

J.H. Baek, E. Bereczki, D. Aarsland (Stockholm, Sweden)

12:00pm-1:30pm: The writer’s cramp and its connections with sensory deficits

F.C. Paquet, A. Kreisler, A. Bartolo (Fouquières-Lès-Lens, France)

12:00pm-1:30pm: Therapeutic effect of onabotulinumtoxinA (BoNT/A) in hemifacial spasm and trigeminal neuralgia post Ramsay Hunt Syndrome type II

R. López-Castellanos, R. López-Contreras (San Salvador, El Salvador)

12:00pm-1:30pm: Therapeutic potential of compounds preferring specific GABAA receptor subunits for the treatment of dystonia?

F. Richter, C. Bode, C. Spröte, A. Bauer, A. Richter (Leipzig, Germany)

12:00pm-1:30pm: Therapeutic protocol for Parkinson’s patient with freezing based on action observation plus sonification: Preliminary results

S. Mezzarobba, M. Grassi, M. Catalan, L. Pellegrini, R. Valentini, B. Krüger, P. Manganotti, P. Bernardis (Trieste, Italy)

12:00pm-1:30pm: Therapeutic yoga improves balance and balance confidence in Parkinson’s disease

F. Revilla, K. Woschkolup, A.A. Walter, B.L. Hawkins, E. Urrea-Mendoza, A.A. Schmid, J. Park, J. Sharp, M. VanPuymbroeck (Greenville, SC, USA)

12:00pm-1:30pm: Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey

F. Gandor, A. Kühn, J. Müller, F. Klostermann, T. Müller, D. Gruber, A. Lipp, A. Kivi, D. Kübler, F. Ehlen, G. Ebersbach (Beelitz-Heilstätten, Germany)

12:00pm-1:30pm: TNF compromises lysosome acidification and reduces α-synuclein degradation via autophagy in dopaminergic cells

X. Cheng, M. Wang (Suzhou, People's Republic of China)

12:00pm-1:30pm: Tourette syndrome and attention deficit hyperactivity disorders

K. Aminov (Tashkent, Uzbekistan)

12:00pm-1:30pm: Transcranial versus root repeated magnetic stimulation as a treatment of psychogenic movement disorders

B. Garcin, C. Hubsch, L. Lliescu, L. Naccache, M. Vidailhet, E. Fournier, F. Mesrati, E. Roze, B. Degos (Paris, France)

12:00pm-1:30pm: Triad-conditioning transcranial magnetic stimulation in focal hand dystonia

T. Popa, R. Hunt, O. Ahmad, K. Mente, R. Paine, M. Hallett (Bethesda, MD, USA)

12:00pm-1:30pm: Unilateral pallidotomy for cervical dystonia

S. Horisawa, T. Ishikawa, T. Hanada, T. Kawamata, T. Taira (Shinjuku, Japan)

12:00pm-1:30pm: Upper limb motor tests are related to clinical ratings of motor function in advanced Parkinson’s disease

M. Memedi, S. Aghanavesi, D. Nyholm, H. Askmark, S.M. Aquilonius, R. Constantinescu, F. Bergquist, A. Medvedev, A. Ericsson, F. Ohlsson, S. Lycke, J. Spira, M. Senek, J. Westin (Falun, Sweden)

12:00pm-1:30pm: Use of nicotine gum to treat acute low blood pressure in Parkinson’s disease

J. DiFrancisco-Donoghue, A. Leder, M.K. Jung, W.G. Werner (Old Westbury, NY, USA)

12:00pm-1:30pm: Utility of IgGs subtypes in hemolytic anemia prevention and treatment maintenance in patients treated with continous infusion of apomorphine

P. Sanchez-Lozano, E. Suarez, R. Ribacoba (Gijon, Spain)

12:00pm-1:30pm: Utilization and longitudinal impact of amantadine use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry

V. Felix Saunders, T. Simuni, K. Li, S. Luo (Chicago, IL, USA)

12:00pm-1:30pm: Utilization and longitudinal impact of anticholinergic use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry

V. Felix Saunders, K. Li, S. Luo, T. Simuni (Chicago, IL, USA)

12:00pm-1:30pm: Utilizing remote blood pressure monitoring in a phase III clinical drug trial for Parkinson’s disease

J.L. Adams, R.A. Biemiller, K.L. Andrzejewski, S. Sharma, R.L. Rockhill, B.L. Greco, K.C. Hodgeman, P. Singh, S. Khanuja, T. Simuni, K.M. Biglan (Rochester, NY, USA)

12:00pm-1:30pm: Validation of a screening questionnaire for X-linked dystonia parkinsonism (XDP): The first phase of the population based prevalence study of XDP in Panay

J.D.B. Diestro, P.M.D. Pasco, L.V. Lee (Manila, Philippines)

12:00pm-1:30pm: Validation of the XDP-MDSP rating scale for the evaluation of patients with X-linked dystonia-parkinsonism (XDP)

P.D. Pasco, L.V. Lee, R.G. Jamora, C.E. Diesta, A.R. Ng, R.A. Teleg, C.L. Go, R.L. Rosales, H.H. Fernandez (Manila, Philippines)

12:00pm-1:30pm: Validity and reliability of the test d evaluation des membres superieurs de personnes agees (TEMPA) to assess upper limb in Parkinson’s disease

C.L. Correa, P.R. de-Freitas, A.E. Lemos, S.M. Michaelsen, A. Swarowsky (Rio de Janeiro, Brazil)

12:00pm-1:30pm: VANTAGE trial: Three year outcomes of a prospective, multi-center trial evaluating deep brain stimulation with a new multiple-source, constant-current rechargeable system in Parkinson’s disease

L. Timmerman, R. Jain, L. Chen, T. Brucke, F. Seijo, E. Suarez San Martin, C. Haegelen, M. Verin, V. Visser-Vandewalle, M.T. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Cologne, Germany)

12:00pm-1:30pm: Video assessment of writer’s cramp

J.E. Park, B. Karp (Bethesda, MD, USA)

12:00pm-1:30pm: Virtual rehabilitation: A therapy for parkinsonism?

B.S. Zeigelboim, G.J.B. Santos, M.I.R. Severiano, H.A.G. Teive, A.B.M. Lacerda, C.M. Porto (Curitiba, Brazil)

12:00pm-1:30pm: Virtual-reality balance training with Nintendo-Wii games improves dynamic balance in Parkinson’s disease patients

G.H. Lee (Cheon-An, Korea)

12:00pm-1:30pm: Voice harmonic amplitude differences before and after LSVT LOUD^TM in Parkinson’s disease

M.P. Cannito, L.O. Ramig, A.E. Halpern, J.L. Spielman (Lafayette, LA, USA)

12:00pm-1:30pm: When is the worst period of nocturnal hypokinesia in Parkinson’s disease? A sensor-based analysis

J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

12:00pm-1:30pm: White matter connectome in patients with genetic dystonia

S. Basaia, F. Agosta, A. Tomic, E. Sarasso, N. Kresojevic, S. Galantucci, M. Svetel, V. Kostic, M. Filippi (Milano, Italy)

12:00pm-1:30pm: Whole body vibration therapy with exercise enhances motor function and improves quality of life in Parkinson’s disease

O.K. Gruder, D.Y. Edmonston, G.Q. Barr, C.G. Maitland (Tallahassee, FL, USA)

12:00pm-1:30pm: Yearly four months’ disability gap in cervical dystonia due to run-out botulinum toxin effect

K.K. Martikainen, S. Kinos, R.J. Marttila (Turku, Finland)

« View all sessions from the .